



Department of Health logo



Evaluation of the Health Care Homes trial

Volume 3: Methods and data supplement

Revision history

|  |  |  |
| --- | --- | --- |
| Version | Date | Modification |
| 0.1 | 20 May 2022 | Final draft. |
| 1.0 | 29 July 2022 | Final report. |

**Suggested citation:** Pearse, J.1, Mazevska, D.1, McElduff, P.1, Stone, C.1, Tuccia, J.1, Cho, O.1, Mitchell, S.1, McElduff, B.1, Tran, D. T.2, Falster, M. O.2, Pearson, S.2, Jorm, L.2, Yu, S.3, Naghsh Nejadm, M.3, van Gool, K.3, Wright, M.3, Hall, J.3, Bower, M.,4 Dunbar, J.5, Henryks, J., Rosen, R.6, & Smyth, T. (2022). *Health Care Homes trial final evaluation report, Volume 3: Methods and Data Supplement. Health Policy Analysis*. Commissioned by the Australian Government Department of Health.

1 Health Policy Analysis; 2 Centre for Big Data Research in Health (CBDRH), University of NSW; 3 Centre for Health Economics Research and Evaluation (CHERE), University of Technology; 4 Flinders University; 5 Deakin University; 6 Nuffield Trust London.

**Acknowledgements:** Additional collaborators included: Prof. Robyn McDermott, James Cook University; Dr Kathryn Mack McDonald, Stanford University/Johns Hopkins University; Dr Steve Sutch, Sutch Consulting International Ltd; Charles Dove and Anna Lethborg Social Research Centre, Australian National University. The evaluation was also guided by the HCH Evaluation Working Group (see Appendix 1). The evaluation team acknowledges the contribution of the many participants in the HCH trial, including patients and carers, practices, practice staff, and the Primary Health Networks (PHNs), who generously shared their experiences and insights through surveys and interviews. The PHNs also provided other valuable support for the evaluation, as did the Australian Medical Services Alliance Northern Territory (AMSANT).

**Disclaimer:** In accordance with Health Policy Analysis’ policy, we are obliged to advise that neither Health Policy Analysis nor any employee nor sub-contractor undertakes responsibility in any way whatsoever to any person or organisation (other than the Australian Government Department of Health) in respect of information set out in this report, including any errors or omissions therein, arising through negligence or otherwise however caused.

Health Policy Analysis Pty Ltd

Suite 101, 30 Atchison Street, St Leonards NSW 2065

PO Box 403, St Leonards NSW 1590

ABN: 54 105 830 920

ACN: 105 830 920

www.healthpolicy.com.au

Phone: +61 2 8065 6491

Contents

[1. Introduction 1](#_Toc109997498)

[Overview of evaluation methods and data sources 1](#_Toc109997499)

[2. Description of evaluation data sources 6](#_Toc109997500)

[Patient surveys 6](#_Toc109997501)

[Practice surveys 8](#_Toc109997502)

[Case studies 9](#_Toc109997503)

[Extracts from practice clinical management systems 11](#_Toc109997504)

[Linked data 24](#_Toc109997505)

[HCH program data 25](#_Toc109997506)

[3. Comparative analysis using propensity score matching 26](#_Toc109997507)

[4. Patient surveys 52](#_Toc109997508)

[5. Practice and practice staff surveys 66](#_Toc109997509)

[Practice self-assessment using HCH-A 68](#_Toc109997510)

[Staff surveys 72](#_Toc109997511)

[6. Benchmark reports 74](#_Toc109997512)

[Aims of the benchmark reports 74](#_Toc109997513)

[Contents 74](#_Toc109997514)

[Delivery 75](#_Toc109997515)

[7. Economic analysis technical notes 76](#_Toc109997516)

[Data 76](#_Toc109997517)

[Methods 76](#_Toc109997518)

[Appendix 1: HCH evaluation team and HCH Evaluation Working Group membership 80](#_Toc109997519)

[HCH Evaluation Working Group membership 81](#_Toc109997520)

[Appendix 2: Health conditions in the predictive risk model vs derived in Pen CS extracts 82](#_Toc109997521)

[Appendix 3: Keywords to identify health conditions from practice extracts 83](#_Toc109997522)

[Appendix 4: Keywords to identify medicine use and flu vaccine from practice extracts 85](#_Toc109997523)

[Appendix 5: Changes to chronic disease management detailed tables 87](#_Toc109997524)

[Changes in the quality of chronic illness care 87](#_Toc109997525)

[Changes in the use of primary care providers 105](#_Toc109997526)

[Changes in the use of other health providers 109](#_Toc109997527)

[Appendix 6: Changes in patient outcomes detailed tables 116](#_Toc109997528)

[Changes in blood pressure, glycaemic control and renal function 116](#_Toc109997529)

[Changes in the use of hospital services 121](#_Toc109997530)

[Entry into aged care facility 131](#_Toc109997531)

[Serious cardiovascular event and death 132](#_Toc109997532)

[Appendix 7: Patient surveys detailed tables 133](#_Toc109997533)

[Respondent characteristics 133](#_Toc109997534)

[Use of services and access 136](#_Toc109997535)

[Care planning 142](#_Toc109997536)

[Medications review 143](#_Toc109997537)

[Patient and carer experience and rating of quality of care 145](#_Toc109997538)

[Patient activation 151](#_Toc109997539)

[Patient-reported health status 155](#_Toc109997540)

[Patient-reported use of hospital services 160](#_Toc109997541)

[Appendix 8: Practice surveys detailed tables 161](#_Toc109997542)

[Practice characteristics 161](#_Toc109997543)

[Practice staff levels 163](#_Toc109997544)

[Relationships with other local health services – baseline (round 1) 165](#_Toc109997545)

[Access measures 166](#_Toc109997546)

[Systems to support chronic disease management – baseline (round 1) 169](#_Toc109997547)

[Other practice characteristics 172](#_Toc109997548)

[Enrolment and risk stratification 173](#_Toc109997549)

[Shared care planning and use of My Health Record 176](#_Toc109997550)

[Changes implemented within practice 181](#_Toc109997551)

[Impact of COVID-19 186](#_Toc109997552)

[Patient engagement and activation 189](#_Toc109997553)

[Practice assessment of impact on outcomes 191](#_Toc109997554)

[Economic issues 192](#_Toc109997555)

[Wish to continue in HCH or a similar program 193](#_Toc109997556)

[Appendix 9: HCH-A Practice self-assessment 196](#_Toc109997557)

[Appendix 10: Practice staff surveys detailed tables 212](#_Toc109997558)

[Appendix 11: Sample practice benchmark report 252](#_Toc109997559)

[References 260](#_Toc109997560)

1

1. Introduction

This document is the methods and data supplement of the final evaluation report of the Health Care Homes Trial (HCH) trial. It is one of three volumes detailing the findings of the evaluation. Table 1 describes the volumes.

Table 1: Final evaluation report volumes

|  |  |
| --- | --- |
| Volume | Description |
| Volume 1 Summary report | Summarises the findings of the evaluation. |
| Volume 2 Main report | Presents the findings from the evaluation. |
| Volume 3 Methods and data supplement | Further details on evaluation methods, data sources and quality issues and additional analyses. |

## Overview of evaluation methods and data sources

A detailed description of the evaluation methods is in the HCH Evaluation plan.[[1]](#footnote-2)Briefly, the evaluation aimed to answer the following key questions:

1. How was the HCH model implemented and what were the barriers and enablers?
2. How does the HCH model change the way practices approach chronic disease management?
3. Do patients enrolled in HCH experience better quality care?
4. What are the financial effects of the HCH model on governments, providers and individuals?

Additional key evaluation questions for the community pharmacy component were:

1. Is the community pharmacy component beneficial to the broader HCH coordinated care model and should it be included as part of any future roll out?
2. Did patients who received medication management services as part of the HCH trial experience better health outcomes than patients who did not?
3. What was the level of engagement between HCH practices and community pharmacy (care coordination)?
4. Is the inclusion of a pharmacy component in HCH financially viable?

These questions have many dimensions. Therefore, more detailed questions were developed for each key question.

The evaluation used mixed methods, predominantly a convergent design (that is, quantitative and qualitative data collected separately but compared at the time of analysis to corroborate or expand findings), with some sequential elements (that is, quantitative results informing qualitative data collection or vice-versa, for example, results of practice surveys informing exploration in case study interviews).

The quantitative components used quasi-experimental and before-and-after designs. For the quasi-experimental analyses, selected outcomes for HCH patients were compared with outcomes for equivalent patients from non-HCH practices. Similarly, measures for HCH practices were also compared with non-HCH practices. For the before-and-after analyses, measures for HCH practices and patients were compared before or at the start of the trial with measures after implementation.

Quantitative data sources included extracts from practice clinical management systems and linked data that included Medical Benefits Schedule (MBS) data, Pharmaceutical Benefits (PBS) data, hospitalisations data, emergency department data, residential aged care data and national deaths data.

The qualitative components aimed to provide information about how the trial was implemented, and insights into participants’ experiences with the trial. These data were collected through case studies of selected practices that included interviews with the practices, practice staff, practice patients and their carers and other stakeholders. These were undertaken in 20 locations across Australia at three different time points.[[2]](#footnote-3)

Table 2 lists the data sources, labelled as “primary” (data collected specifically for the evaluation), and “secondary” (data requested from other sources). The evaluation was split into five “rounds” and primary data collection activities were organised according to these. There were also three “waves” of patient surveys. Table 3 shows the dates relating to key primary data collection activities.

Table 2: Evaluation data sources

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Data source** | **Key questions** | **Collection type** | **Evaluation report in which data were used and data collection round/period** | | |
| **Interim 2019** | **Interim 2020** | **Final report 2021** |
| Patient surveys | 3, 6 | Primary | Wave 1 (baseline) | n.a. | Waves 1, 2 and 3 |
| Practice surveys | 1, 2, 4 | Primary | R1 R2 | R4 | R1 R2 R4 R5 |
| Practice staff surveys | 1, 2, 4, 5, 7 | Primary | R1 | n.a. | R1 R5 |
| PHN surveys | 1, 2, 4 | Primary | R1 | R4 | R1 R4 R5 |
| PHN interviews | 1, 2, 4, 5, 7 | Primary | R1 R2 | R4 | R1 R2 R4 R5 |
| Case studies1 | 2, 4, 5, 6, 7 | Primary | R2 | R4 | R1 R2 R4 R5 |
| HCH program data2 | 1, 4 | Secondary | Oct 2017 –Aug 2019 | Oct 2017 –Jun 2020 | Oct 2017 –  June 2021 |
| Community pharmacy Health Outcomes Data | 5, 6, 7, 8 | Secondary | July 2018 –June 2019 | July 2018 –June 2020 | July 2018 –  June 2021 |
| Risk stratification | 2 | Secondary | July 2018 –June 2019 | July 2018 – June 2020 | July 2018 –  June 2021 |
| Practice extracts3 | 2, 3 | Secondary | To June 2019 | To June 2020 | To June 2021 |
| Linked data4 | 3, 4 | Secondary | n.a. | n.a. | Various5 |

Notes: 1Case studies include patient interviews/focus groups, practice interviews, related provider interviews (e.g. pharmacists, allied health), PHN interviews; 2Data related to the administration of the program from the Department of Health and Services Australia; 3For some practices, data were obtained two years before the start of the trial, see Chapter 2 for details; 4Includes MBS, PBS, hospital, emergency department, aged care, and fact of death data; 5 See Chapter 2 for details.

Table 3: Timing of primary data collection activities

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Evaluation round** | **Practice surveys and staff surveys** | **PHN surveys** | **Patient surveys** | **PHN interviews** | **Case study interviews** |
| Round 1 (R1) | Dec 2017–Jul 2018 (incl. staff survey) | Aug 2018 | Wave 1: Dec 2017–Mar 2019 | Jan – Jun 2018 |  |
| Round 2 (R2) | Nov 2018–Mar 2019 |  |  | Nov–Dec 2018 | Sept–Oct 2018 |
| Round 4 (R4) | Nov 2019–Mar 2020 | Mar–Apr 2020 | Wave 2: Dec 2019–Mar 2020 | Jul–Oct 2019 | Nov 2019–  Mar 2020 (incl. NT ACCHS case studies) |
| Round 5 (R5) | Mar–May 2021 (incl. staff survey) | May–June 2021 | Wave 3: Mar–Apr 2021 | Mar–Apr 2021 | Mar–May 2021 (incl. NT ACCHS case studies) |

Table 4 shows further details of the data used for the evaluation, including a summary of response rates where applicable.

Table 4: Responses by data source

| **Data source and responses** | **Evaluation round** | | | | |
| --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **4** | **5** |
| **Patient surveys:**  Wave 1: 2,018 completed surveys, raw response rate of 64.6%  Wave 2: 1,859 completed surveys, raw response rate of 68.0%  1,275 respondents had completed a response to wave 1  Wave 3: 1,385 completed surveys, raw response rate of 72.0%  1,001 respondents had completed a response to wave 1  1,312 respondents had completed a response to wave 2 | **ü** | |  | **ü** | **ü** |
| **Practice surveys:**  Round 1 survey responses: Part A – 178, Part B – 170  Round 2 survey responses: 106  Round 4 survey responses: 57  Round 5 survey responses: Part A – 74, Part B – 65 | **ü** | **ü** |  | **ü** | **ü** |
| **Practice staff surveys:**  Round 1 survey responses 529 staff from 146 practices (100 GPs, 125 practice nurses/nurse practitioners, 131 receptionists, and 128 practices managers)  Round 5 survey responses 182 staff from 78 practices (36 GPs, 42 practice nurses/nurse practitioners, 32 receptionists, 48 practice managers, 24 others) | **ü** |  |  |  | **ü** |
| **Practice exit interviews/surveys:** Methods for conducting exit interviews and surveys changed over time. By September 2018, interviews had been conducted with eight individuals covering 17 practices (some individuals spoke on behalf of multiple practices). Written reasons for withdrawal were provided by three other practices. These responses were incorporated into the *Interim evaluation report 2019*. An online exit survey was subsequently used, although responses to this were low (7 practices). Since the *Interim evaluation report 2019*, a further 13 practices withdrew from the trial. From the 13 withdrawn practices, the evaluation team received exit surveys or conducted interviews with 10. | **ü** | **ü** | **ü** | **ü** | **ü** |
| **PHN surveys:**  Round 1: survey responses: 10  Round 4: survey responses 9  Round 5: survey responses 7 | **ü** |  |  | **ü** | **ü** |
| **PHN interviews:**  All 10 PHNs were interviewed in rounds 1, 2, 4 and 5. | **ü** | **ü** |  | **ü** | **ü** |
| **Case studies:** See Table 7, page 10 |  | **ü** |  | **ü** | **ü** |
| **Practice data extracts:** Data were received via third party extraction software as follows: Pen CS (this included data from the Northern Territory ACCHS clinics), POLAR, and SONIC. Data for comparator practices was from practices participating in NPS MedicineWise’s MedicineInsight program and consenting to providing their data for the evaluation. Details are provided in Chapter 2. | **ü** | **ü** | **ü** | **ü** | **ü** |
| **HCH program data:** Data on program establishment from the Department of Health and on administration of the program by Services Australia, including weekly enrolment numbers and withdrawals. | **ü** | **ü** | **ü** | **ü** | **ü** |
| **Linked data:** The first instalment of data covering the period from July 2015 to June 2017 was received at the end of 2019. The second instalment (July 2017 to June 2019) was received June 2021. The third instalment (July 2019 to June 2020 for hospital & aged care data and July 2019 to June 2021 for MBS, PBS & fact of death data) was received in October 2021. |  |  | **ü** | **ü** | **ü** |
| **Other data sources:** De-identified risk stratification data from Precedence, covering the period up until the end of June 2020 received. Data on participation and evaluation of training activities collected by AGPAL was also supplied and reported in the *Interim evaluation report 2019*. Guildlink supplied the Community Pharmacy Health Outcomes Data. Data to 30 June 2021 was received. |  | **ü** | **ü** | **ü** | **ü** |

2

1. Description of evaluation data sources

The chapter provides further details of the evaluation data sources.

## Patient surveys

Appendix F of the evaluation plan[[3]](#footnote-4) includes the patient survey questions. The patient surveys aimed to obtain perspectives on patients’ relationship with their HCH, addressing the key evaluation question: “Do patients enrolled in HCH experience better quality care”, and the following sub-questions:

* Did patients enrolled in the HCH program have improved access to primary care services, including alternates to face-to-face contacts?
* How did use of services from within the HCH practice change?
* Did the HCH model result in increased continuity in the provision of primary care?
* Were the patients enrolled in the HCH program and their families/ carers more engaged in managing patients’ health needs?
* What strategies resulted in the greatest impact on patient activation?
* Did patients enrolled in HCH report improved experiences of primary care, including coordination of their care and communication with their primary care providers?

The survey incorporated items from the following instruments:

* Patient Assessment of Chronic Illness Care (13-item version)[[4]](#footnote-5)
* Patient Activation Measure (PAM) (13-item version)[[5]](#footnote-6)
* EQ-5D-5L[[6]](#footnote-7)
* Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Group adult survey (CG-CAHPS)[[7]](#footnote-8) – selected items only
* Care Coordination Quality Measure for Primary Care (CCQM-PC)[[8]](#footnote-9) – selected items only.

PAM and EQ-5D-5L are proprietary tools for which HPA obtained licenses for the evaluation. For translations into other languages, to preserve the psychometric properties of the tools, HPA obtained official translations of tools where available (for example, PACIC, EQ-5D-5L). For others, a translation service was used.

The surveys were translated into five languages: Arabic, Italian, Greek, Chinese and Tamil. The first four languages were chosen as they are the most common in Australia according to Australian Bureau of Statistics data as well as advice from a culturally and linguistically diverse public relations specialist. Tamil was nominated by one of the PHNs due to a particular cluster of Tamil speakers in its region. These five languages were the same as those into which the patient information and consent form was translated.

Only patients aged 18 years and over were invited to complete a survey. This is because children were expected to be a small proportion of HCH enrolees and given this, the costs of addressing additional ethical and legal issues of surveying children were estimated to be disproportional. Patients of the Northern Territory ACCHS clinics were not surveyed (see “Case studies” below).

HPA subcontracted The Social Research Centre (a business unit of the Australian National University) to administer the surveys via a computer assisted telephone interview (CATI).

The patient surveys were conducted in three waves. In wave 1, patients were approached to complete a survey about four to six weeks following enrolment. In wave 2, patients surveyed during wave 1 were followed up if they had not died and had not withdrawn from HCH (due to their own reasons or because their practice withdrew from the trial). In wave 2, additional patients not surveyed in wave 1 were added. The additional cohort targeted patients referred to community pharmacy as part of the HCH trial. Wave 3 followed-up patients interviewed in wave 2.

The aim was to survey 2,000 patients in wave 1 and 2,500 in waves 2 and 3. Table 5 shows the number of patients invited and the response rates per wave.

Table 5: HCH evaluation patient survey response rates

| **Wave** | **Time frame** | **Patients surveyed** | **Invited** | **Completed surveys** | **Response rate** |
| --- | --- | --- | --- | --- | --- |
| Wave 1 (Baseline) | December 2017 to March 2019 | Sample drawn from HCH practices | 3,125 | 2,018 | 65% |
| Wave 2 | December 2019 to March 2020 | Wave 1 patients | 1,7621 | 1,275 | 72% |
| Additional patients drawn from those referred to community pharmacists | 970 | 584 | 60% |
| Total wave 2 | 2,732 | 1,859 | 68% |
| Wave 3 | March to April 2021 | Wave 1 only patients | 260 | 73 | 28% |
| Wave 2 only patients | 523 | 384 | 73% |
| Wave 1 & Wave 2 patients | 1,153 | 928 | 80% |
| Total wave 3 | 1,936 | 1,385 | 72% |

Notes: 1 Number decreased from 2,018 patients surveyed in wave 1 due to various factors, including number disconnected, patient deceased.

Source: The Social Research Centre.

## Practice surveys

Appendix C of the evaluation plan[[9]](#footnote-10) includes the practice surveys. The surveys were administered online using the Qualtrics application. Surveys of HCH practices were conducted in rounds 1, 2, 4 and 5. The surveys aimed to capture information on:

* Practice characteristics at baseline.
* Key features of the practice relevant to HCH approach.
* The capabilities of the practice before joining the program (for example, participation in other chronic disease management and related initiatives).
* Changes implemented as a result of participation in HCH.
* Practice experience of and feedback on HCH.
* Practice perspectives on the effectiveness of HCH.

Table 6 shows the response rates for the surveys. Response rates declined as the trial progressed. Strategies to maximise completion of surveys included:

* Letting practices know upfront about the approximate time frames during which surveys would be issued.
* Letters to practices during each survey round outlining the importance of the survey and details about completion.
* Setting a generous time window for completion of the survey (usually two months, and extensions were granted where practices asked for one).
* Reminder letter to practices not completing the survey by the due date.
* Assistance to individual practices to access the evaluation portal to complete the survey (for example, reissue lost/ forgotten passwords, issue logins to additional people in the practice).
* Inclusion in the survey tool of a skip function for questions that were conditional on a previous answer (to minimise respondents going through questions that were not relevant to them).
* Where questions in the survey referred to responses that the practice had given in an earlier survey round, those responses were provided in the survey tool for easy reference.
* Letters to PHNs letting them know which of their practices had not completed a survey and asking them to follow up.
* Department of Health reminders to PHN practice facilitators at regular meetings and email correspondence with this group to follow up with practices with outstanding surveys.

Table 6: HCH evaluation practice survey response rates

| **Survey** | **Dates that the bulk of the practices completed the survey**  **[A]** | **Number of practices responding** | **Number of practices active,  at the end of [A]** | **Response rate** | **Number of practices that responded that were still in the HCH trial at 31 Match 2021** |
| --- | --- | --- | --- | --- | --- |
| 1 Part A | Dec 2017 – Jul 2018 | 164 | *185 (July 2018)* | 88.6% | 100 |
| 1 Part B | 158 | 85.4% | 98 |
| 2 | Nov 2018 – Mar 2019 | 105 | *162 (Feb 2019)* | 64.8% | 78 |
| 4 | Nov 2019 – Mar 2020 | 57 | *123 (March 2020)* | 46.3% | 54 |
| 5 Part A | Mar – May 2021 | 74 (incl. one withdrawn 27 April 2021) | *109 (March 2021)* | 67.9% | 74 |
| 5 Part B | 65 | 59.6% | 65 |

## Case studies

The case studies aimed to provide a comprehensive view of the implementation of HCH at the practice level. Practices included in the case studies were selected to maximise diversity across the dimensions of the sampling frame established for the HCH trial (which included practice size, location and type). PHNs reviewed a list of the practices selected by HPA, and in some cases suggested alternatives to better fit the evaluation strata. Practices that withdrew from HCH in subsequent interview rounds were replaced by an alternative practice from within the same PHN (and with similar features if possible according to the sampling frame).

The case studies involved visits to selected locations within each of the 10 participating PHNs, studying two practices in each location, with interviews or focus groups conducted with:

* Patients and their carers and family.
* Practice staff, speaking on behalf of the practice as well as individual perspectives of GPs, nurses, allied health professionals and technical and administrative staff employed by the practice.
* External allied health and other service providers that the practices referred patients to.
* Pharmacists participating in the community pharmacy trial.
* PHN representatives.
* Local Hospital Network (LHN) and state/territory health authority representatives (associated with all 10 PHNs).

Site visits and interviews were conducted in rounds 2, 4 and 5. Interviews for round 5 (March to May 2021) were largely conducted by videoconference or telephone, due to restrictions related to the COVID-19 pandemic. Table 7 provides information about the case study interviews.

Table 7: HCH evaluation case studies: interviews for rounds 2, 4 and 5

| **Informants interviewed or participating in focus group** | **Round 2** | **Round 4** | **Round 5** |
| --- | --- | --- | --- |
| *Dates:* | *Sept–Oct*  *2018* | *Nov 2019–*  *Mar 2020* | *Mar–May*  *2021* |
| **Practices interviewed** | |  |  |
| *Total* | *181* | *202* | *17* |
| **Practice staff interviewed** | |  |  |
| GPs | 24 | 27 | 20 |
| Nurses | 13 | 15 | 11 |
| Practice managers | 14 | 15 | 13 |
| Receptionist | 6 | 5 | 6 |
| Other | 8 | 14 | 11 |
| *Total* | *65* | *76* | *51* |
| **Patients and carers** | |  |  |
| Patients | 42 | 49 | 433 |
| Carers | 4 | 2 | 3 |
| *Total* | *44* | *51* | *46* |
| **Primary Health Networks** | 10 | 10 | 10 |

Notes: 1 Research ethics approval had not been obtained for two case studies based in ACCHS clinics at the time the R2 case studies were undertaken. These were included in R4 and R5. 2 Four practices that withdrew in R2 were replaced with four other HCH practices; 3 Two patients were not from the practice case study sites.

Participants in interviews were offered a voucher or payment as follows:

* Patients and their carers/ family: a $30 gift voucher or cash payment.
* Practices: $1,000 per round of interviews.
* External allied health providers and community pharmacists: $160 per interview.

## Extracts from practice clinical management systems

Extracts from practice clinical management systems were supplied for the HCH evaluation, using several sources. Practice data were used to address **Key question 3: Do patients enrolled in HCH experience better quality care?** Practice extract data enabled examination of the quality of chronic illness care such as recording of HbA1c and blood pressure, use of primary care services, and clinical outcomes such as control of diabetes and high blood pressure. The measures for patients enrolled in the HCH trial were compared with those for “comparator patients” who received care from practices not participating in the HCH trial. During the evaluation, practice data were also analysed for six-monthly periods to produce benchmark reports, which were provided to individual HCH practices and PHNs as a means of providing feedback about completeness and quality of data recording (See Chapter 6: Benchmark reports).

This section describes the sources of practice data extracts, including how the data were collected and managed for the evaluation, the patient information that was extracted and provided for the evaluation, and similarities and differences of the data sources. It reports the accuracy of practice recording of HCH enrolees in clinical management systems by comparing with HCH registrations in the Health Professional Online Services (HPOS) system (that is, for receipt of the bundled payment).

|  |
| --- |
| Box 1: Practice data extracts – Key points   * Practice data extracts were obtained from four sources: Pen CS, Population Level Analysis and Reporting (POLAR), Sonic Clinical Services (Sonic), and MedicineInsight. For the HCH evaluation, practice extracts were received from 151 HCH practices (including 13 Northern Territory ACCHS clinics). The final MedicineInsight extract included data from 403 practices that were not participating in HCH. * Practice extracts from the four data sources contained information about patient demographic characteristics, service encounters, diagnoses, clinical measurements, pathology results, prescriptions, immunisations and MBS billing. There was variation between data sources in terms of data extraction arrangements, information included and data processing before delivery of the data set for the evaluation. This warranted efforts to harmonise data content for the evaluation. Some evaluation outcomes of could not be harmonised, and were measured in HCH patients only (for example, number of encounters with practice nurses, allied health providers in the practice; recording of smoking status). * There were some discrepancies between the number of HCH patients identified in practice data extracts and the number of enrolled patients registered in HPOS. |

### Sources of practice data extracts

For the evaluation, practices participating in the HCH trial provided data extracts from their clinical management systems through third party software (Pen CS and POLAR), or through their corporate office (Sonic Clinical Services). Data extracts from practices not participating in the HCH trial were obtained from NPS MedicineWise’s MedicineInsight program. At the start of the evaluation, the Department of Health and the evaluation consortium explored options for obtaining extracts from practice clinical management systems for the evaluation. The approach to obtaining practice data was guided by three criteria:

* Leveraging existing arrangements for data sharing. This was important so as not to introduce new processes for practices, and to use existing licences for data extraction where available so as not to add cost.
* Creating infrastructure or processes that would have value beyond the evaluation.
* Selecting an approach that is compatible with most of the clinical management systems used by practices.

A survey of PHNs was conducted early 2017 by the Department and HPA to explore the extent to which the practices were already sharing their data with the PHNs. Most of the 10 PHNs were using Pen CS software for data extracts, with PHNs covering the licensing costs for practices within their region. Therefore, Pen CS data were leveraged within these PHNs for the evaluation for the majority of HCH practices.

However, Pen CS was not feasible for several subsets of HCH practices, as follows:

* The Northern Territory ACCHS agreed for their data only relating to HCH patients to be extracted for evaluation. All ACCHS were provided with instructions on how to do this extraction. ACCHS used the Pen CS platform to supply data directly to the evaluators.
* Within the South East Melbourne PHN, POLAR software, developed by Outcome Health, was being used to share data between practices and the PHN. The evaluation therefore leveraged the data extracted through the POLAR software for participating HCH practices within this PHN.
* Eleven HCH practices who were part of Sonic Clinical Service’s Independent Practitioner Network agreed to provide extracts for HCH patients. For those Sonic practices, data relating to HCH patients were extracted directly from their Best Practice clinical management system and transferred to the evaluation team.

An additional source of practice data was sought for comparisons of process and clinical measures with HCH practices as well as completeness and quality of data. The comparison data were obtained from NPS MedicineWise’s MedicineInsight program. MedicineInsight is a quality improvement program developed and managed by NPS MedicineWise. The initial exploration indicated that about 25 practice members of MedicineInsight were also participating in the HCH trial. Therefore, the Department negotiated with NPS MedicineWise to use MedicineInsight data as a source of data for both HCH and comparator practices. NPS MedicineWise obtained consent from member practices for their data to be used for the HCH evaluation and provided data from the practices that consented.[[10]](#footnote-11) In the initial MedicineInsight data extract delivered in September 2018, there were three HCH practices that had consented to sharing their data. In both the second extract (delivered in August 2019), and the third extract (delivered in February 2020), there were four HCH practices that had consented to share their data. In the final extract (delivered in August 2021), there were three HCH practices that had consented to share their data.

By the end of the evaluation (June 2021), the evaluation team received extracts for 151 HCH practices (Figure 1) through Pen CS (14 Northern Territory ACCHS clinics and 109 other practices), POLAR (17 practices), Sonic (11 practices) or MedicineInsight (three practices in the final delivery).

Of the 14 Northern Territory ACCHS clinics providing data through Pen CS, four clinics provided data individually and 10 arranged for the data to be combined and supplied as three entities.

Practice data extracts were not available for 14 HCH practices for the entire evaluation. Of these, one practice shared their Pen CS database with another location.

The final MedicineInsight extract delivered in August 2021 included data for 403 non-HCH practices and three HCH practices. The three HCH practices participating in MedicineInsight program also supplied data via Pen CS. For greater data consistency, Pen CS extracts for these three practices were analysed for the evaluation.

HCH practices were required to provide data until the practice withdrew from the trial or the end of June 2021; therefore, extracts from some practices covered longer timespans than others. Extracts from non-HCH practices covered the period from December 2015 to June 2021.

Figure 1: Sources and numbers of practices providing extracts for the evaluation, by end of the evaluation

**Pen CS**123 HCH practices (including 14 NT ACCHS1,2)

Monthly snapshot

Raw & derived variables

**MedicineInsight**3 HCH practices3  
403 non-HCH practices

Data extract   
not available (or shared with another practice site)  
  
14 HCH practices4

Data extract available

151 HCH practices

Practices enrolled in HCH

Data extract available   
  
403 comparator practices

**POLAR**17 HCH practices

Monthly full extract

Raw & derived variables

Complete full extract

Raw & derived variables

**Sonic1**11 HCH practices

Monthly full extract

Raw variables

Notes: 1 Extracts from Northern Territory ACCHS clinics and Sonic practices related to HCH patients only. 2 Extracts from 10 Northern Territory ACCHS clinics were combined and supplied as three entities (two entities of three sites each and one entity of four sites). 3 The three HCH practices participating in MedicineInsight also supplied data through Pen CS. 4 This included one practice that already shared Pen CS database with another site.

#### Pen CS extracts

Pen CS data extraction software captures a snapshot of a patient’s data from the practice clinical management system at monthly intervals. At the time of the extraction, information from the most recent record for a patient is extracted. For example, if a patient had three visits to the practice within a data extraction period and had blood pressure measured and recorded in each visit, only the most recent blood pressure measurement would be included in the extract. If a patient did not have any contact with the practice within the current extract period, the data included in the extract would reflect the measurement undertaken in the previous period. For this reason, a single record of patient measurement (for example, blood pressure or HbA1c result) may be extracted multiple times. Thus the evaluation team filtered out duplicate records before data analyses. In the practice clinical management system, when the practice updates patient smoking status and alcohol use, the prior value is overwritten. Obtaining monthly extracts of smoking status and alcohol use allowed the evaluation team to examine the recording of smoking and alcohol use over time.

In addition to the extraction of raw information (for example, patient age, systolic and diastolic blood pressure), Pen CS extraction software derives a range of indicators such as flags for multiple patient conditions, whether a patient condition is active, and whether a clinical observation or a pathology test has been completed. The software calculates the number of times that a clinician in the practice has used the practice clinical management system during a defined period. It also classifies prescription information into classes of medications.

Extracts from Northern Territory ACCHS clinics provided through Pen CS platform only include records belonging to HCH patients, while other extracts from other HCH practices provided through the Pen CS platform included all patients in the practice.

For the HCH evaluation, Pen CS extracts were transferred to a secure server managed by HPA. Data were processed to remove duplicate records across extracts and combined into longitudinal tables. The longitudinal tables were updated quarterly and transferred to the SURE environment for analysis.

#### POLAR extracts

The POLAR software, developed by Outcome Health, also extracts data from practice clinical management systems monthly. The software retrieves patient data that were recorded in the clinical management system within the extraction period. For example, if a patient had three visits to the practice within a data extraction period and had blood pressure measured and recorded during each visit, each of the three measurements would be included in the data extract. If a patient did not have any contact with the practice within the current extract interval, then no patient measurement records would be included. In the practice clinical management system, when the practice updates patient smoking status and alcohol use, the prior value is overwritten. Monthly extracts of information relating smoking status and alcohol consumption allowed the evaluation team to examine the recording of smoking and alcohol use over time.

In addition to the retrieval of raw information (for example, patient age, systolic and diastolic blood pressure), POLAR also derives variables, such as mapping of extracted patient diagnosis information to Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT). The SNOMED-CT coded textual descriptions are provided in the data extracts.

For the HCH evaluation, POLAR data were delivered monthly to South East Melbourne PHN, who then transferred the data directly into the SURE environment for analysis. Within the SURE environment, the monthly extracts were combined to create longitudinal tables.

#### Sonic extracts

Eleven HCH practices were part of Sonic Clinical Service’s Independent Practitioner Network. For these practices, information belonging to HCH patients was extracted directly from Best Practice clinical management system via a Structured Query Language query. Similar to POLAR data, patient information recorded in the clinical management system within the extraction period is extracted. For example, if a patient had three visits to the practice during the period and had blood pressure measured and recorded in each visit, each of the three measurements would be included in the data extract. If a patient did not have any contact with the practice within the current extract interval, no patient measurement records would be included. In clinical management system, when the practice updates patient smoking status and alcohol use, the prior value would be overwritten. Monthly extracts of smoking status and alcohol use allowed the evaluation team to examine the recording of smoking and alcohol use over time. Patient diagnoses were provided as a free-text field. The evaluation team created flags for specific patient conditions.

Sonic data for the HCH evaluation were delivered monthly to the secure data server managed by HPA before being transferred to the SURE environment.

#### MedicineInsight extracts

MedicineInsight software regularly extracts data from practice clinical management systems. The software retrieves patient data recorded in the clinical management system during the period of extraction. For example, if a patient had three visits to the practice during the period and had blood pressure measured and recorded in each visit, each of the three measurements would be included in the data extract. If a patient did not have any contact with the practice within the current extract interval, then no patient measurement records would be included. In the clinical management system, when the practice updates patient smoking status and alcohol use, the prior value may be overwritten. (While some clinical management systems are now retaining multiple recordings of these values, they are usually not extracted.) Patient smoking status and alcohol use in the latest MedicineInsight extract reflects the most recently recorded status (not necessarily the last time these were assessed).

In addition to the extraction of raw information (for example, patient age, systolic and diastolic blood pressure, diagnosis and diagnosis active status), MedicineInsight also derives a range of variables, such as multiple patient condition flags using patient diagnoses, reasons for prescription and reasons for encounter.

The initial MedicineInsight extract was delivered in September 2018. Subsequently, NPS MedicineWise advised that complete longitudinal data extracts, rather than quarterly updates, would facilitate the ability to follow through individual patients over time. In June 2019 a revised agreement between the Department and NPS MedicineWise was executed. The second extract was delivered in August 2019, covering the period December 2015 to June 2019 while the third extract was delivered in February 2020 for data in the December 2015 to January 2020. The final extract, delivered in August 2021, included data from December 2015 to end of June 2021.

### Description of patient information in practice extracts

For the HCH evaluation, practice extracts provided rich information about the patient and their receipt of care (Table 8). All four sources of extracts contained information about patient demographics, lifestyle factors, clinical encounters, diagnoses, clinical observations, results of pathology tests, prescriptions, and immunisations. Three data sources provided information about type of service providers (that is, user of clinical management system, with designation defined by and within the practice).

None of the sources extracted clinical information stored in scanned documents or PDF documents (for example specialist letters or hospital discharge summaries that may come in these formats).

Table 8: Patient information available for evaluation within each source of extracts

| **Information type** | **Source of practice data extracts1** | | | |
| --- | --- | --- | --- | --- |
| **Pen CS** | **POLAR** | **Sonic2** | **MedicineInsight** |
| Demographic information | √ | √ | √ | √ |
| Lifestyle factors | √ | √ | √ | √ |
| Clinical encounters | √ | √ | √ | √ |
| Service providers3 | √ | √ |  | √ |
| Diagnoses | √ | √ | √ | √ |
| Clinical observations | √ | √ | √ | √ |
| Pathology results | √ | √ | √ | √ |
| Prescriptions | √ | √ | √ | √ |
| Immunisations | √ | √ | √ | √ |
| MBS billing | √ | √ |  | √ |

Notes: 1 A tick indicates patient information is provided for the evaluation. 2 Sonic data relate to HCH patients only. 3Service providers are users of practice clinical management system, with designation defined by the practice.

To examine pre- and post-enrolment changes in evaluation outcomes, patient information recorded in the two years before practice enrolment (that is, a two-year lookback) was provided for the evaluation. Because the Pen CS extraction tool captures a snapshot for each patient, only the record for each patient with the date of service most recent to the first data extract was available for the evaluation. In the POLAR, Sonic and MedicineInsight extracts, all patient activities that took place in the lookback period were included.

The evaluation team examined the consistency of patient information between data sources and between practices. Where variation in data capture was observed (for example, when extracts from a practice did not include flags for HCH enrolees), clarification was sought from the data providers. It is recognised that several factors may contribute to completeness and quality of data extracts, including:

* Completeness and quality of data in the extractable fields of the source practice clinical management system.
* Version and compatibility of the practice clinical management and billing systems, and compatibility of the extraction software.
* Licence for clinical audit tools that may enable additional data to be extracted.
* Policies and methods or procedures of third party data providers in terms of data extraction, manipulation and provision.

**Patient demographics** included age and sex, concessional beneficiary status, and Aboriginal and Torres Strait Islander status. No personally identifiable information (for example, name, date of birth, postcode) was included in any of the data extracts. While Pen CS, POLAR and Sonic data were extracted for patients of all ages, MedicineInsight data provided for the evaluation were limited to patients aged 15 years and older (changes in evaluation outcomes in children were not in scope for the evaluation). Remoteness of practice geographical area was categorised according to the Australian Statistical Geography Standard Remoteness Area. Quintiles of the Index of Relative Socio-economic Disadvantage (IRSD) were mapped to practice geographical area.

**Lifestyle factors** included smoking status, alcohol consumption and physical activity. Smoking status reflected a person's current and past smoking behaviour. Alcohol consumption included amount of alcohol drinks per day and/or frequency of alcohol consumption per week. Sufficiency of physical activity (derived and provided by Pen CS extracts only) indicated whether the level of moderate or vigorous physical activity was sufficient to confer a health benefit.

Practice clinical management systems do not store historical information relating to these lifestyle factors, for example, when patient smoking status is updated, prior values will be overwritten. Data for most HCH practices were obtained monthly through Pen CS, POLAR and Sonic sources, thus enabling examination of changes in practice recording of smoking status over time. Meanwhile, smoking status in MedicineInsight data reflected the patient’s most recent smoking status (that is, cross-sectional).

**Clinical encounter**, in the general practice setting, refers to an interaction between a patient and the service. An encounter record can be generated when patients have a consultation with clinician.

**Service provider** refers to a user of clinical management system, with provider designation being defined by the practice. Pen CS software extracted only date of the most recent encounter (that is, snapshot of encounters in each extraction period) and calculated the number of encounters with a specified provider type within a specified timeframe (that is, number of GP encounters in the last 12 months, number of practice nurse encounters in the last six months). Meanwhile, the extracts provided by POLAR, Sonic and MedicineInsight included unit record data for each patient encounter, with information about date of the encounter, mode of encounter (for example, visit, consultation, telehealth, administrative purpose) together with provider types.

**Diagnoses** can be entered into the practice clinical management system in several ways. A clinician can select a relevant term from a medical classification taxonomy embedded in the clinical management system, such as “Docle” in Medical Director or “Pyefinch” in Best Practice. A clinician can also describe a patient’s diagnostic information in the free-text field in the diagnosis window, reason for visit, or reason for prescription. Diagnostic information may also be written in progress notes but these notes are not extracted as they may contain confidential information.

Pen CS software extracted patient diagnosis recorded in the clinical record window (for example, “Past History” screen in Best Practice, Medical Director). The extracted information was mapped to more than 80 condition categories according to Pen CS mapping guides.[[11]](#footnote-12) These mapped condition categories were provided for the evaluation.

In POLAR extracts, both classified and free-text descriptions of diagnosis were extracted and mapped to SNOMED-CT.[[12]](#footnote-13) Both free-text descriptions of diagnosis and text descriptions of SNOMED-CT concepts were provided for the evaluation.

In Sonic extracts, textual descriptions of patient diagnosis were provided.

MedicineInsight extracted both classified diagnoses (for example, those selected by clinicians through Docle or Pyefinch) and free-text fields (descriptions of diagnosis, reasons for encounter and reasons for prescription). This information was provided for the evaluation.

In addition to diagnosis text descriptions, all data extracts included a field indicating whether the diagnosis was flagged as active or inactive in the clinical management system alongside diagnosis onset date (that is, the date the diagnosed condition is thought to have commenced).

The evaluation team developed approaches to harmonise patient diagnosis data. The evaluation team reviewed health conditions included in the predictive risk model (PRM) that was part of the RST used by practices to identify eligible HCH patients. There are 19 PRM conditions for which Pen CS data have equivalent condition categories as presented in Appendix 2. Accordingly, the evaluation team developed methods to search for relevant textual description of these 19 diagnoses in POLAR, Sonic and MedicineInsight extracts (Appendix 3), informed by advice and documentation obtained from data providers.

**Clinical observations** refer to physiologic measurements at the time of the encounter such as blood pressure, heart rate, body height, body weight and waist circumference. There are also other assessments such as screening for cardiovascular and diabetes risk, hearing and vision. Pen CS derives 20 broad categories of clinical measurements, such as blood pressure, HbA1c glycated haemoglobin, albumin-creatinine ratio. Meanwhile, the POLAR, Sonic and MedicineInsight data included raw clinical measurement results as recorded in clinical management systems.

**Pathology results** include results of investigations such as blood sugar, HbA1c, cholesterol and estimated glomerular filtration rate. Pathology results may be transferred electronically from pathology labs or may be manually entered into the practice systems. Electronic pathology results received in atomised form (that is, predefined coded segments format) are generally compatible with data extraction software. Scanned or PDF copies of pathology reports were not extracted.[[13]](#footnote-14),[[14]](#footnote-15)

Textual description or labelling for a test may vary according to pathology methods and techniques. For example, a test for microalbumin creatine ratio (ACR) could be labelled, as reported by the lab, as “ACR”, “albumin/creatinine”, “albumin/creatine ratio (ACR)”, “%Albumin/Creat%” and other forms. Pen CS extraction software derives 26 broad categories of pathology test results (for example, microalbumin creatine ratio, spirometry). Meanwhile, POLAR, Sonic and MedicineInsight data included raw and extractable pathology results.

Units of measure for a test may also vary according to pathology techniques and clinical guidelines. Results of HbA1c tests could be expressed as %HbA1c according to National Glycohemoglobin Standardization Program (NGSP unit) or expressed as mmol/mol according to International Federation of Clinical Chemistry (IFCC unit). The evaluation team undertook data preparation to harmonise pathology records across sources. Values of HbA1c in IFCC units were converted to NGSP units using a recommended formula.[[15]](#footnote-16)

**Prescription data** provide information about a patient’s current or past medicines prescribed by a provider and/or scripts printed out from the practice system. Over-the-counter medicines and those prescribed by providers elsewhere are only included if manually entered into the practice system.[[16]](#footnote-17)

Within Pen CS extracts, medicines present in the patient’s current medication list are mapped into categories,[[17]](#footnote-18) such as “ACE inhibitors”, “beta blockers”, and sub-categories such as “beta-blockers antihypertensives” and “beta-blockers for myocardial infarction”. Since 2019, Pen CS has extracted medicine names (generic and brand names) from practices that use Medical Director, Best Practice or Zedmed.

The POLAR data provided for the evaluation contained only generic and brand names of prescribed medicines. Sonic extracts contained brand name, strength, dose, units of the medication and script date. MedicineInsight data included details of prescribed medicines, including names (generic and brand names), strength, dose, form, quantity, route of administration and number of repeats. MedicineInsight further map medicines to Anatomical Therapeutic Chemical (ATC) Classification systems and these ATC codes were also provided for the evaluation.

As the four data sources have different approaches to the extraction and presentation of prescription data, the evaluation team developed methods to identify whether a patient used diabetes medications, antithrombotic agents and medications for cardiovascular, nervous and respiratory systems. Methods to harmonize influenza vaccination data were also developed.

**MBS billing** data contain billing claims from the practice for services (MBS item number) provided to the patient. The process of extracting MBS billing data is supported when the practice uses integrated clinical and practice management software from the same vendor, and the billing system is compatible with the clinical management system. When a practice changed clinical and/or billing software, this could affect the completeness of billing data over time. Extracts provided by several Pen CS, POLAR and MedicineInsight practices for the evaluation did not contain MBS billing data for the entire time period.

All data collections contain unique IDs for the practice and unique IDs for the patient. Currently, it is not possible for the data extraction software to identify a patient who visited two or more practices.[[18]](#footnote-19) Neither it is possible to identify patients whose records were extracted by different software. Therefore, data for a patient were analysed within the practice and within the data source. For the HCH practices, however, based on practice name, it is possible to identify the practices whose data were extracted by two extraction tools (for example, by both Pen CS and MedicineInsight).

### Identifying HCH enrolees in practice extracts

The practice needed to flag HCH enrolled patients in their clinical management system to enable clinicians in the practice to identify the patients. The practice also needed to flag HCH patients in such a manner that allowed the flags to be extracted by the relevant extraction software.

Practices supplying data through Pen CS were instructed to record patient tier and withdrawal status in Topbar, a Pen CS clinical decision support system, or where the practice did not have Topbar, in CAT 4, a Pen CS clinical audit tool. Because date of patient enrolment was not recorded, the evaluators used date of the extract in which patient tier was first identified as a proxy for patient date of enrolment. During the course of the evaluation, the evaluation team monitored the recording of patient enrolment in data extracts and discussed these findings with the PHNs and Pen CS provider to improve the ascertainment of HCH patients.

Practices in South East Melbourne PHN were requested to follow Australian Association of Practice Management guidance on using the practice clinical management system for HCH recording and reporting.[[19]](#footnote-20) Preliminary analysis of the POLAR data found that patient enrolment flags were absent in extracts from several practices. The South East Melbourne PHN advised this might be due to practices flagging patients in MBS billing software (for example, Zedmed), which was incompatible with the extraction software, or practices using their own approaches so that flags were not extractable. The evaluation team and South East Melbourne PHN implemented two approaches to solve the issue. The first solution was to provide a template spreadsheet for practices to manually enter de-identified patient unique ID, the most recent patient tier and active/withdrawn enrolment status. This was only practical for practice with small number of enrolments. The second solution was that the evaluation team provided the practices with identifiers of enrolled patients to allow searches in their system. This was done via a secure portal managed by HPA. Efforts to identify HCH enrolments from POLAR extracts were disrupted due to the COVID-19 pandemic in Victoria in 2020. For the final evaluation report, patient enrolments (date of enrolment, tier but no withdrawal status) were identified in POLAR extracts from six practices.

Practices that were part of Sonic Clinical Service were also advised to follow Australian Association of Practice Management guidance on using the practice clinical management system for HCH recording and reporting.[[20]](#footnote-21) The Sonic data included date of enrolment, tier and withdrawal status.

MedicineInsight advised practices participating in the HCH trial to record patients’ risk tier in the patient diagnosis screen of the practice clinical management system using a specific text string.

To assess the accuracy of practice recording of HCH enrolments, the total number of HCH patients and risk tier identified in practice extracts were compared with the HCH registrations in the HPOS system. The HPOS data with information about patient age, sex, tier, dates of enrolment and withdrawal were provided quarterly for the evaluation by the Department of Health and Services Australia.

Throughout the evaluation, 151 practices provided data extracts. As presented in Table 9, flags identifying HCH enrolees were present in data for 117 practices (100 Pen CS, 6 POLAR and 11 Sonic) and absent in data for 34 practices (23 Pen CS and 11 POLAR). From the 117 practices with flags for identifying enrolled patients, 10,174 HCH patients were identified (9,065 Pen CS, 322 POLAR and 787 Sonic patients).

When the counts of HCH patients in the practice data were compared with HPOS registrations, 26 individual practices had matching counts. Forty-nine practices had fewer number of HCH patients identified from practice data than the HPOS registration, while 35 practices had more HCH patients identified from practice data.

Table 9: Number of HCH enrolees identified in practice extract data compared with HPOS registration

| **Measure** | **No. practices** | **Total no. patients identified** | |
| --- | --- | --- | --- |
| **In practice extracts** | **In HPOS registration** |
| **Presence of flags for HCH enrolees in practice extract data** | | | |
| Practice data not available for evaluation | 14 | Not applicable | 505 |
| Practice data with no flags for enrolees1 | 34 | Not applicable | 793 |
| Practice data with flags for HCH enrolees2 | 117 | 10,174 | 10,037 |
| **Number of HCH enrolees identified in practice extract data versus HPOS registration** | | | |
| Equal number of enrolees in each source | 26 | 1,318 | 1,318 |
| Fewer HCH enrolees in practice data |  |  |  |
| Between 1 and 9 enrolees | 42 | 3,183 | 3,315 |
| 10 or more enrolees | 7 | 911 | 1,095 |
| More HCH enrolees in practice data |  |  |  |
| Between 1 and 9 enrolees | 25 | 3,239 | 3,256 |
| 10 or more enrolees | 10 | 1,433 | 1,053 |

Notes: 1 Practice extract were provided for the evaluation but flags for identifying enrolees were absent (23 Pen CS and 11 POLAR practices). 2 These included 100 Pen CS practices (9,065 patients), 6 POLAR practices (322 patients) and 11 Sonic practices (787 patients).

Figure 2 shows cumulative numbers of HCH enrolees and Figure 3 shows number of patients in each tier recorded in data extracts of 117 practices that contained flags for HCH enrolees. The numbers were compared with patients registered in HPOS in the same 117 practices and in all 165 practices that enrolled patients in the HCH trial.

Figure 2: Cumulative number of HCH enrolees recorded in practice extracts versus HPOS registrations


Chart, Cumulative number of HCH enrolees recorded in practice extracts versus HPOS registrations



Notes: Patients without derived date/tier at enrolment were excluded.

Source: Practice extracts.

Figure 3: Number of patients in each tier recorded in practice extracts versus HPOS registrations



Notes: Patients without derived date/tier at enrolment were excluded.

Source: Practice extracts.

## Linked data

The Commonwealth and state and territory governments entered into *Bilateral Agreements on Coordinated Care*, which set out reforms to improve patient health outcomes and reduce avoidable demand for health services. The Commonwealth and states and territories also agreed to share data and develop a linked data set to contribute to the evidence base for improving primary care, including through the evaluation of initiatives set out in the Bilateral Agreements, such as HCH.

### Data collections

The Department of Health commissioned the AIHW to create the “Bilaterals” data set. This involved linking records across several Commonwealth and jurisdictional data collections, constructing a HCH project cohort and extracting data for individuals in the cohort. Data sets linked included the following:

* Medicare Enrolment (ME) database
* National Death Index (NDI)
* HCH enrolment
* Medical Benefit Schedules (MBS)
* Pharmaceutical Benefit Scheme (PBS)
* Admitted Patient Care
* Non-admitted Emergency Department (ED) Patient Care
* National Non-Admitted Patient Care (outpatient)
* National Aged Care Data Clearing House (NACDCH).

Following ethics approval, the evaluation team worked with the Department and the AIHW to agree on the number of non-HCH patients for which data would be obtained, from which to draw comparator patients. A sample of 100,000 patients from each PHN was settled on as the minimum required to evaluate HCH, except Victoria and South Australia who agreed to include every eligible individual living in the geographical areas covered by the PHN participating in HCH.

Table 10: Number of non-HCH individuals selected for linkage, by PHN

| **PHN name** | **Non-HCH individuals** |
| --- | --- |
| Adelaide | 1,032,395 |
| Country South Australia | 366,938 |
| South Eastern Melbourne | 1,300,129 |
| Brisbane North | 1,000,00 |
| Hunter New England and Central Coast | 99,149 |
| Nepean Blue Mountains | 100,000 |
| Western Sydney | 100,000 |
| Northern Territory1 | 89,459 |
| Perth North | 100,000 |
| Tasmania | 100,000 |
| **Total** | **3,388,070** |

Notes: 1 About 10,000 individuals selected for the PHN had an address in Queensland and were excluded.

Source: AIHW data linkage report in November 2010 for Project EO2017-5-321: Bilateral Agreements on Coordinated Care and Health Care Homes.

A propensity scoring approach was used to match HCH enrolees with similar patients (comparators). One of the challenges was stratifying HCH enrolees and comparators into risk groups. To do this, HPA obtained a license from Johns Hopkins University for the Adjusted Clinical Group® (ACG®) system.

An issue for the evaluation is that a limited period of follow-up data was available for the final evaluation. Table 11 shows the time coverage of each of the linked datasets provided for the evaluation. The October 2021 data drop was used for the final evaluation.

Table 11: Linked data provided for the evaluation

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Date of data drop** | **HCH patients** | **MBS/PBS data** | **Hospital data** | **Aged care** | **National Death Index** |
| October 2019 | Enrolled to 30 June 2019 | July 2015 – June 2017 | July 2015 – June 2017 | July 2015 – June 2017 | July 2015 – June 2018 |
| June 2021 | Enrolled to 30 June 2019 | July 2017 – June 2019 | July 2017 – June 2019 | July 2017 – June 2019 | July 2017 – June 2019 |
| October 2021 | Enrolled to 30 June 2019 | July 2019 – June 2021 | July 2019 – June 2020 | July 2019 – June 2020 | July 2019 – June 2021 |

### Data cleaning

Linked data records were checked for logical consistency between dates of services, for example date of hospital admission versus date of discharge, date of death versus date of service utilisation. There were 48,806 comparator patients who were died between December 2015 and October 2017, and thus were excluded from the evaluation. For 3,104 people (3,082 comparator patients and 22 HCH patients) there was inconsistency between the date of service use and date of death (for example, a hospital admission being after the date of death). These individuals were excluded from the evaluation as they may have had linkage errors. Among the HCH patients, 28 were enrolled after data linkage was completed and 126 other patients were under 16 years old These were not included in the analyses.

## HCH program data

The Department of Health maintained a database of participating practices that included geographic location, type of practice (that is, independent, corporately owned, or ACCHS), information technology systems used, and other characteristics to assess eligibility for the program. These data were provided for the evaluation.

The Department of Health also negotiated with Services Australia to regularly receive the following de-identified data related to the administration of HCH:

* Summary of enrolments by practice and risk tier. These data are derived from the HCH registrations in HPOS.
* Claims made by enrolled patients separate to the bundled payment from HCH and non-HCH practices (by MBS Item No.).
* Demographic and socio-economic characteristics of enrolled patients (HCH start and end dates, age, sex, SEIFA, concession card status).

These data were used for the evaluation.

3

1. Comparative analysis using propensity score matching

A propensity score matching technique was used to create cohorts of HCH patients and “comparator” patients. Because practice extracts and linked data were obtained and analysed independently, propensity score matching was performed separately for the patient cohorts identified through practice extracts and patient cohorts identified through linked data.

Broadly, propensity score matching aimed to identify comparator patients who were not participating in the HCH and who had similar characteristics to HCH patients in terms of demographic characteristics, health risk profile, utilisation of services and receipt of chronic disease management. These characteristics were derived retrospectively, in the same manner for both HCH patients and non-HCH comparator patients, based on episodes of care that preceded enrolment to the HCH trial.

The date of enrolment was recorded for HCH patients (that is, month and year of enrolment within linked data; date of enrolment as recorded in or estimated from practice extracts). For non-HCH patients, there was no date of enrolment. Therefore, for non-HCH patients, patient characteristics were measured at various “potential enrolment points”, defined pragmatically as the first day of each calendar month in the HCH recruitment period (October 2017 to July 2019). Hereafter, the period before a HCH patient’s date of enrolment and before the relevant “potential enrolment point” for a matched non-HCH comparator patient is referred to as “before enrolment” or “pre-enrolment”.

The propensity score was calculated using a logistic regression model, with HCH enrolment as the dependent variable and characteristics of the practice and individual patients as explanatory variables. HCH patients were matched with potential comparator patients based on their propensity score with a 1:1 ratio, using a greedy matching algorithm and a caliper of 0.25. Matching was undertaken for each month of HCH recruitment, using data from the corresponding “potential enrolment point” for potential comparators. Once a comparator patient was matched, they were removed from the pool of potential comparators for matching in future months of enrolment.

The variables used for matching within each data source differed slightly, according to the information available (further details below). Additional criteria for matching within the linked data required that HCH and potential comparator patients were living in the same PHN geographical catchment area. This ensured that the patient matching procedure was consistent with the framework for selection of non-HCH patients as per the approval from the AIHW HREC. Within the linked data, PHNs were not mapped for 800 HCH patients because the postcodes recorded in the Medicare Enrolment database were outside of the 10 PHN catchment areas. For these patients, the evaluation team mapped the patient to a PHN using the PHN associated with the GP provider as recorded in the MBS claims in the pre-enrolment period.

The SAS PSMATCH package[[21]](#footnote-22) was used for propensity score calculation and matching. Following the matching, absolute standardised differences were calculated in order to assess balance in characteristics of the matched cohort (balance is achieved if standardised difference <0.1).[[22]](#footnote-23) Results of the matching (Table 13 and Table 15) indicated that the matched HCH patients and comparator patients were well-balanced in all matching variables with absolute standardised differences being less than 0.01.

### Matching for patient cohorts identified through practice extracts

Records belonging to HCH patients were obtained through Pen CS, POLAR and Sonic extracts and records belonging to non-HCH patients were obtained through the latest MedicineInsight extracts. Information was harmonised across data sources before variables denoting characteristics of practices and individual patients were derived.

#### Definitions of practice and patient characteristics

Definitions and methods for deriving practice and patient characteristics are presented in Table 12. Practice characteristics included geographic remoteness and socio-economic disadvantage of the geographic area where the practice is located. Patient demographic factors included age at enrolment, sex, Indigenous status, and beneficiary status. Patient characteristics related to the health risk profile included specific health conditions, number of morbidities, and the prescription of classes of medication in the last 12 months. Patient characteristics related to access to health care providers included number of GP encounters within the practice. Patient characteristics related to processes of care included influenza vaccination, as well as recording of body weight, body height, blood pressure, lipid, HbA1c, and kidney function. Patient characteristics related to chronic disease control included values of blood pressure, HbA1c and estimated glomerular filtration rate (eGFR) tests.

Table 12: Description of practice and patient characteristics based on practice extracts

| **Characteristics** | **Definition and methods1** |
| --- | --- |
| **Practice characteristics** |  |
| Remoteness | Remoteness categories included major cities, inner regional, outer regional, remote or very remote Australia, according to Australian Statistical Geography Standard (ASGS) 2016 classification of Remoteness Areas.[[23]](#footnote-24) For HCH practices, remoteness categories were mapped according to Statistical Area Level 2 (SA2) of the practice location. For non-HCH practices, remoteness categories were obtained directly from MedicineInsight extracts where remoteness categories were mapped according to postcode of the practice location. |
| Index of Relative Socioeconomic Disadvantage (IRSD) quintiles | IRSD quintiles were derived based on IRSD deciles, with quintile 1 indicating the most disadvantage and quintile 5 indicating the least disadvantage status. For HCH practices, 2016 IRSD deciles ranking within Australia[[24]](#footnote-25) were mapped according to SA2 of the practice location. For non-HCH practices, 2016 IRSD deciles were obtained directly from MedicineInsight extracts where the 2016 deciles were mapped according to postcode of the practice location. |
| **Patient demographics** |  |
| Age | Age at time of enrolment (an integer number). |
| Sex | Male or female. |
| Aboriginal and/or Torres Strait Islander status | A patient was categorised as of Aboriginal and/or Torres Strait Islander origin if this was ever recorded in the extracts. For HCH patients, this was based on all extract records provided for the evaluation. For comparator patients, this was based on the latest extract provided in August 2021. |
| Beneficiary status | Beneficiary status was categorised as Department of Veterans’ Affairs (DVA), pension or health care card, or none of the above. For HCH patients, this was based on health care card status and DVA status recorded in the extract associated with time of enrolment. For comparator patients, this was based on the latest extract provided in August 2021, thus reflecting the most recent beneficiary status. |
| **Health risk profile** |  |
| Chronic health conditions | Nineteen individual health conditions were derived, including asthma, COPD, atrial fibrillation, coronary heart disease, stroke, congestive heart failure, osteoarthritis, osteoporosis, anxiety, depression, bipolar disorder, schizophrenia, dementia, cancer (any), high blood pressure, high cholesterol, diabetes type 1, diabetes type 2, and chronic kidney disease. These conditions must have been flagged as “active” in clinical management system and had date of onset was any time before enrolment. See Appendix 3 for further descriptions of the search for these diagnoses in POLAR, Sonic and MedicineInsight extracts.  These individual health conditions were grouped into respiratory (asthma or COPD), diabetes (type 1 or type 2), CVD (atrial fibrillation, coronary heart disease, stroke, congestive heart failure, high blood pressure and high cholesterol), joint/bone disorder (osteoarthritis or osteoporosis), mental health (anxiety, depression, bipolar disorder, schizophrenia), dementia, cancer and chronic kidney disease. |
| Number of morbidities | The number of the above-listed individual conditions identified for a patient, ranging from 0 to 19. Categorised as nil, one, 2 to 4, and 5 or more. |
| Use of medication for specific conditions | Medicines used were grouped into medications for diabetes, antithrombotic therapies, cardiovascular medications, medications for nervous system, and medications for respiratory system (see Appendix 4).  For both HCH and comparator patients, this was based on prescriptions for these medications with prescription date in the 12 months before enrolment. |
| **Use of health services** |  |
| Number of GP encounters in the six and 12 months before enrolment2 | For Pen CS extracts, this was based on Pen CS derived variables indicating the numbers of GP encounters in the last six and 12 months, respectively. For POLAR and MedicineInsight extracts, this was calculated as the number of patient encounters of any modality (for example, visit, surgery, telephone, non-visit) with GP/doctor providers where the date of the encounter was within six and 12 months before enrolment. For Sonic data, this was not estimated because type of provider was not available in Sonic extracts.  In instances where there were multiple encounters in one day with the same provider and same encounter modality, only one encounter was counted. |
| **Process of care** |  |
| Receipt of influenza vaccination in the 12 months before enrolment | This was based on presence of an immunisation record for influenza where date of service was in the 12 months before enrolment. |
| Recording of body weight in the 12 months before enrolment | This was based on presence of a body weight measurement with date of service in the 12 months before enrolment. |
| Ever recording of body height before enrolment | This was based on presence of body height measurement with date of service any time before enrolment, acknowledging that body height may not require regular updates. |
| Recording of lipid test in the six and 12 months before enrolment | This was based on presence of a lipid test (total cholesterol, HDL, LDL or triglycerides) with date of service in the six and 12 months before enrolment. |
| Recording of blood pressure in the six and 12 months before enrolment | This was based on presence of blood pressure with date of service in the six and 12 months before enrolment. |
| Recording of HbA1c test in the six and 12 months before enrolment2 | This was based on presence of HbA1c pathology test in patients with type 2 diabetes with date of service in the six and 12 months before enrolment. |
| Recording of kidney function3 test in the six and 12 months before enrolment | This was based on presence of either estimated glomerular filtration rate test (eGFR), serum creatinine, urinary creatinine or albumin-creatinine ratio test in patients with type 2 diabetes or cardiovascular disease, with date of service in the six and 12 months before enrolment. |
| **Chronic disease control** |  |
| Results of the most recent blood pressure measured in the six and 12 months before enrolment | This was based on presence of blood pressure measurements with date of service in the six and 12 months before enrolment; where there were multiple measurements in the respective periods, the most recent measurement was selected. Blood pressure reading was classified as ≤130/80 mmHg (that is, systolic pressure ≤130mmHg and diastolic pressure ≤80mmHg), greater than 130/30 (that is, systolic pressure >130mmHg or diastolic pressure >80mmHg). |
| Results of the most recent HbA1c2 measured in the six and 12 months before enrolment. | This was based on presence of HbA1c pathology tests in patients with type 2 diabetes, with date of service in the six and 12 months before enrolment; where there were multiple measurements in the respective periods, the most recent measurement was selected. HbA1c results were categorised as less than or equal to 7%, greater than 7% but less than or equal to 8%, greater than 8% but less than 10%, and greater than or equal to 10. |
| Result of the most recent eGFR3 in the six and 12 months prior | This was based on presence of eGFR tests in patients with type 2 diabetes or cardiovascular disease, with date of service in the six and 12 months before enrolment; where there were multiple eGFR measurements in the respective periods, the most recent measurement was selected  Results of eGFR were categorised as greater than or equal to 90, greater than or equal to 60 but less than 90, greater than or equal to 45 but less than 60, greater than or equal to 30 but less than 45, greater than or equal to 15 but less than 30, less than 15. |

Notes: 1 The six months and 12 months before enrolment were defined as a period from 1 day to 180 days and from 1 day to 365 days, respectively, before date of enrolment for HCH patients; before the first day of each calendar month between October 2017 and July 2019 for comparison patients. 2 Calculated in patients with type 2 diabetes. 3Calculated among patients with type 2 diabetes and/or CVDs.

#### Exclusion and inclusion criteria

A total of 10,174 HCH patients were identified through practice extracts that contained flags for HCH enrolees. Among those, 49 patients had records indicating “withdrawal” only, and information about date of enrolment was absent. Sex was not recorded for 38 patients and there were 118 HCH patients who were under 15 years of age. These patients were excluded from propensity score matching.

Extracts from non-HCH practices contain year of death, this information would be recorded only if a patient’s death was known to practice. For the purposes of propensity score matching, it was required that comparator patients were alive at the “potential enrolment points”, thus patients who died before or in the year of “potential enrolment” were excluded from propensity score matching procedures.

Three different cohorts were created using the practice extracts, corresponding to population groups required for evaluating different study outcomes. The first cohort included all HCH patients. The second cohort included patients with a diagnosis of type 2 diabetes. The third cohort included patients with a diagnosis of type 2 diabetes and/or cardiovascular disease.

The propensity score model for all HCH patients (that is, with any diagnosis) included all variables shown in Table 12, relating to demographic characterises, health risk profile, number of encounters with GPs, process of care and results of the most recent blood pressure. Models for patients with type 2 diabetes further included variables indicating recording of HbA1c tests and results of the most recent HbA1c test. Models for patients with type 2 diabetes and/or CVDs included the same sets of variables as the model for all patients, plus variables indicating recording of kidney function tests and results of the most recent eGFR test.

After propensity score matching, 9,811 (98.4%) HCH patients who had any diagnosis, 2,816 (92.1%) patients with type 2 diabetes, and 6,811 (95.5%) patients with type 2 diabetes and/or CVDs were matched to comparator patients (Figure 4). Most of the unmatched HCH patients came from a small number of practices and were enrolled in the second quarter of 2019.

Figure 4: Flowchart of propensity score matching for patient cohorts, using practice extracts

**Excluded**

* Under 15 years old (n=118)
* Sex not recorded (n=38)
* Enrolment date unknown (n=49)

**Patients in Health Care Homes**

10,174 patients of all ages  
identified in practice extracts

**Patients in comparison practices**1

3.49 million patients aged 15 years or older

Alive at potential enrolment point2

**Matched cohorts using propensity score** (1: 1 match)

All patients (any diagnosis): 9,811 HCH & 9,811 Comparators

Type 2 diabetes: 2,816 HCH & 2,816 Comparators

Type 2 diabetes and/or CVDs: 6,811 HCH & 6,811 Comparators

All patients (any diagnosis): 9,969 patients

Type 2 diabetes : 3,058 patients

Type 2 diabetes or CVDs: 7,135 patients

Notes: 1Practices not participating in the HCH program. 2The first day of each calendar month in the HCH trial period (October 2017 to July 2019) was assigned as a “potential enrolment point”. Pre-enrolment characteristics of comparator patients and propensity scores were calculated repeatedly at each “potential enrolment point”. MedicineInsight extracts contained year of death (if recorded in clinical management system); comparator patients who died before or in the year of “potential enrolment” were excluded from propensity score matching.

#### Descriptions of matched patient cohorts

Pre-enrolment characteristics of HCH and comparator patients before and after propensity score matching are presented in Table 13. Following propensity score matching, all pre-enrolment characteristics of HCH patients and comparators were well-balanced, with absolute standardised differences for all matching variables being less than 0.01. Patients with any diagnosis were balanced on demographic characteristics, health risk profile, number of GP encounters, process of care and blood pressure results. As presented in Table 13, among patients with type 2 diabetes, the recording of HbA1c and levels of HbA1c control in the pre-enrolment period was similar between HCH and matched comparators. In patients with type 2 diabetes and/or CVDs, HCH patients and comparators had similar pre-enrolment recording of kidney function and results of eGFR tests.

Table 13: Pre-enrolment characteristics of HCH & comparator patients derived from practice extracts, before & after propensity score matching

| **Pre-enrolment characteristics 1** | **Before matching – number (%) & standardised difference** | | | **After matching – number (%) & standardised difference** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **HCH**  **patients2**  **(n=9,969)** | **Potential comparator**  **patients3**  **(n=3,465,102)** | **Std Diff 4** | **HCH**  **patients2**  **(n=9,811)** | **Comparator patients3**  **(n=9,811)** | **Std Diff4** |
| **Demographic characteristics** | | | | | | |
| **Sex** | | | | | | |
| Female | 5,437 (54.5%) | 1,906,936 (55.0%) | 0.01 | 5,332 (54.3%) | 5,262 (53.6%) | 0.01 |
| Male | 4,532 (45.5%) | 1,558,166 (45.0%) | 0.01 | 4,479 (45.7%) | 4,549 (46.4%) | 0.01 |
| **Age (years)** | | | | | | |
| Mean (SD) | 62.6 (16.9) | 43.9 (19.1) | 1.04 | 62.8 (16.9) | 63.6 (16.9) | 0.05 |
| 15 to 44 | 1,503 (15.1%) | 1,846,254 (53.3%) | 0.88 | 1,469 (15.0%) | 1,301 (13.3%) | 0.05 |
| 45 to 64 | 3,320 (33.3%) | 978,524 (28.2%) | 0.11 | 3,227 (32.9%) | 3,196 (32.6%) | 0.01 |
| 65 to 74 | 2,471 (24.8%) | 353,875 (10.2%) | 0.39 | 2,454 (25.0%) | 2,461 (25.1%) | 0.00 |
| 75 to 84 | 1,977 (19.8%) | 176,274 (5.1%) | 0.46 | 1,967 (20.0%) | 2,089 (21.3%) | 0.03 |
| 85 and older | 698 (7.0%) | 67,925 (2.0%) | 0.25 | 694 (7.1%) | 764 (7.8%) | 0.03 |
| **Aboriginal and Torres Strait Islander** | | | | | | |
| Aboriginal | 1,535 (15.4%) | 71,676 (2.1%) | 0.49 | 1,379 (14.1%) | 1,316 (13.4%) | 0.02 |
| Non-Aboriginal | 7,627 (76.5%) | 2,573,981 (74.3%) | 0.05 | 7,625 (77.7%) | 7,741 (78.9%) | 0.03 |
| Not stated, unknown | 807 (8.1%) | 819,445 (23.6%) | 0.44 | 807 (8.2%) | 754 (7.7%) | 0.02 |
| **Beneficiary status** | | | | | | |
| Department of Veterans' Affairs | 52 (0.5%) | 8,361 (0.2%) | 0.05 | 52 (0.5%) | 47 (0.5%) | 0.01 |
| Pension or health care card | 6,291 (63.1%) | 917,020 (26.5%) | 0.79 | 6,290 (64.1%) | 6,591 (67.2%) | 0.06 |
| None of the above | 3,626 (36.4%) | 2,539,721 (73.3%) | 0.80 | 3,469 (35.4%) | 3,173 (32.3%) | 0.06 |
| **Practice remoteness** | | | | | | |
| Major cities | 6,575 (66.0%) | 2,340,113 (67.5%) | 0.03 | 6,573 (67.0%) | 6,701 (68.3%) | 0.03 |
| Inner regional | 1,316 (13.2%) | 774,134 (22.3%) | 0.24 | 1,316 (13.4%) | 1,340 (13.7%) | 0.01 |
| Outer region, remote, very remote | 2,078 (20.8%) | 350,855 (10.1%) | 0.30 | 1,922 (19.6%) | 1,770 (18.0%) | 0.04 |
| **Practice Index of Relative Socioeconomic Disadvantage quintile** | | | | | | |
| Quintile 1 (most disadvantaged) | 3,219 (32.3%) | 547,389 (15.8%) | 0.39 | 3,063 (31.2%) | 3,053 (31.1%) | 0.00 |
| Quintile 2 | 2,153 (21.6%) | 650,769 (18.8%) | 0.07 | 2,151 (21.9%) | 2,161 (22.0%) | 0.00 |
| Quintile 3 | 2,198 (22.0%) | 751,399 (21.7%) | 0.01 | 2,198 (22.4%) | 2,116 (21.6%) | 0.02 |
| Quintile 4 | 1,545 (15.5%) | 725,989 (21.0%) | 0.14 | 1,545 (15.7%) | 1,626 (16.6%) | 0.02 |
| Quintile 5 (least disadvantaged) | 854 (8.6%) | 789,556 (22.8%) | 0.4 | 854 (8.7%) | 855 (8.7%) | 0.00 |
| **Health risk profile** | | | | | | |
| **Health conditions** | | | | | | |
| Respiratory | 2,566 (25.7%) | 281,859 (8.1%) | 0.48 | 2,521 (25.7%) | 2,408 (24.5%) | 0.03 |
| Diabetes | 3,187 (32.0%) | 129,415 (3.7%) | 0.79 | 3,065 (31.2%) | 3,068 (31.3%) | 0.00 |
| Cardiovascular | 6,604 (66.2%) | 585,465 (16.9%) | 1.16 | 6,479 (66.0%) | 6,589 (67.2%) | 0.02 |
| Join or bone disorder | 3,224 (32.3%) | 237,023 (6.8%) | 0.68 | 3,207 (32.7%) | 3,268 (33.3%) | 0.01 |
| Mental health | 2,757 (27.7%) | 414,331 (12.0%) | 0.40 | 2,746 (28.0%) | 2,796 (28.5%) | 0.01 |
| Dementia | 178 (1.8%) | 9,775 (0.3%) | 0.15 | 175 (1.8%) | 194 (2.0%) | 0.01 |
| Cancer | 1,232 (12.4%) | 132,563 (3.8%) | 0.32 | 1,232 (12.6%) | 1,234 (12.6%) | 0.00 |
| Chronic renal disease | 1,314 (13.2%) | 25,485 (0.7%) | 0.50 | 1,165 (11.9%) | 1,056 (10.8%) | 0.04 |
| **Number of morbidities5** | | | | | | |
| Nil | 1,097 (11.0%) | 2,336,444 (67.4%) | 1.42 | 1,096 (11.2%) | 1,001 (10.2%) | 0.03 |
| One | 1,536 (15.4%) | 533,781 (15.4%) | 0.00 | 1,531 (15.6%) | 1,560 (15.9%) | 0.01 |
| 2 to 4 | 5,527 (55.4%) | 528,203 (15.2%) | 0.93 | 5,426 (55.3%) | 5,547 (56.5%) | 0.02 |
| 5 or more | 1,809 (18.1%) | 66,674 (1.9%) | 0.56 | 1,758 (17.9%) | 1,703 (17.4%) | 0.01 |
| **Use of medicine in 12 months prior** | | | | | | |
| Medicine for diabetes | 1,631 (16.4%) | 43,113 (1.2%) | 0.55 | 1,573 (16.0%) | 1,502 (15.3%) | 0.02 |
| Antithrombotic therapies | 1,335 (13.4%) | 52,230 (1.5%) | 0.46 | 1,283 (13.1%) | 1,259 (12.8%) | 0.01 |
| Medicine for cardiovascular disease | 3,496 (35.1%) | 156,227 (4.5%) | 0.83 | 3,444 (35.1%) | 3,408 (34.7%) | 0.01 |
| Medicine for nervous system | 3,215 (32.2%) | 287,530 (8.3%) | 0.62 | 3,210 (32.7%) | 3,272 (33.4%) | 0.01 |
| Medicine for respiratory system | 1,866 (18.7%) | 109,723 (3.2%) | 0.51 | 1,843 (18.8%) | 1,816 (18.5%) | 0.01 |
| **Use of health services** | | | | | | |
| **GP encounters in the six months pre-enrolment6** | | | | | | |
| Mean (Std) | 7.2 (5.2) | 1.4 (2.9) | 1.38 | 7.2 (5.2) | 7.0 (6.3) | 0.03 |
| None | 257 (3.1%) | 2,201,549 (63.5%) | 1.67 | 257 (3.1%) | 235 (2.8%) | 0.02 |
| 1 to 4 | 2,781 (33.4%) | 920,440 (26.6%) | 0.15 | 2,779 (33.4%) | 2,728 (32.8%) | 0.01 |
| 5 to 9 | 3,225 (38.7%) | 256,931 (7.4%) | 0.80 | 3,225 (38.7%) | 3,368 (40.5%) | 0.04 |
| 10 to 14 | 1,380 (16.6%) | 60,163 (1.7%) | 0.53 | 1,380 (16.6%) | 1,301 (15.6%) | 0.03 |
| 15 to 19 | 450 (5.4%) | 16,793 (0.5%) | 0.29 | 450 (5.4%) | 454 (5.5%) | 0.00 |
| 20 or more | 234 (2.8%) | 9,226 (0.3%) | 0.21 | 234 (2.8%) | 239 (2.9%) | 0.00 |
| **GP encounters in the 12 months pre-enrolment6** | | | | | | |
| Mean (Std) | 13.4 (9.9) | 2.6 (5.2) | 1.37 | 13.4 (9.9) | 13.3 (9.7) | 0.00 |
| None | 70 (0.8%) | 1,975,684 (57.0%) | 1.58 | 70 (0.8%) | 45 (0.5%) | 0.04 |
| 1 to 4 | 1,209 (14.5%) | 824,852 (23.8%) | 0.24 | 1,208 (14.5%) | 1,184 (14.2%) | 0.01 |
| 5 to 9 | 2,023 (24.3%) | 387,381 (11.2%) | 0.35 | 2,020 (24.3%) | 2,025 (24.3%) | 0.00 |
| 10 to 14 | 1,973 (23.7%) | 149,165 (4.3%) | 0.58 | 1,973 (23.7%) | 2,044 (24.6%) | 0.02 |
| 15 to 19 | 1,374 (16.5%) | 65,091 (1.9%) | 0.52 | 1,374 (16.5%) | 1,407 (16.9%) | 0.01 |
| 20 to 24 | 758 (9.1%) | 30,037 (0.9%) | 0.39 | 758 (9.1%) | 706 (8.5%) | 0.02 |
| 25 or more | 920 (11.0%) | 32,892 (0.9%) | 0.44 | 919 (11.1%) | 911 (11.0%) | 0.00 |
| **Process of care** | | | | | | |
| **In the six months pre-enrolment** | | | | | | |
| Lipid recorded7 | 5,626 (56.4%) | 343,760 (9.9%) | 1.14 | 5,558 (56.7%) | 5,658 (57.7%) | 0.02 |
| Blood pressure recorded | 7,491 (75.1%) | 678,621 (19.6%) | 1.34 | 7,486 (76.3%) | 7,580 (77.3%) | 0.02 |
| HbA1c recorded8 | 2,189 (71.6%) | 56,096 (47.8%) | 0.50 | 2,063 (73.3%) | 2,094 (74.4%) | 0.03 |
| Kidney function recorded9 | 5,120 (71.8%) | 231,900 (37.8%) | 0.73 | 4,925 (72.3%) | 4,941 (72.5%) | 0.01 |
| **In the 12 months pre-enrolment** | | | | | | |
| Influenza vaccination | 5,675 (56.9%) | 362,189 (10.5%) | 1.13 | 5,628 (57.4%) | 5,769 (58.8%) | 0.03 |
| Body height recorded10 | 8,421 (84.5%) | 1,030,966 (29.8%) | 1.33 | 8,329 (84.9%) | 8,353 (85.1%) | 0.01 |
| Body weight recorded | 7,324 (73.5%) | 504,693 (14.6%) | 1.47 | 7,282 (74.2%) | 7,296 (74.4%) | 0.00 |
| Lipid recorded | 7,498 (75.2%) | 573,080 (16.5%) | 1.46 | 7,408 (75.5%) | 7,473 (76.2%) | 0.02 |
| Blood pressure recorded8 | 8,260 (82.9%) | 941,139 (27.2%) | 1.35 | 8,254 (84.1%) | 8,353 (85.1%) | 0.03 |
| HbA1c recorded8 | 2,557 (83.6%) | 72,834 (62.0%) | 0.50 | 2,414 (85.7%) | 2,436 (86.5%) | 0.02 |
| Kidney function recorded 9 | 6,285 (88.1%) | 343,196 (56.0%) | 0.77 | 6,044 (88.7%) | 6,048 (88.8%) | 0.00 |
| **Chronic disease control** | | | | | | |
| **Most recent blood pressure, measured in the six months pre-enrolment** 8 | | | | | | |
| ≤130/80 mmHg | 989 (32.3%) | 23,565 (20.1%) | 0.28 | 953 (33.8%) | 932 (33.1%) | 0.02 |
| >130/80 mmHg | 1,475 (48.2%) | 45,488 (38.7%) | 0.19 | 1,425 (50.6%) | 1,478 (52.5%) | 0.04 |
| Not measured | 594 (19.4%) | 48,386 (41.2%) | 0.49 | 438 (15.6%) | 406 (14.4%) | 0.03 |
| **Most recent blood pressure, measured in the 12 months pre-enrolment** 8 | | | | | | |
| ≤130/80 mmHg | 1,054 (34.5%) | 28,143 (24.0%) | 0.23 | 1,017 (36.1%) | 1,005 (35.7%) | 0.01 |
| >130/80 mmHg | 1,561 (51.0%) | 53,076 (45.2%) | 0.12 | 1,510 (53.6%) | 1,554 (55.2%) | 0.03 |
| Not measured | 443 (14.5%) | 36,220 (30.8%) | 0.40 | 289 (10.3%) | 257 (9.1%) | 0.04 |
| **Most recent HbA1c, measured in the six months pre-enrolment** 8 | | | | | | |
| HbA1c ≤7% | 1,155 (37.8%) | 31,961 (27.2%) | 0.23 | 1,126 (40.0%) | 1,151 (40.9%) | 0.02 |
| 7% <HbA1c ≤8% | 513 (16.8%) | 13,125 (11.2%) | 0.16 | 492 (17.5%) | 474 (16.8%) | 0.02 |
| 8% <HbA1c <10% | 354 (11.6%) | 8,391 (7.1%) | 0.15 | 323 (11.5%) | 334 (11.9%) | 0.01 |
| HbA1c ≥10% | 167 (5.5%) | 2,619 (2.2%) | 0.17 | 122 (4.3%) | 135 (4.8%) | 0.02 |
| Not measured | 869 (28.4%) | 61,343 (52.2%) | 0.50 | 753 (26.7%) | 722 (25.6%) | 0.03 |
| **Most recent HbA1c, measured in the 12 months pre-enrolment** 8 | | | | | | |
| HbA1c ≤7% | 1,391 (45.5%) | 43,037 (36.6%) | 0.18 | 1,355 (48.1%) | 1,371 (48.7%) | 0.01 |
| 7% <HbA1c ≤8% | 572 (18.7%) | 16,180 (13.8%) | 0.13 | 550 (19.5%) | 534 (19.0%) | 0.01 |
| 8% <HbA1c <10% | 398 (13.0%) | 10,256 (8.7%) | 0.14 | 366 (13.0%) | 376 (13.4%) | 0.01 |
| HbA1c ≥10% | 196 (6.4%) | 3,361 (2.9%) | 0.17 | 143 (5.1%) | 155 (5.5%) | 0.02 |
| Not measured | 501 (16.4%) | 44,605 (38.0%) | 0.50 | 402 (14.3%) | 380 (13.5%) | 0.02 |
| **Most recent eGFR, measured in the six months pre-enrolment** 9 | | | | | | |
| eGFR ≥ 90 | 680 (9.5%) | 69,672 (11.4%) | 0.06 | 652 (9.6%) | 622 (9.1%) | 0.02 |
| 60 ≤ eGFR <90 | 2,409 (33.8%) | 112,594 (18.4%) | 0.36 | 2,377 (34.9%) | 2,428 (35.6%) | 0.02 |
| 45 ≤ eGFR <60 | 659 (9.2%) | 24,202 (3.9%) | 0.21 | 658 (9.7%) | 625 (9.2%) | 0.02 |
| 30 ≤ eGFR <45 | 338 (4.7%) | 11,223 (1.8%) | 0.16 | 336 (4.9%) | 308 (4.5%) | 0.02 |
| 15 ≤ eGFR <30 | 112 (1.6%) | 3,135 (0.5%) | 0.10 | 112 (1.6%) | 111 (1.6%) | 0.00 |
| eGFR <15 | 684 (9.6%) | 671 (0.1%) | 0.45 | 597 (8.8%) | 682 (10.0%) | 0.04 |
| Not measured | 2,253 (31.6%) | 391,554 (63.9%) | 0.68 | 2,079 (30.5%) | 2,035 (29.9%) | 0.01 |
| **Most recent eGFR, measured in the 12 months pre-enrolment** 9 | | | | | | |
| eGFR ≥ 90 | 904 (12.7%) | 107,008 (17.5%) | 0.13 | 857 (12.6%) | 817 (12.0%) | 0.02 |
| 60 ≤ eGFR <90 | 2,995 (42.0%) | 171,116 (27.9%) | 0.30 | 2,960 (43.5%) | 3,002 (44.1%) | 0.01 |
| 45 ≤ eGFR <60 | 799 (11.2%) | 34,075 (5.6%) | 0.20 | 796 (11.7%) | 747 (11.0%) | 0.02 |
| 30 ≤ eGFR <45 | 394 (5.5%) | 14,382 (2.3%) | 0.16 | 391 (5.7%) | 344 (5.1%) | 0.03 |
| 15 ≤ eGFR <30 | 122 (1.7%) | 3,746 (0.6%) | 0.10 | 122 (1.8%) | 119 (1.7%) | 0.00 |
| eGFR <15 | 865 (12.1%) | 802 (0.1%) | 0.52 | 756 (11.1%) | 867 (12.7%) | 0.05 |
| Not measured | 1,056 (14.8%) | 281,922 (46.0%) | 0.72 | 929 (13.6%) | 915 (13.4%) | 0.01 |

Notes: 1 See Table 12 for definition and methods relating pre-enrolment characteristics. 2Among HCH patients in both before-matching and after-matching samples, health risk profile, GP encounters, process of care and chronic disease control were calculated for the period before date of enrolment into the HCH program. 3Among comparison patients in the before-matching sample, health risk profile, GP encounters, process of care and chronic disease control were calculated for the period before October 2017; in the after-matching sample, these characteristics reflected the period before month/year when their matched HCH patients were enrolled in the HCH. 4Absolute standardised difference; two patient groups had similar characteristic (balanced) if absolute standardised difference is less than 0.1. **5**The number of individual conditions identified for a patient, ranging from 0 to 19 and includes asthma, COPD, type 1 diabetes, type 2 diabetes, atrial fibrillation, coronary heart disease, stroke, heart failure, hypertension, hyperlipidaemia, osteoarthritis, osteoporosis, anxiety, depression, bipolar, schizophrenia, dementia, cancer and chronic kidney disease. 6GP encounters were not calculated for HCH patients identified through Sonic extracts (provider type not available). 7Lipid test included total cholesterol, HDL, LDL or triglycerides. 8HbA1c recording, HbA1c results and blood pressure results were calculated among patients with type 2 diabetes. 9Kidney function recording (including eGFR, serum creatinine, urinary creatinine or albumin-creatinine ratio) and eGFR results were calculated among patients with type 2 diabetes and/or CVDs. 10Body height recorded any time before enrolment.

### Matching for patient cohorts identified through linked data

Linked data were delivered in stages, with the final delivery in October 2021. Records delivered across stages were combined to create a complete dataset.

#### Definitions of patient characteristics

Similar to practice extracts, linked data were used to derive patient demographic factors, health risk profile and access to primary care and other MBS-funded services in the period before enrolment. Pre-enrolment utilisation of hospital and aged care services was also ascertained. Demographic factors included age, sex, PBS beneficiary status, remoteness and IRSD quintiles of patient’s residential area. Health risk profile variables included morbidity diagnoses recorded in hospital admission data, use of medicines for specific conditions, and number of unique medicines dispensed. Utilisation of primary care and other health providers were measured in terms of numbers of claims for consultations with GPs, specialists, allied health providers and number of claims for any pathology test and any imaging service. Utilisation of hospital services included the numbers of hospital admissions (any cause, emergency reason, and potentially preventable conditions), total number of bed-days and total National Weighted Activity Units – a proxy for weighted intensity of hospital stay. Use of aged care services was classified as use of community-based services and residential care services. Definitions and detailed methods for deriving patient characteristics in the pre-enrolment period are presented in Table 14.

Table 14: Description of patient characteristics based on linked data

| **Characteristics** | **Definition and methodsa** |
| --- | --- |
| **Demographic factors** | |
| Age | Age at time of enrolment (an integer number). |
| Sex | Male or female. |
| Remoteness of residential location | Remoteness categories included major cities, inner regional, outer regional, remove or very remote Australia, according to Australian Statistical Geography Standard (ASGS) 2016 classification of Remoteness Areas.[[25]](#footnote-26) Remoteness categories were mapped to SA2 of patient’s residential areas. |
| Index of Relative Socioeconomic Disadvantage quintiles of residential area | IRSD quintiles were derived based on IRSD deciles, with quintile 1 indicating the most disadvantage and quintile 5 indicating the least disadvantage status. The 2016 IRSD deciles ranking within Australia[[26]](#footnote-27) were mapped to SA2 of patient’s residential areas. |
| PBS beneficiary status | Beneficiary status in the 12 months before enrolment was categorised as always concessional, ever general, and no dispensing. Among those with one or more PBS items dispensed in the pre-enrolment period, beneficiary status was categorised as “always concessional” if the patient’s entitlement status was recorded as “C0- Concessional Safety Net prescription” or “C1-Concessional non-Safety Net prescription” for all PBS items dispensed in this period, otherwise, “ever general”, which was equivalent to presence of one or more dispensed items where entitlement status was recorded as “G1-General Safety Net prescription” or “G2-General non-Safety Net prescription”. Patient entitlement status at the time the PBS item was supplied was recorded as per the AIHW METeOR identifier 604103.[[27]](#footnote-28) |
| **Health risk profile** | |
| Morbidity diagnoses recorded in hospital admissionsb | Patient morbidities included hypertension, cardiovascular diseases, digestive disorders, mental health, diabetes, chronic airway, joint or bone disorders, neurological disorder, cancer and chronic renal disease. These conditions were listed in the Risk Stratification Tool that practices used to identify patients suitable for enrolment in HCH and to assign patient tiers. These morbidities were identified from the principal diagnosis and four additional diagnosis fields (coded according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification [ICD-10-AM]) in hospital admissions that occurred in the 12 months before enrolment. The Johns Hopkins ACG System software-version 12.0[[28]](#footnote-29) the Charlson Comorbidity Index[[29]](#footnote-30),[[30]](#footnote-31) and previously reported methods[[31]](#footnote-32),[[32]](#footnote-33) were used to derive these morbidity conditions. The condition was assigned if it was flagged by any one of these methods. |
| Use of medications for specific health conditions in the 12 months before enrolment | Types of medication include medications for hyperlipidaemia, hypertension, cardiovascular diseases, pain relief, digestive disorders, mental health, diabetes, chronic airway, coagulation disorders, joint or bone disorders, inflammation, hypothyroidism, neurological disorder, cancer and chronic renal disease. These medicines (coded according to the Anatomical Therapeutic Chemical [ATC] classification system) were identified from PBS dispensing records where date of dispensing was in the 12 months before enrolment. The Johns Hopkins ACG System software-version 12.0[[33]](#footnote-34) and the Rx-Risk grouping methods[[34]](#footnote-35) were used to derive the use of these medications. The use of medications for specific health condition was assigned if it was flagged by any one of these methods. |
| Number of unique medicines dispensed | Number of unique medicines was measured as the total numbers of unique medicines dispensed in the three timeframes that is, 12 months, six months and three months before enrolment in order to account for seasonal fluctuations in medicine dispensing. Unique medicines were identified according to the fifth level of their ATC code, which represents the chemical substance of the medicine for example, A10AB04 is for insulin lispro, A10AB06 is for insulin glulisine. Each active component of a combination therapy was counted separately.[[35]](#footnote-36) |
| **Utilisation of primary care and other MBS-funded services** | |
| Number of MBS claims for GP and practice nurse attendance in the 12 months before enrolment. | The total number of MBS claims for GP and practice nurse attendances in the 12 months before enrolment were quantified. MBS items used to identify GP attendance were all items in Groups A1, A2, A5, A6, A7, A11, A14, A15 Subgroup 1, A12 Subgroup 2 (items 735-758), A17, A18, A19, A20, A22, A23, A23, A30.[[36]](#footnote-37) MBS items used to identify practice nurse attendance were all items in Groups M2, M12, and M14.[[37]](#footnote-38) |
| Number of MBS claims for specialist consultation in the 12 months before enrolment | The total number of MBS claims for consultations with specialist providers in the 12 months before enrolment was calculated. MBS items used to identify specialist consultations were all items in Groups A3, A4, A8, A9, A12, A13, A15 Subgroup 2 (only item 820-880) A16, A21, A24, A26, A28, A29, A32, and T6 Subgroup1.[[38]](#footnote-39) |
| Number of MBS claims for any allied health services in the 12 months before enrolment | The total number of MBS claims for any allied health services in the 12 months before enrolment was quantified. MBS items used to identify allied health services were all items in Groups M3, M6, M7, M8, M9, M10, M11, M15.[[39]](#footnote-40) |
| Number of MBS claims for any pathology services in the 12 months before enrolment | The total number of MBS claims for any pathology services in the 12 months before enrolment was quantified. MBS items used to identify pathology services were all items in Groups P01 to P09.[[40]](#footnote-41) |
| Had a MBS claim for HbA1c test in the six months and 12 months before enrolmentb | This was based on the presence of a MBS claim for HbA1c test (MBS items 66551 and 73840) in the six months and 12 months before enrolment. |
| Number of MBS claims for any imaging services in the 12 months before enrolment | The total number of MBS claims for any imaging services in the 12 months before enrolment was quantified. MBS items used to identify imaging services were all items in Groups I01 to I05.[[41]](#footnote-42) |
| Usual provider of care continuity of care score in the 12 months before enrolment | The usual provider of care index (UPC)[[42]](#footnote-43) was used to measure concentration or continuity of care with a usual GP provider in the 12 months before enrolment. For patients who had four or more unreferred GP claims (MBS items Groups A1 and A2), the UPC score was calculated as the number of claims for visits to the GP with the highest number of visits (“usual provider”) divided by the total number of claims for GP visits. |
| **Utilisation of hospital servicesc** | |
| All-cause admissions in the 12 months before enrolment | This was calculated as the total number of hospital admission episodes for any cause in the 12 months before enrolment, excluding renal dialysis (Z49 recorded as principal diagnosis) and transfers during hospital stay. |
| All-cause day-only admissions in the 12 months before enrolment | This was calculated as the total number of hospital admission episodes for any cause in the 12 months before enrolment when the patient was discharged on the same date as admission, excluding renal dialysis and transfers during hospital stay. |
| All-cause overnight-stay admissions in the 12 months before enrolment | This was calculated as the total number of hospital admission episodes for any cause in the 12 months before enrolment when date of discharge was subsequent to date of admission (that is, discharge not on the same date as admission). Renal dialysis and transfers during hospital stay were excluded. |
| All-cause emergency admission in the 12 months before enrolment | This was calculated as the total number of hospital admission episodes for any cause in the 12 months before enrolment where the urgency status of the admission was recorded as “emergency”. |
| Potentially preventable hospitalisations in the 12 months before enrolment | This was calculated as the total number of hospital admission episodes for potentially preventable conditions in in the 12 months before enrolment. Potentially preventable conditions were based on the definition used in the 2019 National Healthcare Agreement.[[43]](#footnote-44) |
| Number of bed-days in the 12 months before enrolment | This was calculated as the total number of hospital bed-days associated with hospital admissions for any cause in the 12 months before enrolment, excluding renal dialysis and transfers during hospital stay. |
| National Weighted Activity Units (NWAU) in the 12 months before enrolment | NWAUs associated with hospital admissions in the 12 months before enrolment were calculated, using a calculator developed by the Independent Hospital Pricing Authority for financial year 2018–19.[[44]](#footnote-45) |
| Number of emergency department (ED) presentations in the 12 months before enrolment | This was calculated as the total number of presentations to any hospital EDs for any reason based on presence of records in the non-admitted ED patient care data in the 12 months before enrolment. |
| **Use of aged care services** | |
| Use of aged care services in the 24 months before enrolment | Use of aged care services in the 24 months before enrolment was categorised as use of community-based services and residential care services. Use of community-based services was identified based on presence of a record in three data files: Home Care Package Period of Care, Home Care Package Period of Leave and Transitional Care Program. Meanwhile, use of residential care services was identified based on presence of a record in three data files: Residential Aged Care (RAC) Assessment, RAC Episode of Care and RAC Period of Leave. |

Notes: a The six months, 12 months and 24 months before enrolment were defined as a period from 1 day to 180 days, from 1 day to 365 days, and from 1 day to 730 days respectively, before date of enrolment for HCH patients; before the first day of each calendar month between October 2017 and July 2019 for comparison patients. b Calculated among patients with diabetes. c Calculated for patients from five states (NSW, Vic, Qld, SA and Tas).

#### Exclusion and inclusion criteria

There were 11,334 HCH enrolees in the HCH trial. Of those, 175 patients were not included in the propensity score matching process. These included 125 patients aged under 16 years, 28 patients who were enrolled after completion of the data linkage, and 22 patients with inconsistent dates in linked records (for example, dates of health service use recorded after date of death).

Two different cohorts were created using the linked data, corresponding to population groups required for evaluating different study outcomes. The first cohort included all HCH patients. The second cohort included patients with a diagnosis of diabetes only.

All variables denoting pre-enrolment characteristics of patients as shown in Table 14 were included in the propensity score models, although the variable on claims for HbA1c tests was only included in the matching for patients with diabetes.

Following propensity score matching, 10,682 HCH patients (with any diagnosis), and 3,198 HCH patients with a diagnosis of diabetes or who used medications for diabetes were matched with comparator patients (Figure 5). Most of the unmatched patients were enrolled in 2019, resided in Western Australia and Northern Territory, and had a residential area that was not mapped to an IRSD score.

Figure 5: Flowchart of linked data cleaning and propensity score matching for patient cohorts

**Excluded**

* Date inconsistency2 (n=22)
* Not linked3 (n=28)
* Age <16 years (n=125)

**Patients in Health Care Homes**

11,334 patients of all ages

**Non-HCH comparison patients in the same PHN**1

3.39 million patients aged 16 years or older

**Excluded**

* Deceased before Oct 2017 (n=48,806)
* Date inconsistency2 (n=3082)

**Matched cohorts using propensity score** (1: 1 match)

All patients (any diagnosis): 10,682 HCH & 10,682 Comparators

Patient with diabetes: 3,193 HCH & 3,193 Comparators

All patients (any diagnosis): 11,159 patients

Patient with diabetes4: 3,403 patients

Alive at potential enrolment point5

Notes: 1PHNs participate in the HCH. 2Date of health service use was subsequent to date of death. 3HCH patients enrolled after the data linkage was completed. 4Having a diagnosis of diabetes or used medication for diabetes. 5The first day of each calendar month in the HCH trial enrolment period (October 2017 to July 2019) was assigned as a “potential enrolment point”. Pre-enrolment characteristics of comparison patients and propensity scores were calculated repeatedly at each “potential enrolment point”. Comparison patients who died before “potential enrolment point” were not included in propensity score matching.

#### Descriptions of matched patient cohorts

Pre-enrolment characteristics of HCH and comparator patients before and after propensity score matching are presented in Table 15. Following propensity score matching, all pre-enrolment characteristics of HCH patients and comparators were well-balanced, with absolute standardised differences for all matching variables being less than 0.01. Patients with any diagnosis were balanced on demographic characteristics, health risk profile, use of MBS-funded services, number of hospital admission, and use of aged care services. Patients with diabetes were also balanced on these variables, as well as claims for HbA1c tests.

Table 15: Pre-enrolment characteristics of HCH and comparison patients derived from linked data, before and after propensity score matching

| **Pre-enrolment characteristics1** | **Before matching – number (%) & standardised difference** | | | **After matching – number (%) & standardised difference** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **HCH**  **Patients2**  **(n=11,159)** | **Potential comparator**  **patients3**  **(n=3,332,270)** | **Std Diff4** | **HCH**  **patients2**  **(n=10,682)** | **Comparator**  **patients3**  **(n=10,682)** | **Std Diff4** |
| **Demographic characteristics** | | | | | | |
| **Sex** | | | | | | |
| Female | 6,036 (54.1%) | 1,711,845 (51.4%) | 0.05 | 5,752 (53.8%) | 5,842 (54.7%) | 0.02 |
| Male | 5,123 (45.9%) | 1,620,425 (48.6%) | 0.05 | 4,930 (46.2%) | 4,840 (45.3%) | 0.02 |
| **Age (years)** | | | | | | |
| Mean (SD) | 62.8 (16.4) | 47.0 (18.9) | 0.89 | 63.3 (16.3) | 63.0 (16.4) | 0.02 |
| 16 to 44 | 1,585 (14.2%) | 1,595,008 (47.9%) | 0.78 | 1,441 (13.5%) | 1,424 (13.3%) | 0.00 |
| 45 to 64 | 3,802 (34.1%) | 1,061,026 (31.8%) | 0.05 | 3,554 (33.3%) | 3,610 (33.8%) | 0.01 |
| 65 to 74 | 2,870 (25.7%) | 381,664 (11.5%) | 0.37 | 2,815 (26.4%) | 2,809 (26.3%) | 0.00 |
| 75 to 84 | 2,172 (19.5%) | 205,199 (6.2%) | 0.41 | 2,149 (20.1%) | 2,131 (19.9%) | 0.00 |
| 85 and older | 730 (6.5%) | 89,373 (2.7%) | 0.18 | 723 (6.8%) | 708 (6.6%) | 0.01 |
| **PBS beneficiary status** | | | | | | |
| Ever general | 3,321 (29.8%) | 1,672,142 (50.2%) | 0.43 | 3,256 (30.5%) | 3,338 (31.2%) | 0.02 |
| Always concession | 6,852 (61.4%) | 818,753 (24.6%) | 0.80 | 6,732 (63.0%) | 6,657 (62.3%) | 0.01 |
| No dispensing in 12 months | 986 (8.8%) | 841,375 (25.2%) | 0.45 | 694 (6.5%) | 687 (6.4%) | 0.00 |
| **Remoteness of residential area** | | | | | | |
| Major cities | 7,206 (64.6%) | 2,628,990 (78.9%) | 0.32 | 7,171 (67.1%) | 7,074 (66.2%) | 0.02 |
| Inner regional | 1,582 (14.2%) | 346,417 (10.4%) | 0.12 | 1,572 (14.7%) | 1,838 (17.2%) | 0.07 |
| Outer region, remote, very remote | 1,999 (17.9%) | 338,400 (10.2%) | 0.22 | 1,939 (18.2%) | 1,770 (16.6%) | 0.04 |
| **Index of Relative Socioeconomic Disadvantage quintile of residential area** | | | | | | |
| Quintile 1 (most disadvantaged) | 3,111 (27.9%) | 615,657 (18.5%) | 0.22 | 2,784 (26.1%) | 3,064 (28.7%) | 0.06 |
| Quintile 2 | 2,705 (24.2%) | 615,132 (18.5%) | 0.14 | 2,678 (25.1%) | 2,669 (25.0%) | 0.00 |
| Quintile 3 | 2,664 (23.9%) | 632,325 (19.0%) | 0.12 | 2,602 (24.4%) | 2,523 (23.6%) | 0.02 |
| Quintile 4 | 1,579 (14.2%) | 740,385 (22.2%) | 0.21 | 1,575 (14.7%) | 1,400 (13.1%) | 0.05 |
| Quintile 5 (least disadvantaged) | 1,049 (9.4%) | 728,485 (21.9%) | 0.35 | 1,043 (9.8%) | 1,026 (9.6%) | 0.01 |
| **Health risk profile** | | | | | | |
| **Diagnoses in hospital admissions 5** | | | | | | |
| Hypertension | 244 (2.6%) | 17,471 (0.5%) | 0.17 | 241 (2.6%) | 258 (2.8%) | 0.01 |
| Cardiovascular diseases | 661 (7.2%) | 46,884 (1.4%) | 0.29 | 652 (7.1%) | 610 (6.7%) | 0.02 |
| Digestive disorders | 477 (5.2%) | 70,664 (2.1%) | 0.16 | 464 (5.1%) | 458 (5.0%) | 0.00 |
| Mental health | 648 (7.0%) | 85,664 (2.6%) | 0.21 | 615 (6.7%) | 609 (6.7%) | 0.00 |
| Diabetes | 1,074 (11.6%) | 54,272 (1.6%) | 0.41 | 1,061 (11.6%) | 971 (10.6%) | 0.03 |
| Chronic airway | 303 (3.3%) | 15,553 (0.5%) | 0.21 | 290 (3.2%) | 248 (2.7%) | 0.03 |
| Joint or bone disorders | 788 (8.5%) | 83,384 (2.5%) | 0.27 | 783 (8.6%) | 793 (8.7%) | 0.00 |
| Neurological disorder | 83 (0.9%) | 7,405 (0.2%) | 0.09 | 82 (0.9%) | 81 (0.9%) | 0.00 |
| Cancer | 197 (2.1%) | 20,118 (0.6%) | 0.13 | 197 (2.2%) | 182 (2.0%) | 0.01 |
| Chronic renal disease | 224 (2.4%) | 10,948 (0.3%) | 0.18 | 220 (2.4%) | 185 (2.0%) | 0.03 |
| **Use of medications for specific health conditions** | | | | | | |
| Hyperlipidaemia | 5,700 (51.1%) | 527,973 (15.8%) | 0.80 | 5,622 (52.6%) | 5,526 (51.7%) | 0.02 |
| Hypertension | 6,770 (60.7%) | 742,336 (22.3%) | 0.85 | 6,672 (62.5%) | 6,588 (61.7%) | 0.02 |
| Cardiovascular diseases | 5,251 (47.1%) | 526,761 (15.8%) | 0.71 | 5,170 (48.4%) | 5,010 (46.9%) | 0.03 |
| Pain relief | 5,219 (46.8%) | 809,974 (24.3%) | 0.48 | 5,154 (48.2%) | 5,109 (47.8%) | 0.01 |
| Digestive disorders | 4,770 (42.7%) | 573,118 (17.2%) | 0.58 | 4,695 (44.0%) | 4,701 (44.0%) | 0.00 |
| Mental health | 4,546 (40.7%) | 625,553 (18.8%) | 0.49 | 4,462 (41.8%) | 4,370 (40.9%) | 0.02 |
| Diabetes | 3,248 (29.1%) | 206,703 (6.2%) | 0.63 | 3,195 (29.9%) | 3,112 (29.1%) | 0.02 |
| Chronic airway | 2,994 (26.8%) | 386,797 (11.6%) | 0.39 | 2,946 (27.6%) | 2,856 (26.7%) | 0.02 |
| Coagulation disorders | 2,518 (22.6%) | 207,024 (6.2%) | 0.48 | 2,463 (23.1%) | 2,323 (21.7%) | 0.03 |
| Joint or bone disorders | 1,803 (16.2%) | 149,891 (4.5%) | 0.39 | 1,786 (16.7%) | 1,902 (17.8%) | 0.03 |
| Inflammation | 2,373 (21.3%) | 279,241 (8.4%) | 0.37 | 2,342 (21.9%) | 2,188 (20.5%) | 0.04 |
| Hypothyroidism | 1,224 (11.0%) | 141,020 (4.2%) | 0.26 | 1,210 (11.3%) | 1,259 (11.8%) | 0.01 |
| Neurological disorder | 1,027 (9.2%) | 89,474 (2.7%) | 0.28 | 985 (9.2%) | 938 (8.8%) | 0.02 |
| Cancer | 673 (6.0%) | 65,328 (2.0%) | 0.21 | 665 (6.2%) | 658 (6.2%) | 0.00 |
| Chronic renal disease | 301 (2.7%) | 15,776 (0.5%) | 0.18 | 288 (2.7%) | 253 (2.4%) | 0.02 |
| **Number of unique medicines in 12 months** | | | | | | |
| Mean (Std) | 9.0 (6.4) | 4.0 (4.8) | 0.88 | 9.2 (6.3) | 9.2 (6.5) | 0.00 |
| None | 986 (8.8%) | 840,732 (25.2%) | 0.45 | 692 (6.5%) | 687 (6.4%) | 0.00 |
| 1 to 4 | 1,947 (17.4%) | 1,424,937 (42.8%) | 0.57 | 1,892 (17.7%) | 1,916 (17.9%) | 0.01 |
| 5 to 9 | 3,683 (33.0%) | 685,010 (20.6%) | 0.28 | 3,613 (33.8%) | 3,737 (35.0%) | 0.02 |
| 10 to 14 | 2,552 (22.9%) | 240,691 (7.2%) | 0.45 | 2,520 (23.6%) | 2,466 (23.1%) | 0.01 |
| 15 or more | 1,991 (17.8%) | 140,900 (4.2%) | 0.45 | 1,965 (18.4%) | 1,876 (17.6%) | 0.02 |
| **Number of unique medicines in six months** | | | | | | |
| Mean (Std) | 7.1 (5.3) | 2.9 (3.8) | 0.90 | 7.3 (5.2) | 7.1 (5.3) | 0.02 |
| None | 1,193 (10.7%) | 1,165,140 (35.0%) | 0.60 | 880 (8.2%) | 852 (8.0%) | 0.01 |
| 1 to 4 | 2,793 (25.0%) | 1,400,699 (42.0%) | 0.37 | 2,731 (25.6%) | 2,868 (26.8%) | 0.03 |
| 5 to 9 | 4,050 (36.3%) | 539,291 (16.2%) | 0.47 | 3,990 (37.4%) | 4,058 (38.0%) | 0.01 |
| 10 to 14 | 2,096 (18.8%) | 160,872 (4.8%) | 0.44 | 2,070 (19.4%) | 1,997 (18.7%) | 0.02 |
| 15 or more | 1,027 (9.2%) | 66,268 (2.0%) | 0.32 | 1,011 (9.5%) | 907 (8.5%) | 0.03 |
| **Number of unique medicines in three months** | | | | | | |
| Mean (Std) | 5.7 (4.5) | 2.2 (3.2) | 0.90 | 5.8 (4.4) | 5.7 (4.4) | 0.03 |
| None | 1,468 (13.2%) | 1,470,159 (44.1%) | 0.73 | 1,141 (10.7%) | 1,123 (10.5%) | 0.01 |
| 1 to 4 | 3,599 (32.3%) | 1,302,082 (39.1%) | 0.14 | 3,530 (33.0%) | 3,672 (34.4%) | 0.03 |
| 5 to 9 | 4,096 (36.7%) | 422,964 (12.7%) | 0.58 | 4,046 (37.9%) | 4,071 (38.1%) | 0.00 |
| 10 to 14 | 1,521 (13.6%) | 105,309 (3.2%) | 0.38 | 1,496 (14.0%) | 1,383 (12.9%) | 0.03 |
| 15 or more | 475 (4.3%) | 31,756 (1.0%) | 0.21 | 469 (4.4%) | 433 (4.1%) | 0.02 |
| **Utilisation of MBS-funded services** | | | | | | |
| **Number of MBS claims for GP and practice nurse attendance** | | | | | | |
| Mean (Std) | 15.0 (10.0) | 6.6 (7.1) | 0.97 | 15.0 (9.9) | 14.8 (9.9) | 0.01 |
| None | 56 (0.5%) | 350,501 (10.5%) | 0.45 | 47 (0.4%) | 39 (0.4%) | 0.01 |
| 1 to 3 | 483 (4.3%) | 990,382 (29.7%) | 0.72 | 444 (4.2%) | 379 (3.5%) | 0.03 |
| 4 to 6 | 1,256 (11.3%) | 760,038 (22.8%) | 0.31 | 1,187 (11.1%) | 1,177 (11.0%) | 0.00 |
| 7 to 9 | 1,700 (15.2%) | 470,181 (14.1%) | 0.03 | 1,616 (15.1%) | 1,706 (16.0%) | 0.02 |
| 10 to 14 | 2,852 (25.6%) | 407,905 (12.2%) | 0.35 | 2,767 (25.9%) | 2,849 (26.7%) | 0.02 |
| 15 or more | 4,812 (43.1%) | 353,263 (10.6%) | 0.79 | 4,621 (43.3%) | 4,532 (42.4%) | 0.02 |
| **Number of MBS claims for specialist consultations** | | | | | | |
| Mean (Std) | 3.3 (6.7) | 1.5 (4.7) | 0.30 | 3.4 (6.8) | 3.3 (6.6) | 0.01 |
| None | 4,492 (40.3%) | 2,118,987 (63.6%) | 0.48 | 4,141 (38.8%) | 4,142 (38.8%) | 0.00 |
| 1 to 3 | 3,529 (31.6%) | 793,483 (23.8%) | 0.18 | 3,430 (32.1%) | 3,446 (32.3%) | 0.00 |
| 4 to 6 | 1,522 (13.6%) | 229,462 (6.9%) | 0.22 | 1,509 (14.1%) | 1,505 (14.1%) | 0.00 |
| 7 to 9 | 673 (6.0%) | 85,320 (2.6%) | 0.17 | 666 (6.2%) | 663 (6.2%) | 0.00 |
| 10 to 14 | 510 (4.6%) | 54,776 (1.6%) | 0.17 | 509 (4.8%) | 520 (4.9%) | 0.00 |
| 15 or more | 433 (3.9%) | 50,242 (1.5%) | 0.15 | 427 (4.0%) | 406 (3.8%) | 0.01 |
| **Number of MBS claims for any allied health services** | | | | | | |
| Mean (Std) | 2.0 (2.7) | 0.6 (1.8) | 0.60 | 2.1 (2.7) | 1.9 (2.7) | 0.04 |
| None | 5,689 (51.0%) | 2,833,684 (85.0%) | 0.78 | 5,326 (49.9%) | 5,524 (51.7%) | 0.04 |
| 1 to 3 | 2,308 (20.7%) | 224,342 (6.7%) | 0.41 | 2,238 (21.0%) | 2,280 (21.3%) | 0.01 |
| 4 to 6 | 2,625 (23.5%) | 209,790 (6.3%) | 0.50 | 2,594 (24.3%) | 2,357 (22.1%) | 0.05 |
| 7 to 9 | 295 (2.6%) | 37,627 (1.1%) | 0.11 | 290 (2.7%) | 287 (2.7%) | 0.00 |
| 10 to 14 | 212 (1.9%) | 22,945 (0.7%) | 0.11 | 205 (1.9%) | 211 (2.0%) | 0.00 |
| 15 or more | 30 (0.3%) | 3,882 (0.1%) | 0.03 | 29 (0.3%) | 23 (0.2%) | 0.01 |
| **Number of MBS claims for any pathology services** | | | | | | |
| Mean (Std) | 11.1 (13.5) | 4.6 (8.5) | 0.58 | 11.0 (13.1) | 10.9 (12.8) | 0.01 |
| None | 745 (6.7%) | 1,180,488 (35.4%) | 0.75 | 714 (6.7%) | 703 (6.6%) | 0.00 |
| 1 to 3 | 1,616 (14.5%) | 846,451 (25.4%) | 0.28 | 1,573 (14.7%) | 1,533 (14.4%) | 0.01 |
| 4 to 6 | 2,324 (20.8%) | 581,319 (17.4%) | 0.09 | 2,258 (21.1%) | 2,285 (21.4%) | 0.01 |
| 7 to 9 | 2,030 (18.2%) | 294,220 (8.8%) | 0.28 | 1,948 (18.2%) | 1,996 (18.7%) | 0.01 |
| 10 to 14 | 1,997 (17.9%) | 218,216 (6.5%) | 0.35 | 1,892 (17.7%) | 1,930 (18.1%) | 0.01 |
| 15 or more | 2,447 (21.9%) | 211,576 (6.3%) | 0.46 | 2,297 (21.5%) | 2,235 (20.9%) | 0.01 |
| **Had a claim for HbA1c test 6** | | | | | | |
| In the six months pre-enrolment | 1,291 (37.9%) | 64,426 (29.6%) | 0.18 | 1,201 (37.6%) | 1,213 (38.0%) | 0.01 |
| In the 12 months pre-enrolment | 1,854 (54.5%) | 103,982 (47.8%) | 0.13 | 1,732 (54.2%) | 1,716 (53.7%) | 0.01 |
| **Number of MBS claims for any imaging services** | | | | | | |
| Mean (Std) | 2.6 (3.5) | 1.2 (2.2) | 0.47 | 2.6 (3.5) | 2.6 (3.5) | 0.01 |
| None | 3,788 (33.9%) | 1,915,051 (57.5%) | 0.49 | 3,521 (33.0%) | 3,451 (32.3%) | 0.01 |
| 1 to 3 | 4,437 (39.8%) | 1,066,218 (32.0%) | 0.16 | 4,280 (40.1%) | 4,352 (40.7%) | 0.01 |
| 4 to 6 | 1,777 (15.9%) | 246,026 (7.4%) | 0.27 | 1,739 (16.3%) | 1,716 (16.1%) | 0.01 |
| 7 to 9 | 694 (6.2%) | 66,886 (2.0%) | 0.21 | 684 (6.4%) | 689 (6.5%) | 0.00 |
| 10 to 14 | 330 (3.0%) | 28,532 (0.9%) | 0.15 | 330 (3.1%) | 334 (3.1%) | 0.00 |
| 15 or more | 133 (1.2%) | 9,557 (0.3%) | 0.11 | 128 (1.2%) | 140 (1.3%) | 0.01 |
| **Usual provider score (UPC) continuity of care** | | | | | | |
| No GP visit | 150 (1.3%) | 435,376 (13.1%) | 0.47 | 116 (1.1%) | 108 (1.0%) | 0.01 |
| 1 to 3 visits | 1,463 (13.1%) | 1,137,073 (34.1%) | 0.51 | 1,327 (12.4%) | 1,257 (11.8%) | 0.02 |
| Low continuity (0<UPC<0.75) | 5,216 (46.7%) | 1,048,198 (31.5%) | 0.32 | 4,964 (46.5%) | 4,880 (45.7%) | 0.02 |
| High continuity (0.75≤UPC<1) | 2,841 (25.5%) | 424,328 (12.7%) | 0.33 | 2,803 (26.2%) | 2,869 (26.9%) | 0.01 |
| Perfect continuity (UPC=1) | 1,489 (13.3%) | 287,295 (8.6%) | 0.15 | 1,472 (13.8%) | 1,568 (14.7%) | 0.03 |
| **Utilisation of hospital services 5** | | | | | | |
| **All-cause admissions 5** | | | | | | |
| Mean (Std) | 0.5 (1.5) | 0.2 (1.0) | 0.23 | 0.5 (1.4) | 0.5 (1.6) | 0.01 |
| None | 6,706 (72.7%) | 2,674,230 (80.3%) | 0.18 | 6,639 (72.8%) | 6,620 (72.6%) | 0.00 |
| 1 or 2 | 2,048 (22.2%) | 408,355 (12.3%) | 0.27 | 2,029 (22.2%) | 2,032 (22.3%) | 0.00 |
| 3 or 4 | 319 (3.5%) | 42,547 (1.3%) | 0.14 | 315 (3.5%) | 329 (3.6%) | 0.01 |
| 5 or more | 152 (1.6%) | 19,895 (0.6%) | 0.10 | 137 (1.5%) | 139 (1.5%) | 0.00 |
| **All-cause day-only admissions 5** | | | | | | |
| Mean (Std) | 0.2 (1.0) | 0.1 (0.8) | 0.10 | 0.2 (0.9) | 0.2 (1.3) | 0.01 |
| None | 7,990 (86.6%) | 2,874,744 (86.3%) | 0.01 | 7,904 (86.7%) | 7,916 (86.8%) | 0.00 |
| 1 or 2 | 1,106 (12.0%) | 248,672 (7.5%) | 0.15 | 1,093 (12.0%) | 1,067 (11.7%) | 0.01 |
| 3 or 4 | 87 (0.9%) | 12,409 (0.4%) | 0.07 | 83 (0.9%) | 94 (1.0%) | 0.01 |
| 5 or more | 42 (0.5%) | 9,202 (0.3%) | 0.03 | 40 (0.4%) | 43 (0.5%) | 0.00 |
| **All-cause overnight stay admissions 5** | | | | | | |
| Mean (Std) | 0.3 (0.9) | 0.1 (0.5) | 0.27 | 0.3 (0.8) | 0.3 (0.8) | 0.00 |
| None | 7,445 (80.7%) | 2,870,415 (86.1%) | 0.15 | 7,373 (80.8%) | 7,339 (80.5%) | 0.01 |
| 1 or 2 | 1,538 (16.7%) | 251,080 (7.5%) | 0.28 | 1,519 (16.7%) | 1,568 (17.2%) | 0.01 |
| 3 or 4 | 180 (2.0%) | 18,593 (0.6%) | 0.13 | 177 (1.9%) | 171 (1.9%) | 0.00 |
| 5 or more | 62 (0.7%) | 4,939 (0.1%) | 0.08 | 51 (0.6%) | 42 (0.5%) | 0.01 |
| **Emergency admission 5** | | | | | | |
| Mean (Std) | 0.3 (1.0) | 0.1 (0.5) | 0.26 | 0.3 (0.9) | 0.3 (0.8) | 0.02 |
| None | 7,528 (81.6%) | 2,900,823 (87.1%) | 0.15 | 7,455 (81.7%) | 7,456 (81.8%) | 0.00 |
| 1 or 2 | 1,426 (15.5%) | 217,798 (6.5%) | 0.29 | 1,412 (15.5%) | 1,455 (16.0%) | 0.01 |
| 3 or 4 | 194 (2.1%) | 19,901 (0.6%) | 0.13 | 190 (2.1%) | 161 (1.8%) | 0.02 |
| 5 or more | 77 (0.8%) | 6,505 (0.2%) | 0.09 | 63 (0.7%) | 48 (0.5%) | 0.02 |
| **Potentially preventable hospitalisations 5** | | | | | | |
| Mean (Std) | 0.1 (0.5) | 0.0 (0.2) | 0.16 | 0.1 (0.4) | 0.1 (0.3) | 0.03 |
| None | 8,706 (94.4%) | 3,090,810 (92.8%) | 0.07 | 8,620 (94.5%) | 8,695 (95.3%) | 0.04 |
| 1 or 2 | 456 (4.9%) | 50,678 (1.5%) | 0.19 | 453 (5.0%) | 383 (4.2%) | 0.04 |
| 3 or more | 49 (0.5%) | 2,763 (0.1%) | 0.08 | 47 (0.5%) | 42 (0.5%) | 0.01 |
| **Total number of bed-days 5** | | | | | | |
| Mean (Std) | 2.3 (9.5) | 0.8 (6.2) | 0.18 | 1.9 (2.0) | 1.9 (2.6) | 0.02 |
| No admission | 6,706 (72.7%) | 2,674,230 (80.3%) | 0.18 | 6,639 (72.8%) | 6,620 (72.6%) | 0.00 |
| 1 to 9 days | 1,979 (21.5%) | 410,046 (12.3%) | 0.25 | 1,956 (21.4%) | 1,994 (21.9%) | 0.01 |
| 10 to 19 days | 275 (3.0%) | 29,470 (0.9%) | 0.15 | 272 (3.0%) | 273 (3.0%) | 0.00 |
| 20 to 29 days | 97 (1.1%) | 12,219 (0.4%) | 0.08 | 97 (1.1%) | 94 (1.0%) | 0.00 |
| 30 days or more | 168 (1.8%) | 19,062 (0.6%) | 0.12 | 156 (1.7%) | 139 (1.5%) | 0.01 |
| **Total National Weighted Activity Units (NWAU) 5** | | | | | | |
| Mean (Std) | 0.8 (2.7) | 0.3 (1.6) | 0.22 | 0.8 (2.5) | 0.7 (2.4) | 0.02 |
| Quintile 1 (0 <NWAU≤0.34) | 375 (4.1%) | 86,998 (2.6%) | 0.08 | 370 (4.1%) | 355 (3.9%) | 0.01 |
| Quintile 2 (0.34<NWAU≤0.78) | 503 (5.5%) | 107,522 (3.2%) | 0.11 | 500 (5.5%) | 490 (5.4%) | 0.00 |
| Quintile 3 (0.78<NWAU≤1.36) | 438 (4.7%) | 100,730 (3.0%) | 0.09 | 435 (4.8%) | 472 (5.2%) | 0.02 |
| Quintile 4 (1.36<NWAU≤2.83) | 472 (5.1%) | 93,906 (2.8%) | 0.12 | 468 (5.1%) | 487 (5.3%) | 0.01 |
| Quintile 5 (2.83<NWAU) | 726 (7.9%) | 81,447 (2.4%) | 0.25 | 708 (7.8%) | 696 (7.6%) | 0.00 |
| No admission | 6,711 (72.7%) | 2,674,230 (80.3%) | 0.18 | 6,639 (72.8%) | 6,620 (72.6%) | 0.00 |
| **Presentations to ED 5** | | | | | | |
| Mean (Std) | 0.6 (1.7) | 0.2 (0.9) | 0.25 | 0.6 (1.5) | 0.5 (1.4) | 0.01 |
| No ED visit | 6,636 (71.9%) | 2,659,451 (79.8%) | 0.18 | 6,577 (72.1%) | 6,515 (71.4%) | 0.02 |
| 1 or 2 | 2,042 (22.1%) | 420,737 (12.6%) | 0.25 | 2,016 (22.1%) | 2,120 (23.2%) | 0.03 |
| 3 or 4 | 362 (3.9%) | 46,784 (1.4%) | 0.16 | 358 (3.9%) | 336 (3.7%) | 0.01 |
| 5 or more | 185 (2.0%) | 18,055 (0.5%) | 0.13 | 169 (1.9%) | 149 (1.6%) | 0.02 |
| **Use of aged care services in 24 months** | | | | | | |
| Community based services | 250 (2.2%) | 15,193 (0.5%) | 0.16 | 234 (2.2%) | 240 (2.2%) | 0.00 |
| Residential care services | 107 (1.0%) | 29,964 (0.9%) | 0.01 | 103 (1.0%) | 85 (0.8%) | 0.02 |

Notes: 1See Table 14 for definition and methods relating pre-enrolment characteristics. 2Among HCH patients in both before-matching and after-matching samples, pre-enrolment characteristics were calculated for the respective period before enrolment into the HCH program. 3 Among comparison patients in the before-matching sample, pre-enrolment characteristics were calculated for the respective period before October 2017; in the after-matching sample, these characteristics reflected the period before month/year when their matched HCH patients were enrolled in HCH. 4 Absolute standardised difference; two patient groups had similar characteristic (balanced) if absolute standardised difference is less than 0.1. 5 Calculated for patients from five states (NSW, Vic, Qld, SA and Tas). 6Calculated among patients with diabetes.

4

1. Patient surveys

Patients were surveyed using computer assisted telephone interviews (CATI). HPA collaborated with The Social Research Centre to administer the surveys. The surveys were organised into three waves (Table 5, p. 8).

The wave 1 survey aimed to profile patients and their experience of primary health care at the time of enrolment into the HCH program (or shortly after). Subsequent interviews were used to track changes following enrolment. Complete survey instruments (including changes in questions through the three waves) are in the Evaluation plan.[[45]](#footnote-46)

A weighted random sample of patients was selected by HPA from patients who had recently enrolled in the HCH trial and who had agreed to be contacted to participate in the evaluation. Practices provided contact details for these patients through a purposefully designed secure portal established by HPA. HPA regularly drew samples from the patients registered in this system – initially approximately every month then, as enrolments increased, every fortnight. Only patients enrolled in the most recent period were included in each sample. The sampling approach aimed to capture enough patients from each practice to be able to develop practice level estimates for relevant measures. A maximum number of patients from any practice was initially established (100), but this was relaxed in later waves. The sampling approach aimed to ensure patients surveyed were spread across the enrolment period. As enrolment occurred at different rates between practices, the sampling approach needed to be recalibrated over time.

For waves 2 and 3, patients who had responded to the previous survey were approached, provided the practice continued to participate in the HCH trial. Additional patients were also sampled for wave 2 to attempt to achieve the targets for the patient survey samples.

Once contact details for patients were received, The Social Research Centre followed a protocol developed with HPA, which reflects best practice in conducting surveys:[[46]](#footnote-47)

1. Within seven days of receiving contact details, The Social Research Centre sent enrolees a primary approach letter with a non-contingent incentive of $10 (in the form of a card). Patients could access the voucher regardless of whether they agreed to participate in the survey. If only an email address was available, an approach letter was emailed with an electronic voucher.
2. Telephone contact was then made at least seven days after the initial approach to allow for delivery of the letter.
3. An SMS was sent to enrolees with a valid mobile number before the initial call to reduce non-contacts.
4. If an enrolee didn’t answer, The Social Research Centre continued to call up to eight times. If the enrolee or a family member answered and hung up or the enrolee declined to participate, then they were not contacted further.
5. When contacted the interviewee could also choose: (a) not to participate in the survey at the time they received a telephone call from The Social Research Centre interviewer; (b) to stop the interview at any time; and/ or (c) not answer certain questions.
6. The Social Research Centre interviewers followed a script to ensure the same questions were asked of all the participants, subject to the conditional statements within the survey. The interviewee asked the patient which language they would prefer the interview to be conducted in. The interviewer also gave the patient the opportunity to reschedule the interview at another time. The interviews took 15 to 20 minutes.
7. For waves 1 and 2, respondents were sent a thank you email (or letter if no email address), reminding them that they will be contacted again in the next wave, and allowing an opportunity to opt-out if they didn’t wish to be re-surveyed.

Table 16 presents data on response rates for each survey wave. Crude response rates were 64.6% for wave 1, 68% for wave 2 and 71.5% for wave 3. For some patients the contact information was classified as unusable. If these are excluded from the denominator, the response rates were 66.7% for wave 1, 72.1% for wave 2 and 77.1% for wave 3. Contact could not be made with some patients (17.6%, 14.4% and 10.3% for waves 1 to 3 respectively).

Table 16: Patient participation in HCH surveys

| **Sample size/ status** | | **Number of patients n (%)** | | |
| --- | --- | --- | --- | --- |
| **Wave 1** | **Wave 2** | **Wave 3** |
| Patient sample | | 3,125 (100.0%) | 2,733 (100.0%) | 1,936 (100.0%) |
| Interviews completed | | 2,018 (64.6%) | 1,859 (68.0%) | 1,385 (71.5%) |
| Unusable sample | Deceased | 5 | 19 | 23 |
| Named person not known | 32 | 23 | 17 |
| Not a residential number | 6 | 1 | 1 |
| Incoming call restriction | 1 | 2 | 1 |
| Number disconnected | 55 | 109 | 98 |
| Total | 99 (3.2%) | 154 (5.6%) | 140 (7.2%) |
| Non contacts | Answering machine | 347 | 246 | 145 |
| Answering machine message left | 12 | 9 | 3 |
| Engaged | 19 | 22 | 10 |
| No answer | 173 | 117 | 41 |
| Total | 551 (17.6%) | 394 (14.4%) | 199 (10.3%) |
| Other contacts | Re-appointment not completed | 67 | 26 | 4 |
| Away for duration | 30 | 13 | 17 |
| Claims to have done survey | 4 | 3 | 6 |
| Language difficulty | 25 | 7 | 3 |
| No longer part of HCH | 22 | 44 | 38 |
| Too frail / ill-health | 76 | 51 | 29 |
| Intoxicated respondent | 1 | 1 | 2 |
| Total other contacts | 225 (7.2%) | 145 (5.3%) | 99 (5.2%) |
| Refusal | Incoming call solution hard refusal | 42 | 46 | 19 |
| Household refusal | 47 | 17 | 7 |
| Respondent refusal | 112 | 95 | 66 |
| Midway termination | 31 | 22 | 21 |
| Total refusals | 232 (7.4%) | 180 (6.6%) | 113 (5.8%) |

Source: The Social Research Centre.

Summary tables from the surveys are presented in Appendix 7. These provide cross tabulations of responses by wave and patient tier. In Table 17, key socio-demographic characteristics of patients for all patients surveyed are presented by the tier to which the patient was assigned. Key points to note include:

* The age and sex distribution of patients who completed the surveys were similar to the population of HCH patients (although only patients aged 18 years and over were approached for the survey). Almost one-third of the patients who agreed to participate in the survey were aged 65 to 74 years and there was a fairly even split of participants by gender (males 44.9%, females 55.1%). Patients in tier 3 tended to be older (p < 0.001).
* 3.3% of patients interviewed identified as Aboriginal or Torres Strait Islander, even though the sample did not include patients enrolled by ACCHS in the Northern Territory.
* 68.0% of respondents were born in Australia, 15.4% in the United Kingdom and 16.6% in other countries.
* Respondents were offered the opportunity to conduct the interview in one of several languages. The vast majority (99%) were conducted in English. Eighteen were conducted in other languages: Maltese, Tagalog, Hindi, Filipino, French, Punjabi, Croatian, Romanian and Polish (data not shown in the Table).
* 5.6% of patients had the survey completed by a proxy and 3.7% needed help to answer some of the questions.
* Respondents’ most common living arrangement was living in a household consisting of a couple only (45.8%). A further 25.9% of respondents were living alone. There was a statistically significant difference in household composition between tiers (p < 0.001). Specifically, a higher proportion of patients in tier 1 and tier 2 were living in couple only households, and a higher proportion of tier 3 patients were living alone.

Table 17: Socio-demographic characteristics of HCH patients responding to the survey

| **Respondent characteristics** | **Total Individuals** | **Tier** | | |
| --- | --- | --- | --- | --- |
| **1** | **2** | **3** |
| **A1 Sex** | | | | |
| Female | 1,418 (55.1%) | 686 (56.2%) | 1,526 (55.4%) | 625 (55.7%) |
| Male | 1,157 (44.9%) | 535 (43.8%) | 1,230 (44.6%) | 497 (44.3%) |
| **A2 Age group** | | | | |
| 25–44 | 156 (6.0%) | 65 (5.3%) | 164 (6.0%) | 79 (7.0%) |
| 45–64 | 599 (23.1%) | 273 (22.4%) | 654 (23.8%) | 326 (28.8%) |
| 65–74 | 784 (30.2%) | 446 (36.6%) | 894 (32.5%) | 261 (23.1%) |
| 75–84 | 754 (29.0%) | 356 (29.2%) | 794 (28.9%) | 309 (27.3%) |
| 85+ | 286 (11.0%) | 77 (6.3%) | 232 (8.4%) | 139 (12.3%) |
| **A3 Indigenous status (Q34)** | | | | |
| Aboriginal or Torres Strait Islander | 87 (3.3%) | 19 (1.6%) | 87 (3.2%) | 50 (4.5%) |
| Not Aboriginal or Torres Strait Islander | 2,494 (95.8%) | 1,201 (98.4%) | 2,651 (96.8%) | 1,073 (95.5%) |
| Don't know/ Refused | 21 (0.8%) |  |  |  |
| **A4 Country of birth (Q35)** | | | | |
| Australia | 1,769 (68.0%) | 847 (69.2%) | 1,850 (67.0%) | 791 (69.9%) |
| United Kingdom | 402 (15.4%) | 193 (15.8%) | 440 (15.9%) | 157 (13.9%) |
| Other | 431 (16.6%) | 184 (15.0%) | 472 (17.1%) | 183 (16.2%) |
| **A5 Highest level of education (Q36)** | | | | |
| Year 9 or below | 541 (20.8%) | 202 (16.6%) | 593 (21.7%) | 258 (23.2%) |
| Year 10 or equivalent | 406 (15.6%) | 210 (17.3%) | 425 (15.6%) | 169 (15.2%) |
| Year 11 or equivalent | 145 (5.6%) | 67 (5.5%) | 168 (6.2%) | 54 (4.9%) |
| Year 12 or equivalent | 332 (12.8%) | 167 (13.8%) | 295 (10.8%) | 148 (13.3%) |
| Certificate I to IV (inc. trade certificate) | 554 (21.3%) | 239 (19.7%) | 609 (22.3%) | 242 (21.7%) |
| Advanced diploma/Diploma | 216 (8.3%) | 134 (11.0%) | 226 (8.3%) | 86 (7.7%) |
| Bachelor Degree | 227 (8.7%) | 143 (11.8%) | 240 (8.8%) | 96 (8.6%) |
| Post-Graduate Degree | 82 (3.2%) | 34 (2.8%) | 98 (3.6%) | 24 (2.2%) |
| Other | 69 (2.7%) | 18 (1.5%) | 74 (2.7%) | 36 (3.2%) |
| Refused | 30 (1.2%) |  |  |  |
| **A6 Household composition (Q33)** | | | | |
| Person living alone | 675 (25.9%) | 217 (17.7%) | 732 (26.5%) | 328 (29.0%) |
| Couple only | 1,193 (45.8%) | 723 (59.1%) | 1,318 (47.7%) | 417 (36.9%) |
| Couple with non-dependent child/ren | 179 (6.9%) | 82 (6.7%) | 200 (7.2%) | 82 (7.3%) |
| Couple with dependent child/ren | 171 (6.6%) | 102 (8.3%) | 179 (6.5%) | 64 (5.7%) |
| Single parent with non-dependent child/ren | 93 (3.6%) | 29 (2.4%) | 74 (2.7%) | 66 (5.8%) |
| Single parent with dependent child or children | 53 (2.0%) | 11 (0.9%) | 45 (1.6%) | 27 (2.4%) |
| Other household type | 238 (9.1%) | 60 (4.9%) | 214 (7.7%) | 147 (13.0%) |

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Additional tables derived from the patient surveys are in Appendix 7.

An aim of HCH was to encourage patients to become more informed about their health and, with the help of their practice, to take a more active role in managing it. “Patient activation” is the term used to describe this concept. The Patient Activation Measure (PAM)[[47]](#footnote-48) is a validated tool measuring patient activation. Survey respondents completed the 13-item version of PAM. A valid response to each item is the patient’s level of agreement with a statement (they can strongly disagree, disagree, agree, or strongly agree). Using the Rasch approach that underpinned the development of the PAM, patients’ responses were transformed to a score ranging from 0 to 100. The score measures the psychometric properties of a patient’s skills, knowledge and confidence for managing their health. The score out of 100 can then be used to categorise each patient as:

* disengaged and overwhelmed (lowest level of activation)
* becoming aware but still struggling
* taking action and gaining control
* maintaining behaviours and pushing further (highest level of activation).

Table 87 in Appendix 7 presents the PAM results.

The PACIC is a validated tool designed to assess the implementation of the chronic care model from the patient perspective.[[48]](#footnote-49) It focuses on the patient’s perspective of the receipt of patient-centred chronic disease management. The 12-item version of the tool was used in the evaluation, and the possible responses to each item are on a five-point scale from 1 (none of the time) to 5 (always). There are five domains within the PACIC:

* patient activation score
* decision support score
* goal setting score
* problem solving score
* follow-up/ co-ordination score.

Responses for each question were assigned a score of 1–5, and then averaged for each dimension. A total average score was also calculated. Table 84 in Appendix 7 presents the PACIC results.

The EQ-5D-5L is a health-related quality of life measure which can be used to estimate a respondent’s health related quality of life.[[49]](#footnote-50) It is also used to estimate quality adjusted life years when comparing health interventions. The EQ-5D-5L has five basic questions about five key dimensions of a patient’s health related quality of life at the time of interview. The dimensions include: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Responses reflect the level of difficulty patients experience with these dimensions. Responses to the five questions are mapped to a utility score ranging from just below zero to one, where scores at zero or below represent the worst health related quality of life and a score of one represents the best health related quality of life. Table 90 in Appendix 7 presents the EQ-5D-5L results.

### Longitudinal analysis

This section presents the results from the longitudinal analysis of patients’ responses to questions in the CATI. In particular, to their scores on instruments that measure patient activation, experience of chronic illness care, and quality of life. Total scores from the PAM, PACIC and EQ-5D-5L are numeric and change in the mean scores between surveys is estimated using generalised linear mixed models (GLMM). For each patient outcome we estimated a GLMM with fixed effects for HCH tier, wave, categorized age, practice size, practice ownership, location and with random intercepts for practice and patient. These models estimate the effect of each of the fixed effects on the outcome, with an adjustment for practice and respondent mean. The main variable of interest in these models is wave, which provides an estimate of the change in the mean score on the instrument from wave 1 to wave 2 and from wave 1 to wave 3.

GLMM are similar to linear regression but adjust for the lack of independence of residuals, which occur due to surveying the same patients multiple times, and also for the clustering that occurs due to patients being selected from practices (rather than randomly from the population). Like linear regression, the models assume linearity and normally distributed residuals with constant variance, but they also assume that variation between patients is normally distributed and that variation between practices is normally distributed. Additional models were fit to the data to explore whether practices that recruited more than 50 patients did better or worse that practices that recruited fewer than 50 patients. Before fitting these additional models, logistic regression was used to obtain propensity scores for each practice and the propensity scores were included in the models as inverse probability weights to balance the potential confounders of the analysis between the two groups of practices.

Total scores on each of the instruments were dichotomised and change between waves in the dichotomised outcome were estimated using a logistic regression model fitted within a generalised estimating equation (GEE) framework. Like GLMM, these models also adjust for the lack of independence within the data but only for one level, which we have set to be patient for the longitudinal analysis. The outcomes from a logistic regression model are usually expressed as odds ratio, for example the odds of having the outcome of interest in wave 2 relative to wave 1. We chose to use GEEs primarily because they give population-based estimates of the odds ratio rather than individual estimates, the former of which are more relevant for this study. GEEs also tend to converge more readily than GLMM for dichotomous outcomes with a logit link function. Generalised estimating equations do have a slightly less robust assumptions regarding missing data; they are valid when the data are missing completely at random. This means they are valid when the missing data is independent of both the observed and unobserved data, or equivalently the observed data is a random sample of the complete data. GLMMs are valid when the data are missing at random, which means they are valid when the missing data is independent of its unobserved value. To overcome this potential weakness, we have conducted sensitivity analysis to determine if p-values are similar between the two models. In addition, when we have dichotomised outcomes, we have undertaken sensitivity analysis to check that the results are robust to the choice of the cut-point.

Summaries of the responses for individual items, total scores, and categories derived from the total scores are given in Table 87 for the PAM, Table 84 for the PACIC, and Table 90 for the EQ-5D-5L.

#### Patient activation measure (PAM)

The longitudinal analysis found there was no significant difference in the mean PAM score at the second [0.67 (95% CI -0.07 to 1.38)] or third wave [0.30 (95% CI -0.44 to 0.99)] compared with the mean score at the first wave (Table 18). Patients enrolled in HCH tended to score relatively high on the PAM, with 40.5% being categorised as “taking action and gaining control” across waves and another 34.7% being classified as “maintaining behaviours and pushing further” (Figure 6). The proportions of patients categorised as “taking action and gaining control” or “maintaining behaviours and pushing further” were similar across waves and the proportion of patients in each category remained relatively constant across the three waves (Table 19).

Table 18: Estimated change (95% confidence intervals) in mean scores from wave 1 to wave 2 and wave three patient surveys

| **Outcome** | **Wave 1** | **Change from wave 1†** | |
| --- | --- | --- | --- |
| **Mean (median)** | **Wave 2** | **Wave 3** |
| Total score (PAM) | 66.2 (65.5) | 0.67 (-0.07, 1.38) | 0.30 (-0.44, 0.99) |
| PACIC: Patient activation score | 3.4 (3.5) | -0.02 (-0.08, 0.05) | -0.10 (-0.18, -0.03) |
| PACIC: Decision support score | 3.7 (3.7) | -0.06 (-0.11, -0.02) | -0.21 (-0.26, -0.16) |
| PACIC: Goal setting score | 3.4 (3.7) | -0.02 (-0.07, 0.04) | -0.10 (-0.17, -0.04) |
| PACIC: Problem solving score | 4.2 (5.0) | -0.09 (-0.16, -0.02) | -0.13 (-0.21, -0.05) |
| PACIC: Follow-up/ co-ordination score | 2.6 (2.7) | 0.04 (-0.02, 0.09) | -0.10 (-0.17, -0.04) |
| Total score (PACIC) | 3.4 (3.5) | -0.02 (-0.06, 0.02) | -0.13 (-0.18, -0.09) |
| Total score (EQ-5D-5L) | 0.7 (0.7) | 0.00 (-0.01, 0.01) | -0.01 (-0.02, 0.00) |

Notes: † Change is estimated from an analysis involving all patients who completed at least one survey using generalised linear mixed model with random intercept terms for patient and practice. Very similar results were obtained from the same analysis using only those patients who completed all three surveys.

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Table 19: Odds of being categories as 4 or 5 in the PACIC in waves 2 and 3 relative to wave 1

| **Outcome** | **Odds ratio‡ (95% CI)  relative to wave 1** | |
| --- | --- | --- |
| **Wave 2** | **Wave 3** |
| PAM† | 1.09 (0.97, 1.21) | 1.00 (0.88, 1.12) |
| PACIC: Patient activation score (≥4) | 0.96 (0.85, 1.08) | 0.84 (0.74, 0.95) |
| PACIC: Decision support score (≥4) | 0.82 (0.73, 0.92) | 0.62 (0.55, 0.70) |
| PACIC: Goal setting score (≥4) | 0.95 (0.85, 1.06) | 0.80 (0.71, 0.90) |
| PACIC: Problem solving score (≥4) | 0.82 (0.70, 0.94) | 0.79 (0.67, 0.93) |
| PACIC: Follow-up/ co-ordination score (≥4) | 1.04 (0.89, 1.22) | 0.79 (0.66, 0.95) |
| Total score (PACIC) (≥4) | 0.93 (0.82, 1.04) | 0.73 (0.64, 0.83) |
| Patient rating of overall health (Excellent or very good) | 1.13 (1.00, 1.28) | 1.06 (0.93, 1.21) |
| Patient rating of overall mental or emotional health (Excellent or very good) | 0.97 (0.87, 1.08) | 0.93 (0.82, 1.04) |

Notes: ‡ Odds ratios were estimated from an analysis involving all patients using a generalised estimating equation with patient as the repeated measure. † Categorised as “taking action and gaining control” or “maintaining behaviours and pushing further”.

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 6: Proportion of patients at each wave by the category of their PAM scores

Chart, bar chart

Proportion of patients at each wave by the category of their PAM scores

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

There was no difference in the change in PAM scores between patients at practices that recruited more than 50 patients and those that recruited less than 50 (p = 0.93) (Figure 7).

Figure 7: Mean PAM score during each wave by practice and number of patients who completed the survey within each practice

Chart, scatter chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

#### Patient Assessment of Chronic Illness Care (PACIC)

On average patients scored -0.13 (95% CI -0.18 to -0.09) lower for the total PACIC score at wave 3 than wave 1 (Table 18), although the mean of response at wave 2 was similar to wave 1 [difference = -0.02 (95% CI -0.06 to 0.02)]. This suggests patients assessed the quality of care for their chronic condition to have deteriorated as the trial progressed. This pattern was consistent throughout the five components of the PACIC (Table 18). The PACIC was dichotomised as “greater than or equal to 4” or “less than 4”, where a score of 4 or more is consistent with responses of “Most of the time” or “Always”. The results suggest that the odds of having a total score of 4 or more on the PACIC in wave 3 was 0.73 (95% CI 0.64, 0.83) of the odds in wave 1 (Table 19). Similar results were found for the five components of the PACIC. The results were similar with the cut point for the dichotomy was change to 3 or 5.

We did some additional analysis to try and understand the reason for the reduction in PACIC scores that occurred across waves. People got older and they tended to report having more chronic conditions as time passed (Figure 8 and Figure 9). Peoples’ age and the number of chronic conditions they had may have influenced the way they scored the PACIC. Although older people do tend to score lower on the PACIC, the opposite is true for number of chronic conditions (Figure 10 and Figure 11). People with more chronic conditions tended to score higher on the PACIC. Interestingly, the mean PACIC score increased among the youngest age group (< 25 years) but the number of patients in that group is relatively small (16 in wave 1). Adjusting for these variables had little impact on the size of the change. Similarly, removing the oldest age group and/or restricted the model to people who completed the 3 surveys had little impact on the size of the change in mean PACIC scores between wave 1 and wave 3.

Figure 8: Percentage of patients in each age group by wave

Chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 9: Percentage of patients by number of chronic conditions, by wave

Chart, treemap chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 10: Mean PACIC scores by age group, by wave

Chart, line chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 11: Mean PACIC scores by number of chronic conditions, by wave

Chart, line chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 12 shows the mean PACIC score at each practice by the number of patients who completed the survey, with the colour of the circles indicating characteristics of the practice. There was no difference in the change in PACIC scores between patients at practices that recruited more than 50 patients and those that recruited less than 50 patients (p = 0.06), although there was an indication that the decline was slower at wave 2 as the number of patients recruited increased.

Figure 12: Mean PACIC score at each survey by practice and number of patients who completed the CATI

Chart, scatter chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

EQ-5D-5L

There was no difference in the mean EQ-5D-5L scores at the second wave [0.00 (95% CI -0.01 to 0.01)] or third wave [-0.01 (95% CI -0.02 to 0.00)] compared with the first wave (Table 18). There was no difference in the change in EQ-5D-5L scores between patients at practises that recruited more than 50 patients and those that recruited less than 50 patients (p = 0.68) and there were no obvious differences in average scores when examined by the number of patients who completed the CATI. Nor was there a difference in the trend across the three waves (Figure 13).

Figure 13: Mean EQ-5D-5L score at each survey by practice and number of patients who completed the CATI

Chart, scatter chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Quality of life

Question 25 of the patient survey was a general question on how the patient rated their overall health (In general, how would you rate your overall health, is it…?). Question 26 was similar but specific to mental and emotional health (In general, how would you rate your overall mental or emotional health, is it…?). The responses to these two questions are shown in Figure 14 and Figure 15. Most patients rated their overall health and their mental health as good, very good, or excellent.

In a model adjusted for age group, patient tier, and the practice characteristics of size, location and ownership, the odds of a patient rating their overall health as poor or fair at wave 2 was 0.84 (95% CI 0.76 to 0.94) compared with wave 1. Although still lower at wave 3 the odds were not statistically different to wave 1 [0.95 (95% CI 0.84 to 1.07)].

The model results suggest there was an increase in patients reporting poor or fair mental health in wave 3 relative to wave 1 [1.16 (95% CI 1.02 to 1.33)].

In similar models, the odds of a patient rating their overall health as very good or excellent at wave 2 was 1.13 (95% CI 1.00 to 1.28) compared with wave 1 and at wave 3 was 1.06 (95% CI 0.93 to 1.21). The results for mental health were 0.97 (0.87 to 1.08) at wave 2 relative to wave 1 and 0.93 (0.82 to 1.04).

Figure 14: Summary of responses to the question of overall health by wave

Chart, treemap chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

Figure 15: Summary of responses to the question of overall health by wave

Chart, treemap chart

Description automatically generated

*Source: Patient survey Wave 1, Dec 2017–Mar 2019; Wave 2, Dec 2019–Mar 2020; and Wave 3 Mar–Apr 2021.*

5

1. Practice and practice staff surveys

Surveys of HCH practices were conducted in rounds 1, 2, 4 and 5. The topics included in each round are described in Table 20. The surveys were administered online using the Qualtrics application. To accompany the surveys in rounds 1 and 5, HPA developed a Microsoft Excel tool that practices could use to compile assessments from individual staff members to derive their overall HCH-A result. The intention was for practices to use the tool to discuss individual staff members’ scoring (anonymously), and achieve a consensus response for the practice.

Table 20: Topic areas for each practice survey

| **Survey** | **When undertaken** | **Contents of survey** |
| --- | --- | --- |
| 1 | Dec 2017 – Jul 2018 | **Part A**   * Characteristic of the practice at baseline * Staffing * Opening hours * Accessibility of other services in the local community * Information technology infrastructure and capabilities * Participation in PIP and quality improvement activities * Co-payment policies * Practice costs   **Part B**   * Self-assessment against dimension of the Patient Centred Medical Home using the HCH-A tool |
| 2 | Nov 2018 – Mar 2019 | * Perspectives on patient enrolment and risk stratification * Perspectives on training and support * Focus for initiatives implemented/ enhanced as part of HCH |
| 4 | Nov 2019 – Mar 2020 | * Progress on initiatives implemented/ enhanced as part of HCH |
| 5 | Mar 2020 – May 2021 | **Part A**   * Assessment of initiatives implemented/ enhanced as part of HCH * Shared care planning * Patient engagement and activation * Chronic disease management * Assessment of training and support * Changes in staffing * Financial impacts of HCH * Impact of COVID-19   **Part B**   * Self-assessment against dimension of the Patient Centred Medical Home using the HCH-A tool |

Table 21 shows the response rates to the surveys and the characteristics of practices responding. Response rates were very high across all study strata in round 1 (88.6%) but reduced over the course of the evaluation.

Table 21: Response rates and characteristics of practices responding to survey requests

| **Study strata** | **Practice surveys n (response rate, calculated based on active practices)** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Round 1 Part A** | **Round 1 Part B** | **Round 2** | **Round 4** | **Round 5 Part A** | **Round 5 Part B** |
| **1. Total practices at time of survey** | | | | | | |
| Responding to survey | 164 (88.6%) | 161 (87.0%) | 105 (64.8%) | 57 (46.3%) | 74 (67.9%) | 65 (59.6%) |
| **Total practices** | **185** | | **162** | **123** | **109** | |
| **2. Size (active practices only)1** | | | | | | |
| Large practice | 35 (92.1%) | 34 (89.5%) | 18 (52.9%) | 10 (50.0%) | 14 (73.7%) | 11 (57.9%) |
| Medium practice | 31 (96.9%) | 30 (93.8%) | 25 (83.3%) | 12 (44.4%) | 15 (65.2%) | 14 (60.9%) |
| Small practice | 78 (83.0%) | 77 (81.9%) | 47 (61.0%) | 30 (48.4%) | 37 (66.1%) | 32 (57.1%) |
| Sole practitioner | 20 (95.2%) | 20 (95.2%) | 15 (71.4%) | 5 (35.7%) | 8 (72.7%) | 8 (72.7%) |
| **3. Ownership (active practices only)2** | | | | | | |
| AMS | 21 (84.0%) | 21 (84.0%) | 10 (45.5%) | 6 (35.3%) | 4 (25.0%) | 5 (31.2%) |
| Corporate | 35 (89.7%) | 35 (89.7%) | 17 (54.8%) | 5 (31.2%) | 9 (64.3%) | 7 (50.0%) |
| Independent | 108 (89.3%) | 105 (86.8%) | 78 (71.6%) | 46 (51.1%) | 61 (77.2%) | 53 (67.1%) |
| **4. MMM (active practices only)3** | | | | | | |
| MMM 1 | 109 (92.4%) | 109 (92.4%) | 84 (79.2%) | 43 (50.6%) | 62 (79.5%) | 52 (66.7%) |
| MMM 2 | 22 (75.9%) | 20 (69.0%) | 5 (20.0%) | 2 (15.4%) | 2 (25.0%) | 2 (25.0%) |
| MMM 3 | 8 (88.9%) | 7 (77.8%) | 5 (83.3%) | 3 (60.0%) | 4 (100.0%) | 4 (100.0%) |
| MMM 4 & 5 | 10 (90.9%) | 9 (81.8%) | 5 (71.4%) | 3 (50.0%) | 4 (66.7%) | 4 (66.7%) |
| MMM 6 & 7 | 15 (83.3%) | 16 (88.9%) | 6 (33.3%) | 6 (42.9%) | 2 (15.4%) | 3 (23.1%) |

Notes: 1 Large practice defined as 8+ FTE GPs; Medium practice defined as 5 to 8 FTE GPs; Small practice defined as <5 FTE GPs. 2 Aboriginal Medical Service is used to refer to both Indigenous Health Services and ACCHS clinics. In this Table, all but one AMS is an ACCHS clinic; 3 MMM refers to the Modified Monash Model. It classifies metropolitan, regional, rural and remote areas according to both geographical remoteness and town size. It is intended to enhance the Australian Statistical Geographic Standard, Remoteness Areas (ASGS-RA) used by the Australian Bureau of Statistics (ABS). The classification has been adopted by several Government programs, including the General Practice Rural Incentives Programme (GPRIP). MMM 1 aligns fully with the ASGS-RA category of “Major cities”. MMM 7 relates to the most remote areas.

Source: Department of Health database of practices and Practice surveys.

Of the 109 practices still participating in the trial on 31 April 2021, 100 had responded to the round 1 Part A survey (response rate of 91.7%), 78 to the round 2 survey (response rate of 71.6%), 54 to the round 4 survey (response rate of 49.5%), and 67 to the round 5 survey (response rate of 61.5%).

Tables derived from the responses to the practice surveys are provided in Appendix 8.

## Practice self-assessment using HCH-A

Practices initially used the Health Care Homes Assessment (HCH-A) tool to assess the extent to which they operate as a HCH. The recommended approach for applying the tool is for individual practice staff to undertake the assessment separately, and then discuss results as a group to reach a consensus. This was not always the approach taken by practices, and this should be considered when interpreting the results presented here.

HCH-A results were received for 169 practices in round 1 of the evaluation and for 65 practices in round 5. Practices reported that 282 staff were involved in completing the assessment in round 5 (Table 135). Across the practices, 83 GPs participated in the assessment, 78 nurses, 52 reception/administration staff, 51 practice managers, 2 Aboriginal health practitioners and 12 allied health staff.

Figure 16 and Figure 17 show the distributions of the HCH-A scores on each of the questions in the HCH-A tool in round 1. For each question, scores are represented on a scale of 1 to 12. These are grouped into eight dimensions. Scores of 1 to 3 on any item reflect absent or minimal implementation of an element of the patient centred medical home. Scores of 10 to 12 reflect that most or all the critical aspects of the element are well established in the practice. Summaries of the scores for rounds 1 and 5 can be found in Appendix 9.

Overall, the median and mean self-assessment scores in round 1 were in the range of 6 to 9. These suggest that most practices believed they had many of the elements of a patient centred medical home in place when HCH started, but there were still opportunities for improvement.

Change in scores between round 1 and round 5 were estimated using generalised linear mixed models with a random intercept term for practice. These models use all available data and provide unbiased estimates under the assumption that missing data is missing at random. Additional estimates of change were calculated using data from those practices that completed the HCH-A tool at both timepoints. The estimated change from round 1 to round 5 in this case is the mean of the observed change from each of the practices. This approach gives an unbiased estimate of change for those practices but inference to all practices assumes the unobserved values (that is, the non-responders) are missing completely at random. There was some improvement in scores from round 1 to round 5. The estimated change in scores when data from all practices who completed the HCH-A tool in round 1 and/or round 5 were included in the analysis (Table 137) was slightly greater than when data from those practices who completed the survey in both rounds were analysed (Table 138). The data are presented graphically in Figure 18 to Figure 25 with a separate figure for each subscale of the HCH-A. The 8 figures show the direction of change for each aspect within the subscale depicted by the figure. Practices are grouped by whether the change within the practice was a “Decrease”, “No change”, or an “Increase”, and within the change component of the figure there are arrows showing the starting location and change for each practice. There is substantial variation in scores between the two rounds, but the figures tend to show more practices scored themselves higher (compared with lower) in round 5 than in round 1.

An element of patient-centred care that practices generally assessed that they had only minimally implemented was “measurement of patient-centred interactions” (Dimension 6, item 26). For this element, 50% of practices scored themselves between 3 and 7 in round 1 (median = 5). Values between 4 and 6 represents that measurement of patient-centred interactions is “*accomplished through patient representation on boards and regularly soliciting patient input through surveys”*. A high score on this item (10 to 12) “*is accomplished by getting regular and actionable input from patients and families on all care delivery issues, and incorporating their feedback in quality improvement activities*”. Practices scored themselves 1.12 (95% CI 0.37 to 1.85) units higher on this element in round 5, but it was still scored lower on average than the other elements in the HCH-A tool (Table 137). This improvement was of a similar magnitude when the analysis was restricted to those practices that completed the tool in both the round 1 and the round 5 survey (0.98 (95% CI 0.03 to 1.94) (Table 138, Figure 23).

An element that practices generally assessed they had most of the critical aspects in place in round 1 was “Care plans” (Dimension 5: Organised, evidenced-based care, item 18). Many practices scored themselves between 7 and 9, which indicates that care plans “*are developed collaboratively with patients (and their families and carers where applicable), and include self-management and clinical goals, but they are not routinely recorded or used to guide subsequent care”*. The goal for this item (scores 10 to 12) is that care plans “*are developed collaboratively, by the patient (and their families and carers where applicable) and care team to include self-management and clinical management goals are routinely recorded, and guide patient care in the practice and across the health care neighbourhood”*. There was a non-significant improvement of 0.44 (95% CI -0.17 to 1.03) units on this element between round 1 and round 5 (0.36 (95% CI -0.39 to 1.12) for practices completing both rounds), with the median improving from 9 to 10.

Figure 16: Distribution of reported HCH-A scores: Dimensions 1 to 5

Chart, box and whisker chart

Description automatically generated

*Notes: The box represents the range from the first quartile and the third quartile. This is where 50% of scores occurred. The vertical line crossing the middle of the box is the median score. The horizontal lines extending from the box (the “whiskers”) show the values up to quartile 1 minus 1.5 times the interquartile range (to the left of the box) and the values up to quartile 3 plus 1.5 times the interquartile range (to the right of the box). Points outside these are often considered outliers. For more values for these distributions see Appendix 9*.

*Source: Practice survey R1 Dec 2017–Jul 2018.*

Figure 17: Distribution of reported HCH-A scores: Dimensions 6 to 8

Chart, box and whisker chart

Description automatically generated

Notes: See notes in Figure 16 for interpretation of the box plots. For more values for these distributions see Appendix 9.

*Source: Practice survey R1 Dec 2017–Jul 2018.*

## Staff surveys

Practice staff were surveyed in rounds 1 and 5. Table 22 provides details of staff responding to these surveys. Staff were asked to provide their views on various aspects of HCH in their practice but could choose not to answer questions that they felt they could not adequately assess.

Table 22: Response rates and characteristics of staff responding to survey requests

| **Study strata** | **Staff surveys (n)1** | | **Practices from which staff surveys were received (n)2** | |
| --- | --- | --- | --- | --- |
| **Round 1** | **Round 5** | **Round 1** | **Round 5** |
| **1. Total** | | | | |
| Active practices | 559 | 182 | 146 | 78 |
| Withdrawn practices3 | 18 | 0 | 8 | 0 |
| All practices | 577 | 182 | 154 | 78 |
| **2. Size (active practices only)** | | | | |
| Large practice | 123 (22.0%) | 39 (21.4%) | 31 (21.2%) | 14 (17.9%) |
| Medium practice | 129 (23.1%) | 34 (18.7%) | 27 (18.5%) | 16 (20.5%) |
| Small practice | 261 (46.7%) | 92 (50.5%) | 69 (47.3%) | 39 (50.0%) |
| Sole practitioner | 46 (8.2%) | 17 (9.3%) | 19 (13.0%) | 9 (11.5%) |
| **3. Ownership (active practices only)** | | | | |
| AMS | 67 (12.0%) | 21 (11.5%) | 15 (10.3%) | 5 (6.4%) |
| Corporate | 101 (18.1%) | 25 (13.7%) | 30 (20.5%) | 9 (11.5%) |
| Independent | 391 (69.9%) | 136 (74.7%) | 101 (69.2%) | 64 (82.1%) |
| **4. MMM (active practices only)** | | | | |
| MMM 1 | 417 (74.6%) | 132 (72.5%) | 100 (68.5%) | 63 (80.8%) |
| MMM 2 | 30 (5.4%) | 5 (2.7%) | 18 (12.3%) | 4 (5.1%) |
| MMM 3 | 25 (4.5%) | 12 (6.6%) | 8 (5.5%) | 4 (5.1%) |
| MMM 4 & 5 | 31 (5.5%) | 15 (8.2%) | 9 (6.2%) | 4 (5.1%) |
| MMM 6 & 7 | 56 (10.0%) | 18 (9.9%) | 11 (7.5%) | 3 (3.8%) |

*Notes: 1 Percentages are calculated using the denominator of the total number of surveys completed by staff at active practices; 2 Percentages are calculated using the denominator of the total number of active practices where at least one member of staff completed the survey; 3 Withdrawn as at 1August 2018 for R1 and 1 April 2021 for R5.*

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021.

Appendix 10 of this volume provides extensive details of the responses to the staff surveys. The results are presented in tables with summaries of staff responses to the round 5 survey, followed by a table with a longitudinal view of the data. The longitudinal analysis is generally a summary of the number and percentage of positive responses to a dichotomised version of the original response, followed by a p-value testing the null hypothesis of no change in the percentage of positive responses from round 1 to round 5. For example, Table 23 shows the results for the roles of the primary care team. The questions shown in the Table are preceded with, “The primary care team is …”, and staff could respond with options on a five-point Likert scale from “Disagree (1)” to “Agree (5)” or they could respond “Don’t know”. These responses have been dichotomised with a positive response being “Agree or Somewhat agree”. A statistical model fitted using generalised estimating equations, to control for the repeated measurements within practice at each timepoint and over time, is fit to the data to calculate the p-value. Models have been fit using all available data (that is, all responses to the round 1 and round 5 surveys) and separately using only the data for those practices that had completed surveys in both rounds. Table 23 shows that the percentage of positive results increased for all three questions, regardless of which data were used, but there was only a statistically significant improvement (using both approaches) for the response to the question, “is characterised by collaboration and trust”.

Table 23: Primary care team role

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... is made up of members with clearly defined roles, such as responsibility for patient self-management education, proactive follow up, and resource coordination | 378 (89%) | 172 (95%) | 0.038 | 262 (91%) | 148 (94%) | 0.285 |
| ... is characterised by collaboration and trust | 389 (92%) | 176 (97%) | 0.020 | 266 (93%) | 153 (97%) | 0.034 |
| ... works with patients to help them understand their roles and responsibilities in care | 390 (92%) | 173 (95%) | 0.149 | 266 (93%) | 151 (96%) | 0.086 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 5.

In almost all tables there was an increase in positive responses from round 1 to round 5 (see Table 148, Table 151, Table 154, Table 160, Table 163, Table 166, Table 169, Table 172, Table 175, Table 178, Table 181, Table 194, Table 197, Table 200, Table 206, Table 216) but most were not statistically significant changes. The exceptions were responses to questions that assessed the extent to which the practice engaged the patient in their care (see Table 166 Table 169, Table 172 & Table 175).

6

1. Benchmark reports

Throughout the evaluation, benchmark reports were provided to practices and PHNs based on extracts from practice clinical management systems and program data from Services Australia. This chapter describes the reports.

## Aims of the benchmark reports

The benchmark reports were initially proposed by the Evaluation Working Group (EWG) to help practices identify areas for improvement in their data, such as the completeness and quality of data collected. They were also provided to feedback data supplied for the evaluation.

The practice and PHN benchmark reports provided the following information:

* An assessment of completeness of practice data, including the recording of HCH enrolled patients.
* An indication of quality of care processes, that is, whether the practice had recorded key health measures (for example, smoking status, body height, body weight) and timeliness of patient examinations and tests (for example, blood pressure, pulse, lipids, kidney function, HbA1c).
* An understanding of the profile of HCH patients such as distribution of patient age, sex, risk tier, diagnoses, and recording of key health measures in the practice (or in the PHN) in comparison to HCH patients in other practices (or other PHNs).

## Contents

PHNs were consulted on the draft design of the practice and PHN benchmark reports. In the round 4 surveys, both practices and PHNs were asked for feedback on the benchmark reports. Feedback provided is summarised in Volume 2.

Contents of the practice and PHN benchmark reports were derived from the HCH program data (obtained through Services Australia) and practice extracts, and were organised in three sections:

* Summary of background information and key findings
* Section 1: A profile of HCH enrolments derived from HPOS registration data
* Section 2: A profile of HCH patients based on the practice extracts.

In each report provided to practices, data were presented for the HCH patients in the practice, HCH patients in similar practices (that is, similar practice size and geographical remoteness), and HCH patients in all other HCH practices. The practice size was the number of full-time equivalent GPs working in the practice while the practice remoteness was defined using the Monash Modified remoteness categories of the practice geographic location. A sample of practice benchmark reports is provided Appendix 11.

In the reports provided to PHNs, data were presented collectively for HCH practices within the PHN and in all other PHNs combined.

In Section 1, patient demographic characteristics (age and sex) and enrolment characteristics (date of enrolment and risk tier) were derived from HPOS registration data. The number of HCH enrolments, timing of enrolment and risk tier from HPOS registrations were then compared with findings from practice extracts (presented in Section 2). This aimed to inform the practice whether HCH patients had been accurately flagged in their local systems.

In Section 2, findings derived from practice extracts included recording of patient clinical measures (for example, smoking status, height, weight, blood pressure, cholesterol, HbA1c), and patient health conditions. Graphs showing trends in the practice’s recording of blood pressure, pulse, cholesterol, kidney function and HbA1c were included in the reports in the round 4 (December 2018 to June 2020) and round 5 (July 2020 to December 2020).

Data analysis for each round of benchmark reports included patients who remained enrolled in the HCH trial (withdrawn patients were excluded), irrespective of whether patients visited the practice.

## Delivery

Practice and PHN benchmark reports were distributed to practices and PHNs five times throughout the trial (Table 24).

Table 24: Dissemination of practice and PHN benchmark reports

| **Round of report and delivery time** | **Coverage** | **Included practices** | **Included PHNs** |
| --- | --- | --- | --- |
| Round 1, March 20191 | February 2018 to December 2018 | 94 | 9 |
| Round 2, September 20192 | February 2018 to June 2019 | 132 | 10 |
| Round 3, April 20203 | June 2019 to December 2019 | 125 | 10 |
| Round 4, October 20204,5 | January 2020 to June 2020 | 1135 | 10 |
| Round 5, June 20215,6 | July 2020 to December 2020 | 106 | 10 |

*Notes: 1 Practices participating in HCH as at 31 December 2018.* *Reports were not generated for practices or PHN where practice extracts were not available or there were too few enrolments for the report to be meaningful. 2 Practices participating in HCH as at 31 July 2019. 3 Practices participating in HCH as at 31 December 2019. 4 Practices participating in HCH as at 30 June 2020. 5 Three groups of 10 practices combined their practice extracts, for each group, a single report was generated presenting combined data. 6 Practices participating in HCH as at 31 December 2020.*

7

1. Economic analysis technical notes

## Data

The main economic analysis draws on linked administrative data for both HCH-enrolled patients and non-enrolled propensity score-matched comparator patients. This includes Medicare (MBS) and Pharmaceutical Benefits Scheme (PBS) claims data, hospital admissions and emergency department data. The administrative data was extracted in June 2021, spanning the period from July 2017 to June 2021.

Individual-level MBS claims data includes the type of service (for example, GP consultation), the provider fee charged, and the Medicare rebate paid, on every service delivered to patients. This data is used to examine changes in public Medicare expenditures, as well as fees charged and patient out-of-pocket costs (provider charge minus rebate paid). PBS claims data includes the cost to the PBS as well as to the patient for each script supplied. This data was used to assess changes in government PBS expenditures, as well as patient contributions to the cost of medicines.

Hospital admissions data was used to similarly examine the number and cost of admissions. The administrative data on state-level hospital admissions was linked to cost data as follows:

* Public patient admissions recorded using AR-DRG version 8.0 were mapped to total cost estimates from the NHCDC round 21 (2016–17).
* Public hospital admissions recorded using AR-DRG version 7.0 were mapped to cost estimates from the NHCDC round 18 (2013–14).
* Private patient admissions (in both private and public hospitals) were mapped to cost data from the HCP Annual Report (2018–19) using AR-DRG versions 7 and 8.
* Public patient cost estimates were indexed to 2019 dollars using the inflation rate for medical and hospital services (ABS cat.no6401).

## Methods

For analysis of the administrative data, a graphical event study was undertaken first, comparing average outcomes between enrolled HCH patients (“treatment group”), and propensity score-matched comparator patients (“control group”). Control group patients were matched based on 12 months of data on health, socioeconomic, and healthcare use, and were assigned a placebo enrolment month and year. Consequently, we compare outcomes in the treatment and comparator groups in the 12 months before, and 24 months following the month of enrolment. We aggregate outcomes (for example, out-of-pocket costs) in 6-monthly periods (for example, months 1–6, 7–12, etc where enrolment month = 1), and plot their change graphically relative to the 6-month period before enrolment. Outcomes associated with health care use in the month of enrolment is included in the first 6-month period post-enrolment. This approach is necessary because we do not observe exact dates of service use, but only the month and year of service.

Following the graphical event study, we implemented a difference-in-difference event-study regression model, again comparing outcomes between enrolled HCH patients (“treatment group”) and propensity-score matched comparator patients (“control group”). The model provides a causal interpretation on the impact of the HCH trial on economic outcomes. Formally, the estimating equation is given by:

(1)

Here, *yit* denotes an outcome of interest, such as out-of-pocket costs and public expenditures associated with MBS, PBS and hospital use. The variable *treati* denotes whether an individual was enrolled in the HCH trial; *I*r denotes the time (in 6-month periods) relative to enrolment month, ranging from -1 that is, the period 12 to 6 months before enrolment) to 4 (that is, the period ranging from 18 to 24 months post-enrolment). The treatment effects, captured by parameters , represent the impact of the HCH trial on the outcomes for enrolled patients in each post-enrolment period (relative to the 6-month period pre-enrolment), compared with control group patients. The actual enrolment month was used for HCH treatment group patients, and a placebo enrolment month was assigned to control group patients during the matching process. The model does not include additional covariates due to the matching process which ensured balanced covariates between the treatment and control groups; indeed, the inclusion of further covariates had no impact on the magnitude or significance of our estimates. We estimate equation (1) using ordinary least squares and report standard errors clustered at the PHN level.

In addition to the linked administrative data, we also report on the staffing impacts of the HCH trial on GP practices, using separate data from practice surveys. A descriptive analysis is presented for the 67 practices who completed questions on staffing in both the round 1 and round 5 practice surveys, which were undertaken about October 2017 and March 2021 respectively.

### Cohort analysis

The enrolment period was from October 2017 to July 2019. Potential enrolment cohort differences between early and later enrolees could bias our analysis, particularly if there were substantial differences in cohort characteristics such as patient complexity. We therefore undertook a preliminary cohort analysis, examining the following outcomes in the year before enrolment, by year of enrolment: number of GP visits, number of specialist visits, patient out-of-pocket costs, number of hospital admissions, and cost of hospital care. We evaluated differences between those enrolled in 2018 and 2019 (since only 3.8% of patients were enrolled in 2017), using a “normalised difference” measure.[[50]](#footnote-51) Differences between any two groups are found to be significant if the normalised difference exceeds an absolute value of 0.25. As reported in Table 25, we found that these outcomes were statistically similar between cohorts in the year before enrolment. In the analysis which follows, we have therefore combined data of all HCH-enrolled patients, without distinguishing enrolment cohort.

Table 25: Enrolment-year cohort differences

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **2017** | **2018** | **2019** | **Normalised difference (2019 vs 2018)** |
| n | 438 | 7,499 | 3,395 |  |
| No. GP visits |  |  |  |  |
| 6–12 months pre-enrolment | 5.9 | 6.0 | 5.4 | 0.08 |
| 6 months pre-enrolment | 6.2 | 6.1 | 5.4 | 0.11 |
| No. specialist visits |  |  |  |  |
| 6–12 months pre-enrolment | 0.7 | 0.6 | 0.5 | 0.1 |
| 6 months pre-enrolment | 0.6 | 0.6 | 0.4 | 0.1 |
| Total OOP ($)^ |  |  |  |  |
| 6–12 months pre-enrolment | 212 | 236 | 201 | 0.03 |
| 6 months pre-enrolment | 286 | 236 | 183 | 0.05 |
| No. overnight hospital admissions\* | |  |  |  |
| 6–12 months pre-enrolment | 0.7 | 0.8 | 0.7 | 0.06 |
| 6 months pre-enrolment | 1.0 | 0.8 | 0.8 | 0.00 |
| No. same-day admissions\* |  |  |  |  |
| 6–12 months pre-enrolment | 1.8 | 1.9 | 1.8 | 0.01 |
| 6 months pre-enrolment | 2.5 | 1.9 | 1.8 | 0.01 |
| Total cost of hospital care |  |  |  |  |
| 6–12 months pre-enrolment | 16,549 | 13,978 | 13,200 | 0.03 |
| 6 months pre-enrolment | 16,863 | 13,459 | 13,689 | -0.01 |

Notes: \*Including patients with no admissions; ^includes bulk-billed patients.

In addition to enrolment cohort differences, we also examined potential differences between patients who remained in the HCH trial, and those who withdrew or died. Table 26 shows that there was no significant difference between the two cohorts across a number of key health use and cost metrics in the year before enrolment. For those patients who withdrew or died, we analysed their service use data for completed 6-month periods only.

Table 26: Comparison of enrolled vs withdrawn patients

|  | **Stayed enrolled** | **Withdrew or died** | **Normalised difference** |
| --- | --- | --- | --- |
| n | 7,241 | 3,439 | - |
| % | 67.8 | 32.2 |  |
| No. GP visits |  |  |  |
| 6–12 months pre-enrolment | 5.6 | 6.5 | 0.14 |
| 6 months pre-enrolment | 5.6 | 6.6 | 0.14 |
| No. specialist visits |  |  |  |
| 6–12 months pre-enrolment | 0.5 | 0.6 | 0.03 |
| 6 months pre-enrolment | 0.6 | 0.6 | 0.01 |
| Total OOP ($)^ |  |  |  |
| 6–12 months pre-enrolment | 228 | 244 | 0.01 |
| 6 months pre-enrolment | 230 | 239 | 0.01 |
| No. overnight hospital admissions\* | |  |  |
| 6–12 months pre-enrolment | 0.7 | 0.7 | 0.04 |
| 6 months pre-enrolment | 0.7 | 0.9 | 0.09 |
| Cost of admissions |  |  |  |
| 6–12 months pre-enrolment | 13,032 | 14,345 | 0.05 |
| 6 months pre-enrolment | 12,178 | 15,268 | 0.13 |

Notes: \*Including patients with no admissions; ^includes bulk-billed patients.

# Appendix 1: HCH evaluation team and HCH Evaluation Working Group membership

**Health Policy Analysis (HPA)**

* Jim Pearse (HCH Evaluation director)
* Deniza Mazevska (HCH Project manager and Quality manager)
* Prof. Patrick McElduff
* Christine Stone
* Joel Tuccia
* Owen Cho
* Susan Mitchell
* Ben McElduff

**Centre for Big Data Research in Health (CBDRH), University of NSW**

* Prof. Louisa Jorm
* Prof. Sallie-Anne Pearson
* Dr Michael Falster
* Dr Duong (Danielle) Tran

**Centre for Health Economics Research and Evaluation (CHERE), University of Technology**

* Prof. Jane Hall
* Prof. Kees van Gool
* Dr Serena Yu
* Dr Maryam Naghsh Nejad
* Dr Michael Wright

**Collaborating researchers, Australia**

* Prof. James Dunbar, Deakin University
* Prof. Robyn McDermott, James Cook University
* Dr Tim Smyth, Consultant
* Dr Joanna Henryks, Consultant (Central Australia case study)
* Maddie Bower, Flinders University (Top End case study)

**Expert advisors**

* Dr Rebecca Rosen, Nuffield Trust London
* Dr Steve Sutch, Sutch Consulting International Ltd
* Dr Kathryn Mack McDonald, Stanford University

**Social Research Centre, Australian National University**

* Anna Lethborg
* Charles Dove

## HCH Evaluation Working Group membership

|  |  |
| --- | --- |
| Chair (Assistant Secretary, Primary Health and Palliative Care Branch, Australian Government Department of Health) | Currently Dr Bronwyn Morrish |
| Member (Practice Manager) | Ms Tracey Johnson |
| Member (Practice Research and Evaluation) | Dr Cameron Martin |
| Member (Academic) | Prof John Wakerman |
| Member (Consumer Rep) | Ms Jo Root |
| Member (Consumer Rep) | Ms Jan Donovan |
| Member (Researcher) | Dr Karen Gardner |
| Member (Indigenous) | Dr John Boffa |
| Member (Researcher) | Prof Mark Harris |
| Member (Pharmacy Guild) | Ms Marsha Gomez |

# Appendix 2: Health conditions in the predictive risk model vs derived in Pen CS extracts

| **Predictive risk model – Condition group** | **Predictive risk model – Individual condition** | **Derived in Pen CS extract1** |
| --- | --- | --- |
| **Respiratory** | Asthma | √ |
| Chronic obstructive pulmonary disease (COPD) | √ |
| **Atrial fibrillation** | Atrial fibrillation | √ |
| **Cardiovascular** | Coronary heart disease | √ |
| Stroke | √ |
| Transient ischaemic attack |  |
| Congestive heart failure | √ |
| Rheumatic heart disease |  |
| **Osteoarthritis** | Osteoarthritis | √ |
| **Osteoporosis** | Osteoporosis | √ |
| **Rheumatoid arthritis** | Rheumatoid arthritis |  |
| **Mental health** | Depression | √ |
| Anxiety | √ |
| Bipolar disorder | √ |
| Schizophrenia | √ |
| Dementia | √ |
| Learning difficulties |  |
| **Cancer** | Cancer | Any cancer |
| **Digestive** | Crohn’s disease |  |
| Ulcerative colitis |  |
| Coeliac disease |  |
| Steatorrhea |  |
| Malabsorption syndrome |  |
| Chronic liver disease |  |
| Pancreatitis |  |
| **Hypertension** | Hypertension | √ |
| **Blood fats** | Hyperlipidaemia | √ |
| Hypercholesterolaemia |  |
| Hypertriglyceridemia |  |
| **Chronic kidney** | Chronic kidney disease | √ |
| **Diabetes type I** | Diabetes type I | √ |
| **Diabetes type 2** | Diabetes type 2 | √ |
| **Venous thromboembolism** | Venous thromboembolism |  |
| **Other** | Falls |  |
| Epilepsy |  |

*Notes: 1 A tick indicates that a health condition listed in the Predictive Risk Model was also derived by Pen CS extract and available for evaluation.*

# Appendix 3: Keywords to identify health conditions from practice extracts

| **Patient conditions** | **Textual descriptions** |
| --- | --- |
| Asthma | Acute asthma, acute exacerbation of asthma, allergic asthma, asthma, asthma attack, asthmatic bronchitis, childhood asthma, chronic obstructive airway disease with asthma, cough variant asthma, eosinophilic asthma, exacerbation of asthma, exercise-induced asthma, hay fever with asthma, late onset asthma, occupational asthma, seasonal asthma, severe asthma, thunderstorm asthma, viral exacerbation of asthma. |
| COPD | Acute exacerbation of chronic obstructive airways disease, COPD, chronic lung disease, chronic obstructive airway disease with asthma, interstitial lung disease, pulmonary fibrosis, restrictive lung disease. |
| Atrial fibrillation | Atrial fibrillation, atrial fibrillation and flutter, chronic atrial fibrillation, controlled atrial fibrillation, non-rheumatic atrial fibrillation, paroxysmal atrial fibrillation, rapid atrial fibrillation. |
| Coronary heart disease | Acute ST segment elevation myocardial infarction, acute coronary syndrome, acute myocardial infarction, acute non-ST segment elevation myocardial infarction, angina, cardiac arrest, coronary angioplasty, coronary artery bypass graft, coronary artery bypass graft, myocardial infarction, percutaneous transluminal coronary angioplasty, prinzmetal angina, silent myocardial infarction, stable angina. |
| Stroke | Brain stem infarction, brainstem stroke syndrome, cerebral embolism, cerebral haemorrhage, cerebral infarction, cerebrovascular accident, embolic stroke, haemorrhagic cerebral infarction, intracranial haemorrhage, left sided cerebral hemisphere cerebrovascular accident, subarachnoid haemorrhage, subdural haemorrhage, thalamic infarction, thrombotic stroke. |
| Congestive heart failure | Biventricular congestive heart failure, chronic heart failure, congestive heart failure, diastolic heart failure, heart failure, heart failure with reduced ejection fraction, hypertensive heart failure, left ventricular diastolic dysfunction, right heart failure. |
| Osteoarthritis | Patellofemoral osteoarthritis, osteoarthritis. |
| Osteoporosis | Osteoporosis, osteoporosis due to corticosteroids, osteoporotic fracture, posttraumatic osteoporosis, postmenopausal osteoporosis. |
| Anxiety | Adjustment disorder with anxious mood, anxiety, anxiety attack, anxiety disorder, anxiety neurosis, anxious personality disorder, chronic anxiety, generalised anxiety disorder, mixed anxiety and depressive disorder, separation anxiety disorder of childhood, social phobia. |
| Depression | adjustment disorder with depressed mood, agitated depression, chronic depression, depressed mood, depression, endogenous depression, major depressive disorder, mixed anxiety and depressive disorder, recurrent depression, severe depression, severe major depression with psychotic features, symptoms of depression. |
| Bipolar disorder | Bipolar, bipolar i disorder, bipolar ii disorder, bipolar disorder, schizoaffective disorder, bipolar type. |
| Schizophrenia | Catatonic schizophrenia, chronic paranoid schizophrenia, chronic schizophrenia, paranoid schizophrenia, psychotic disorder, schizoaffective disorder, schizophrenia. |
| Dementia | Dementia, dementia associated with alcoholism, dementia of frontal lobe type, frontotemporal dementia, senile dementia of the Lewy body type, senile dementia with psychosis multi-infarct dementia, vascular dementia. |
| High blood pressure | Antihypertensive therapy, diastolic hypertension, essential hypertension, hypertensive, malignant hypertension, ocular hypertension, portal hypertension, pulmonary hypertension, renal hypertension, renovascular hypertension, systolic hypertension. |
| High cholesterol | Cholesterol, dyslipidaemia, familial combined hyperlipidaemia, familial hypercholesterolaemia, hypercholesterolaemia, hyperlipidaemia, mixed hyperlipidaemia. |
| Diabetes type 1 | Diabetes mellitus type 1 |
| Diabetes type 2 | Diabetes mellitus type 2 |
| Chronic kidney disease | Anaemia of chronic renal failure, chronic kidney disease, chronic renal impairment, end stage renal disease, hypertensive renal disease, IGA nephropathy, medullary sponge kidney, renal dialysis, transplant of kidney |
| Cancer | Cancer, malignant, metastatic, carcino, leukaemia, neoplasm, neoplastic, lymphoma, melanoma, blastoma, mesothelioma, sarcoma, seminoma |

Notes: 1 These keywords were searched in a field containing SNOMED-CT concept textual descriptions in POLAR extracts, a field containing textual description of patient diagnosis in Sonic extracts, and a free-text field containing description of diagnosis in MedicineInsight extracts. The search considered common spelling variations for example, diabetes type 2, diabetes type ii, NIDDM. The search did not include an unconfirmed diagnosis i.e. text descriptions contain terms such as “likely”, “possible”, “suspected”, “investigation”, a question mark, or other similar terminology.

# Appendix 4: Keywords to identify medicine use and flu vaccine from practice extracts

| **Use of medication and flu vaccination** | **Keywords for medicine1** |
| --- | --- |
| **Medication for diabetes** | Acarbose, alogliptin, canagliflozin, dapagliflozin, dulaglutide, empagliflozin, ertugliflozin, exanatide, glibenclamide, gliclazide, glimepiride, glipizide, glyburide, insulin, linagliptin, liraglutide, metformin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin, vildagliptin |
| **Antithrombotic agents** | Abciximab, apixaban, aspirin, bivalirudin, clopidogrel, dabigatran, dalteparin, danaparoid, dipyridamole, enoxaparin, eptifibatide, fondaparinux, heparin, nadroparin, prasugrel, rivaroxaban, ticagrelo, ticlopidine, tirofiban, warfarin |
| **Medications for cardiovascular disease** |  |
| Diuretics | Bumetanide, ethacrynic acid, frusemide, hydrochlorothiazide, hydrochlorothiazide amiloride, indapamide hemihydrate |
| Beta blockers | Atenolol, bisoprolol fumarate, carvedilol, esmolol hydrochloride, labetalol hydrochloride, metoprolol succinate, metoprolol tartrate, oxprenolol hydrochloride, pindolol, propranolol hydrochloride, sotalol |
| Calcium channel blockers | Amlodipine, atorvastatin, diltiazem hydrochloride, felodipine, lercanidipine hydrochloride, nifedipine, verapamil hydrochloride |
| Agents acting on the renin-angiotensin system | Candesartan cilexetil, captopril, enalapril, eprosartan mesylate, fosinopril sodium, irbesartan, lisinopril, losartan potassium, imesartan medoxomil, perindopril, perindopril arginine, quinapril, ramipril, telmisartan, trandolapril, valsartan |
| Lipid modifying agents | Atorvastatin, alirocumab, cerivastatin, cholestyramine, clofibrate, colestipol, evolocumab, ezetimibe, fenofibrate, fluvastatin, gemfibrozil, policosanol, pravastatin sodium, probucol, rosuvastatin, simvastatin |
| **Medications for nervous system** |  |
| Analgesics- opioids | Buprenorphine, codein, hydromorphone, morphine, oxycodone, pentanyl, tapentadol, tramadol |
| Antidepressants | Carbamazepine, amitriptyline hydrochloride, citalopram, hydrobromide, clomipramine hydrochloride, desvenlafaxine, dothiepin hydrochloride, doxepin hydrochloride, duloxetine, escitalopram oxalate, fluoxetine hydrochloride, fluvoxamine maleate, imipramine hydrochloride, lithium carbonate, mianserin hydrochloride, mirtazapine, moclobemide, nortriptyline hydrochloride, paroxetine hydrochloride, phenelzine sulfate, reboxetine mesylate, tranylcypromine sulfate, trimipramine maleate |
| Anti-anxiety | Clonazepam, alprazolam, bromazepam, clobazam, diazepam, flunitrazepam, lorazepam, midazolam, nitrazepam, oxazepam, temazepam, triazolam |
| Antipsychotics | Amisulpride, aripiprazole, asenapine, brexpiprazole, chlorpromazine hydrochloride, clozapine, clozapine, flupenthixol decanoate, haloperidol, haloperidol decanoate, levomepromazine, olanzapine, paliperidone, periciazine, quetiapine, risperidone, thioridazine, ziprasidone, zuclopenthixol decanoate |
| Stimulants | Atomoxetine hydrochloride, dexamphetamine sulfate, methylphenidate |
| **Medications for respiratory system** | Aclidinium, budesonide, eformoterol fumarate dihydrate, fluticasone, fluticasone propionate, glycopyrronium, indacaterol, salbutamol sulfate, salmeterol xinafoate, terbutaline sulfate, tiotropium, umeclinium |
| **Influenza vaccine** | Flu vaccine, influenza vaccine, agrippal, afluria quad, fluad, fluad quad, fluquadri, fluarix, luarix tetra, fluvax, fluvirin, fluzone high dose, influvac tetra, vaxigrip, vaxigrip tetra |

Notes: 1 These keywords were searched in a field containing generic names of prescribed medicines in POLAR extracts, a field containing textual description of brand name of prescribed medicines in Sonic extract, a field containing brand names of prescribed medicines in MedicineInsight extracts.

# Appendix 5: Changes to chronic disease management detailed tables

## Changes in the quality of chronic illness care

Table 27: Recording of HbA1c among HCH and comparator patients with type 2 diabetes, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number 1** | **Number2** | **Percentage (95%CI)** |
| **Recording of HbA1c in the last 12 months** | | | | | | | |
| Pre-enrolment | 2,816 | 2,414 | 85.7% (84.4-87.0) | 2,816 | 2,436 | 86.5% (85.2-87.8) | 0.396 |
| First year | 2,722 | 2,282 | 83.8% (82.4-85.2) | 2,722 | 2,155 | 79.2% (77.8-80.5) | <0.001 |
| Second year | 2,607 | 2,058 | 78.9% (77.3-80.5) | 2,607 | 1,854 | 71.1% (69.6-72.6) | <0.001 |
| Third year | 381 | 274 | 71.9% (67.2-76.2) | 381 | 260 | 68.2% (63.7-72.4) | 0.268 |
| **Recording of HbA1c in the last six months** | | | | | | | |
| Pre-enrolment | 2,816 | 2,063 | 73.3% (71.6-74.9) | 2,816 | 2,094 | 74.4% (72.7-76.0) | 0.347 |
| 6 months | 2,756 | 1,840 | 66.8% (65.0-68.5) | 2,756 | 1,786 | 64.8% (63.1-66.5) | 0.125 |
| 12 months | 2,722 | 1,825 | 67.0% (65.3-68.8) | 2,722 | 1,690 | 62.1% (60.4-63.8) | <0.001 |
| 18 months | 2,679 | 1715 | 64.0% (62.2-65.8) | 2,679 | 1529 | 57.1% (55.3-58.8) | <0.001 |
| 24 months | 2,607 | 1,671 | 64.1% (62.2-65.9) | 2,607 | 1,461 | 56.0% (54.3-57.8) | <0.001 |
| 30 months | 1,679 | 1,001 | 59.6% (57.3-61.9) | 1,679 | 912 | 54.3% (52.1-56.5) | 0.002 |
| 36 months | 381 | 218 | 57.2% (52.2-62.1) | 381 | 200 | 52.5% (47.7-57.2) | 0.190 |

Notes: 1 The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2 Number of patients who had a test recorded (i.e. numerator). 3 Chi-square test for proportions, 1df.

Table 28: Having MBS claims for HbA1c tests among HCH and comparator patients with diabetes, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for HbA1c test in the last 12 months** | | | | | | | |
| Pre-enrolment | 3,193 | 1,732 | 54.2% (52.5-56.0) | 3,193 | 1,716 | 53.7% (52.0-55.5) | 0.687 |
| First year | 3,131 | 1,646 | 52.6% (50.8-54.3) | 3,118 | 1,503 | 48.2% (46.5-49.9) | <0.001 |
| Second year | 3,058 | 1,534 | 50.2% (48.4-51.9) | 3,019 | 1,365 | 45.2% (43.5-46.9) | <0.001 |
| Third year | 952 | 463 | 48.6% (45.5-51.8) | 951 | 399 | 42.0% (39.0-44.9) | 0.003 |
| **Having MBS claims for HbA1c test in the last six months** | | | | | | | |
| Pre-enrolment | 3,193 | 1,201 | 37.6% (35.9-39.3) | 3,193 | 1,213 | 38.0% (36.3-39.7) | 0.756 |
| 6 months | 3,164 | 1,087 | 34.4% (32.7-36.0) | 3,157 | 1,050 | 33.3% (31.7-34.9) | 0.357 |
| 12 months | 3,131 | 1,131 | 36.1% (34.5-37.8) | 3,118 | 1,018 | 32.6% (31.1-34.3) | 0.003 |
| 18 months | 3,092 | 1,046 | 33.8% (32.2-35.5) | 3,071 | 948 | 30.9% (29.3-32.5) | 0.013 |
| 24 months | 3,058 | 1,030 | 33.7% (32.0-35.4) | 3,019 | 900 | 29.8% (28.3-31.4) | 0.001 |
| 30 months | 2,379 | 771 | 32.4% (30.6-34.3) | 2,342 | 682 | 29.1% (27.4-31.0) | 0.014 |
| 36 months | 952 | 301 | 31.6% (28.7-34.6) | 951 | 262 | 27.5% (24.9-30.4) | 0.051 |

Notes: 1 The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2 Number of patients who had one or more MBS claims (i.e. numerator). 3 Chi-square test for proportions, 1df.

Table 29: Recording of blood pressure among all HCH and comparator patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of blood pressure in the last 12 months** | | | | | | | |
| Pre-enrolment | 9,811 | 8,254 | 84.1% (83.4-84.8) | 9,811 | 8,353 | 85.1% (84.4-85.9) | 0.05 |
| First year | 9,433 | 7,940 | 84.2% (83.4-84.9) | 9,433 | 7,259 | 77.0% (76.2-77.6) | <0.001 |
| Second year | 9,080 | 6,795 | 74.8% (73.9-75.7) | 9,080 | 6,106 | 67.2% (66.4-68.1) | <0.001 |
| Third year | 1190 | 830 | 69.7% (67.1-72.3) | 1190 | 782 | 65.7% (63.1-68.2) | 0.035 |
| **Recording of blood pressure in the last six months** | | | | | | | |
| Pre-enrolment | 9,811 | 7,486 | 76.3% (75.5-77.1) | 9,811 | 7,580 | 77.3% (76.4-78.1) | 0.112 |
| 6 months | 9,544 | 7,038 | 73.7% (72.9-74.6) | 9,544 | 6,291 | 65.9% (65.1-66.7) | <0.001 |
| 12 months | 9,433 | 6,505 | 69.0% (68.0-69.9) | 9,433 | 5,932 | 62.9% (62.0-63.8) | <0.001 |
| 18 months | 9,247 | 5,833 | 63.1% (62.1-64.1) | 9,247 | 5,161 | 55.8% (54.9-56.7) | <0.001 |
| 24 months | 9,080 | 5,432 | 59.8% (58.8-60.8) | 9,080 | 4,793 | 52.8% (51.8-53.7) | <0.001 |
| 30 months | 5,786 | 3,241 | 56.0% (54.7-57.3) | 5,786 | 2,919 | 50.4% (49.2-51.7) | <0.001 |
| 36 months | 1190 | 630 | 52.9% (50.1-55.8) | 1190 | 640 | 53.8% (50.9-56.6) | 0.681 |

Notes: 1 The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2 Number of patients who had blood pressure recorded (i.e. numerator). 3 Chi-square test for proportions, 1df.

Table 30: Recording of blood pressure among HCH and comparator patients with type 2 diabetes, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of blood pressure in the last 12 months** | | | | | | | |
| Pre-enrolment | 2,816 | 2,527 | 89.7% (88.6-90.8) | 2,816 | 2,559 | 90.9% (89.7-91.9) | 0.149 |
| First year | 2,722 | 2,520 | 92.6% (91.5-93.5) | 2,722 | 2,308 | 84.8% (83.8-85.7) | <0.001 |
| Second year | 2,607 | 2,217 | 85.0% (83.6-86.4) | 2,607 | 1,951 | 74.8% (73.5-76.1) | <0.001 |
| Third year | 381 | 300 | 78.7% (74.4-82.6) | 381 | 266 | 69.8% (65.8-73.5) | 0.005 |
| **Recording of blood pressure in the last six months** | | | | | | | |
| Pre-enrolment | 2,816 | 2,378 | 84.4% (83.1-85.7) | 2,816 | 2,410 | 85.6% (84.2-86.9) | 0.232 |
| 6 months | 2,756 | 2,305 | 83.6% (82.2-85.0) | 2,756 | 2,082 | 75.5% (74.2-76.8) | <0.001 |
| 12 months | 2,722 | 2,180 | 80.1% (78.5-81.5) | 2,722 | 1,977 | 72.6% (71.2-74.0) | <0.001 |
| 18 months | 2,679 | 1,989 | 74.2% (72.6-75.9) | 2,679 | 1,699 | 63.4% (61.9-64.9) | <0.001 |
| 24 months | 2,607 | 1,817 | 69.7% (67.9-71.4) | 2,607 | 1,584 | 60.8% (59.1-62.4) | <0.001 |
| 30 months | 1,679 | 1,139 | 67.8% (65.6-70.0) | 1,679 | 1,029 | 61.3% (59.1-63.4) | <0.001 |
| 36 months | 381 | 232 | 60.9% (55.9-65.7) | 381 | 223 | 58.5% (53.7-63.2) | 0.506 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had blood pressure recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 31: Recording of lipid tests among HCH and comparators patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of lipid tests in the last 12 months** | | | | | | | |
| Pre-enrolment | 9,811 | 7,408 | 75.5% (74.6-76.3) | 9,811 | 7,473 | 76.2% (75.3-77.0) | 0.278 |
| First year | 9,433 | 6,573 | 69.7% (68.7-70.6) | 9,433 | 5,551 | 58.8% (58.0-59.7) | <0.001 |
| Second year | 9,080 | 5,688 | 62.6% (61.6-63.6) | 9,080 | 5,073 | 55.9% (54.9-56.8) | <0.001 |
| Third year | 1,190 | 722 | 60.7% (57.9-63.4) | 1,190 | 685 | 57.6% (54.8-60.2) | 0.123 |
| **Recording of lipid tests in the last six months** | | | | | | | |
| Pre-enrolment | 9,811 | 5,558 | 56.7% (55.7-57.6) | 9,811 | 5,658 | 57.7% (56.7-58.7) | 0.149 |
| 6 months | 9,544 | 4,590 | 48.1% (47.1-49.1) | 9,544 | 3,721 | 39.0% (38.1-39.9) | <0.001 |
| 12 months | 9,433 | 4,414 | 46.8% (45.8-47.8) | 9,433 | 3,762 | 39.9% (39.0-40.8) | <0.001 |
| 18 months | 9,247 | 4,009 | 43.4% (42.3-44.4) | 9,247 | 3,424 | 37.0% (36.1-38.0) | <0.001 |
| 24 months | 9,080 | 3,883 | 42.8% (41.7-43.8) | 9,080 | 3,405 | 37.5% (36.6-38.5) | <0.001 |
| 30 months | 5,786 | 2,257 | 39.0% (37.8-40.3) | 5,786 | 2,019 | 34.9% (33.7-36.1) | <0.001 |
| 36 months | 1,190 | 464 | 39.0% (36.3-41.8) | 1,190 | 484 | 40.7% (37.9-43.5) | 0.402 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a test recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 32: Having MBS claims for lipid tests among HCH and comparator patients, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for lipid test in the last 12 months** | | | | | | | |
| Pre-enrolment | 10,682 | 2,658 | 24.9% (24.1-25.7) | 10,682 | 2,598 | 24.3% (23.5-25.1) | 0.341 |
| First year | 10,454 | 2,411 | 23.1% (22.3-23.9) | 10,459 | 2,217 | 21.2% (20.4-22.0) | 0.001 |
| Second year | 10,196 | 2,074 | 20.3% (19.6-21.1) | 10,224 | 1,899 | 18.6% (17.8-19.3) | 0.001 |
| Third year | 2,873 | 568 | 19.8% (18.4-21.3) | 2,930 | 545 | 18.6% (17.2-20.0) | 0.258 |
| **Having MBS claims for lipid test in the last six months** | | | | | | | |
| Pre-enrolment | 10,682 | 1,625 | 15.2% (14.5-15.9) | 10,682 | 1,541 | 14.4% (13.8-15.1) | 0.106 |
| 6 months | 10,579 | 1,452 | 13.7% (13.1-14.4) | 10,585 | 1,381 | 13.0% (12.4-13.7) | 0.147 |
| 12 months | 10,454 | 1,358 | 13.0% (12.4-13.6) | 10,459 | 1,205 | 11.5% (10.9-12.1) | 0.001 |
| 18 months | 10,333 | 1,207 | 11.7% (11.1-12.3) | 10,344 | 1,136 | 11.0% (10.4-11.6) | 0.113 |
| 24 months | 10,196 | 1,213 | 11.9% (11.3-12.5) | 10,224 | 1,060 | 10.4% (9.8-11.0) | <0.001 |
| 30 months | 7,588 | 878 | 11.6% (10.9-12.3) | 7,616 | 823 | 10.8% (10.1-11.5) | 0.135 |
| 36 months | 2,873 | 334 | 11.6% (10.5-12.8) | 2,930 | 309 | 10.5% (9.5-11.7) | 0.190 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had one or more MBS claims (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 33: Recording of kidney function tests among HCH and comparator patients with type 2 diabetes or cardiovascular disease, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of kidney function tests4 in the last 12 months** | | | | | | | |
| Pre-enrolment | 6,811 | 6,044 | 88.7% (88.0-89.5) | 6,811 | 6,048 | 88.8% (88.0-89.5) | 0.913 |
| First year | 6,539 | 5,600 | 85.6% (84.8-86.5) | 6,539 | 4,972 | 76.0% (75.2-76.8) | <0.001 |
| Second year | 6,313 | 4,989 | 79.0% (78.0-80.0) | 6,313 | 4,389 | 69.5% (68.6-70.5) | <0.001 |
| Third year | 866 | 627 | 72.4% (69.3-75.3) | 866 | 556 | 64.2% (61.3-66.9) | <0.001 |
| **Recording of kidney function tests4 in the last six months** | | | | | | | |
| Pre-enrolment | 6,811 | 4,925 | 72.3% (71.2-73.4) | 6,811 | 4,941 | 72.5% (71.5-73.6) | 0.759 |
| 6 months | 6,625 | 4,367 | 65.9% (64.8-67.0) | 6,625 | 3,893 | 58.8% (57.7-59.8) | <0.001 |
| 12 months | 6,539 | 4,265 | 65.2% (64.1-66.4) | 6,539 | 3,722 | 56.9% (55.8-58.0) | <0.001 |
| 18 months | 6,430 | 3,911 | 60.8% (59.6-62.0) | 6,430 | 3,394 | 52.8% (51.7-53.9) | <0.001 |
| 24 months | 6,313 | 3,838 | 60.8% (59.6-62.0) | 6,313 | 3,385 | 53.6% (52.5-54.7) | <0.001 |
| 30 months | 4,049 | 2,294 | 56.7% (55.1-58.2) | 4,049 | 2,050 | 50.6% (49.2-52.1) | <0.001 |
| 36 months | 866 | 461 | 53.2% (49.9-56.5) | 866 | 425 | 49.1% (45.9-52.3) | 0.084 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a test recorded (i.e. numerator). 3Chi-square test for proportions, 1df. 4Kidney function tests included estimated glomerular filtration rate (eGFR), creatinine and albumin-creatine ratio.

Table 34: Recording of eGFR tests among HCH and comparator patients with type 2 diabetes or cardiovascular disease, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of eGFR tests in the last 12 months** | | | | | | | |
| Pre-enrolment | 6,811 | 5,882 | 86.4% (85.5-87.2) | 6,811 | 5,896 | 86.6% (85.7-87.4) | 0.726 |
| First year | 6,539 | 5,506 | 84.2% (83.3-85.1) | 6,539 | 4,833 | 73.9% (73.1-74.7) | <0.001 |
| Second year | 6,313 | 4,896 | 77.6% (76.5-78.6) | 6,313 | 4,302 | 68.1% (67.2-69.1) | <0.001 |
| Third year | 866 | 618 | 71.4% (68.3-74.3) | 866 | 545 | 62.9% (60.1-65.7) | <0.001 |
| **Recording of eGFR tests in the last six months** | | | | | | | |
| Pre-enrolment | 6,811 | 4,732 | 69.5% (68.4-70.6) | 6,811 | 4,776 | 70.1% (69.0-71.2) | 0.412 |
| 6 months | 6,625 | 4,218 | 63.7% (62.5-64.8) | 6,625 | 3,754 | 56.7% (55.6-57.8) | <0.001 |
| 12 months | 6,539 | 4,147 | 63.4% (62.2-64.6) | 6,539 | 3,598 | 55.0% (53.9-56.1) | <0.001 |
| 18 months | 6,430 | 3,809 | 59.2% (58.0-60.4) | 6,430 | 3,287 | 51.1% (50.0-52.2) | <0.001 |
| 24 months | 6,313 | 3,673 | 58.2% (57.0-59.4) | 6,313 | 3,301 | 52.3% (51.1-53.4) | <0.001 |
| 30 months | 4,049 | 2,108 | 52.1% (50.5-53.6) | 4,049 | 2,009 | 49.6% (48.1-51.1) | 0.026 |
| 36 months | 866 | 450 | 52.0% (48.6-55.3) | 866 | 411 | 47.5% (44.3-50.6) | 0.061 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a test recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 35: Smoking status ever recorded in HCH patients, derived from practice extracts

|  |  |  |  |
| --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| Pre-enrolment | 9,811 | 7,631 | 77.8% (76.9-78.6) |
| 6 months | 9544 | 8286 | 86.8% (86.1-87.5) |
| 12 months | 9433 | 8751 | 92.8% (92.2-93.3) |
| 18 months | 9,247 | 8,794 | 95.1% (94.6-95.5) |
| 24 months | 9,080 | 8,730 | 96.1% (95.7-96.5) |
| 30 months | 5,786 | 5,603 | 96.8% (96.4-97.3) |
| 36 months | 1,190 | 1,171 | 98.4% (97.5-99.0) |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had smoking status ever recorded (i.e. numerator).

Table 36: Body height ever recorded among HCH and comparator patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| Pre-enrolment | 9,811 | 8329 | 84.9% (84.2-85.6) | 9,811 | 8353 | 85.1% (84.4-85.8) | 0.631 |
| 6 months | 9,544 | 8,548 | 89.6% (88.9-90.2) | 9,544 | 8,232 | 86.3% (85.6-86.8) | <0.001 |
| 12 months | 9,433 | 8,560 | 90.7% (90.1-91.3) | 9,433 | 8,229 | 87.2% (86.6-87.8) | <0.001 |
| 18 months | 9,247 | 8,471 | 91.6% (91.0-92.2) | 9,247 | 8,143 | 88.1% (87.5-88.6) | <0.001 |
| 24 months | 9,080 | 8,367 | 92.1% (91.6-92.7) | 9,080 | 8,055 | 88.7% (88.2-89.2) | <0.001 |
| 30 months | 5,786 | 5,288 | 91.4% (90.6-92.1) | 5,786 | 5,130 | 88.7% (87.9-89.3) | <0.001 |
| 36 months | 1,190 | 1,111 | 93.4% (91.8-94.6) | 1,190 | 1,079 | 90.7% (89.1-91.9) | 0.016 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had body height ever recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 37: Recording of body weight among HCH and comparator patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of body weight in the last 12 months** | | | | | | | |
| Pre-enrolment | 9,811 | 7,282 | 74.2% (73.3-75.1) | 9,811 | 7,296 | 74.4% (73.5-75.2) | 0.819 |
| First year | 9,433 | 6,710 | 71.1% (70.2-72.0) | 9,433 | 5,459 | 57.9% (57.0-58.7) | <0.001 |
| Second year | 9,080 | 5,652 | 62.2% (61.2-63.2) | 9,080 | 4,436 | 48.9% (48.0-49.7) | <0.001 |
| Third year | 1,190 | 684 | 57.5% (54.7-60.3) | 1,190 | 561 | 47.1% (44.6-49.7) | <0.001 |
| **Recording of body weight in the last six months** | | | | | | | |
| Pre-enrolment | 9,811 | 6,007 | 61.2% (60.3-62.2) | 9,811 | 5,450 | 55.5% (54.6-56.5) | <0.001 |
| 6 months | 9,544 | 5,050 | 52.9% (51.9-53.9) | 9,544 | 4,009 | 42.0% (41.1-42.9) | <0.001 |
| 12 months | 9,433 | 4,886 | 51.8% (50.8-52.8) | 9,433 | 3,885 | 41.2% (40.3-42.1) | <0.001 |
| 18 months | 9,247 | 4,251 | 46.0% (45.0-47.0) | 9,247 | 3,209 | 34.7% (33.8-35.6) | <0.001 |
| 24 months | 9,080 | 4,113 | 45.3% (44.3-46.3) | 9,080 | 3,110 | 34.3% (33.4-35.1) | <0.001 |
| 30 months | 5,786 | 2,469 | 42.7% (41.4-44.0) | 5,786 | 1,846 | 31.9% (30.8-33.0) | <0.001 |
| 36 months | 1,190 | 470 | 39.5% (36.8-42.3) | 1,190 | 415 | 34.9% (32.3-37.5) | 0.020 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had body weight recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 38: Recording of three CVD risk factors (age, cholesterol and blood pressure) among HCH and comparator patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Recording of the three risk factors in the last 12 months** | | | | | | | |
| Pre-enrolment | 9,811 | 6,857 | 69.9% (69.0-70.8) | 9,811 | 6,957 | 70.9% (70.0-71.8) | 0.118 |
| First year | 9,433 | 6,141 | 65.1% (64.1-66.1) | 9,433 | 5,182 | 54.9% (54.0-55.8) | <0.001 |
| Second year | 9,080 | 5,212 | 57.4% (56.4-58.4) | 9,080 | 4,597 | 50.6% (49.7-51.6) | <0.001 |
| Third year | 1,190 | 636 | 53.4% (50.6-56.3) | 1,190 | 613 | 51.5% (48.7-54.3) | 0.345 |
| **Recording of the three risk factors in the last six months** | | | | | | | |
| Pre-enrolment | 9,811 | 4,897 | 49.9% (48.9-50.9) | 9,811 | 5,053 | 51.5% (50.5-52.5) | 0.026 |
| 6 months | 9,544 | 3,984 | 41.7% (40.8-42.7) | 9,544 | 3,230 | 33.8% (33.0-34.7) | <0.001 |
| 12 months | 9,433 | 3,804 | 40.3% (39.3-41.3) | 9,433 | 3,250 | 34.5% (33.5-35.4) | <0.001 |
| 18 months | 9,247 | 3,298 | 35.7% (34.7-36.6) | 9,247 | 2,824 | 30.5% (29.6-31.5) | <0.001 |
| 24 months | 9,080 | 3,202 | 35.3% (34.3-36.3) | 9,080 | 2,773 | 30.5% (29.6-31.5) | <0.001 |
| 30 months | 5,786 | 1,861 | 32.2% (31.0-33.4) | 5,786 | 1,639 | 28.3% (27.2-29.5) | <0.001 |
| 36 months | 1,190 | 342 | 28.7% (26.2-31.4) | 1,190 | 397 | 33.4% (30.6-36.2) | 0.015 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had all the three risk factors recorded (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 39: Immunisation against influenza among HCH and comparator patients, derived from practice extracts

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Influenza immunisation in the last 12 months** | | | | | | | |
| Pre-enrolment | 9,811 | 5,628 | 57.4% (56.4-58.3) | 9,811 | 5,769 | 58.8% (57.8-59.8) | 0.051 |
| First year | 9,433 | 6,241 | 66.2% (65.2-67.1) | 9,433 | 5,221 | 55.3% (54.5-56.2) | <0.001 |
| Second year | 9,080 | 5,541 | 61.0% (60.0-62.0) | 9,080 | 4,644 | 51.1% (50.2-52.1) | <0.001 |
| Third year | 1,190 | 662 | 55.6% (52.8-58.4) | 1,190 | 615 | 51.7% (49.0-54.4) | 0.053 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had an influenza immunisation (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 40: Having MBS claims for development of a GP Management Plan among HCH and comparator patients, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for development of a GP Management Plan in the last 24 months** | | | | | | | |
| Pre-enrolment | 10,682 | 8,117 | 76.0% (75.2-76.8) | 10,682 | 6,374 | 59.7% (58.9-60.4) | <0.001 |
| First biennium | 10,196 | 1,970 | 19.3% (18.6-20.1) | 10,224 | 5,586 | 54.6% (53.3-55.9) | <0.001 |
| **Having MBS claims for development of a GP Management Plan in the last 12 months** | | | | | | | |
| Pre-enrolment | 10,682 | 5,961 | 55.8% (54.9-56.7) | 10,682 | 4,396 | 41.2% (40.3-42.0) | <0.001 |
| First year | 10,454 | 898 | 8.6% (8.1-9.1) | 10,459 | 3,863 | 36.9% (35.8-38.1) | <0.001 |
| Second year | 10,196 | 1,299 | 12.7% (12.1-13.4) | 10,224 | 3,373 | 33.0% (32.0-34.0) | <0.001 |
| Third year | 2,873 | 497 | 17.3% (16.0-18.7) | 2,930 | 893 | 30.5% (28.7-32.3) | <0.001 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a claim for MBS item 721 (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 41: Having MBS claims for Team Care Arrangement development among HCH and comparator patients, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for development of a Team Care Arrangement in the last 24 months** | | | | | | | |
| Pre-enrolment | 10,682 | 7,333 | 68.6% (67.8-69.5) | 10,682 | 5,894 | 55.2% (54.4-56.0) | <0.001 |
| First biennium | 10,196 | 1,807 | 17.7% (17.0-18.5) | 10,224 | 5,102 | 49.9% (48.7-51.1) | <0.001 |
| **Having MBS claims for development of a Team Care Arrangement in the last 12 months** | | | | | | | |
| Pre-enrolment | 10682 | 5,261 | 49.3% (48.3-50.2) | 10,682 | 4,041 | 37.8% (37.0-38.7) | <0.001 |
| First year | 10,454 | 841 | 8.0% (7.5-8.6) | 10,459 | 3,505 | 33.5% (32.5-34.6) | <0.001 |
| Second year | 10,196 | 1,171 | 11.5% (10.9-12.1) | 10,224 | 3,057 | 29.9% (28.9-30.9) | <0.001 |
| Third year | 2,873 | 470 | 16.4% (15.1-17.8) | 2,930 | 801 | 27.3% (25.6-29.1) | <0.001 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a claim for MBS item 723 (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 42: Having MBS claims for review of chronic disease management plans among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for review of chronic disease management plans in the last 24 months** | | | | | | | |
| Pre-enrolment | 10,682 | 6,186 | 57.9% (57.0-58.8) | 10,682 | 4,298 | 40.2% (39.5-41.0) | <0.001 |
| First biennium | 10196 | 1,444 | 14.2% (13.5-14.9) | 10,224 | 4,157 | 40.7% (39.5-41.8) | <0.001 |
| **Having MBS claims for review of chronic disease management plans in the last 12 months** | | | | | | | |
| Pre-enrolment | 10,682 | 4,793 | 44.9% (43.9-45.8) | 10,682 | 3,342 | 31.3% (30.5-32.1) | <0.001 |
| First year | 10,454 | 807 | 7.7% (7.2-8.2) | 10,459 | 3,229 | 30.9% (29.9-31.9) | <0.001 |
| Second year | 10,196 | 919 | 9.0% (8.5-9.6) | 10,224 | 2,798 | 27.4% (26.4-28.3) | <0.001 |
| Third year | 2,873 | 403 | 14.0% (12.8-15.3) | 2,930 | 765 | 26.1% (24.4-27.9) | <0.001 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a claim for MBS items 731, 732 and 729 (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 43: Having MBS claims for Health Assessment for Aboriginal and Torres Strait Islander People among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for Health Assessment in the last 24 months** | | | | | | | |
| Pre-enrolment | 10,682 | 996 | 9.3% (8.8-9.9) | 10,682 | 577 | 5.4% (5.0-5.8) | <0.001 |
| First biennium | 10,196 | 859 | 8.4% (7.9-9.0) | 10,224 | 509 | 5.0% (4.6-5.4) | <0.001 |
| **Having MBS claims for Health Assessment in the last 12 months** | | | | | | | |
| Pre-enrolment | 10,682 | 775 | 7.3% (6.8-7.8) | 10,682 | 439 | 4.1% (3.8-4.5) | <0.001 |
| First year | 10,454 | 592 | 5.7% (5.2-6.1) | 10,459 | 380 | 3.6% (3.3-4.0) | <0.001 |
| Second year | 10,196 | 604 | 5.9% (5.5-6.4) | 10,224 | 322 | 3.1% (2.8-3.5) | <0.001 |
| Third year | 2873 | 40 | 1.4% (1.0-1.9) | 2,930 | 46 | 1.6% (1.2-2.1) | 0.575 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. Note, Aboriginal and Torres Strait Islander people were unable to be identified within the data. 2Number of patients who had a claim for MBS item 715 (i.e. numerator). 3Chi-square test for proportions, 1df.

Table 44: Number of PBS dispensings in 12 months among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 52.9 | (43.7) | 51.2 | (44.2) |  |
| Median (IQR) | 45 | (20-76) | 43 | (17-73) |  |
| None | 680 | 6.4% (6.0-6.9) | 687 | 6.4% (6.0-6.9) | <0.001 |
| 1 to 9 | 947 | 8.9% (8.4-9.4) | 1,101 | 10.3% (9.7-10.9) |  |
| 10 to 29 | 2,044 | 19.1% (18.4-19.9) | 2,205 | 20.6% (19.9-21.4) |  |
| 30 to 59 | 3,081 | 28.8% (28-29.7) | 2,933 | 27.5% (26.6-28.3) |  |
| 60 to 89 | 2,027 | 19.0% (18.3-19.8) | 2,008 | 18.8% (18.1-19.5) |  |
| 90 or more | 1,903 | 17.8% (17.1-18.5) | 1,748 | 16.4% (15.7-17.1) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 53.9 | (43.8) | 51.6 | (45.0) |  |
| Median (IQR) | 46 | (21-77) | 43 | (17-73) |  |
| None | 670 | 6.4% (6.0-6.9) | 702 | 6.7% (6.2-7.2) | <0.001 |
| 1 to 9 | 873 | 8.4% (7.9-8.9) | 1,102 | 10.5% (10.0-11.1) |  |
| 10 to 29 | 1,925 | 18.4% (17.7-19.2) | 2,079 | 19.9% (19.1-20.7) |  |
| 30 to 59 | 3,049 | 29.2% (28.4-30.1) | 2,899 | 27.7% (26.9-28.6) |  |
| 60 to 89 | 2,039 | 19.5% (18.8-20.3) | 1,924 | 18.4% (17.7-19.1) |  |
| 90 or more | 1,898 | 18.2% (17.5-19.0) | 1,753 | 16.8% (16.1-17.5) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 53.4 | (43.4) | 50.9 | (44.6) |  |
| Median (IQR) | 46 | (20-77) | 42 | (16-74) |  |
| None | 690 | 6.8% (6.4-7.3) | 740 | 7.2% (6.8-7.8) | <0.001 |
| 1 to 9 | 878 | 8.6% (8.1-9.2) | 1,137 | 11.1% (10.5-11.8) |  |
| 10 to 29 | 1,821 | 17.9% (17.2-18.7) | 2,001 | 19.6% (18.8-20.4) |  |
| 30 to 59 | 2,957 | 29% (28.2-29.9) | 2,762 | 27.0% (26.2-27.9) |  |
| 60 to 89 | 2,051 | 20.1% (19.4-20.9) | 1,871 | 18.3% (17.6-19.1) |  |
| 90 or more | 1,799 | 17.6% (16.9-18.4) | 1,713 | 16.8% (16.0-17.5) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 57.1 | (43.6) | 55.9 | (47.8) |  |
| Median (IQR) | 49 | (26-79) | 47 | (21-79) |  |
| None | 85 | 3.0% (2.5-3.6) | 116 | 4.0% (3.4-4.7) | <0.001 |
| 1 to 9 | 240 | 8.4% (7.5-9.4) | 288 | 9.8% (8.8-11.0) |  |
| 10 to 29 | 497 | 17.3% (16.0-18.7) | 562 | 19.2% (17.8-20.7) |  |
| 30 to 59 | 897 | 31.2% (29.6-32.9) | 813 | 27.7% (26.2-29.3) |  |
| 60 to 89 | 607 | 21.1% (19.7-22.6) | 591 | 20.2% (18.8-21.6) |  |
| 90 or more | 547 | 19.0% (17.6-20.4) | 560 | 19.1% (17.7-20.5) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 5df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 45: Number of unique medicines dispensed in three months among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 5.9 | (4.4) | 5.7 | (4.4) |  |
| Median (IQR) | 5 | (3-8) | 5 | (2-8) |  |
| None | 1,141 | 10.7% (10.1-11.3) | 1,123 | 10.5% (9.9-11.1) | 0.064 |
| 1 to 4 | 3,530 | 33.0% (32.2-33.9) | 3,672 | 34.4% (33.5-35.3) |  |
| 5 to 9 | 4,046 | 37.9% (37.0-38.8) | 4,071 | 38.1% (37.2-39.0) |  |
| 10 to 14 | 1,496 | 14.0% (13.4-14.7) | 1,383 | 12.9% (12.3-13.6) |  |
| 15 or more | 469 | 4.4% (4.0-4.8) | 433 | 4.1% (3.7-4.4) |  |
| Total | 10,682 | 100% | 10,682 | 100% |  |
| **First year2** |  |  |  |  |  |
| Mean (std) | 5.9 | (4.5) | 5.6 | (4.6) |  |
| Median (IQR) | 5 | (3-8) | 5 | (2-8) |  |
| None | 1,175 | 11.2% (10.6-11.9) | 1,303 | 12.5% (11.8-13.1) | <0.001 |
| 1 to 4 | 3,332 | 31.9% (31.0-32.8) | 3,589 | 34.3% (33.4-35.2) |  |
| 5 to 9 | 3,966 | 37.9% (37.0-38.9) | 3,709 | 35.5% (34.6-36.4) |  |
| 10 to 14 | 1,490 | 14.3% (13.6-14.9) | 1,363 | 13.0% (12.4-13.7) |  |
| 15 or more | 491 | 4.7% (4.3-5.1) | 495 | 4.7% (4.3-5.2) |  |
| Total3 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year2** |  |  |  |  |  |
| Mean (std) | 5.8 | (4.4) | 5.4 | (4.4) |  |
| Median (IQR) | 5 | (3-8) | 5 | (2-8) |  |
| None | 1,144 | 11.2% (10.6-11.8) | 1,322 | 12.9% (12.3-13.6) | <0.001 |
| 1 to 4 | 3,381 | 33.2% (32.3-34.1) | 3,558 | 34.8% (33.9-35.7) |  |
| 5 to 9 | 3,816 | 37.4% (36.5-38.4) | 3,669 | 35.9% (35.0-36.8) |  |
| 10 to 14 | 1,444 | 14.2% (13.5-14.9) | 1,278 | 12.5% (11.9-13.1) |  |
| 15 or more | 411 | 4.0% (3.7-4.4) | 397 | 3.9% (3.5-4.3) |  |
| Total3 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year2** |  |  |  |  |  |
| Mean (std) | 6.0 | (4.3) | 5.9 | (4.4) |  |
| Median (IQR) | 5 | (3-8) | 5 | (3-8) |  |
| None | 206 | 7.2% (6.3-8.2) | 264 | 9.0% (8.0-10.1) | 0.118 |
| 1 to 4 | 996 | 34.7% (32.9-36.4) | 1,026 | 35.0% (33.3-36.8) |  |
| 5 to 9 | 1,127 | 39.2% (37.5-41.0) | 1,103 | 37.6% (35.9-39.4) |  |
| 10 to 14 | 421 | 14.7% (13.4-16.0) | 414 | 14.1% (12.9-15.4) |  |
| 15 or more | 123 | 4.3% (3.6-5.1) | 123 | 4.2% (3.5-5.0) |  |
| Total3 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 4df. 2The number of unique medicines dispensed in the last three months of the first year, second year or third year following enrolment. 3Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 46: Having MBS claims for medication management review among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | **p-value3** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Total number1** | **Number2** | **Percentage (95%CI)** | **Total number1** | **Number2** | **Percentage (95%CI)** |
| **Having MBS claims for medication management review in the last 24 months** | | | | | | | |
| Pre-enrolment | 10,682 | 893 | 8.4% (7.8-8.9) | 10,682 | 424 | 4.0% (3.6-4.3) | <0.001 |
| First biennium | 10,196 | 388 | 3.8% (3.5-4.2) | 10,224 | 478 | 4.7% (4.3-5.1) | 0.002 |
| **Having MBS claims for medication management review in the last 12 months** | | | | | | | |
| Pre-enrolment | 10,682 | 526 | 4.9% (4.5-5.4) | 10,682 | 260 | 2.4% (2.2-2.7) | <0.001 |
| First year | 10,454 | 210 | 2.0% (1.8-2.3) | 10,459 | 280 | 2.7% (2.4-3.0) | 0.001 |
| Second year | 10,196 | 212 | 2.1% (1.8-2.4) | 10,224 | 259 | 2.5% (2.2-2.9) | 0.031 |
| Third year | 2,873 | 63 | 2.2% (1.7-2.8) | 2,930 | 92 | 3.1% (2.6-3.8) | 0.025 |

Notes: 1The total number of patients included in the analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were not included. 2Number of patients who had a claim for MBS items 900 and 903 (i.e. numerator). 3Chi-square test for proportions, 1df.

## Changes in the use of primary care providers

Table 47: Number of GP encounters within the practice, among HCH and comparator patients, derived from practice extracts

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 13.4 | (9.9) | 13.3 | (9.7) |  |
| Median (IQR) | 11 | (7-18) | 11 | (7-17) |  |
| None | 70 | 0.8% (0.7-1.1) | 45 | 0.5% (0.4-0.7) | 0.162 |
| 1 to 4 | 1,208 | 14.5% (13.8-15.3) | 1,184 | 14.2% (13.5-15.0) |  |
| 5 to 9 | 2,020 | 24.3% (23.4-25.2) | 2,025 | 24.3% (23.4-25.3) |  |
| 10 to 14 | 1,973 | 23.7% (22.8-24.6) | 2,044 | 24.6% (23.6-25.5) |  |
| 15 to 19 | 1,374 | 16.5% (15.7-17.3) | 1,407 | 16.9% (16.1-17.7) |  |
| 20 to 24 | 758 | 9.1% (8.5-9.7) | 706 | 8.5% (7.9-9.1) |  |
| 25 or more | 919 | 11.0% (10.4-11.7) | 911 | 10.9% (10.3-11.6) |  |
| Total2 | 8,322 | 100% | 8,322 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 13.7 | 10.3 | 12 | 10.2 |  |
| Median (IQR) | 12 | (7-18) | 10 | (5-17) |  |
| None | 117 | 1.5% (1.2-1.8) | 601 | 7.6% (7.0-8.2) | <0.001 |
| 1 to 4 | 1,089 | 13.7% (13.0-14.5) | 1,209 | 15.2% (14.4-16.0) |  |
| 5 to 9 | 1,944 | 24.5% (23.5-25.4) | 2,029 | 25.5% (24.6-26.5) |  |
| 10 to 14 | 1,792 | 22.5% (21.6-23.5) | 1,598 | 20.1% (19.2-21.0) |  |
| 15 to 19 | 1,281 | 16.1% (15.3-16.9) | 1,056 | 13.3% (12.6-14.0) |  |
| 20 to 24 | 743 | 9.3% (8.7-10.0) | 625 | 7.9% (7.3-8.5) |  |
| 25 or more | 984 | 12.4% (11.7-13.1) | 832 | 10.5% (9.8-11.2) |  |
| Total2 | 7,950 | 100% | 7,950 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 13.7 | 12.5 | 11.5 | 10.7 |  |
| Median (IQR) | 11 | (5-19) | 9 | (3-17) |  |
| None | 604 | 7.8% (7.3-8.5) | 1,170 | 15.2% (14.4-16.0) | <0.001 |
| 1 to 4 | 1,062 | 13.8% (13.0-14.6) | 1,074 | 13.9% (13.2-14.7) |  |
| 5 to 9 | 1,652 | 21.4% (20.5-22.4) | 1,684 | 21.9% (20.9-22.8) |  |
| 10 to 14 | 1,535 | 19.9% (19.0-20.8) | 1,363 | 17.7% (16.9-18.5) |  |
| 15 to 19 | 1,047 | 13.6% (12.8-14.4) | 977 | 12.7% (12.0-13.4) |  |
| 20 to 24 | 690 | 9.0% (8.3-9.6) | 605 | 7.9% (7.3-8.5) |  |
| 25 or more | 1,115 | 14.5% (13.7-15.3) | 832 | 10.8% (10.1-11.5) |  |
| Total2 | 7,705 | 100% | 7,705 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 12 | 10 | 11.6 | 11.3 |  |
| Median (IQR) | 10 | (5-17) | 9 | (3-16) |  |
| None | 114 | 12.5% (10.5-14.8) | 178 | 19.5% (17.0-22.3) | 0.002 |
| 1 to 4 | 103 | 11.3% (9.4-13.5) | 98 | 10.7% (8.9-12.9) |  |
| 5 to 9 | 203 | 22.3% (19.7-25.1) | 184 | 20.2% (17.7-22.9) |  |
| 10 to 14 | 181 | 19.8% (17.4-22.6) | 167 | 18.3% (16.0-20.9) |  |
| 15 to 19 | 139 | 15.2% (13.1-17.7) | 110 | 12.1% (10.1-14.3) |  |
| 20 to 24 | 79 | 8.7% (7.0-10.7) | 68 | 7.5% (5.9-9.3) |  |
| 25 or more | 93 | 10.2% (8.4-12.3) | 107 | 11.7% (9.8-14.0) |  |
| Total2 | 912 | 100% | 912 | 100% |  |

Notes: 1Chi-square test for proportions, 6df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Source: Data extracted from 106 HCH practices (Pen CS, POLAR) and 403 comparator practices (MedicineInsight).

Table 48: MBS claims for unreferred GP consultations, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 11.0 | (8.2) | 11.4 | (8.4) |  |
| Median (IQR) | 9 | (6-14) | 10 | (6-15) |  |
| None | 104 | 1.0% (0.8-1.2) | 108 | 1.0% (0.8-1.2) | <0.001 |
| 1 to 3 | 1,190 | 11.1% (10.6-11.8) | 1,257 | 11.8% (11.2-12.4) |  |
| 4 to 6 | 2,058 | 19.3% (18.5-20.0) | 1,699 | 15.9% (15.2-16.6) |  |
| 7 to 9 | 2,149 | 20.1% (19.4-20.9) | 2,134 | 20.0% (19.2-20.7) |  |
| 10 to 14 | 2,581 | 24.2% (23.4-25.0) | 2,693 | 25.2% (24.4-26.0) |  |
| 15 or more | 2,600 | 24.3% (23.5-25.2) | 2,791 | 26.1% (25.3-27.0) |  |
| Total | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 7.0 | (7.0) | 10.6 | (8.5) |  |
| Median (IQR) | 5 | (2-9) | 9 | (5-14) |  |
| None | 662 | 6.3% (5.9-6.8) | 316 | 3.0% (2.7-3.4) | <0.001 |
| 1 to 3 | 3,013 | 28.8% (28.0-29.7) | 1,399 | 13.4% (12.8-14.0) |  |
| 4 to 6 | 2,496 | 23.9% (23.1-24.7) | 2,070 | 19.8% (19.1-20.5) |  |
| 7 to 9 | 1,706 | 16.3% (15.6-17.0) | 1,895 | 18.1% (17.4-18.9) |  |
| 10 to 14 | 1,475 | 14.1% (13.5-14.8) | 2,293 | 21.9% (21.1-22.8) |  |
| 15 or more | 1,102 | 10.5% (10.0-11.1) | 2,486 | 23.8% (22.9-24.7) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 6.6 | (6.7) | 9.4 | (8.0) |  |
| Median (IQR) | 5 | (2-9) | 8 | (4-13) |  |
| None | 889 | 8.7% (8.2-9.3) | 449 | 4.4% (4.0-4.8) | <0.001 |
| 1 to 3 | 3,029 | 29.7% (28.8-30.6) | 1,697 | 16.6% (15.9-17.3) |  |
| 4 to 6 | 2,459 | 24.1% (23.3-25.0) | 2,198 | 21.5% (20.7-22.3) |  |
| 7 to 9 | 1,508 | 14.8% (14.1-15.5) | 1,928 | 18.9% (18.1-19.6) |  |
| 10 to 14 | 1,312 | 12.9% (12.2-13.5) | 2,061 | 20.2% (19.4-21.0) |  |
| 15 or more | 999 | 9.8% (9.2-10.4) | 1,891 | 18.5% (17.7-19.3) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 6.6 | (6.3) | 8.8 | (8.1) |  |
| Median (IQR) | 5 | (2-9) | 7 | (4-12) |  |
| None | 258 | 9.0% (8.0-10.1) | 171 | 5.8% (5.1-6.7) | <0.001 |
| 1 to 3 | 809 | 28.2% (26.5-29.8) | 528 | 18.0% (16.8-19.4) |  |
| 4 to 6 | 696 | 24.2% (22.7-25.8) | 670 | 22.9% (21.4-24.4) |  |
| 7 to 9 | 433 | 15.1% (13.8-16.4) | 524 | 17.9% (16.5-19.3) |  |
| 10 to 14 | 396 | 13.8% (12.6-15.1) | 570 | 19.5% (18.0-21.0) |  |
| 15 or more | 281 | 9.8% (8.7-10.9) | 467 | 15.9% (14.6-17.4) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 5df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims of items in Groups A1 & A2.

Table 49: Usual provider of care (UPC) index score1 of continuity of care in MBS claims, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value2** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Low continuity | 5,064 | 53.9% (52.9-54.9) | 4,880 | 52.4% (51.4-53.4) | 0.100 |
| High continuity | 2,799 | 29.8% (28.9-30.7) | 2,869 | 30.8% (29.9-31.7) |  |
| Perfect continuity | 1,527 | 16.3% (15.5-17.0) | 1,568 | 16.8% (16.1-17.6) |  |
| Total | 9,388 | 100% | 9,317 | 100% |  |
| **First year** |  |  |  |  |  |
| Low continuity | 4,078 | 60.2% (59.0-61.3) | 4,442 | 50.8% (49.5-51.7) | <0.001 |
| High continuity | 1,806 | 26.6% (25.6-27.7) | 2,678 | 30.6% (29.6-31.6) |  |
| Perfect continuity | 895 | 13.2% (12.4-14.0) | 1,624 | 18.6% (17.7-19.4) |  |
| Total3 | 6,779 | 100% | 8,744 | 100% |  |
| **Second year** |  |  |  |  |  |
| Low continuity | 3,643 | 58.0% (56.8-59.2) | 3,979 | 49.3% (48.3-50.2) | <0.001 |
| High continuity | 1,727 | 27.5% (26.4-28.6) | 2,493 | 30.9% (29.8-31.9) |  |
| Perfect continuity | 908 | 14.5% (13.6-15.4) | 1,606 | 19.9% (19.0-20.8) |  |
| Total3 | 6,278 | 100% | 8,078 | 100% |  |
| **Third year** |  |  |  |  |  |
| Low continuity | 1,027 | 56.9% (54.6-59.1) | 1,062 | 47.6% (45.7-49.5) | <0.001 |
| High continuity | 486 | 26.9% (24.9-29.0) | 692 | 31.0% (29.1-33.0) |  |
| Perfect continuity | 293 | 16.2% (14.6-18.0) | 477 | 21.4% (19.7-23.2) |  |
| Total3 | 1,806 | 100% | 2.231 | 100% |  |

Notes: 1UPC score was calculated for patients having four or more claims in the 12 months; Low continuity was defined as 0<UPC<0.75, high continuity was defined as 0.75≤UPC<1; perfect continuity was defined as UPC=1. 2Chi-square test for proportions, 2df. 3Patients with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims of items in Groups A1 & A2.

## Changes in the use of other health providers

Table 50: MBS claims for specialist consultations among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 3.4 | (6.8) | 3.3 | (6.6) |  |
| Median (IQR) | 1 | (0-4) | 1 | (0-4) |  |
| None | 4,141 | 38.8% (37.9-39.7) | 4,142 | 38.8% (37.9-39.7) | 0.998 |
| 1 to 3 | 3,430 | 32.1% (31.2-33.0) | 3,446 | 32.3% (31.4-33.2) |  |
| 4 to 6 | 1,509 | 14.1% (13.5-14.8) | 1,505 | 14.1% (13.5-14.8) |  |
| 7 to 9 | 666 | 6.2% (5.8-6.7) | 663 | 6.2% (5.8-6.7) |  |
| 10 or more | 936 | 8.8% (8.3-9.3) | 926 | 8.7% (8.2-9.2) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 3.4 | (6.9) | 3.2 | (7.0) |  |
| Median (IQR) | 1 | (0-4) | 1 | (0-4) |  |
| None | 3,983 | 38.1% (37.2-39.1) | 4,208 | 40.2% (39.3-41.2) | 0.002 |
| 1 to 3 | 3,422 | 32.7% (31.8-33.6) | 3,394 | 32.5% (31.6-33.4) |  |
| 4 to 6 | 1,547 | 14.8% (14.2-15.5) | 1,386 | 13.3% (12.6-13.9) |  |
| 7 to 9 | 630 | 6.0% (5.6-6.5) | 656 | 6.3% (5.9-6.8) |  |
| 10 or more | 872 | 8.3% (7.8-8.8) | 815 | 7.8% (7.3-8.3) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 2.9 | (6.6) | 2.8 | (5.9) |  |
| Median (IQR) | 1 | (0-3) | 1 | (0-3) |  |
| None | 4,237 | 41.6% (40.7-42.6) | 4,369 | 42.7% (41.8-43.7) | 0.394 |
| 1 to 3 | 3,484 | 34.2% (33.3-35.1) | 3,398 | 33.2% (32.3-34.1) |  |
| 4 to 6 | 1,234 | 12.1% (11.5-12.7) | 1,258 | 12.3% (11.7-12.9) |  |
| 7 to 9 | 573 | 5.6% (5.2-6.1) | 547 | 5.4% (4.9-5.8) |  |
| 10 or more | 668 | 6.6% (6.2-7.1) | 652 | 6.4% (5.9-6.9) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 2.8 | (6.3) | 2.8 | (5.4) |  |
| Median (IQR) | 1 | (0-3) | 1 | (0-3) |  |
| None | 1,147 | 39.9% (38.1-41.7) | 1,254 | 42.8% (41.0-44.6) | 0.003 |
| 1 to 3 | 1,065 | 37.1% (35.4-38.9) | 949 | 32.4% (30.8-34) |  |
| 4 to 6 | 337 | 11.7% (10.6-13.0) | 393 | 13.4% (12.2-14.6) |  |
| 7 to 9 | 154 | 5.4% (4.7-6.2) | 148 | 5.1% (4.3-5.9) |  |
| 10 or more | 170 | 5.9% (5.1-6.7) | 186 | 6.3% (5.5-7.3) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 2df. 2Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims for items in Groups A3, A4, A8, A9, A12, A13, A16, A21, A24, A26, A28, A29, A31, A32, subgroup A15-02 (items 820 to 880) and subgroup T06-01.

Table 51: Number of encounters with practice nurses within the practice, among HCH patients only, derived from practice extracts

| **Pre-and post-enrolment period** | **HCH patients** | |
| --- | --- | --- |
| **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |
| None | 6,787 | 81.6% (80.7-82.4) |
| 1 to 4 | 1,170 | 14.1% (13.3-14.8) |
| 5 or more | 365 | 4.4% (4.0-4.8) |
| Total2 | 8,322 | 100% |
| **6 months** |  |  |
| None | 6,233 | 77.4% (76.5-78.3) |
| 1 to 4 | 1,364 | 16.9% (16.1-17.8) |
| 5 or more | 458 | 5.7% (5.2-6.2) |
| Total2 | 8,055 | 100% |
| **12 months** |  |  |
| None | 6,172 | 77.6% (76.7-78.5) |
| 1 to 4 | 1,329 | 16.7% (15.9-17.6) |
| 5 or more | 449 | 5.6% (5.2-6.2) |
| Total2 | 7,950 | 100% |
| **18 months** |  |  |
| None | 5,971 | 76.2% (75.3-77.2) |
| 1 to 4 | 1,395 | 17.8% (17.0-18.7) |
| 5 or more | 465 | 5.9% (5.4-6.5) |
| Total2 | 7,831 | 100% |
| **24 months** |  |  |
| None | 5,983 | 77.7% (76.7-78.6) |
| 1 to 4 | 1,258 | 16.3% (15.5-17.2) |
| 5 or more | 464 | 6.0% (5.5-6.6) |
| Total2 | 7,705 | 100% |
| **30 months** |  |  |
| None | 3,884 | 78.7% (77.5-79.8) |
| 1 to 4 | 821 | 16.6% (15.6-17.7) |
| 5 or more | 233 | 4.7% (4.2-5.3) |
| Total2 | 4,938 | 100% |

Notes: 1Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: Data extracted from 106 HCH practices (Pen CS, POLAR).

Table 52: Encounters with podiatrists, dieticians and psychologists within the practice, among HCH patients only, derived from practice extracts

| **Pre-and post-enrolment period** | **Total number 1** | **Number** | **Percentage (95%CI)** |
| --- | --- | --- | --- |
| **Podiatrist encounters in the last six months** | | | |
| Pre-enrolment | 8325 | 671 | 8.1% (7.5-8.7) |
| 6 months | 8058 | 777 | 9.6% (9.0-10.3) |
| 12 months | 7953 | 701 | 8.8% (8.2-9.5) |
| 18 months | 7834 | 636 | 8.1% (7.5-8.7) |
| 24 months | 7708 | 606 | 7.9% (7.3-8.5) |
| 30 months | 4941 | 366 | 7.4% (6.7-8.2) |
| **Dietician encounters in the last six months** | | | |
| Pre-enrolment | 8,325 | 294 | 3.5% (3.2-3.9) |
| 6 months | 8,058 | 294 | 3.6% (3.3-4.1) |
| 12 months | 7,953 | 256 | 3.2% (2.9-3.6) |
| 18 months | 7,834 | 226 | 2.9% (2.5-3.3) |
| 24 months | 7,708 | 178 | 2.3% (2.0-2.7) |
| 30 months | 4,941 | 61 | 1.2% (1.0-1.6) |
| **Psychologist encounters in the last six months** | | | |
| Pre-enrolment | 8,325 | 129 | 1.5% (1.3-1.8) |
| 6 months | 8,058 | 120 | 1.5% (1.2-1.8) |
| 12 months | 7,953 | 107 | 1.3% (1.1-1.6) |
| 18 months | 7,834 | 83 | 1.1% (0.9-1.3) |
| 24 months | 7,708 | 73 | 0.9% (0.8-1.2) |
| 30 months | 4,941 | 26 | 0.5% (0.4-0.8) |

Notes: 1Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: Data extracted from 106 HCH practices (Pen CS, POLAR).

Table 53: MBS claims for any allied health services, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 2.1 | (2.7) | 2.0 | (2.7) |  |
| Median (IQR) | 1 | (0-4) | 0 | (0-3) |  |
| None | 5,326 | 49.9% (48.9-50.8) | 5,524 | 51.7% (50.7-52.7) | 0.007 |
| 1 or 2 | 1,487 | 13.9% (13.3-14.6) | 1,528 | 14.3% (13.7-15.0) |  |
| 3 or 4 | 1,685 | 15.8% (15.1-16.5) | 1,557 | 14.6% (13.9-15.3) |  |
| 5 or more | 2,184 | 20.4% (19.7-21.2) | 2,073 | 19.4% (18.7-20.2) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 2.3 | (2.8) | 1.8 | (2.7) |  |
| Median (IQR) | 1 | (0-4) | 0 | (0-4) |  |
| None | 4,537 | 43.4% (42.5-44.4) | 5,912 | 56.5% (55.4-57.6) | <0.001 |
| 1 or 2 | 1,730 | 16.5% (15.8-17.3) | 1,238 | 11.8% (11.2-12.5) |  |
| 3 or 4 | 1,770 | 16.9% (16.2-17.7) | 1,381 | 13.2% (12.6-13.9) |  |
| 5 or more | 2,417 | 23.1% (22.3-23.9) | 1,928 | 18.4% (17.7-19.2) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 1.9 | (2.5) | 1.6 | (2.5) |  |
| Median (IQR) | 0 | (0-4) | 0 | (0-3) |  |
| None | 5,146 | 50.5% (49.5-51.4) | 6,040 | 59.1% (58.0-60.1) | <0.001 |
| 1 or 2 | 1,450 | 14.2% (13.6-14.9) | 1,115 | 10.9% (10.3-11.5) |  |
| 3 or 4 | 1,634 | 16.0% (15.3-16.8) | 1,308 | 12.8% (12.2-13.4) |  |
| 5 or more | 1,966 | 19.3% (18.5-20.1) | 1,761 | 17.2% (16.5-18.0) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 2.0 | (2.6) | 1.7 | (2.5) |  |
| Median (IQR) | 1 | (0-4) | 0 | (0-4) |  |
| None | 1,410 | 49.1% (47.3-50.9) | 1,718 | 58.6% (56.6-60.6) | <0.001 |
| 1 or 2 | 402 | 14.0% (12.8-15.3) | 317 | 10.8% (9.8-12.0) |  |
| 3 or 4 | 474 | 16.5% (15.2-17.9) | 408 | 13.9% (12.7-15.2) |  |
| 5 or more | 587 | 20.4% (19.0-21.9) | 487 | 16.6% (15.3-18.0) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 3df. 2 Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims of items in Groups M3, M6, M7, M8, M9, M10, M11, M15.

Table 54: MBS claims for allied health services for chronic disease management, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 1.7 | (2.3) | 1.5 | (2.2) |  |
| Median (IQR) | 0 | (0-4) | 0 | (0-3) |  |
| None | 5,689 | 53.3% (52.4-54.3) | 6,202 | 58.1% (57.1-59.1) | <0.001 |
| 1 or 2 | 1,486 | 13.9% (13.3-14.6) | 1,382 | 12.9% (12.3-13.5) |  |
| 3 or 4 | 1,653 | 15.5% (14.9-16.2) | 1,468 | 13.7% (13.1-14.4) |  |
| 5 or more | 1,854 | 17.4% (16.7-18.1) | 1,630 | 15.3% (14.7-15.9) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 2.0 | (2.4) | 1.5 | (2.2) |  |
| Median (IQR) | 1 | (0-4) | 0 | (0-3) |  |
| None | 4,961 | 47.5% (46.6-48.5) | 6,410 | 61.3% (60.2-62.4) | <0.001 |
| 1 or 2 | 1,686 | 16.1% (15.4-16.8) | 1,120 | 10.7% (10.2-11.3) |  |
| 3 or 4 | 1,742 | 16.7% (16.0-17.4) | 1,327 | 12.7% (12.1-13.3) |  |
| 5 or more | 2,065 | 19.8% (19.1-20.6) | 1,602 | 15.3% (14.7-16.0) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 1.7 | (2.2) | 1.4 | (2.1) |  |
| Median (IQR) | 0 | (0-4) | 0 | (0-3) |  |
| None | 5,476 | 53.7% (52.8-54.7) | 6,442 | 63.0% (62.0-64.1) | <0.001 |
| 1 or 2 | 1,402 | 13.8% (13.2-14.5) | 1,031 | 10.1% (9.6-10.7) |  |
| 3 or 4 | 1,592 | 15.6% (14.9-16.3) | 1,248 | 12.2% (11.6-12.8) |  |
| 5 or more | 1,727 | 16.9% (16.2-17.6) | 1,503 | 14.7% (14.1-15.4) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 1.8 | (2.3) | 1.4 | (2.1) |  |
| Median (IQR) | 0 | (0-4) | 0 | (0-3) |  |
| None | 1,486 | 51.7% (49.9-53.6) | 1,805 | 61.6% (60.6-62.6) | <0.001 |
| 1 or 2 | 391 | 13.6% (12.4-14.8) | 300 | 10.2% (9.2-11.3) |  |
| 3 or 4 | 472 | 16.4% (15.1-17.7) | 391 | 13.3% (12.2-14.5) |  |
| 5 or more | 524 | 18.2% (16.9-19.6) | 434 | 14.8% (13.6-16.1) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 3df. 2Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims of items 10950-10970; 81100- 81125.

Table 55: MBS claims for any pathology tests, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 11.0 | (13.1) | 10.9 | (12.8) |  |
| Median (IQR) | 8 | (4-13) | 8 | (4-13) |  |
| None | 714 | 6.7% (6.2-7.2) | 703 | 6.6% (6.1-7.1) | 0.766 |
| 1 to 3 | 1,573 | 14.7% (14.1-15.4) | 1,533 | 14.4% (13.7-15.0) |  |
| 4 to 6 | 2,258 | 21.1% (20.4-21.9) | 2,285 | 21.4% (20.6-22.2) |  |
| 7 to 9 | 1,948 | 18.2% (17.5-19.0) | 1,996 | 18.7% (18.0-19.4) |  |
| 10 to 14 | 1,892 | 17.7% (17.0-18.4) | 1,930 | 18.1% (17.3-18.8) |  |
| 15 or more | 2,297 | 21.5% (20.7-22.3) | 2,235 | 20.9% (20.2-21.7) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 10.6 | (13.0) | 10.2 | (14.5) |  |
| Median (IQR) | 7 | (4-13) | 7 | (3-12) |  |
| None | 808 | 7.7% (7.2-8.3) | 1,078 | 10.3% (9.7-10.9) | <0.001 |
| 1 to 3 | 1,671 | 16.0% (15.3-16.7) | 1,868 | 17.9% (17.1-18.6) |  |
| 4 to 6 | 2,313 | 22.1% (21.3-22.9) | 2,210 | 21.1% (20.4-21.9) |  |
| 7 to 9 | 1,828 | 17.5% (16.8-18.2) | 1,700 | 16.3% (15.6-17.0) |  |
| 10 to 14 | 1,705 | 16.3% (15.6-17.0) | 1,545 | 14.8% (14.1-15.5) |  |
| 15 or more | 2,129 | 20.4% (19.6-21.1) | 2,058 | 19.7% (18.9-20.4) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 10.6 | (13.8) | 9.9 | (13.6) |  |
| Median (IQR) | 7 | (4-13) | 6 | (3-12) |  |
| None | 820 | 8.0% (7.5-8.6) | 1,075 | 10.5% (9.9-11.1) | <0.001 |
| 1 to 3 | 1,653 | 16.2% (15.5-16.9) | 1,799 | 17.6% (16.9-18.4) |  |
| 4 to 6 | 2,148 | 21.1% (20.3-21.9) | 2,254 | 22.0% (21.2-22.9) |  |
| 7 to 9 | 1,756 | 17.2% (16.5-18.0) | 1,636 | 16.0% (15.3-16.7) |  |
| 10 to 14 | 1,773 | 17.4% (16.7-18.1) | 1,587 | 15.5% (14.8-16.2) |  |
| 15 or more | 2,046 | 20.1% (19.3-20.9) | 1,873 | 18.3% (17.6-19.1) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 10.6 | (13.3) | 10.1 | (13.4) |  |
| Median (IQR) | 7 | (4-13) | 7 | (3-12) |  |
| None | 207 | 7.2% (6.3-8.2) | 319 | 10.9% (9.8-12.1) | <0.001 |
| 1 to 3 | 477 | 16.6% (15.3-18.0) | 489 | 16.7% (15.4-18.1) |  |
| 4 to 6 | 631 | 22.0% (20.5-23.5) | 634 | 21.6% (20.2-23.2) |  |
| 7 to 9 | 510 | 17.8% (16.4-19.2) | 484 | 16.5% (15.2-17.9) |  |
| 10 to 14 | 475 | 16.5% (15.2-17.9) | 437 | 14.9% (13.7-16.2) |  |
| 15 or more | 573 | 19.9% (18.5-21.4) | 567 | 19.4% (18.0-20.8) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 3df. 2Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective measurement period were excluded.

Source: MBS claims of items Groups P01 to P09.

Table 56: MBS claims for imaging services, among HCH and comparator patients, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 2.6 | (3.5) | 2.6 | (3.5) |  |
| Median (IQR) | 1 | (0-4) | 2 | (0-4) |  |
| None | 3,521 | 33.0% (32.1-33.9) | 3,451 | 32.3% (31.4-33.2) | 0.649 |
| 1 to 3 | 4,280 | 40.1% (39.1-41.0) | 4,352 | 40.7% (39.8-41.7) |  |
| 4 to 6 | 1,739 | 16.3% (15.6-17.0) | 1,716 | 16.1% (15.4-16.8) |  |
| 7 or more | 1,142 | 10.7% (10.2-11.3) | 1,163 | 10.9% (10.3-11.5) |  |
| Total2 | 10,682 | 100% | 10,682 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 2.6 | (3.6) | 2.5 | (3.6) |  |
| Median (IQR) | 1 | (0-4) | 1 | (0-4) |  |
| None | 3,527 | 33.7% (32.8-34.7) | 3,682 | 35.2% (34.3-36.1) | 0.013 |
| 1 to 3 | 4,068 | 38.9% (38.0-39.9) | 4,105 | 39.2% (38.3-40.2) |  |
| 4 to 6 | 1,644 | 15.7% (15.0-16.4) | 1,571 | 15.0% (14.4-15.7) |  |
| 7 or more | 1,215 | 11.6% (11-12.2) | 1,101 | 10.5% (10-11.1) |  |
| Total2 | 10,454 | 100% | 10,459 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 2.5 | (3.6) | 2.5 | (3.4) |  |
| Median (IQR) | 1 | (0-4) | 1 | (0-4) |  |
| None | 3,652 | 35.8% (34.9-36.8) | 3,681 | 36.0% (35.1-36.9) | 0.357 |
| 1 to 3 | 3,925 | 38.5% (37.6-39.4) | 3,982 | 38.9% (38.0-39.9) |  |
| 4 to 6 | 1,522 | 14.9% (14.2-15.6) | 1,539 | 15.1% (14.4-15.8) |  |
| 7 or more | 1,097 | 10.8% (10.2-11.4) | 1,022 | 10% (9.5-10.6) |  |
| Total2 | 10,196 | 100% | 10,224 | 100% |  |
| **Third year** |  |  |  |  |  |
| Mean (std) | 2.5 | (3.3) | 2.6 | (3.8) |  |
| Median (IQR) | 1 | (0-4) | 1 | (0-4) |  |
| None | 967 | 33.7% (32.0-35.4) | 1,010 | 34.5% (32.8-36.2) | 0.461 |
| 1 to 3 | 1,148 | 40.0% (38.2-41.8) | 1,157 | 39.5% (37.7-41.3) |  |
| 4 to 6 | 470 | 16.4% (15.1-17.8) | 445 | 15.2% (13.9-16.5) |  |
| 7 or more | 288 | 10% (9-11.1) | 318 | 10.9% (9.8-12) |  |
| Total2 | 2,873 | 100% | 2,930 | 100% |  |

Notes: 1Chi-square test for proportions, 3df. 2Number of patients included in analysis within each measurement period (i.e. denominator); those with the follow-up period shorter than the respective anniversary were excluded.

Source: MBS claims of items in Groups I01 to I05.

# Appendix 6: Changes in patient outcomes detailed tables

## Changes in blood pressure, glycaemic control and renal function

Table 57: Blood pressure in HCH patients and comparators with type 2 diabetes who had blood pressure recorded, derived from practice data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Most recent blood pressure, measured in the last 12 months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| ≤130/80 mmHg | 1,017 | 40.2% (38.3-42.2) | 1,005 | 39.3% (37.4-41.2) | 0.479 |
| >130/80 mmHg | 1,510 | 59.8% (57.8-61.7) | 1,554 | 60.7% (58.8-62.6) |  |
| Total2 | 2,527 | 100% | 2,559 | 100% |  |
| **First year** |  |  |  |  |  |
| ≤130/80 mmHg | 1,049 | 41.6% (39.7-43.6) | 890 | 38.6% (36.6-40.5) | 0.030 |
| >130/80 mmHg | 1,471 | 58.4% (56.4-60.3) | 1,418 | 61.4% (59.4-63.5) |  |
| Total2 | 2,520 | 100% | 2,308 | 100% |  |
| **Second year** |  |  |  |  |  |
| ≤130/80 mmHg | 832 | 37.5% (35.5-39.6) | 718 | 36.8% (34.7-39.0) | 0.628 |
| >130/80 mmHg | 1,385 | 62.5% (60.4-64.5) | 1,233 | 63.2% (61.0-65.3) |  |
| Total2 | 2,217 | 100% | 1,951 | 100% |  |
| **Third year** |  |  |  |  |  |
| ≤130/80 mmHg | 98 | 32.7% (27.6-38.2) | 102 | 38.3% (32.5-44.6) | 0.158 |
| >130/80 mmHg | 202 | 67.3% (61.8-72.4) | 164 | 61.7% (56.1-66.9) |  |
| Total2 | 300 | 100% | 266 | 100% |  |
| **Most recent blood pressure, measured in the last six months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| ≤130/80 mmHg | 953 | 40.1% (38.1-42.1) | 932 | 38.7% (36.8-40.6) | 0.320 |
| >130/80 mmHg | 1,425 | 59.9% (57.9-61.9) | 1,478 | 61.3% (59.3-63.3) |  |
| Total2 | 2378 | 100% | 2,410 | 100% |  |
| **6 months** |  |  |  |  |  |
| ≤130/80 mmHg | 913 | 39.6% (37.6-41.6) | 811 | 39.0% (36.9-41.1) | 0.657 |
| >130/80 mmHg | 1,392 | 60.4% (58.4-62.4) | 1,271 | 61.0% (58.9-63.1) |  |
| Total2 | 2,305 | 100% | 2,082 | 100% |  |
| **12 months** |  |  |  |  |  |
| ≤130/80 mmHg | 897 | 41.1% (39.1-43.2) | 758 | 38.3% (36.3-40.5) | 0.065 |
| >130/80 mmHg | 1,283 | 58.9% (56.8-60.9) | 1,219 | 61.7% (59.4-63.9) |  |
| Total2 | 2,180 | 100% | 1,977 | 100% |  |
| **18 months** |  |  |  |  |  |
| ≤130/80 mmHg | 711 | 35.7% (33.7-37.9) | 656 | 38.6% (36.3-41.0) | 0.073 |
| >130/80 mmHg | 1,278 | 64.3% (62.1-66.3) | 1,043 | 61.4% (59.1-63.6) |  |
| Total2 | 1,989 | 100% | 1,699 | 100% |  |
| **24 months** |  |  |  |  |  |
| ≤130/80 mmHg | 683 | 37.6% (35.4-39.8) | 574 | 36.2% (33.9-38.6) | 0.415 |
| >130/80 mmHg | 1,134 | 62.4% (60.2-64.6) | 1,010 | 63.8% (61.3-66.1) |  |
| Total2 | 1,817 | 100% | 1,584 | 100% |  |
| **30 months** |  |  |  |  |  |
| ≤130/80 mmHg | 396 | 34.8% (32.1-37.6) | 370 | 36.0% (33.1-39.0) | 0.563 |
| >130/80 mmHg | 743 | 65.2% (62.4-67.9) | 659 | 64.0% (61.1-66.9) |  |
| Total2 | 1,139 | 100% | 1,029 | 100% |  |
| **36 months** |  |  |  |  |  |
| ≤130/80 mmHg | 82 | 35.3% (29.5-41.7) | 85 | 38.1% (31.9-44.8) | 0.540 |
| >130/80 mmHg | 150 | 64.7% (58.3-70.5) | 138 | 61.9% (55.6-67.8) |  |
| Total2 | 232 | 100% | 223 | 100% |  |

Notes: 1Chi-square test for proportions, 1df. 2Diabetes patients with the follow-up period shorter than the respective measurement period and those without blood pressure measurement were excluded.

Table 58: HbA1c results in HCH patients and comparators with type 2 diabetes who had a HbA1c test recorded, derived from practice data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Most recent HbA1c, measured in the last 12 months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| HbA1c ≤7% | 1,355 | 56.1% (54.1-58.1) | 1,371 | 56.3% (54.3-58.2) | 0.838 |
| 7% <HbA1c ≤8% | 550 | 22.8% (21.2-24.5) | 534 | 21.9% (20.3-23.6) |  |
| 8% <HbA1c <10% | 366 | 15.2% (13.8-16.6) | 376 | 15.4% (14.1-16.9) |  |
| HbA1c ≥10% | 143 | 5.9% (5.1-6.9) | 155 | 6.4% (5.5-7.4) |  |
| Total2 | 2414 | 100% | 2436 | 100% |  |
| **First year** |  |  |  |  |  |
| HbA1c ≤7% | 1,315 | 57.6% (55.6-59.6) | 1,219 | 56.6% (54.5-58.6) | 0.020 |
| 7% <HbA1c ≤8% | 464 | 20.3% (18.7-22.0) | 501 | 23.2% (21.5-25.1) |  |
| 8% <HbA1c <10% | 353 | 15.5% (14.0-17.0) | 329 | 15.3% (13.8-16.8) |  |
| HbA1c ≥10% | 150 | 6.6% (5.6-7.7) | 106 | 4.9% (4.1-5.9) |  |
| Total2 | 2282 | 100% | 2155 | 100% |  |
| **Second year** |  |  |  |  |  |
| HbA1c ≤7% | 1,051 | 51.1% (48.9-53.2) | 984 | 53.1% (50.8-55.4) | <0.0001 |
| 7% <HbA1c ≤8% | 497 | 24.1% (22.3-26.0) | 449 | 24.2% (22.3-26.2) |  |
| 8% <HbA1c <10% | 331 | 16.1% (14.6-17.7) | 328 | 17.7% (16.0-19.5) |  |
| HbA1c ≥10% | 179 | 8.7% (7.6-10.0) | 93 | 5.0% (4.1-6.1) |  |
| Total2 | 2058 | 100% | 1854 | 100% |  |
| **Most recent HbA1c, measured in the last six months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| HbA1c ≤7% | 1,126 | 54.6% (52.4-56.7) | 1,151 | 55.0% (52.8-57.1) | 0.748 |
| 7% <HbA1c ≤8% | 492 | 23.8% (22.1-25.7) | 474 | 22.6% (20.9-24.5) |  |
| 8% <HbA1c <10% | 323 | 15.7% (14.2-17.3) | 334 | 16.0% (14.4-17.6) |  |
| HbA1c ≥10% | 122 | 5.9% (5.0-7.0) | 135 | 6.4% (5.5-7.6) |  |
| Total2 | 2063 |  | 2094 | 100% |  |
| **6 months** |  |  |  |  |  |
| HbA1c ≤7% | 1,030 | 56.0% (53.7-58.2) | 1,003 | 56.2% (53.8-58.4) | 0.020 |
| 7% <HbA1c ≤8% | 431 | 23.4% (21.5-25.4) | 437 | 24.5% (22.5-26.5) |  |
| 8% <HbA1c <10% | 255 | 13.9% (12.4-15.5) | 267 | 14.9% (13.4-16.7) |  |
| HbA1c ≥10% | 124 | 6.7% (5.7-8.0) | 79 | 4.4% (3.6-5.5) |  |
| Total2 | 1840 | 100% | 1786 | 100% |  |
| **12 months** |  |  |  |  |  |
| HbA1c ≤7% | 1,024 | 56.1% (53.8-58.4) | 928 | 54.9% (52.6-57.2) | 0.013 |
| 7% <HbA1c ≤8% | 383 | 21.0% (19.2-22.9) | 418 | 24.7% (22.7-26.9) |  |
| 8% <HbA1c <10% | 301 | 16.5% (14.9-18.3) | 265 | 15.7% (14.0-17.5) |  |
| HbA1c ≥10% | 117 | 6.4% (5.4-7.6) | 79 | 4.7% (3.8-5.8) |  |
| Total2 | 1825 | 100% | 1690 | 100% |  |
| **18 months** |  |  |  |  |  |
| HbA1c ≤7% | 887 | 51.7% (49.4-54.1) | 836 | 54.7% (52.1-57.2) | 0.020 |
| 7% <HbA1c ≤8% | 429 | 25.0% (23.0-27.1) | 358 | 23.4% (21.4-25.6) |  |
| 8% <HbA1c <10% | 273 | 15.9% (14.3-17.7) | 267 | 17.5% (15.6-19.5) |  |
| HbA1c ≥10% | 126 | 7.3% (6.2-8.7) | 68 | 4.4% (3.5-5.6) |  |
| Total2 | 1715 | 100% | 1529 | 100% |  |
| **24 months** |  |  |  |  |  |
| HbA1c ≤7% | 826 | 49.4% (47.0-51.8) | 750 | 51.3% (48.7-53.9) | <0.001 |
| 7% <HbA1c ≤8% | 411 | 24.6% (22.6-26.7) | 378 | 25.9% (23.7-28.2) |  |
| 8% <HbA1c <10% | 285 | 17.1% (15.3-18.9) | 260 | 17.8% (15.9-19.8) |  |
| HbA1c ≥10% | 149 | 8.9% (7.6-10.4) | 73 | 5.0% (4.0-6.2) |  |
| Total2 | 1671 | 100% | 1461 | 100% |  |

Notes: 1Chi-square test for proportions, 3df. 2Diabetes patients with the follow-up period shorter than the respective measurement period and those without HbA1c measurement were excluded.

Table 59: eGFR results in HCH patients and comparators with type 2 diabetes or cardiovascular disease, derived from practice data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Most recent eGFR, measured in the last 12 months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| eGFR ≥ 90 | 857 | 14.6% (13.7-15.5) | 817 | 13.9% (13.0-14.8) | 0.020 |
| 60 ≤ eGFR <90 | 2,960 | 50.3% (49.0-51.6) | 3,002 | 50.9% (49.6-52.2) |  |
| 45 ≤ eGFR <60 | 796 | 13.5% (12.7-14.4) | 747 | 12.7% (11.8-13.5) |  |
| 30 ≤ eGFR <45 | 391 | 6.6% (6.0-7.3) | 344 | 5.8% (5.3-6.5) |  |
| 15 ≤ eGFR <30 | 122 | 2.1% (1.7-2.5) | 119 | 2.0% (1.7-2.4) |  |
| eGFR <15 | 756 | 12.9% (12.0-13.7) | 867 | 14.7% (13.8-15.6) |  |
| Total2 | 5882 | 100% | 5896 | 100% |  |
| **First year** |  |  |  |  |  |
| eGFR ≥ 90 | 785 | 14.3% (13.4-15.2) | 754 | 15.6% (14.6-16.7) | <0.001 |
| 60 ≤ eGFR <90 | 2,751 | 50.0% (48.6-51.3) | 2,359 | 48.8% (47.4-50.2) |  |
| 45 ≤ eGFR <60 | 805 | 14.6% (13.7-15.6) | 674 | 13.9% (13.0-14.9) |  |
| 30 ≤ eGFR <45 | 387 | 7.0% (6.4-7.7) | 374 | 7.7% (7.0-8.5) |  |
| 15 ≤ eGFR <30 | 148 | 2.7% (2.3-3.1) | 203 | 4.2% (3.7-4.8) |  |
| eGFR <15 | 630 | 11.4% (10.6-12.3) | 469 | 9.7% (8.9-10.6) |  |
| Total2 | 5506 | 100% | 4833 | 100% |  |
| **Second year** |  |  |  |  |  |
| eGFR ≥ 90 | 643 | 13.1% (12.2-14.1) | 675 | 15.7% (14.6-16.8) | <0.001 |
| 60 ≤ eGFR <90 | 2,425 | 49.5% (48.1-50.9) | 2,101 | 48.8% (47.4-50.3) |  |
| 45 ≤ eGFR <60 | 745 | 15.2% (14.2-16.2) | 663 | 15.4% (14.4-16.5) |  |
| 30 ≤ eGFR <45 | 372 | 7.6% (6.9-8.4) | 326 | 7.6% (6.8-8.4) |  |
| 15 ≤ eGFR <30 | 150 | 3.1% (2.6-3.6) | 179 | 4.2% (3.6-4.8) |  |
| eGFR <15 | 561 | 11.5% (10.6-12.4) | 358 | 8.3% (7.5-9.2) |  |
| Total2 | 4896 | 100% | 4302 | 100% |  |
| **Third year** |  |  |  |  |  |
| eGFR ≥ 90 | 68 | 11.0% (8.8-13.7) | 82 | 15.0% (12.2-18.4) | 0.177 |
| 60 ≤ eGFR <90 | 331 | 53.6% (49.6-57.5) | 256 | 47.0% (43.1-50.9) |  |
| 45 ≤ eGFR <60 | 90 | 14.6% (12.0-17.6) | 78 | 14.3% (11.6-17.5) |  |
| 30 ≤ eGFR <45 | 46 | 7.4% (5.6-9.8) | 44 | 8.1% (6.1-10.7) |  |
| 15 ≤ eGFR <30 | 19 | 3.1% (2.0-4.8) | 23 | 4.2% (2.8-6.3) |  |
| eGFR <15 | 64 | 10.4% (8.2-13.0) | 62 | 11.4% (9.0-14.3) |  |
| Total2 | 618 | 100% | 545 | 100% |  |
| **Most recent eGFR, measured in the last six months** | | | | | |
| **Pre-enrolment** |  |  |  |  |  |
| eGFR ≥ 90 | 652 | 13.8% (12.8-14.8) | 622 | 13.0% (12.1-14.0) | 0.119 |
| 60 ≤ eGFR <90 | 2,377 | 50.2% (48.8-51.7) | 2,428 | 50.8% (49.4-52.3) |  |
| 45 ≤ eGFR <60 | 658 | 13.9% (12.9-14.9) | 625 | 13.1% (12.2-14.1) |  |
| 30 ≤ eGFR <45 | 336 | 7.1% (6.4-7.9) | 308 | 6.4% (5.8-7.2) |  |
| 15 ≤ eGFR <30 | 112 | 2.4% (2.0-2.8) | 111 | 2.3% (1.9-2.8) |  |
| eGFR <15 | 597 | 12.6% (11.7-13.6) | 682 | 14.3% (13.3-15.3) |  |
| Total2 | 4732 | 100% | 4776 | 100% |  |
| **6 months** |  |  |  |  |  |
| eGFR ≥ 90 | 563 | 13.3% (12.4-14.4) | 527 | 14.0% (13.0-15.2) | <0.001 |
| 60 ≤ eGFR <90 | 2,082 | 49.4% (47.9-50.9) | 1,757 | 46.8% (45.3-48.4) |  |
| 45 ≤ eGFR <60 | 625 | 14.8% (13.8-15.9) | 523 | 13.9% (12.9-15.1) |  |
| 30 ≤ eGFR <45 | 335 | 7.9% (7.2-8.8) | 321 | 8.6% (7.7-9.5) |  |
| 15 ≤ eGFR <30 | 115 | 2.7% (2.3-3.3) | 199 | 5.3% (4.6-6.1) |  |
| eGFR <15 | 498 | 11.8% (10.9-12.8) | 427 | 11.4% (10.4-12.4) |  |
| Total2 | 4218 | 100% | 3754 | 100% |  |
| **12 months** |  |  |  |  |  |
| eGFR ≥ 90 | 544 | 13.1% (12.1-14.2) | 511 | 14.2% (13.1-15.4) | <0.001 |
| 60 ≤ eGFR <90 | 2,074 | 50.0% (48.5-51.5) | 1,714 | 47.6% (46.0-49.2) |  |
| 45 ≤ eGFR <60 | 628 | 15.1% (14.1-16.3) | 525 | 14.6% (13.5-15.8) |  |
| 30 ≤ eGFR <45 | 318 | 7.7% (6.9-8.5) | 304 | 8.4% (7.6-9.4) |  |
| 15 ≤ eGFR <30 | 129 | 3.1% (2.6-3.7) | 177 | 4.9% (4.3-5.7) |  |
| eGFR <15 | 454 | 10.9% (10.0-11.9) | 367 | 10.2% (9.3-11.2) |  |
| Total2 | 4147 | 100% | 3598 | 100% |  |
| **18 months** |  |  |  |  |  |
| eGFR ≥ 90 | 492 | 12.9% (11.9-14.0) | 464 | 14.1% (13.0-15.4) | <0.001 |
| 60 ≤ eGFR <90 | 1,850 | 48.6% (47.0-50.2) | 1,532 | 46.6% (44.9-48.3) |  |
| 45 ≤ eGFR <60 | 624 | 16.4% (15.2-17.6) | 513 | 15.6% (14.4-16.9) |  |
| 30 ≤ eGFR <45 | 302 | 7.9% (7.1-8.8) | 298 | 9.1% (8.1-10.1) |  |
| 15 ≤ eGFR <30 | 119 | 3.1% (2.6-3.7) | 159 | 4.8% (4.1-5.6) |  |
| eGFR <15 | 422 | 11.1% (10.1-12.1) | 321 | 9.8% (8.8-10.8) |  |
| Total2 | 3809 | 100% | 3287 | 100% |  |
| **24 months** |  |  |  |  |  |
| eGFR ≥ 90 | 415 | 11.3% (10.3-12.4) | 480 | 14.5% (13.4-15.8) | <0.001 |
| 60 ≤ eGFR <90 | 1,837 | 50.0% (48.4-51.6) | 1,599 | 48.4% (46.8-50.1) |  |
| 45 ≤ eGFR <60 | 571 | 15.5% (14.4-16.8) | 539 | 16.3% (15.1-17.6) |  |
| 30 ≤ eGFR <45 | 308 | 8.4% (7.5-9.3) | 269 | 8.1% (7.3-9.1) |  |
| 15 ≤ eGFR <30 | 126 | 3.4% (2.9-4.1) | 142 | 4.3% (3.7-5.1) |  |
| eGFR <15 | 416 | 11.3% (10.3-12.4) | 272 | 8.2% (7.4-9.2) |  |
| Total2 | 3673 | 100% | 3301 | 100% |  |
| **30 months** |  |  |  |  |  |
| eGFR ≥ 90 | 257 | 12.2% (10.9-13.7) | 299 | 14.9% (13.4-16.5) | <0.001 |
| 60 ≤ eGFR <90 | 1,045 | 49.6% (47.4-51.7) | 982 | 48.9% (46.7-51.1) |  |
| 45 ≤ eGFR <60 | 352 | 16.7% (15.2-18.4) | 331 | 16.5% (14.9-18.2) |  |
| 30 ≤ eGFR <45 | 171 | 8.1% (7.0-9.4) | 175 | 8.7% (7.6-10.0) |  |
| 15 ≤ eGFR <30 | 56 | 2.7% (2.1-3.4) | 78 | 3.9% (3.1-4.8) |  |
| eGFR <15 | 227 | 10.8% (9.5-12.2) | 144 | 7.2% (6.1-8.4) |  |
| Total2 | 2108 | 100% | 2009 | 100% |  |
| **36 months** |  |  |  |  |  |
| eGFR ≥ 90 | 51 | 11.3% (8.7-14.6) | 59 | 14.4% (11.2-18.1) | 0.453 |
| 60 ≤ eGFR <90 | 233 | 51.8% (47.2-56.4) | 186 | 45.3% (40.8-49.8) |  |
| 45 ≤ eGFR <60 | 67 | 14.9% (11.9-18.5) | 65 | 15.8% (12.6-19.7) |  |
| 30 ≤ eGFR <45 | 38 | 8.4% (6.2-11.4) | 38 | 9.2% (6.8-12.4) |  |
| 15 ≤ eGFR <30 | 13 | 2.9% (1.7-4.9) | 17 | 4.1% (2.6-6.5) |  |
| eGFR <15 | 48 | 10.7% (8.1-13.9) | 46 | 11.2% (8.5-14.6) |  |
| Total2 | 450 | 100% | 411 | 100% |  |

Notes: 1Chi-square test for proportions, 5df. 2Patients with follow-up period shorter than the respective measurement period and those without eGFR measurement were excluded.

## Changes in the use of hospital services

Changes in the use of hospital services were examined among patients living in five states: New South Wales, Victoria, Queensland, South Australia and Tasmania.

Table 60: Presentations at emergency departments among all HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment anniversary** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 0.6 | (1.5) | 0.5 | (1.4) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 6,577 | 72.1% (71.2-73.0) | 6,515 | 71.4% (70.5-72.3) | 0.157 |
| One | 1,457 | 16.0% (15.2-16.7) | 1,554 | 17.0% (16.3-17.8) |  |
| Two | 559 | 6.1% (5.7-6.6) | 566 | 6.2% (5.7-6.7) |  |
| 3 or more | 527 | 5.8% (5.3-6.3) | 485 | 5.3% (4.9-5.8) |  |
| Total | 9,120 | 100% | 9,120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 0.6 | (1.6) | 0.5 | (1.3) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 6,446 | 72.2% (71.3-73.1) | 6,540 | 73.3% (72.4-74.2) | 0.099 |
| One | 1,411 | 15.8% (15.1-16.6) | 1,356 | 15.2% (14.5-16.0) |  |
| Two | 507 | 5.7% (5.2-6.2) | 530 | 5.9% (5.5-6.5) |  |
| 3 or more | 561 | 6.3% (5.8-6.8) | 496 | 5.6% (5.1-6.1) |  |
| Total2 | 8,925 | 100% | 8,922 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 0.5 | (1.5) | 0.6 | (1.3) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 1,994 | 74.0% (72.4-75.7) | 1,954 | 72.1% (70.4-73.7) | 0.200 |
| One | 414 | 15.4% (14.1-16.8) | 428 | 15.8% (14.5-17.2) |  |
| Two | 143 | 5.3% (4.5-6.2) | 151 | 5.6% (4.8-6.5) |  |
| 3 or more | 142 | 5.3% (4.5-6.2) | 177 | 6.5% (5.7-7.5) |  |
| Total2 | 2,693 | 100% | 2,710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 3df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 61: Presentations to emergency department among HCH and comparator attendants, derived from linked data

| **Pre-and post-enrolment anniversary** | **HCH patients** | **Comparator patients** |
| --- | --- | --- |
| **Pre-enrolment** |  |  |
| Number of attended patients | 2,543 | 2,605 |
| Mean (std) | 2.0 (2.2) | 1.9 (2.0) |
| Median (IQR) | 1 (1-2) | 1 (1-2) |
| **First year** |  |  |
| Number of attended patients | 2,479 | 2,382 |
| Mean (std) | 2.1 (2.4) | 2.0 (1.9) |
| Median (IQR) | 1 (1-2) | 1 (1-2) |
| **Second year** |  |  |
| Number of attended patients | 699 | 756 |
| Mean (std) | 2.0 (2.3) | 2.0 (1.9) |
| Median (IQR) | 1 (1-2) | 1 (1-2) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas).

Table 62: All-cause hospital admissions among all HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 0.5 | (1.4) | 0.5 | (1.6) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 6,639 | 72.8% (71.9-73.7) | 6,620 | 72.6% (71.7-73.5) | 0.835 |
| One | 1,493 | 16.4% (15.6-17.1) | 1,516 | 16.6% (15.9-17.4) |  |
| Two | 536 | 5.9% (5.4-6.4) | 516 | 5.7% (5.2-6.2) |  |
| 3 or more | 452 | 5.0% (4.5-5.4) | 468 | 5.1% (4.7-5.6) |  |
| Total2 | 9,120 | 100% | 9,120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 0.5 | (1.4) | 0.5 | (1.6) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 6,463 | 72.4% (71.5-73.3) | 6,651 | 74.5% (73.6-75.5) | 0.004 |
| One | 1,399 | 15.7% (14.9-16.4) | 1,345 | 15.1% (14.4-15.8) |  |
| Two | 551 | 6.2% (5.7-6.7) | 483 | 5.4% (5.0-5.9) |  |
| 3 or more | 512 | 5.7% (5.3-6.2) | 443 | 5.0% (4.5-5.4) |  |
| Total2 | 8,925 | 100% | 8,922 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 0.6 | (1.8) | 0.6 | (2.0) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| None | 1,959 | 72.7% (71.0-74.4) | 1,959 | 72.3% (70.6-73.9) | 0.720 |
| One | 423 | 15.7% (14.4-17.1) | 449 | 16.6% (15.2-18.0) |  |
| Two | 156 | 5.8% (5.0-6.7) | 143 | 5.3% (4.5-6.2) |  |
| 3 or more | 155 | 5.8% (4.9-6.7) | 159 | 5.9% (5.0-6.8) |  |
| Total2 | 2,693 | 100% | 2,710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 3df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 63: Total number of bed-days for all-cause admissions, among all HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 2.2 | (9.1) | 2.1 | (8.2) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| No admission | 6,639 | 72.8% (71.9-73.7) | 6,620 | 72.6% (71.7-73.5) | 0.749 |
| 1-9 days | 1,956 | 21.4% (20.6-22.3) | 1,994 | 21.9% (21.0-22.7) |  |
| 10-19 days | 272 | 3.0% (2.7-3.4) | 273 | 3.0% (2.7-3.4) |  |
| 20 days or more | 253 | 2.8% (2.5-3.1) | 233 | 2.6% (2.3-2.9) |  |
| Total2 | 9,120 | 100% | 9,120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 2.3 | (9.5) | 2.3 | (10.8) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| No admission | 6,463 | 72.4% (71.5-73.3) | 6,651 | 74.6% (73.6-75.5) | 0.007 |
| 1-9 days | 1,954 | 21.9% (21.0-22.8) | 1,785 | 20.0% (19.2-20.8) |  |
| 10-19 days | 236 | 2.6% (2.3-3.0) | 242 | 2.7% (2.4-3.1) |  |
| 20 days or more | 272 | 3.0% (2.7-3.4) | 243 | 2.7% (2.4-3.1) |  |
| Total2 | 8,925 | 100% | 8,921 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 2.5 | (10.9) | 2.5 | (10.4) |  |
| Median (IQR) | 0 | (0-1) | 0 | (0-1) |  |
| No admission | 1,959 | 72.7% (71.0-74.4) | 1,959 | 72.3% (70.6-73.9) | 0.957 |
| 1-9 days | 571 | 21.2% (19.7-22.8) | 590 | 21.8% (20.3-23.4) |  |
| 10-19 days | 75 | 2.8% (2.2-3.5) | 76 | 2.8% (2.2-3.5) |  |
| 20 days or more | 88 | 3.3% (2.7-4.0) | 85 | 3.1% (2.5-3.9) |  |
| Total2 | 2,693 | 100% | 2,710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 3df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 64: Number of all-cause hospital admissions and total bed-days among admitted HCH patients and comparators, derived from linked data

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | |
| **Number of patients1** | **Mean (std)** | **Median (IQR)** | **Number of patients1** | **Mean (std)** | **Median (IQR)** |
| **Pre-enrolment** |  |  |  |  |  |  |
| All-cause admissions | 2481 | 1.9 (2.0) | 1 (1-2) | 2500 | 1.9 (2.6) | 1 (1-2) |
| Total bed-days |  | 8.2 (16.1) | 3 (1-8) |  | 7.6 (14.3) | 3 (1-8) |
| **First year** |  |  |  |  |  |  |
| All-cause admissions | 2462 | 2.0 (2.0) | 1 (1-2) | 2271 | 2.0 (2.6) | 1 (1-2) |
| Total bed-days |  | 8.3 (16.6) | 3 (1-7) |  | 8.9 (20.1) | 2 (1-8) |
| **Second year** |  |  |  |  |  |  |
| All-cause admissions | 734 | 2.1 (2.9) | 1 (1-2) | 751 | 2.1 (3.3) | 1 (1-2) |
| Total bed-days |  | 9.1 (19.5) | 2.5 (1-8) |  | 9.0 (18.2) | 2 (1-8) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 65: Emergency hospital admissions among HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 0.3 | (0.9) | 0.3 | (0.8) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 7,455 | 81.7% (80.9-82.5) | 7,456 | 81.8% (80.9-82.5) | 0.171 |
| One | 1,078 | 11.8% (11.2-12.5) | 1,101 | 12.1% (11.4-12.8) |  |
| Two | 334 | 3.7% (3.3-4.1) | 354 | 3.9% (3.5-4.3) |  |
| 3 or more | 253 | 2.8% (2.5-3.1) | 209 | 2.3% (2.0-2.6) |  |
| Total2 | 9,120 | 100% | 9,120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 0.3 | (0.9) | 0.3 | (0.8) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 7,310 | 81.9% (81.1-82.7) | 7,437 | 83.4% (82.5-84.1) | 0.010 |
| One | 998 | 11.2% (10.5-11.9) | 972 | 10.9% (10.3-11.6) |  |
| Two | 352 | 3.9% (3.6-4.4) | 285 | 3.2% (2.9-3.6) |  |
| 3 or more | 265 | 3.0% (2.6-3.3) | 228 | 2.6% (2.2-2.9) |  |
| Total2 | 8,925 | 100% | 8,922 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 0.3 | (0.9) | 0.3 | (0.8) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 2,234 | 83.0% (81.5-84.3) | 2,204 | 81.3% (79.9-82.7) | 0.330 |
| One | 279 | 10.4% (9.3-11.6) | 318 | 11.7% (10.6-13.0) |  |
| Two | 97 | 3.6% (3.0-4.4) | 94 | 3.5% (2.8-4.2) |  |
| 3 or more | 83 | 3.1% (2.5-3.8) | 94 | 3.5% (2.8-4.2) |  |
| Total2 | 2,693 | 100% | 2,710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 3df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 66: Total number of bed-days for emergency admissions, among all HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 1.7 | (7.9) | 1.5 | (6.8) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 7,455 | 81.7% (80.9-82.5) | 7,456 | 81.8% (80.9-82.5) | 0.989 |
| 1 or 2 days | 721 | 7.9% (7.4-8.5) | 721 | 7.9% (7.4-8.5) |  |
| 3 days or more | 941 | 10.3% (9.7-11.0) | 935 | 10.3% (9.6-10.9) |  |
| Total2 | 9,117 | 100% | 9,120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 1.7 | (8.2) | 1.6 | (9.2) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 7,310 | 81.9% (81.1-82.7) | 7,437 | 83.4% (82.5-84.1) | 0.019 |
| 1 or 2 days | 683 | 7.7% (7.1-8.2) | 659 | 7.4% (6.9-7.9) |  |
| 3 days or more | 928 | 10.4% (9.8-11.0) | 822 | 9.2% (8.6-9.8) |  |
| Total2 | 8,921 | 100% | 8,918 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 1.8 | (9.8) | 1.7 | (8.0) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 2,234 | 83.0% (81.5-84.3) | 2,204 | 81.3% (79.9-82.7) | 0.029 |
| 1 or 2 days | 180 | 67.% (5.8-7.7) | 233 | 8.6% (7.6-9.7) |  |
| 3 days or more | 278 | 10.3% (9.2-11.5) | 270 | 10.0% (8.9-11.1) |  |
| Total2 | 2,692 | 100% | 2,710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 2df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 67: Number of admissions and bed-days for emergency admissions among admitted HCH patients and comparators, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | |
| **Number of patients1** | **Mean (std)** | **Median (IQR)** | **Number of patients1** | **Mean (std)** | **Median (IQR)** |
| **Pre-enrolment** |  |  |  |  |  |  |
| Emergency admissions | 1665 | 1.7 (1.5) | 1 (1-2) | 1664 | 1.6 (1.2) | 1 (1-2) |
| Total bed-days |  | 9.0 (16.7) | 3 (1-9) |  | 8.0 (14.3) | 3 (1-8) |
| **First year** |  |  |  |  |  |  |
| Emergency admissions | 1615 | 1.7 (1.4) | 1 (1-2) | 1485 | 1.7 (1.3) | 1 (1-2) |
| Total bed-days |  | 9.3 (17.3) | 3 (1-9) |  | 9.8 (20.6) | 3 (1-9) |
| **Second year** |  |  |  |  |  |  |
| Emergency admissions | 459 | 1.7 (1.4) | 1 (1-2) | 506 | 1.7 (1.3) | 1 (1-2) |
| Total bed-days |  | 10.5 (21.6) | 4 (1-10) |  | 9.3 (16.5) | 3 (1-9) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 68: Potentially preventable hospitalisations among HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 0.1 | (0.4) | 0.1 | (0.3) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 8,620 | 94.5% (94.0-95.0) | 8,695 | 95.3% (94.9-95.8) | 0.081 |
| One | 373 | 4.1% (3.7-4.5) | 310 | 3.4% (3.0-3.8) |  |
| Two | 80 | 0.9% (0.7-1.1) | 73 | 0.8% (0.6-1.0) |  |
| 3 or more | 47 | 0.5% (0.4-0.7) | 42 | 0.5% (0.3-0.6) |  |
| Total2 | 9120 | 100% | 9120 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 0.1 | (0.4) | 0.1 | (0.3) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 8,438 | 94.5% (94.1-95.0) | 8,479 | 95.0% (94.5-95.5) | 0.518 |
| One | 369 | 4.1% (3.7-4.6) | 338 | 3.8% (3.4-4.2) |  |
| Two | 76 | 0.9% (0.7-1.1) | 66 | 0.7% (0.6-0.9) |  |
| 3 or more | 42 | 0.5% (0.3-0.6) | 39 | 0.4% (0.3-0.6) |  |
| Total2 | 8925 | 100% | 8922 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 0.1 | (0.6) | 0.1 | (0.4) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| None | 2,560 | 95.1% (94.2-95.8) | 2,559 | 94.4% (93.6-95.2) | 0.636 |
| One | 95 | 3.5% (2.9-4.3) | 114 | 4.2% (3.5-5.0) |  |
| Two | 22 | 0.8% (0.5-1.2) | 22 | 0.8% (0.5-1.2) |  |
| 3 or more | 16 | 0.6% (0.4-1.0) | 15 | 0.6% (0.3-0.9) |  |
| Total2 | 2693 | 100% | 2710 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 3df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 69: Total number of bed-days for potentially preventable hospitalisations, among all HCH patients and comparators, derived from linked data

| **Pre-and post-enrolment period** | **HCH patients** | | **Comparator patients** | | **p-value1** |
| --- | --- | --- | --- | --- | --- |
| **Number** | **Percentage (95%CI)** | **Number** | **Percentage (95%CI)** |
| **Pre-enrolment** |  |  |  |  |  |
| Mean (std) | 0.4 | (2.9) | 0.3 | (2.2) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 8,620 | 94.5% (94.0-95.0) | 8,695 | 95.3% (94.9-95.8) | 0.033 |
| 1 or 2 days | 218 | 2.4% (2.1-2.7) | 189 | 2.1% (1.8-2.4) |  |
| 3 days or more | 276 | 3.0 (2.7-3.4) | 229 | 2.5% (2.2-2.9) |  |
| Total2 | 9,114 | 100% | 9,113 | 100% |  |
| **First year** |  |  |  |  |  |
| Mean (std) | 0.3 | (2.4) | 0.4 | (4.7) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 8,438 | 94.5% (94.1-95.0) | 8,479 | 95.0% (94.5-95.5) | 0.059 |
| 1 or 2 days | 232 | 2.6% (2.3-3.0) | 184 | 2.1% (1.8-2.4) |  |
| 3 days or more | 246 | 2.8% (24-3.1) | 245 | 2.7% (2.4-3.1) |  |
| Total2 | 8,916 | 100% | 8,908 | 100% |  |
| **Second year** |  |  |  |  |  |
| Mean (std) | 0.4 | (6.2) | 0.4 | (3.4) |  |
| Median (IQR) | 0 | (0-0) | 0 | (0-0) |  |
| No admission | 2,560 | 95.1% (94.2-95.8) | 2,559 | 94.4% (93.6-95.2) | 0.368 |
| 1 or 2 days | 50 | 1.9% (1.4-2.4) | 65 | 2.4% (1.9-3.0) |  |
| 3 days or more | 80 | 3.0% (2.4-3.7) | 84 | 3.1% (2.5-3.8) |  |
| Total2 | 2,690 | 100% | 2,708 | 100% |  |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Chi-square test for proportions, 2df. 2Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 70: Number of admission and total bed-days for potentially preventable hospitalisations among admitted HCH patients and comparators, derived from linked data

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | | |
| **Number of patients1** | **Mean (std)** | **Median (IQR)** | **Number of patients1** | **Mean (std)** | **Median (IQR)** |
| **Pre-enrolment** |  |  |  |  |  |  |
| Potentially preventable hospitalisations | 500 | 1.4 (0.8) | 1 (1-2) | 425 | 1.4 (0.8) | 1 (1-2) |
| Total bed-days |  | 6.4 (10.5) | 3 (1-7) |  | 5.9 (8.4) | 3 (1-6) |
| **First year** |  |  |  |  |  |  |
| Potentially preventable hospitalisations | 487 | 1.4 (1.0) | 1 (1-1) | 443 | 1.4 (1.0) | 1 (1-1) |
| Total bed-days |  | 5.8 (8.4) | 3 (1-7) |  | 8.5 (19.5) | 3 (1-8) |
| **Second year** |  |  |  |  |  |  |
| Potentially preventable hospitalisations | 133 | 1.6 (2.2) | 1 (1-2) | 151 | 1.4 (0.9) | 1 (1-1) |
| Total bed-days |  | 8.5 (26.8) | 3 (1-8) |  | 7.6 (12.2) | 3 (1-8) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1Patients with the follow-up period shorter than the respective measurement period were excluded.

Table 71: Total National Weighted Activity Unit among HCH patients and comparators, derived from linked data

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Pre-and post-enrolment period** | **HCH patients** | | | **Comparator patients** | | |
| **Number of patients1** | **Mean (std)** | **Median (IQR)** | **Number of patients1** | **Mean (std)** | **Median (IQR)** |
| **In all patients** | | | | | | |
| Pre-enrolment | 9120 | 0.77 (2.53) | 0 (0-0.23) | 9120 | 0.73 (2.44) | 0 (0-0.24) |
| First year | 8925 | 0.74 (2.54) | 0 (0-0.23) | 8922 | 0.71 (2.81) | 0 (0-0.12) |
| Second year | 2693 | 0.77 (2.95) | 0 (0-0.20) | 2710 | 0.77 (2.70) | 0 (0-0.21) |
| **Amongst admitted patients** | | | | | | |
| Pre-enrolment | 2481 | 2.82 (4.22) | 1.26 (0.53-3.34) | 2500 | 2.66 (4.08) | 1.28 (0.53-3.08) |
| First year | 2462 | 2.66 (4.26) | 1.17 (0.48-2.84) | 2271 | 2.80 (5.00) | 1.19 (0.44-3.19) |
| Second year | 734 | 2.84 (5.10) | 1.15 (0.48-3.38) | 751 | 2.77 (4.55) | 1.19 (0.43-3.09) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 1 Patients with the follow-up period shorter than the respective measurement period were excluded.

## Entry into aged care facility

Table 72: Admission to aged care facility by 30 June 2020 among HCH patients and comparators

|  |  |  |
| --- | --- | --- |
| **Admission to aged care facility** | **HCH patients** | **Comparator patients** |
| **In all patients** | | |
| **Admission to aged care facility,** number (%) | 339 (3.2%) | 292 (2.7%) |
| **Time-to-entry (months)** |  |  |
| Mean (std) | 9.8 (6.6) | 11.2 (6.9) |
| Median (IQR) | 9 (5-14) | 11 (5-16) |
| **In patients who did not use residential aged care services in the 24 months before enrolment** | | |
| **Admission to aged care facility**, number (%) | 281 (2.7%) | 270 (2.5%) |
| **Time-to-entry (months)** |  |  |
| Mean (std) | 10.7 (6.4) | 11.7 (6.8) |
| Median (IQR) | 10 (6-15) | 11 (6-17) |

Source: National Death Index data collection and National Aged Care Data Clearing House – Residential Aged Care Episode of care.

Table 73: Hazard ratio for having an entry to aged care facility by 30 June 2020

|  |  |  |
| --- | --- | --- |
| **Entry to aged care facility** | **Hazard Ratio (95%CI)** | **p-value1** |
| Comparator patients | 1.00 (reference) |  |
| HCH patients | 1.16 (0.97-1.39) | 0.110 |

Notes: 1 Cox proportional hazard model, adjusted for pre-enrolment use of community-based aged care services and residential aged care facility services

## Serious cardiovascular event and death

Table 74: Serious cardiovascular event by 30 June 2020 among HCH patients and comparator patients, derived from linked data

|  |  |  |
| --- | --- | --- |
| **Serious cardiovascular event** | **HCH patients** | **Comparator patients** |
| **Cardiovascular hospitalisation or death,** number (%) | 621 (6.8%) | 604 (6.6%) |
| **Time-to-cardiovascular event (months)** |  |  |
| Mean (std) | 9.3 (6.7) | 10.3 (7.0) |
| Median (IQR) | 9 (4-14) | 9 (4-15) |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas).

Table 75: Hazard ratio for serious cardiovascular event, HCH versus comparator patients, derived from linked data

|  |  |  |
| --- | --- | --- |
| **Serious cardiovascular event** | **Hazard Ratio (95%CI)** | **p-value2** |
| Comparator patients | 1.00 (reference) |  |
| HCH patients | 1.04 (0.92-1.16) | 0.568 |

Notes: Calculated for patients living in five states (NSW, Vic, Qld, SA and Tas). 2Univariate Cox proportional hazard model.

Table 76: Mortality by 30 June 2021 among HCH patients and c comparator patients, derived from linked data

|  |  |  |
| --- | --- | --- |
| **Mortality** | **HCH patients** | **Comparator patients** |
| **Death,** number (%) | 689 (6.5%) | 646 (6.1%) |
| **Time-to-death (months)** |  |  |
| Mean (std) | 17.2 (9.9) | 17.1 (9.9) |
| Median (IQR) | 17 (9-25) | 17 (9-25) |

Source: National Death Index data collection.

Table 77: Hazard ratio for mortality HCH versus comparator patients, derived from linked data

|  |  |  |
| --- | --- | --- |
| **Mortality** | **Hazard Ratio (95%CI)** | **p-value1** |
| Comparator patients | 1.00 (reference) |  |
| HCH patients | 1.07 (0.96-1.20) | 0.217 |

Notes: 1 Univariate Cox proportional hazard model.

# Appendix 7: Patient surveys detailed tables

## Respondent characteristics

Table 78: Respondent characteristics

| **Respondent characteristics** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **A0 Totals** | | | | | | | | |
| Total responses | 2018 | 1859 | 1385 | 5262 | 2602 | 1224 | 2762 | 1131 |
| Total Patients | 2018 | 1859 | 1385 | 2602 | 2602 | 564 | 1340 | 623 |
| Total Practices | 99 | 87 | 73 | 108 | 108 | 77 | 99 | 93 |
| **A1 Sex** | | | | | | | | |
| Female | 1,083 (54.4%) | 1,035 (56.3%) | 767 (56.1%) | 2,885 (55.5%) | 1,418 (55.1%) | 686 (56.2%) | 1,526 (55.4%) | 625 (55.7%) |
| Male | 908 (45.6%) | 804 (43.7%) | 601 (43.9%) | 2,313 (44.5%) | 1,157 (44.9%) | 535 (43.8%) | 1,230 (44.6%) | 497 (44.3%) |
| **A2 Age group** | | | | | | | | |
| 00–24 | 16 (0.8%) | 12 (0.6%) | 4 (0.3%) | 32 (0.6%) | 17 (0.7%) | 1 (0.1%) | 14 (0.5%) | 17 (1.5%) |
| 25–44 | 130 (6.5%) | 104 (5.6%) | 79 (5.7%) | 313 (6.0%) | 156 (6.0%) | 65 (5.3%) | 164 (6.0%) | 79 (7.0%) |
| 45–64 | 542 (26.9%) | 439 (23.7%) | 309 (22.4%) | 1,290 (24.6%) | 599 (23.1%) | 273 (22.4%) | 654 (23.8%) | 326 (28.8%) |
| 65–74 | 652 (32.4%) | 584 (31.5%) | 418 (30.3%) | 1,654 (31.5%) | 784 (30.2%) | 446 (36.6%) | 894 (32.5%) | 261 (23.1%) |
| 75–84 | 523 (26.0%) | 538 (29.0%) | 431 (31.2%) | 1,492 (28.4%) | 754 (29.0%) | 356 (29.2%) | 794 (28.9%) | 309 (27.3%) |
| 85+ | 149 (7.4%) | 177 (9.5%) | 139 (10.1%) | 465 (8.9%) | 286 (11.0%) | 77 (6.3%) | 232 (8.4%) | 139 (12.3%) |
| **A3 Indigenous status (Q34)** | | | | | | | | |
| Aboriginal or Torres Strait Islander | 66 (3.3%) | 57 (3.1%) | 33 (2.4%) | 156 (3.0%) | 87 (3.3%) | 19 (1.6%) | 87 (3.2%) | 50 (4.5%) |
| Not Aboriginal or Torres Strait Islander | 1,936 (96.7%) | 1,789 (96.9%) | 1,345 (97.6%) | 5,070 (96.4%) | 2,494 (95.8%) | 1,201 (98.4%) | 2,651 (96.8%) | 1,073 (95.5%) |
| Don't know/ Refused |  |  |  | 36 (0.7%) | 21 (0.8%) |  |  |  |

| **Respondent characteristics** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **A4 Country of birth (Q35)** | | | | | | | | |
| Australia | 1,379 (68.3%) | 1,269 (68.3%) | 950 (68.6%) | 3,598 (68.4%) | 1,769 (68.0%) | 847 (69.2%) | 1,850 (67.0%) | 791 (69.9%) |
| United Kingdom | 291 (14.4%) | 298 (16.0%) | 223 (16.1%) | 812 (15.4%) | 402 (15.4%) | 193 (15.8%) | 440 (15.9%) | 157 (13.9%) |
| Other | 348 (17.2%) | 292 (15.7%) | 212 (15.3%) | 852 (16.2%) | 431 (16.6%) | 184 (15.0%) | 472 (17.1%) | 183 (16.2%) |
| **A5 Highest level of education (Q36)** | | | | | | | | |
| Year 9 or below | 427 (21.4%) | 391 (21.3%) | 255 (18.6%) | 1,073 (20.4%) | 541 (20.8%) | 202 (16.6%) | 593 (21.7%) | 258 (23.2%) |
| Year 10 or equivalent | 326 (16.3%) | 286 (15.6%) | 223 (16.3%) | 835 (15.9%) | 406 (15.6%) | 210 (17.3%) | 425 (15.6%) | 169 (15.2%) |
| Year 11 or equivalent | 112 (5.6%) | 100 (5.5%) | 80 (5.8%) | 292 (5.5%) | 145 (5.6%) | 67 (5.5%) | 168 (6.2%) | 54 (4.9%) |
| Year 12 or equivalent | 244 (12.2%) | 223 (12.2%) | 161 (11.7%) | 628 (11.9%) | 332 (12.8%) | 167 (13.8%) | 295 (10.8%) | 148 (13.3%) |
| Certificate I to IV (including  trade certificate) | 416 (20.9%) | 401 (21.9%) | 304 (22.2%) | 1,121 (21.3%) | 554 (21.3%) | 239 (19.7%) | 609 (22.3%) | 242 (21.7%) |
| Advanced diploma/Diploma | 167 (8.4%) | 167 (9.1%) | 138 (10.1%) | 472 (9.0%) | 216 (8.3%) | 134 (11.0%) | 226 (8.3%) | 86 (7.7%) |
| Bachelor’s degree | 187 (9.4%) | 166 (9.1%) | 135 (9.8%) | 488 (9.3%) | 227 (8.7%) | 143 (11.8%) | 240 (8.8%) | 96 (8.6%) |
| Post-graduate degree | 66 (3.3%) | 56 (3.1%) | 41 (3.0%) | 163 (3.1%) | 82 (3.2%) | 34 (2.8%) | 98 (3.6%) | 24 (2.2%) |
| Other | 50 (2.5%) | 44 (2.4%) | 34 (2.5%) | 128 (2.4%) | 69 (2.7%) | 18 (1.5%) | 74 (2.7%) | 36 (3.2%) |
| Refused |  |  |  | 62 (1.2%) | 30 (1.2%) |  |  |  |
| **A6 Household composition (Q33)** | | | | | | | | |
| Person living alone | 486 (24.1%) | 486 (26.1%) | 355 (25.6%) | 1,327 (25.2%) | 675 (25.9%) | 217 (17.7%) | 732 (26.5%) | 328 (29.0%) |
| Couple only | 934 (46.3%) | 885 (47.6%) | 697 (50.3%) | 2,516 (47.8%) | 1,193 (45.8%) | 723 (59.1%) | 1,318 (47.7%) | 417 (36.9%) |
| Couple with non-dependent child/ren | 168 (8.3%) | 125 (6.7%) | 78 (5.6%) | 371 (7.1%) | 179 (6.9%) | 82 (6.7%) | 200 (7.2%) | 82 (7.3%) |
| Couple with dependent  child or children | 148 (7.3%) | 125 (6.7%) | 90 (6.5%) | 363 (6.9%) | 171 (6.6%) | 102 (8.3%) | 179 (6.5%) | 64 (5.7%) |
| Single parent with non-dependent child/ren | 85 (4.2%) | 56 (3.0%) | 33 (2.4%) | 174 (3.3%) | 93 (3.6%) | 29 (2.4%) | 74 (2.7%) | 66 (5.8%) |
| Single parent with dependent child/ren | 36 (1.8%) | 32 (1.7%) | 16 (1.2%) | 84 (1.6%) | 53 (2.0%) | 11 (0.9%) | 45 (1.6%) | 27 (2.4%) |
| Other household type | 161 (8.0%) | 150 (8.1%) | 116 (8.4%) | 427 (8.1%) | 238 (9.1%) | 60 (4.9%) | 214 (7.7%) | 147 (13.0%) |
| **A9 Help provided to patient and answering the survey** | | | | | | | | |
| Yes: answered for them (proxy) | 113 (5.6%) | 90 (4.8%) | 58 (4.2%) | 261 (5.0%) | 158 (6.1%) | 22 (1.8%) | 92 (3.3%) | 138 (12.2%) |
| Yes: helped them answer  some questions | 75 (3.7%) | 81 (4.4%) | 39 (2.8%) | 195 (3.7%) | 91 (3.5%) | 30 (2.5%) | 108 (3.9%) | 49 (4.3%) |
| No: did not need any help | 1,830 (90.7%) | 1,688 (90.8%) | 1,288 (93.0%) | 4,806 (91.3%) | 2,353 (90.4%) | 1,172 (95.8%) | 2,562 (92.8%) | 944 (83.5%) |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Use of services and access

Table 79: Use of HCH practice

| **Patient use of HCH practice** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **B01 HCH practice is the GP practice that patient usually attends (Q2)** | | | | | | | | |
| Yes | 1,983 (98.4%) | 1,845 (99.4%) | 1,376 (99.4%) | 5,204 (98.9%) | 2,562 (98.5%) | 1,213 (99.1%) | 2,735 (99.2%) | 1,111 (98.4%) |
| No | 32 (1.6%) | 12 (0.6%) | 8 (0.6%) | 52 (1.0%) | 35 (1.3%) | 11 (0.9%) | 23 (0.8%) | 18 (1.6%) |
| Refused |  |  |  | 6 (0.1%) | 5 (0.2%) |  |  |  |
| **B02 Length of time the patient has been attending the HCH practice (Q3)** | | | | | | | | |
| Less than 6 months | 34 (1.7%) | 8 (1.4%) |  | 42 (1.6%) | 42 (1.6%) | 3 (0.5%) | 13 (1.0%) | 24 (3.9%) |
| At least 6 months but less than 1 year | 52 (2.6%) | 9 (1.5%) |  | 61 (2.3%) | 61 (2.3%) | 7 (1.2%) | 26 (1.9%) | 27 (4.4%) |
| At least 1 year but less than 3 years | 297 (14.8%) | 58 (10.0%) |  | 355 (13.6%) | 355 (13.6%) | 68 (12.1%) | 182 (13.6%) | 98 (15.8%) |
| At least 3 years but less than 5 years | 315 (15.6%) | 73 (12.6%) |  | 388 (14.9%) | 388 (14.9%) | 81 (14.4%) | 211 (15.8%) | 90 (14.5%) |
| 5 years or more | 1,315 (65.3%) | 433 (74.5%) |  | 1,748 (67.2%) | 1,748 (67.2%) | 405 (71.8%) | 903 (67.6%) | 381 (61.5%) |
| Don't know |  |  |  | 8 (0.3%) | 8 (0.3%) |  |  |  |
| **B03 Number of times the patient attending the HCH practice in the last six months (Q4)** | | | | | | | | |
| Never | 16 (0.8%) | 29 (1.6%) | 48 (3.5%) | 93 (1.8%) | 70 (2.7%) | 23 (1.9%) | 41 (1.5%) | 24 (2.1%) |
| Once | 82 (4.1%) | 102 (5.5%) | 102 (7.4%) | 286 (5.4%) | 164 (6.3%) | 94 (7.8%) | 140 (5.1%) | 44 (3.9%) |
| Twice | 244 (12.2%) | 260 (14.1%) | 233 (17.0%) | 737 (14.0%) | 374 (14.4%) | 237 (19.6%) | 372 (13.6%) | 112 (10.0%) |
| 3 times | 324 (16.3%) | 290 (15.7%) | 229 (16.7%) | 843 (16.0%) | 417 (16.0%) | 231 (19.1%) | 437 (16.0%) | 156 (14.0%) |
| 4 times | 296 (14.9%) | 261 (14.2%) | 234 (17.1%) | 791 (15.0%) | 400 (15.4%) | 192 (15.8%) | 446 (16.3%) | 128 (11.4%) |
| 5 to 9 times | 596 (29.9%) | 596 (32.3%) | 372 (27.1%) | 1,564 (29.7%) | 731 (28.1%) | 294 (24.3%) | 838 (30.6%) | 389 (34.8%) |
| 10 or more times | 434 (21.8%) | 306 (16.6%) | 154 (11.2%) | 894 (17.0%) | 415 (15.9%) | 141 (11.6%) | 461 (16.9%) | 265 (23.7%) |
| Don't know |  |  |  | 54 (1.0%) | 31 (1.2%) |  |  |  |

| **Patient use of HCH practice** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **B04 Number of times the patient contacted their GP or other professional at the HCH practice by email or telephone about their health in the last six months (apart from scheduling appointments) (Q5)** | | | | | | | | |
| Never | 1,340 (67.3%) | 966 (52.5%) |  | 2,306 (59.5%) | 1,447 (55.6%) | 559 (64.5%) | 1,237 (61.8%) | 449 (52.5%) |
| Once | 121 (6.1%) | 182 (9.9%) |  | 303 (7.8%) | 217 (8.3%) | 85 (9.8%) | 153 (7.6%) | 58 (6.8%) |
| Twice | 155 (7.8%) | 212 (11.5%) |  | 367 (9.5%) | 270 (10.4%) | 61 (7.0%) | 206 (10.3%) | 89 (10.4%) |
| 3 times | 99 (5.0%) | 128 (7.0%) |  | 227 (5.9%) | 162 (6.2%) | 56 (6.5%) | 109 (5.4%) | 59 (6.9%) |
| 4 times | 70 (3.5%) | 92 (5.0%) |  | 162 (4.2%) | 120 (4.6%) | 27 (3.1%) | 90 (4.5%) | 37 (4.3%) |
| 5 to 9 times | 128 (6.4%) | 184 (10.0%) |  | 312 (8.0%) | 248 (9.5%) | 54 (6.2%) | 147 (7.3%) | 100 (11.7%) |
| 10 or more times | 78 (3.9%) | 75 (4.1%) |  | 153 (3.9%) | 111 (4.3%) | 24 (2.8%) | 60 (3.0%) | 63 (7.4%) |
| Don't know |  |  |  | 47 (1.2%) | 27 (1.0%) |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

Table 80: Use of telemedicine, wave 3

| **Use of telemedicine** | **Total responses** | **Patient tier** | | |
| --- | --- | --- | --- | --- |
| **1** | **2** | **3** |
| **B06 Number of times the patient had a contact with their GP or other professional at the HCH practice by telephone or video in the last 6 months** | | | | |
| Never | 768 (55.5%) | 216 (61.7%) | 410 (56.9%) | 121 (47.1%) |
| Once | 181 (13.1%) | 44 (12.6%) | 100 (13.9%) | 34 (13.2%) |
| Twice | 156 (11.3%) | 34 (9.7%) | 89 (12.4%) | 32 (12.5%) |
| 3 times | 110 (8.0%) | 28 (8.0%) | 53 (7.4%) | 27 (10.5%) |
| 4 times | 54 (3.9%) | 11 (3.1%) | 27 (3.8%) | 15 (5.8%) |
| 5–9 times | 67 (4.8%) | 15 (4.3%) | 31 (4.3%) | 18 (7.0%) |
| 10 or more times | 23 (1.7%) | 2 (0.6%) | 10 (1.4%) | 10 (3.9%) |
| Don’t know | 24 (1.7%) |  |  |  |
| **B07 Modality of consults with the GP or other professional** | | | | |
| All by telephone | 550 (92.4%) | 124 (92.5%) | 291 (93.9%) | 124 (90.5%) |
| All by video | 6 (1.0%) |  | 2 (0.6%) | 4 (2.9%) |
| A mix of telephone and video | 37 (6.2%) | 10 (7.5%) | 17 (5.5%) | 9 (6.6%) |
| Don't know | 2 (0.3%) |  |  |  |
| **B08 Did the patient have their first telephone or video consult with a GP in the last 6 months? (Q6e)** | | | | |
| Yes | 414 (69.6%) | 94 (74.0%) | 213 (74.7%) | 100 (76.9%) |
| No | 138 (23.2%) | 33 (26.0%) | 72 (25.3%) | 30 (23.1%) |
| Don't know | 42 (7.1%) |  |  |  |
| Refused | 1 (0.2%) |  |  |  |
| **B10 Number of times the patient had a contact with a nurse at the HCH practice by telephone or video in the last 6 months (Q6g)** | | | | |
| Never | 1,026 (74.1%) | 267 (76.5%) | 544 (75.2%) | 191 (74.3%) |
| Once | 160 (11.6%) | 39 (11.2%) | 91 (12.6%) | 26 (10.1%) |
| Twice | 85 (6.1%) | 28 (8.0%) | 39 (5.4%) | 14 (5.4%) |
| 3 times | 47 (3.4%) | 8 (2.3%) | 25 (3.5%) | 14 (5.4%) |
| 4 times | 19 (1.4%) | 3 (0.9%) | 12 (1.7%) | 4 (1.6%) |
| 5–9 times | 22 (1.6%) | 4 (1.1%) | 10 (1.4%) | 7 (2.7%) |
| 10 or more times | 3 (0.2%) |  | 2 (0.3%) | 1 (0.4%) |
| Don’t know | 22 (1.6%) |  |  |  |
| **B11 Modality of consults with a nurse (Q6i)** | | | | |
| All by telephone | 327 (96.5%) | 80 (97.6%) | 174 (97.2%) | 64 (97.0%) |
| All by video | 2 (0.6%) |  | 1 (0.6%) | 1 (1.5%) |
| A mix of telephone and video | 7 (2.1%) | 2 (2.4%) | 4 (2.2%) | 1 (1.5%) |
| Don't know | 3 (0.9%) |  |  |  |
| **B12 Did the patient have their first telephone or video consult with a nurse in the last 6 months (Q6j)** | | | | |
| Yes | 231 (68.1%) | 57 (75.0%) | 121 (74.7%) | 46 (76.7%) |
| No | 76 (22.4%) | 19 (25.0%) | 41 (25.3%) | 14 (23.3%) |
| Don't know | 29 (8.6%) |  |  |  |
| Refused | 3 (0.9%) |  |  |  |
| **B13 Do the patient think telephone or video consults were a good option in the future in addition to visiting the practice in person (Q6l)** | | | | |
| Definitely no | 74 (10.0%) | 11 (6.3%) | 51 (13.3%) | 12 (7.6%) |
| Probably no | 119 (16.0%) | 31 (17.7%) | 65 (17.0%) | 20 (12.7%) |
| Probably yes | 211 (28.4%) | 51 (29.1%) | 103 (26.9%) | 51 (32.3%) |
| Definitely yes | 328 (44.1%) | 82 (46.9%) | 164 (42.8%) | 75 (47.5%) |
| Don't know | 11 (1.5%) |  |  |  |
| **B13 Is the practice continuing with telephone or video consults (Q6k)** | | | | |
| Yes | 487 (65.5%) | 118 (87.4%) | 253 (83.8%) | 107 (82.9%) |
| No | 92 (12.4%) | 17 (12.6%) | 49 (16.2%) | 22 (17.1%) |
| Don't know | 164 (22.1%) |  |  |  |

Source: Patient survey Wave 3 Mar–Apr 2021.

Table 81: Access

| **Access measures** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **C1 Over the last 6 months, that patient contacted the HCH to get an appointment for an illness, injury, or condition that needed care right away (Q14)** | | | | | | | | |
| Yes | 973 (48.8%) | 840 (45.7%) | 587 (42.8%) | 2,400 (45.6%) | 1,155 (44.4%) | 499 (41.2%) | 1,249 (45.6%) | 584 (52.3%) |
| No | 1,022 (51.2%) | 998 (54.3%) | 786 (57.2%) | 2,806 (53.3%) | 1,421 (54.6%) | 712 (58.8%) | 1,488 (54.4%) | 532 (47.7%) |
| Don't know |  |  |  | 56 (1.1%) | 26 (1.0%) |  |  |  |
| **C2 When requesting an appointment for care needed right away, how often the patient get an appointment as soon as required (Q15)** | | | | | | | | |
| None of the time | 19 (2.0%) | 31 (3.7%) | 26 (4.5%) | 76 (3.2%) | 42 (3.6%) | 13 (2.6%) | 37 (3.0%) | 25 (4.3%) |
| A little of the time | 37 (3.9%) | 33 (4.0%) | 25 (4.3%) | 95 (4.0%) | 46 (4.0%) | 16 (3.2%) | 49 (4.0%) | 27 (4.7%) |
| Some of the time | 85 (8.9%) | 73 (8.8%) | 77 (13.3%) | 235 (9.8%) | 127 (11.0%) | 60 (12.2%) | 116 (9.4%) | 57 (9.9%) |
| Most of the time | 300 (31.3%) | 266 (32.0%) | 164 (28.2%) | 730 (30.4%) | 335 (29.0%) | 146 (29.6%) | 413 (33.5%) | 159 (27.7%) |
| Always | 516 (53.9%) | 428 (51.5%) | 289 (49.7%) | 1,233 (51.4%) | 591 (51.2%) | 258 (52.3%) | 618 (50.1%) | 307 (53.4%) |
| Don't know |  |  |  | 31 (1.3%) | 14 (1.2%) |  |  |  |
| **C3 Over the last 6 months, did the patient contact the HCH to get an appointment for a check-up or routine care (Q16)** | | | | | | | | |
| Yes | 1,521 (76.8%) | 1,373 (74.6%) | 1,018 (74.6%) | 3,912 (74.3%) | 1,882 (72.3%) | 928 (76.6%) | 2,046 (75.0%) | 826 (74.8%) |
| No | 460 (23.2%) | 468 (25.4%) | 346 (25.4%) | 1,274 (24.2%) | 675 (25.9%) | 283 (23.4%) | 683 (25.0%) | 278 (25.2%) |
| Don't know |  |  |  | 76 (1.4%) | 45 (1.7%) |  |  |  |
| **C4 When requesting an appointment for a check-up or routine care, how often did the patient get an appointment as soon as required (Q17)** | | | | | | | | |
| None of the time | 20 (1.3%) | 37 (2.7%) | 29 (2.9%) | 86 (2.2%) | 46 (2.4%) | 26 (2.8%) | 38 (1.9%) | 21 (2.6%) |
| A little of the time | 42 (2.8%) | 39 (2.9%) | 45 (4.5%) | 126 (3.2%) | 68 (3.6%) | 28 (3.1%) | 65 (3.2%) | 32 (3.9%) |
| Some of the time | 143 (9.6%) | 146 (10.8%) | 126 (12.5%) | 415 (10.6%) | 205 (10.9%) | 111 (12.1%) | 196 (9.7%) | 102 (12.5%) |
| Most of the time | 550 (36.7%) | 491 (36.3%) | 364 (36.1%) | 1,405 (35.9%) | 683 (36.3%) | 325 (35.5%) | 759 (37.6%) | 279 (34.3%) |
| Always | 742 (49.6%) | 640 (47.3%) | 443 (44.0%) | 1,825 (46.7%) | 855 (45.4%) | 425 (46.4%) | 958 (47.5%) | 380 (46.7%) |
| Don't know |  |  |  | 55 (1.4%) | 25 (1.3%) |  |  |  |
| **C5 When requesting an appointment or attending for any reason, how often did the patient see their own personal GP (Q18)** | | | | | | | | |
| None of the time | 21 (1.1%) | 21 (1.1%) | 24 (1.7%) | 66 (1.3%) | 38 (1.5%) | 19 (1.6%) | 36 (1.3%) | 11 (1.0%) |
| A little of the time | 52 (2.6%) | 41 (2.2%) | 43 (3.1%) | 136 (2.6%) | 69 (2.7%) | 42 (3.5%) | 71 (2.6%) | 22 (2.0%) |
| Some of the time | 106 (5.3%) | 116 (6.3%) | 101 (7.4%) | 323 (6.1%) | 162 (6.2%) | 82 (6.8%) | 163 (6.0%) | 71 (6.3%) |
| Most of the time | 633 (31.7%) | 580 (31.5%) | 396 (28.8%) | 1,609 (30.6%) | 743 (28.6%) | 405 (33.5%) | 846 (30.9%) | 319 (28.5%) |
| Always | 1,182 (59.3%) | 1,085 (58.9%) | 809 (58.9%) | 3,076 (58.5%) | 1,563 (60.1%) | 661 (54.7%) | 1,621 (59.2%) | 697 (62.2%) |
| Don't know |  |  |  | 52 (1.0%) | 27 (1.0%) |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Care planning

Table 82: Care planning

| **Care planning** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **D1 Patient has registered for My Health Record (Q6)** | | | | | | | | |
| Yes | 1,449 (81.1%) | 1,227 (78.8%) |  | 2,676 (69.0%) | 1,717 (66.0%) | 642 (84.6%) | 1,426 (80.7%) | 531 (73.3%) |
| No | 338 (18.9%) | 330 (21.2%) |  | 668 (17.2%) | 478 (18.4%) | 117 (15.4%) | 340 (19.3%) | 193 (26.7%) |
| Don't know |  |  |  | 533 (13.7%) | 407 (15.6%) |  |  |  |
| **D2 Before enrolling in HCH, patient had a treatment/shared care plan which their GP or practice staff developed with them (Q7)** | | | | | | | | |
| Yes | 1,159 (60.8%) | 1,520 (86.3%) | 1,109 (83.6%) | 3,788 (72.0%) | 1,887 (72.5%) | 880 (75.2%) | 2,001 (76.1%) | 804 (76.2%) |
| No | 747 (39.2%) | 242 (13.7%) | 217 (16.4%) | 1,206 (22.9%) | 575 (22.1%) | 290 (24.8%) | 627 (23.9%) | 251 (23.8%) |
| Don't know/Refused |  |  |  | 268 (5.1%) | 140(5.3%) |  |  |  |
| **D3 Before enrolling in HCH, frequency the patient discussed their treatment/shared care plan with their GP or practice staff (Q8)** | | | | | | | | |
| At most or all consultations | 485 (45.6%) | 591 (40.7%) | 416 (38.6%) | 1,492 (39.4%) | 724 (38.4%) | 356 (42.7%) | 740 (38.8%) | 354 (46.6%) |
| It was sometimes discussed | 500 (47.0%) | 720 (49.6%) | 560 (52.0%) | 1,780 (47.0%) | 919 (48.7%) | 409 (49.0%) | 971 (51.0%) | 352 (46.3%) |
| It was never discussed | 79 (7.4%) | 142 (9.8%) | 101 (9.4%) | 322 (8.5%) | 164 (8.7%) | 69 (8.3%) | 194 (10.2%) | 54 (7.1%) |
| Don't know/Refused |  |  |  | 194 (5.1%) | 80(4.3%) |  |  |  |
| **D4 Patient was given a copy of their treatment plan/shared care plan in the last 6 months (Q9)** | | | | | | | | |
| Yes | 850 (76.6%) | 882 (61.8%) | 593 (55.9%) | 2,325 (61.4%) | 1,094 (58.0%) | 546 (64.7%) | 1,248 (65.3%) | 475 (63.7%) |
| No | 260 (23.4%) | 545 (38.2%) | 468 (44.1%) | 1,273 (33.6%) | 692 (36.7%) | 298 (35.3%) | 663 (34.7%) | 271 (36.3%) |
| Don't know/Refused |  |  |  | 190 (5.0%) | 101 (5.4%) |  |  |  |
| **D5 Was a copy of the patient's treatment plan/shared care plan included in My Health Record (Q10)** | | | | | | | | |
| Yes | 420 (87.7%) | 535 (90.5%) | 597 (86.1%) | 1,552 (50.6%) | 853 (51.9%) | 379 (87.3%) | 826 (88.8%) | 301 (86.2%) |
| No | 59 (12.3%) | 56 (9.5%) | 96 (13.9%) | 211 (6.9%) | 128 (7.8%) | 55 (12.7%) | 104 (11.2%) | 48 (13.8%) |
| Don't know |  |  |  | 1,304 (42.5%) | 664 (40.4%) |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Medications review

Table 83: Medications review

| **E Medications review** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **E1 Over the last six months, how often did the GP, or someone from the HCH, talk to the patient about all the prescription medicines they were taking, when they attended (Q13)** | | | | | | | | |
| Never | 231 (11.9%) | 222 (12.3%) | 193 (14.3%) | 646 (12.3%) | 350 (13.5%) | 162 (13.9%) | 348 (13.0%) | 122 (11.1%) |
| Some of the times | 577 (29.8%) | 523 (29.1%) | 431 (31.9%) | 1,531 (29.1%) | 751 (28.9%) | 345 (29.5%) | 834 (31.0%) | 316 (28.8%) |
| Most of times | 1,128 (58.3%) | 1,055 (58.6%) | 728 (53.8%) | 2,911 (55.3%) | 1,418 (54.5%) | 661 (56.6%) | 1,505 (56.0%) | 659 (60.1%) |
| Not taking prescription medication |  |  |  | 81 (1.5%) | 42 (1.6%) |  |  |  |
| Don't know |  |  |  | 93 (1.8%) | 41 (1.6%) |  |  |  |
| **E2 In the last 12 months, did the patient have a consultation with a pharmacist who reviewed all the medicines they were taking and explained each medication?** | | | | | | | | |
| Yes |  | 869 (47.2%) | 585 (43.0%) | 1,454 (44.8%) | 836 (43.3%) | 279 (36.0%) | 795 (46.5%) | 346 (53.6%) |
| No |  | 974 (52.8%) | 777 (57.0%) | 1,751 (54.0%) | 1,065 (55.1%) | 497 (64.0%) | 914 (53.5%) | 299 (46.4%) |
| Don't know |  |  |  | 39 (1.2%) | 31 (1.6%) |  |  |  |
| **E3 If the opportunity was made available would the patient like to have a consultation with a pharmacist to review their medicines and the pharmacist questions about them?** | | | | | | | | |
| Yes |  | 384 (41.0%) | 285 (37.4%) | 669 (38.2%) | 390 (36.6%) | 176 (36.3%) | 351 (39.5%) | 124 (43.1%) |
| No |  | 553 (59.0%) | 478 (62.6%) | 1,031 (58.9%) | 647 (60.8%) | 309 (63.7%) | 538 (60.5%) | 164 (56.9%) |
| Don't know |  |  |  | 51 (2.9%) | 28 (2.6%) |  |  |  |
| **E4 Where did the patient see the pharmacist for this consultation?** | | | | | | | | |
| In your GP practice |  | 102 (11.8%) | 73 (12.5%) | 175 (12.0%) | 102 (12.2%) | 29 (10.4%) | 94 (11.9%) | 41 (11.9%) |
| At a community pharmacy |  | 627 (72.3%) | 399 (68.6%) | 1,026 (70.6%) | 566 (67.7%) | 214 (77.0%) | 568 (71.7%) | 228 (66.1%) |
| At home |  | 102 (11.8%) | 71 (12.2%) | 173 (11.9%) | 109 (13.0%) | 22 (7.9%) | 88 (11.1%) | 56 (16.2%) |
| Somewhere else |  | 36 (4.2%) | 39 (6.7%) | 75 (5.2%) | 56 (6.7%) | 13 (4.7%) | 42 (5.3%) | 20 (5.8%) |
| Don't know |  |  |  | 5 (0.3%) | 3 (0.4%) |  |  |  |
| **E5 At the consultation, did the pharmacist give the patient a list of all the medicines they are taking?** | | | | | | | | |
| Yes |  | 572 (67.5%) | 385 (68.1%) | 957 (65.8%) | 548 (65.6%) | 170 (62.3%) | 523 (67.7%) | 241 (72.2%) |
| No |  | 276 (32.5%) | 180 (31.9%) | 456 (31.4%) | 260 (31.1%) | 103 (37.7%) | 249 (32.3%) | 93 (27.8%) |
| Don't know |  |  |  | 41 (2.8%) | 28 (3.3%) |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Patient and carer experience and rating of quality of care

Table 84: Patient assessment of chronic illness care (PACIC)

| **Patient assessment of chronic**  **illness care (PACIC)** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **J01 I was asked for my ideas when we made decisions about my treatment (Q11)** | | | | | | | | |
| None of the time | 287 (15.3%) | 310 (17.3%) | 233 (17.4%) | 830 (16.6%) | 430 (17.4%) | 219 (18.5%) | 444 (16.9%) | 155 (14.5%) |
| A little of the time | 178 (9.5%) | 152 (8.5%) | 145 (10.8%) | 475 (9.5%) | 227 (9.2%) | 107 (9.0%) | 257 (9.8%) | 98 (9.2%) |
| Some of the time | 484 (25.8%) | 484 (27.1%) | 346 (25.8%) | 1,314 (26.2%) | 650 (26.3%) | 305 (25.8%) | 694 (26.5%) | 276 (25.9%) |
| Most of the time | 487 (25.9%) | 418 (23.4%) | 333 (24.8%) | 1,238 (24.7%) | 598 (24.2%) | 275 (23.2%) | 650 (24.8%) | 275 (25.8%) |
| Always | 441 (23.5%) | 423 (23.7%) | 285 (21.2%) | 1,149 (23.0%) | 568 (23.0%) | 277 (23.4%) | 577 (22.0%) | 263 (24.6%) |
| **J02 I was given choices about treatment to think about (Q11)** | | | | | | | | |
| None of the time | 292 (15.3%) | 292 (16.4%) | 228 (17.1%) | 812 (16.1%) | 418 (16.7%) | 214 (18.2%) | 420 (15.9%) | 151 (14.1%) |
| A little of the time | 149 (7.8%) | 97 (5.4%) | 102 (7.6%) | 348 (6.9%) | 175 (7.0%) | 87 (7.4%) | 174 (6.6%) | 75 (7.0%) |
| Some of the time | 373 (19.5%) | 392 (22.0%) | 315 (23.6%) | 1,080 (21.5%) | 554 (22.2%) | 227 (19.3%) | 589 (22.3%) | 232 (21.6%) |
| Most of the time | 445 (23.3%) | 424 (23.8%) | 317 (23.7%) | 1,186 (23.6%) | 564 (22.6%) | 278 (23.7%) | 622 (23.5%) | 253 (23.6%) |
| Always | 651 (34.1%) | 577 (32.4%) | 374 (28.0%) | 1,602 (31.9%) | 786 (31.5%) | 368 (31.3%) | 837 (31.7%) | 361 (33.7%) |
| **J03 I was sure that my doctor or nurse thought about my values, beliefs, and traditions when they recommended treatments to me (Q11)** | | | | | | | | |
| None of the time | 130 (6.9%) | 143 (8.1%) | 121 (9.2%) | 394 (7.9%) | 211 (8.6%) | 94 (8.1%) | 215 (8.3%) | 74 (6.9%) |
| A little of the time | 64 (3.4%) | 51 (2.9%) | 61 (4.6%) | 176 (3.5%) | 96 (3.9%) | 41 (3.5%) | 86 (3.3%) | 45 (4.2%) |
| Some of the time | 169 (8.9%) | 193 (11.0%) | 116 (8.8%) | 478 (9.6%) | 235 (9.6%) | 102 (8.8%) | 252 (9.7%) | 116 (10.8%) |
| Most of the time | 437 (23.1%) | 408 (23.2%) | 294 (22.3%) | 1,139 (22.9%) | 549 (22.3%) | 256 (22.1%) | 626 (24.1%) | 224 (20.8%) |
| Always | 1,094 (57.8%) | 960 (54.7%) | 726 (55.1%) | 2,780 (56.0%) | 1,366 (55.6%) | 664 (57.4%) | 1,417 (54.6%) | 618 (57.4%) |
| **J04 I was shown how what I did to care for myself influenced my condition (Q11)** | | | | | | | | |
| None of the time | 145 (7.7%) | 143 (8.0%) | 129 (9.8%) | 417 (8.4%) | 220 (9.0%) | 103 (8.8%) | 226 (8.6%) | 80 (7.7%) |
| A little of the time | 102 (5.4%) | 76 (4.3%) | 68 (5.1%) | 246 (4.9%) | 118 (4.8%) | 51 (4.3%) | 122 (4.6%) | 64 (6.1%) |
| Some of the time | 269 (14.3%) | 302 (17.0%) | 194 (14.7%) | 765 (15.4%) | 378 (15.4%) | 160 (13.6%) | 432 (16.5%) | 156 (15.0%) |
| Most of the time | 561 (29.9%) | 540 (30.4%) | 420 (31.8%) | 1,521 (30.6%) | 765 (31.1%) | 349 (29.7%) | 792 (30.2%) | 325 (31.2%) |
| Always | 801 (42.7%) | 718 (40.4%) | 510 (38.6%) | 2,029 (40.8%) | 976 (39.7%) | 513 (43.6%) | 1,052 (40.1%) | 416 (40.0%) |
| **J05 I was asked to talk about my goals in caring for my condition (Q11)** | | | | | | | | |
| None of the time | 296 (15.3%) | 276 (15.2%) | 221 (16.5%) | 793 (15.6%) | 418 (16.7%) | 196 (16.5%) | 423 (15.9%) | 152 (13.9%) |
| A little of the time | 146 (7.5%) | 134 (7.4%) | 94 (7.0%) | 374 (7.4%) | 162 (6.5%) | 97 (8.2%) | 186 (7.0%) | 82 (7.5%) |
| Some of the time | 362 (18.7%) | 361 (19.9%) | 273 (20.4%) | 996 (19.6%) | 504 (20.1%) | 193 (16.2%) | 553 (20.7%) | 221 (20.3%) |
| Most of the time | 499 (25.8%) | 476 (26.3%) | 363 (27.1%) | 1,338 (26.3%) | 660 (26.3%) | 312 (26.3%) | 700 (26.2%) | 286 (26.2%) |
| Always | 631 (32.6%) | 563 (31.1%) | 390 (29.1%) | 1,584 (31.2%) | 763 (30.4%) | 390 (32.8%) | 805 (30.2%) | 349 (32.0%) |
| **J06 I was helped to set specific goals to improve my eating or exercise (Q11)** | | | | | | | | |
| None of the time | 306 (15.8%) | 285 (15.7%) | 242 (17.9%) | 833 (16.3%) | 424 (16.9%) | 197 (16.6%) | 440 (16.4%) | 171 (15.6%) |
| A little of the time | 177 (9.2%) | 127 (7.0%) | 115 (8.5%) | 419 (8.2%) | 209 (8.3%) | 91 (7.7%) | 214 (8.0%) | 98 (9.0%) |
| Some of the time | 407 (21.1%) | 424 (23.4%) | 306 (22.6%) | 1,137 (22.3%) | 568 (22.6%) | 235 (19.8%) | 629 (23.5%) | 247 (22.6%) |
| Most of the time | 513 (26.6%) | 479 (26.4%) | 365 (27.0%) | 1,357 (26.6%) | 656 (26.1%) | 315 (26.5%) | 696 (26.0%) | 301 (27.5%) |
| Always | 528 (27.3%) | 497 (27.4%) | 325 (24.0%) | 1,350 (26.5%) | 659 (26.2%) | 349 (29.4%) | 697 (26.0%) | 276 (25.3%) |
| **J07 I was given a written list of things I should do to improve my health (Q12)** | | | | | | | | |
| None of the time | 655 (33.8%) | 722 (40.1%) | 645 (47.9%) | 2,022 (39.7%) | 1,069 (42.6%) | 490 (41.2%) | 1,078 (40.4%) | 388 (35.7%) |
| A little of the time | 185 (9.5%) | 140 (7.8%) | 130 (9.7%) | 455 (8.9%) | 228 (9.1%) | 97 (8.2%) | 228 (8.5%) | 116 (10.7%) |
| Some of the time | 414 (21.3%) | 396 (22.0%) | 246 (18.3%) | 1,056 (20.8%) | 482 (19.2%) | 245 (20.6%) | 556 (20.8%) | 232 (21.3%) |
| Most of the time | 373 (19.2%) | 280 (15.5%) | 198 (14.7%) | 851 (16.7%) | 408 (16.3%) | 180 (15.1%) | 464 (17.4%) | 185 (17.0%) |
| Always | 313 (16.1%) | 263 (14.6%) | 127 (9.4%) | 703 (13.8%) | 322 (12.8%) | 177 (14.9%) | 345 (12.9%) | 167 (15.3%) |
| **J08 I was asked questions, either directly or on a survey, about my health habits (Q12)** | | | | | | | | |
| None of the time | 378 (19.4%) | 391 (21.5%) | 317 (23.4%) | 1,086 (21.2%) | 561 (22.3%) | 250 (20.9%) | 591 (21.9%) | 211 (19.4%) |
| A little of the time | 202 (10.4%) | 145 (8.0%) | 152 (11.2%) | 499 (9.7%) | 256 (10.2%) | 118 (9.9%) | 247 (9.2%) | 121 (11.1%) |
| Some of the time | 448 (23.0%) | 489 (26.9%) | 353 (26.1%) | 1,290 (25.2%) | 641 (25.4%) | 298 (24.9%) | 686 (25.5%) | 270 (24.8%) |
| Most of the time | 503 (25.8%) | 412 (22.6%) | 302 (22.3%) | 1,217 (23.8%) | 576 (22.9%) | 288 (24.1%) | 621 (23.1%) | 272 (25.0%) |
| Always | 415 (21.3%) | 384 (21.1%) | 228 (16.9%) | 1,027 (20.1%) | 486 (19.3%) | 242 (20.2%) | 548 (20.3%) | 216 (19.8%) |
| **J09 I was satisfied that my care was well organised (Q12)** | | | | | | | | |
| None of the time | 38 (1.9%) | 35 (1.9%) | 32 (2.3%) | 105 (2.0%) | 57 (2.2%) | 34 (2.8%) | 44 (1.6%) | 26 (2.3%) |
| A little of the time | 52 (2.6%) | 42 (2.3%) | 46 (3.4%) | 140 (2.7%) | 77 (3.0%) | 26 (2.1%) | 74 (2.7%) | 37 (3.3%) |
| Some of the time | 114 (5.7%) | 132 (7.2%) | 112 (8.2%) | 358 (6.9%) | 200 (7.8%) | 78 (6.4%) | 203 (7.4%) | 74 (6.6%) |
| Most of the time | 469 (23.5%) | 409 (22.2%) | 342 (24.9%) | 1,220 (23.4%) | 629 (24.4%) | 274 (22.6%) | 665 (24.3%) | 252 (22.5%) |
| Always | 1,325 (66.3%) | 1,228 (66.5%) | 839 (61.2%) | 3,392 (65.0%) | 1,611 (62.6%) | 803 (66.1%) | 1,755 (64.0%) | 731 (65.3%) |
| **J10 I was contacted after a visit to see how things were going (Q12)** | | | | | | | | |
| None of the time | 767 (39.5%) | 658 (36.1%) | 516 (37.9%) | 1,941 (37.9%) | 950 (37.5%) | 483 (40.5%) | 1,059 (39.2%) | 352 (32.2%) |
| A little of the time | 186 (9.6%) | 157 (8.6%) | 136 (10.0%) | 479 (9.3%) | 235 (9.3%) | 122 (10.2%) | 242 (9.0%) | 100 (9.1%) |
| Some of the time | 438 (22.5%) | 469 (25.8%) | 363 (26.6%) | 1,270 (24.8%) | 629 (24.8%) | 256 (21.5%) | 682 (25.3%) | 304 (27.8%) |
| Most of the time | 282 (14.5%) | 292 (16.0%) | 197 (14.5%) | 771 (15.0%) | 391 (15.4%) | 178 (14.9%) | 387 (14.3%) | 176 (16.1%) |
| Always | 270 (13.9%) | 245 (13.5%) | 151 (11.1%) | 666 (13.0%) | 327 (12.9%) | 153 (12.8%) | 330 (12.2%) | 162 (14.8%) |
| **J11 I was encouraged to attend programs in the community that could help me (Q12)** | | | | | | | | |
| None of the time | 777 (40.4%) | 762 (42.3%) | 651 (48.4%) | 2,190 (43.2%) | 1,126 (45.1%) | 557 (46.9%) | 1,153 (43.3%) | 408 (37.6%) |
| A little of the time | 195 (10.1%) | 138 (7.7%) | 117 (8.7%) | 450 (8.9%) | 206 (8.2%) | 100 (8.4%) | 233 (8.8%) | 109 (10.1%) |
| Some of the time | 462 (24.0%) | 450 (25.0%) | 283 (21.0%) | 1,195 (23.6%) | 572 (22.9%) | 249 (21.0%) | 661 (24.8%) | 265 (24.4%) |
| Most of the time | 252 (13.1%) | 224 (12.4%) | 143 (10.6%) | 619 (12.2%) | 284 (11.4%) | 131 (11.0%) | 321 (12.1%) | 146 (13.5%) |
| Always | 238 (12.4%) | 228 (12.7%) | 152 (11.3%) | 618 (12.2%) | 311 (12.4%) | 150 (12.6%) | 294 (11.0%) | 156 (14.4%) |
| **J12 I was asked how my visits with other doctors were going (Q12)** | | | | | | | | |
| None of the time | 670 (36.5%) | 637 (36.4%) | 508 (39.1%) | 1,815 (37.2%) | 943 (39.1%) | 465 (41.3%) | 976 (37.7%) | 326 (31.4%) |
| A little of the time | 105 (5.7%) | 92 (5.3%) | 90 (6.9%) | 287 (5.9%) | 149 (6.2%) | 79 (7.0%) | 145 (5.6%) | 56 (5.4%) |
| Some of the time | 290 (15.8%) | 259 (14.8%) | 209 (16.1%) | 758 (15.5%) | 372 (15.4%) | 161 (14.3%) | 393 (15.2%) | 183 (17.6%) |
| Most of the time | 280 (15.2%) | 272 (15.6%) | 189 (14.6%) | 741 (15.2%) | 353 (14.6%) | 156 (13.9%) | 396 (15.3%) | 170 (16.4%) |
| Always | 492 (26.8%) | 489 (28.0%) | 302 (23.3%) | 1,283 (26.3%) | 596 (24.7%) | 264 (23.5%) | 678 (26.2%) | 304 (29.3%) |
| **J13 Total score (PACIC)** | | | | | | | | |
| Mean (median) | 3.4 (3.5) | 3.3 (3.4) | 3.2 (3.3) | 3.3 (3.4) | 3.3 (3.4) | 3.3 (3.4) | 3.3 (3.4) | 3.4 (3.5) |
| Missing |  |  |  | 7 | 5 |  |  |  |
| **J14 PACIC: Patient activation score** | | | | | | | | |
| Mean (median) | 3.4 (3.5) | 3.4 (3.5) | 3.3 (3.5) | 3.4 (3.5) | 3.3 (3.5) | 3.3 (3.5) | 3.4 (3.5) | 3.5 (3.5) |
| Missing |  |  |  | 59 | 29 |  |  |  |
| **J15 PACIC: Decision support score** | | | | | | | | |
| Mean (median) | 3.7 (3.7) | 3.7 (3.7) | 3.5 (3.7) | 3.6 (3.7) | 3.6 (3.7) | 3.7 (3.7) | 3.6 (3.7) | 3.7 (3.7) |
| Missing |  |  |  | 13 | 10 |  |  |  |
| **J16 PACIC: Goal setting score** | | | | | | | | |
| Mean (median) | 3.4 (3.7) | 3.3 (3.7) | 3.2 (3.3) | 3.3 (3.5) | 3.3 (3.3) | 3.4 (3.7) | 3.3 (3.3) | 3.3 (3.7) |
| Missing |  |  |  | 20 | 17 |  |  |  |
| **J17 PACIC: Problem solving score** | | | | | | | | |
| Mean (median) | 4.2 (5.0) | 4.1 (5.0) | 4.1 (5.0) | 4.2 (5.0) | 4.1 (5.0) | 4.2 (5.0) | 4.1 (5.0) | 4.2 (5.0) |
| Missing |  |  |  | 295 | 145 |  |  |  |
| **J18 PACIC: Follow-up/ co-ordination score** | | | | | | | | |
| Mean (median) | 2.6 (2.7) | 2.7 (2.7) | 2.5 (2.3) | 2.6 (2.7) | 2.6 (2.3) | 2.5 (2.3) | 2.6 (2.5) | 2.8 (2.7) |
| Missing |  |  |  | 22 | 14 |  |  |  |

*Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.*

Table 85: Patient rating of HCH practice

| **Patient rating of HCH practice** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **K1 Patient rating of the HCH practice (0–10)** | | | | | | | | |
| Mean (median) | 9.0 (9.0) | 9.0 (9.0) | 8.9 (9.0) | 9.0 (9.0) | 8.9 (9.0) | 9.0 (9.0) | 9.0 (9.0) | 8.9 (9.0) |
| Missing |  |  |  | 35 | 21 |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

Table 86: Carer involvement in patient's treatment

| **Carer involved in patient's treatment** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **L1 In the last six months, how often did the carer attend consultations at the practice with the patient** | | | | | | | | |
| Never |  | 5 (5.6%) | 2 (3.4%) | 7 (4.7%) | 6 (6.1%) | 1 (6.7%) | 5 (8.8%) | 1 (1.4%) |
| Rarely |  | 3 (3.4%) | 4 (6.9%) | 7 (4.7%) | 5 (5.1%) | 1 (6.7%) | 5 (8.8%) | 1 (1.4%) |
| Sometimes |  | 11 (12.4%) | 7 (12.1%) | 18 (12.2%) | 12 (12.1%) | 2 (13.3%) | 10 (17.5%) | 5 (6.8%) |
| Usually |  | 9 (10.1%) | 5 (8.6%) | 14 (9.5%) | 10 (10.1%) | 2 (13.3%) | 2 (3.5%) | 10 (13.7%) |
| Always |  | 61 (68.5%) | 40 (69.0%) | 101 (68.2%) | 66 (66.7%) | 9 (60.0%) | 35 (61.4%) | 56 (76.7%) |
| Not applicable |  |  |  | 1 (0.7%) |  |  |  |  |
| **L2 When the carer attended consultations with the patient, how often were the carer’s personal values, beliefs and circumstances were taken into consideration** | | | | | | | | |
| Never |  | 3 (3.7%) | 4 (7.4%) | 7 (5.0%) | 6 (6.5%) | 1 (7.1%) | 4 (8.2%) | 2 (2.8%) |
| Rarely |  | 2 (2.4%) | 2 (3.7%) | 4 (2.9%) | 3 (3.2%) | 2 (14.3%) |  | 2 (2.8%) |
| Sometimes |  | 9 (11.0%) | 6 (11.1%) | 15 (10.7%) | 12 (12.9%) | 2 (14.3%) | 4 (8.2%) | 9 (12.7%) |
| Usually |  | 16 (19.5%) | 6 (11.1%) | 22 (15.7%) | 11 (11.8%) | 4 (28.6%) | 11 (22.4%) | 7 (9.9%) |
| Always |  | 52 (63.4%) | 36 (66.7%) | 88 (62.9%) | 59 (63.4%) | 5 (35.7%) | 30 (61.2%) | 51 (71.8%) |
| Don't know |  |  |  | 4 (2.9%) | 2 (2.2%) |  |  |  |
| **L3 When the carer attended consultations with the patient, how often was the carer involved in decisions affecting the person under their care** | | | | | | | | |
| Never |  | 2 (2.4%) | 3 (5.4%) | 5 (3.6%) | 4 (4.3%) | 2 (15.4%) | 3 (5.8%) |  |
| Rarely |  | 4 (4.8%) | 2 (3.6%) | 6 (4.3%) | 2 (2.2%) | 2 (15.4%) | 2 (3.8%) | 2 (2.8%) |
| Sometimes |  | 11 (13.3%) | 7 (12.5%) | 18 (12.9%) | 12 (12.9%) | 2 (15.4%) | 10 (19.2%) | 6 (8.3%) |
| Usually |  | 13 (15.7%) | 4 (7.1%) | 17 (12.1%) | 10 (10.8%) | 2 (15.4%) | 5 (9.6%) | 10 (13.9%) |
| Always |  | 53 (63.9%) | 40 (71.4%) | 93 (66.4%) | 64 (68.8%) | 5 (38.5%) | 32 (61.5%) | 54 (75.0%) |
| Don't know |  |  |  | 1 (0.7%) | 1 (1.1%) |  |  |  |
| **L4 When the carer attended consultations with the patient, how often was the carer asked for their input when the GP or nurse was developing the treatment or care plan for the person under their care** | | | | | | | | |
| Never |  | 8 (9.6%) | 5 (9.1%) | 13 (9.3%) | 9 (9.7%) | 3 (21.4%) | 7 (13.7%) | 3 (4.2%) |
| Rarely |  | 3 (3.6%) | 1 (1.8%) | 4 (2.9%) | 2 (2.2%) | 1 (7.1%) | 1 (2.0%) | 2 (2.8%) |
| Sometimes |  | 16 (19.3%) | 6 (10.9%) | 22 (15.7%) | 14 (15.1%) | 3 (21.4%) | 8 (15.7%) | 11 (15.5%) |
| Usually |  | 8 (9.6%) | 15 (27.3%) | 23 (16.4%) | 17 (18.3%) | 1 (7.1%) | 10 (19.6%) | 12 (16.9%) |
| Always |  | 48 (57.8%) | 28 (50.9%) | 76 (54.3%) | 50 (53.8%) | 6 (42.9%) | 25 (49.0%) | 43 (60.6%) |
| Don't know |  |  |  | 2 (1.4%) | 1 (1.1%) |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Patient activation

Table 87: Patient activation measure (PAM)

| **H Patient activation measure (PAM)** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **H01 When all is said and done, I am the person who is responsible for managing my health condition(s) (Q20)** | | | | | | | | |
| Strongly disagree | 19 (1.0%) | 9 (0.5%) | 4 (0.3%) | 32 (0.6%) | 17 (0.7%) | 5 (0.4%) | 13 (0.5%) | 13 (1.2%) |
| Disagree | 70 (3.6%) | 55 (3.0%) | 44 (3.2%) | 169 (3.2%) | 89 (3.4%) | 22 (1.8%) | 87 (3.2%) | 58 (5.3%) |
| Agree | 1,002 (50.9%) | 895 (48.9%) | 671 (49.2%) | 2,568 (48.8%) | 1,295 (49.8%) | 571 (47.2%) | 1,366 (50.4%) | 562 (51.1%) |
| Strongly agree | 877 (44.6%) | 870 (47.6%) | 645 (47.3%) | 2,392 (45.5%) | 1,150 (44.2%) | 611 (50.5%) | 1,245 (45.9%) | 466 (42.4%) |
| Don't know |  |  |  | 101 (1.9%) | 51 (2.0%) |  |  |  |
| **H02 Taking an active role in my own health care is the most important factor in determining my health and ability to function (Q20)** | | | | | | | | |
| Strongly disagree | 13 (0.7%) | 4 (0.2%) | 3 (0.2%) | 20 (0.4%) | 10 (0.4%) | 4 (0.3%) | 9 (0.3%) | 7 (0.6%) |
| Disagree | 31 (1.6%) | 25 (1.4%) | 17 (1.2%) | 73 (1.4%) | 47 (1.8%) | 6 (0.5%) | 29 (1.1%) | 38 (3.4%) |
| Agree | 922 (46.7%) | 872 (47.5%) | 646 (47.0%) | 2,440 (46.4%) | 1,226 (47.1%) | 532 (43.8%) | 1,300 (47.7%) | 546 (49.5%) |
| Strongly agree | 1,009 (51.1%) | 936 (51.0%) | 709 (51.6%) | 2,654 (50.4%) | 1,283 (49.3%) | 672 (55.4%) | 1,388 (50.9%) | 513 (46.5%) |
| Don't know |  |  |  | 75 (1.4%) | 36 (1.4%) |  |  |  |
| **H03 I know what each of my prescribed medications do (Q20)** | | | | | | | | |
| Strongly disagree | 12 (0.6%) | 16 (0.9%) | 13 (1.0%) | 41 (0.8%) | 27 (1.0%) | 5 (0.4%) | 17 (0.6%) | 19 (1.7%) |
| Disagree | 72 (3.6%) | 72 (3.9%) | 49 (3.6%) | 193 (3.7%) | 101 (3.9%) | 25 (2.1%) | 87 (3.2%) | 78 (7.1%) |
| Agree | 859 (43.5%) | 848 (46.2%) | 626 (46.2%) | 2,333 (44.3%) | 1,186 (45.6%) | 554 (46.4%) | 1,223 (44.8%) | 493 (44.9%) |
| Strongly agree | 1,030 (52.2%) | 900 (49.0%) | 667 (49.2%) | 2,597 (49.4%) | 1,236 (47.5%) | 611 (51.1%) | 1,402 (51.4%) | 507 (46.2%) |
| Don't know |  |  |  | 98 (1.9%) | 52 (2.0%) |  |  |  |
| **H04 I understand the nature and causes of my health condition(s) (Q20)** | | | | | | | | |
| Strongly disagree | 10 (0.5%) | 14 (0.8%) | 11 (0.8%) | 35 (0.7%) | 22 (0.8%) | 2 (0.2%) | 13 (0.5%) | 19 (1.7%) |
| Disagree | 53 (2.7%) | 42 (2.3%) | 34 (2.5%) | 129 (2.5%) | 69 (2.7%) | 21 (1.7%) | 62 (2.3%) | 46 (4.2%) |
| Agree | 962 (48.6%) | 847 (46.2%) | 656 (48.1%) | 2,465 (46.8%) | 1,236 (47.5%) | 567 (46.7%) | 1,321 (48.7%) | 511 (46.3%) |
| Strongly agree | 954 (48.2%) | 930 (50.7%) | 663 (48.6%) | 2,547 (48.4%) | 1,225 (47.1%) | 625 (51.4%) | 1,319 (48.6%) | 527 (47.8%) |
| Don't know |  |  |  | 86 (1.6%) | 50 (1.9%) |  |  |  |
| **H05 I know the different medical treatment options available for my health condition(s) (Q20)** | | | | | | | | |
| Strongly disagree | 18 (0.9%) | 11 (0.6%) | 8 (0.6%) | 37 (0.7%) | 22 (0.8%) | 2 (0.2%) | 16 (0.6%) | 19 (1.8%) |
| Disagree | 129 (6.7%) | 127 (7.1%) | 105 (7.8%) | 361 (6.9%) | 192 (7.4%) | 66 (5.6%) | 192 (7.2%) | 100 (9.3%) |
| Agree | 1,081 (56.1%) | 994 (55.2%) | 779 (57.7%) | 2,854 (54.2%) | 1,418 (54.5%) | 693 (58.4%) | 1,495 (55.9%) | 589 (54.5%) |
| Strongly agree | 699 (36.3%) | 669 (37.1%) | 459 (34.0%) | 1,827 (34.7%) | 880 (33.8%) | 426 (35.9%) | 971 (36.3%) | 372 (34.4%) |
| Don't know |  |  |  | 183 (3.5%) | 90 (3.5%) |  |  |  |
| **H06 I have been able to maintain the lifestyle changes for my health that I have made (Q20)** | | | | | | | | |
| Strongly disagree | 28 (1.4%) | 19 (1.0%) | 6 (0.4%) | 53 (1.0%) | 28 (1.1%) | 3 (0.3%) | 20 (0.7%) | 29 (2.7%) |
| Disagree | 135 (7.0%) | 114 (6.3%) | 95 (7.0%) | 344 (6.5%) | 180 (6.9%) | 55 (4.6%) | 171 (6.4%) | 110 (10.2%) |
| Agree | 1,147 (59.4%) | 1,072 (59.2%) | 846 (62.6%) | 3,065 (58.2%) | 1,536 (59.0%) | 709 (59.3%) | 1,640 (61.1%) | 646 (59.9%) |
| Strongly agree | 622 (32.2%) | 607 (33.5%) | 404 (29.9%) | 1,633 (31.0%) | 765 (29.4%) | 428 (35.8%) | 851 (31.7%) | 293 (27.2%) |
| Don't know |  |  |  | 167 (3.2%) | 93 (3.6%) |  |  |  |
| **H07 I know how to prevent further problems with my health condition (Q20)** | | | | | | | | |
| Strongly disagree | 22 (1.1%) | 19 (1.1%) | 10 (0.7%) | 51 (1.0%) | 27 (1.0%) | 4 (0.3%) | 25 (0.9%) | 21 (1.9%) |
| Disagree | 161 (8.4%) | 122 (6.8%) | 84 (6.3%) | 367 (7.0%) | 186 (7.1%) | 60 (5.0%) | 170 (6.4%) | 129 (12.0%) |
| Agree | 1,094 (56.8%) | 1,056 (58.5%) | 830 (62.0%) | 2,980 (56.6%) | 1,491 (57.3%) | 717 (60.0%) | 1,571 (59.2%) | 613 (56.8%) |
| Strongly agree | 648 (33.7%) | 607 (33.6%) | 415 (31.0%) | 1,670 (31.7%) | 792 (30.4%) | 414 (34.6%) | 887 (33.4%) | 316 (29.3%) |
| Don't know |  |  |  | 194 (3.7%) | 106 (4.1%) |  |  |  |
| **H08 I am confident that I can take actions that will help prevent or minimise some symptoms or problems associated with my health condition (Q21)** | | | | | | | | |
| Strongly disagree | 17 (0.9%) | 20 (1.1%) | 6 (0.4%) | 43 (0.8%) | 21 (0.8%) | 6 (0.5%) | 14 (0.5%) | 23 (2.1%) |
| Disagree | 118 (6.0%) | 105 (5.8%) | 74 (5.4%) | 297 (5.6%) | 161 (6.2%) | 38 (3.1%) | 138 (5.1%) | 115 (10.5%) |
| Agree | 1,167 (59.3%) | 1,096 (60.1%) | 810 (59.3%) | 3,073 (58.4%) | 1,521 (58.5%) | 731 (60.6%) | 1,633 (60.3%) | 625 (56.8%) |
| Strongly agree | 665 (33.8%) | 602 (33.0%) | 477 (34.9%) | 1,744 (33.1%) | 851 (32.7%) | 432 (35.8%) | 921 (34.0%) | 337 (30.6%) |
| Don't know |  |  |  | 105 (2.0%) | 48 (1.8%) |  |  |  |
| **H09 I am confident that I can tell when I need to go get medical care and when I can handle a health problem myself (Q21)** | | | | | | | | |
| Strongly disagree | 12 (0.6%) | 20 (1.1%) | 5 (0.4%) | 37 (0.7%) | 18 (0.7%) | 1 (0.1%) | 15 (0.6%) | 21 (1.9%) |
| Disagree | 108 (5.5%) | 84 (4.6%) | 56 (4.1%) | 248 (4.7%) | 133 (5.1%) | 52 (4.3%) | 99 (3.6%) | 92 (8.3%) |
| Agree | 1,036 (52.5%) | 931 (50.6%) | 729 (53.1%) | 2,696 (51.2%) | 1,365 (52.5%) | 623 (51.4%) | 1,447 (53.2%) | 556 (50.0%) |
| Strongly agree | 818 (41.4%) | 805 (43.8%) | 583 (42.5%) | 2,206 (41.9%) | 1,049 (40.3%) | 537 (44.3%) | 1,159 (42.6%) | 443 (39.8%) |
| Don't know |  |  |  | 75 (1.4%) | 37 (1.4%) |  |  |  |
| **H10 I am confident I can tell my health care provider concerns I have even when he or she does not ask (Q21)** | | | | | | | | |
| Strongly disagree | 14 (0.7%) | 10 (0.5%) | 7 (0.5%) | 31 (0.6%) | 18 (0.7%) | 2 (0.2%) | 13 (0.5%) | 15 (1.4%) |
| Disagree | 45 (2.3%) | 45 (2.5%) | 33 (2.4%) | 123 (2.3%) | 70 (2.7%) | 22 (1.8%) | 56 (2.1%) | 45 (4.1%) |
| Agree | 937 (47.2%) | 884 (48.1%) | 635 (46.2%) | 2,456 (46.7%) | 1,221 (46.9%) | 575 (47.6%) | 1,309 (47.9%) | 511 (46.0%) |
| Strongly agree | 988 (49.8%) | 897 (48.9%) | 699 (50.9%) | 2,584 (49.1%) | 1,252 (48.1%) | 610 (50.5%) | 1,352 (49.5%) | 540 (48.6%) |
| Don't know |  |  |  | 68 (1.3%) | 41 (1.6%) |  |  |  |
| **H11 I am confident that I can follow through on medical treatments I need to do at home (Q21)** | | | | | | | | |
| Strongly disagree | 13 (0.7%) | 12 (0.7%) | 4 (0.3%) | 29 (0.6%) | 16 (0.6%) | 4 (0.3%) | 10 (0.4%) | 15 (1.3%) |
| Disagree | 62 (3.1%) | 64 (3.5%) | 43 (3.1%) | 169 (3.2%) | 93 (3.6%) | 27 (2.2%) | 65 (2.4%) | 75 (6.7%) |
| Agree | 1,002 (50.8%) | 944 (51.2%) | 713 (51.9%) | 2,659 (50.5%) | 1,331 (51.2%) | 609 (50.5%) | 1,424 (52.2%) | 563 (50.6%) |
| Strongly agree | 895 (45.4%) | 824 (44.7%) | 613 (44.6%) | 2,332 (44.3%) | 1,124 (43.2%) | 566 (46.9%) | 1,230 (45.1%) | 459 (41.3%) |
| Don't know |  |  |  | 73 (1.4%) | 38 (1.5%) |  |  |  |
| **H12 I am confident I can figure out solutions when new situations or problems arise with my health condition (Q21)** | | | | | | | | |
| Strongly disagree | 25 (1.3%) | 23 (1.3%) | 10 (0.7%) | 58 (1.1%) | 31 (1.2%) | 8 (0.7%) | 20 (0.7%) | 30 (2.7%) |
| Disagree | 247 (12.8%) | 204 (11.2%) | 153 (11.3%) | 604 (11.5%) | 310 (11.9%) | 128 (10.7%) | 287 (10.8%) | 175 (16.0%) |
| Agree | 1,189 (61.7%) | 1,124 (62.0%) | 864 (63.9%) | 3,177 (60.4%) | 1,553 (59.7%) | 753 (63.2%) | 1,717 (64.3%) | 619 (56.7%) |
| Strongly agree | 466 (24.2%) | 463 (25.5%) | 325 (24.0%) | 1,254 (23.8%) | 618 (23.8%) | 303 (25.4%) | 645 (24.2%) | 268 (24.5%) |
| Don't know |  |  |  | 169 (3.2%) | 90 (3.5%) |  |  |  |
| **H13 I am confident that I can maintain lifestyle changes like diet and exercise even during times of stress (Q21)** | | | | | | | | |
| Strongly disagree | 58 (3.0%) | 44 (2.4%) | 20 (1.5%) | 122 (2.3%) | 63 (2.4%) | 13 (1.1%) | 44 (1.6%) | 60 (5.4%) |
| Disagree | 276 (14.1%) | 248 (13.5%) | 176 (12.9%) | 700 (13.3%) | 338 (13.0%) | 127 (10.5%) | 347 (12.8%) | 215 (19.5%) |
| Agree | 1,162 (59.2%) | 1,118 (60.7%) | 837 (61.5%) | 3,117 (59.2%) | 1,534 (59.0%) | 755 (62.4%) | 1,671 (61.6%) | 606 (55.0%) |
| Strongly agree | 466 (23.8%) | 432 (23.5%) | 328 (24.1%) | 1,226 (23.3%) | 611 (23.5%) | 314 (26.0%) | 649 (23.9%) | 220 (20.0%) |
| Don't know |  |  |  | 97 (1.8%) | 56 (2.2%) |  |  |  |
| **H14 PAM level** | | | | | | | | |
| Disengaged and overwhelmed | 111 (5.5%) | 91 (4.9%) | 59 (4.3%) | 261 (5.0%) | 136 (5.2%) | 32 (2.6%) | 110 (4.0%) | 117 (10.3%) |
| Becoming aware but still struggling | 392 (19.5%) | 360 (19.4%) | 285 (20.7%) | 1,037 (19.8%) | 546 (21.0%) | 224 (18.4%) | 568 (20.7%) | 219 (19.4%) |
| Taking action | 822 (40.9%) | 740 (40.0%) | 562 (40.8%) | 2,124 (40.5%) | 1,050 (40.5%) | 515 (42.3%) | 1,097 (39.9%) | 450 (39.8%) |
| Maintaining behaviours/pushing further | 685 (34.1%) | 661 (35.7%) | 473 (34.3%) | 1,819 (34.7%) | 862 (33.2%) | 447 (36.7%) | 972 (35.4%) | 345 (30.5%) |
| **H14 Total score (PAM)** | | | | | | | | |
| Mean (median) | 66 (66) | 67 (66) | 67 (66) | 67 (66) | 66 (63) | 68 (66) | 67 (66) | 64 (63) |
| Missing |  |  |  | 21 | 8 |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Patient-reported health status

Table 88: Overall health and mental and emotional health

| **Overall health** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **F01 Patient rating of overall health (Q25)** | | | | | | | | |
| Excellent | 77 (3.9%) | 85 (4.6%) | 67 (4.9%) | 229 (4.4%) | 115 (4.4%) | 68 (5.6%) | 118 (4.3%) | 32 (2.8%) |
| Very good | 413 (20.7%) | 411 (22.2%) | 306 (22.2%) | 1,130 (21.5%) | 536 (20.6%) | 367 (30.2%) | 589 (21.4%) | 130 (11.6%) |
| Good | 763 (38.2%) | 740 (39.9%) | 541 (39.2%) | 2,044 (38.8%) | 1,003 (38.5%) | 527 (43.3%) | 1,088 (39.6%) | 377 (33.6%) |
| Fair | 543 (27.2%) | 469 (25.3%) | 347 (25.2%) | 1,359 (25.8%) | 677 (26.0%) | 210 (17.3%) | 746 (27.1%) | 381 (33.9%) |
| Poor | 202 (10.1%) | 150 (8.1%) | 118 (8.6%) | 470 (8.9%) | 254 (9.8%) | 44 (3.6%) | 207 (7.5%) | 203 (18.1%) |
| Don't know |  |  |  | 30 (0.6%) | 17 (0.7%) |  |  |  |
| **F02 Patient rating of overall mental or emotional health (Q26)** | | | | | | | | |
| Excellent | 288 (14.4%) | 283 (15.3%) | 198 (14.3%) | 769 (14.6%) | 351 (13.5%) | 254 (20.8%) | 387 (14.1%) | 102 (9.1%) |
| Very good | 530 (26.4%) | 480 (25.9%) | 384 (27.7%) | 1,394 (26.5%) | 682 (26.2%) | 413 (33.8%) | 724 (26.4%) | 215 (19.1%) |
| Good | 717 (35.7%) | 654 (35.4%) | 482 (34.8%) | 1,853 (35.2%) | 919 (35.3%) | 398 (32.6%) | 1,023 (37.2%) | 381 (33.8%) |
| Fair | 372 (18.5%) | 319 (17.2%) | 239 (17.3%) | 930 (17.7%) | 475 (18.3%) | 128 (10.5%) | 499 (18.2%) | 290 (25.8%) |
| Poor | 99 (4.9%) | 114 (6.2%) | 81 (5.9%) | 294 (5.6%) | 166 (6.4%) | 29 (2.4%) | 114 (4.1%) | 138 (12.3%) |
| Don't know |  |  |  | 22 (0.4%) | 9 (0.3%) |  |  |  |

Table 89: Number of chronic conditions and presence of specific health conditions

| **F2 Health conditions** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **F03 Number of chronic conditions** | | | | | | | | |
| None | 28 (1.4%) | 18 (1.0%) | 20 (1.4%) | 66 (1.3%) | 35 (1.3%) | 29 (2.4%) | 22 (0.8%) | 12 (1.1%) |
| One | 173 (8.6%) | 130 (7.0%) | 85 (6.1%) | 388 (7.4%) | 182 (7.0%) | 144 (11.8%) | 163 (5.9%) | 70 (6.2%) |
| Two | 329 (16.3%) | 274 (14.7%) | 190 (13.7%) | 793 (15.1%) | 397 (15.3%) | 239 (19.5%) | 396 (14.3%) | 140 (12.4%) |
| Three | 492 (24.4%) | 415 (22.3%) | 312 (22.5%) | 1,219 (23.2%) | 593 (22.8%) | 298 (24.3%) | 661 (23.9%) | 223 (19.7%) |
| Four | 436 (21.6%) | 403 (21.7%) | 309 (22.3%) | 1,148 (21.8%) | 556 (21.4%) | 262 (21.4%) | 650 (23.5%) | 202 (17.9%) |
| Five or more | 560 (27.8%) | 619 (33.3%) | 469 (33.9%) | 1,648 (31.3%) | 839 (32.2%) | 252 (20.6%) | 870 (31.5%) | 484 (42.8%) |
| **F04 Heart disease (Q22)** | | | | | | | | |
| Yes | 653 (33.1%) | 641 (34.9%) | 487 (35.8%) | 1,781 (33.8%) | 905 (34.8%) | 388 (32.2%) | 919 (33.9%) | 426 (38.4%) |
| No | 1,322 (66.9%) | 1,195 (65.1%) | 874 (64.2%) | 3,391 (64.4%) | 1,651 (63.5%) | 817 (67.8%) | 1,794 (66.1%) | 684 (61.6%) |
| Don't know |  |  |  | 90 (1.7%) | 46 (1.8%) |  |  |  |
| **F05 Stroke (includes mini strokes, TIA, aneurisms) (Q22)** | | | | | | | | |
| Yes | 216 (10.8%) | 210 (11.4%) | 171 (12.4%) | 597 (11.3%) | 319 (12.3%) | 100 (8.2%) | 304 (11.1%) | 177 (15.8%) |
| No | 1,787 (89.2%) | 1,639 (88.6%) | 1,207 (87.6%) | 4,633 (88.0%) | 2,263 (87.0%) | 1,120 (91.8%) | 2,443 (88.9%) | 942 (84.2%) |
| Don't know |  |  |  | 32 (0.6%) | 20 (0.8%) |  |  |  |
| **F06 Cancer (includes skin cancer) (Q22)** | | | | | | | | |
| Yes | 490 (24.5%) | 565 (30.6%) | 402 (29.2%) | 1,457 (27.7%) | 725 (27.9%) | 330 (27.0%) | 795 (29.0%) | 280 (25.0%) |
| No | 1,514 (75.5%) | 1,282 (69.4%) | 973 (70.8%) | 3,769 (71.6%) | 1,860 (71.5%) | 890 (73.0%) | 1,945 (71.0%) | 842 (75.0%) |
| Don't know |  |  |  | 36 (0.7%) | 17 (0.7%) |  |  |  |
| **F07 Osteoporosis (Q22)** | | | | | | | | |
| Yes | 495 (25.1%) | 524 (28.8%) | 384 (28.3%) | 1,403 (26.7%) | 692 (26.6%) | 272 (22.6%) | 767 (28.4%) | 332 (30.1%) |
| No | 1,474 (74.9%) | 1,298 (71.2%) | 974 (71.7%) | 3,746 (71.2%) | 1,855 (71.3%) | 930 (77.4%) | 1,935 (71.6%) | 770 (69.9%) |
| Don't know |  |  |  | 113 (2.1%) | 55 (2.1%) |  |  |  |
| **F08 Depression or anxiety (Q22)** | | | | | | | | |
| Yes | 828 (41.3%) | 787 (42.6%) | 571 (41.4%) | 2,186 (41.5%) | 1,076 (41.4%) | 364 (29.9%) | 1,147 (41.8%) | 611 (54.5%) |
| No | 1,176 (58.7%) | 1,059 (57.4%) | 807 (58.6%) | 3,042 (57.8%) | 1,512 (58.1%) | 854 (70.1%) | 1,598 (58.2%) | 510 (45.5%) |
| Don't know |  |  |  | 34 (0.6%) | 14 (0.5%) |  |  |  |
| **F09 Arthritis (Q22)** | | | | | | | | |
| Yes | 1,170 (58.6%) | 1,109 (60.5%) | 859 (62.5%) | 3,138 (59.6%) | 1,567 (60.2%) | 661 (54.7%) | 1,689 (61.7%) | 700 (62.8%) |
| No | 828 (41.4%) | 725 (39.5%) | 515 (37.5%) | 2,068 (39.3%) | 1,009 (38.8%) | 548 (45.3%) | 1,049 (38.3%) | 415 (37.2%) |
| Don't know |  |  |  | 56 (1.1%) | 26 (1.0%) |  |  |  |
| **F10 Diabetes (Q22)** | | | | | | | | |
| Yes | 703 (35.0%) | 706 (38.2%) | 541 (39.3%) | 1,950 (37.1%) | 975 (37.5%) | 413 (33.9%) | 1,016 (37.0%) | 468 (41.6%) |
| No | 1,305 (65.0%) | 1,144 (61.8%) | 837 (60.7%) | 3,286 (62.4%) | 1,612 (62.0%) | 805 (66.1%) | 1,733 (63.0%) | 656 (58.4%) |
| Don't know |  |  |  | 26 (0.5%) | 15 (0.6%) |  |  |  |
| **F11 High blood pressure (Q22)** | | | | | | | | |
| Yes | 1,230 (61.9%) | 1,202 (65.2%) | 906 (65.8%) | 3,338 (63.4%) | 1,650 (63.4%) | 723 (59.4%) | 1,799 (65.9%) | 730 (65.5%) |
| No | 756 (38.1%) | 642 (34.8%) | 471 (34.2%) | 1,869 (35.5%) | 932 (35.8%) | 495 (40.6%) | 932 (34.1%) | 385 (34.5%) |
| Don't know |  |  |  | 55 (1.0%) | 20 (0.8%) |  |  |  |
| **F12 Asthma (Q22)** | | | | | | | | |
| Yes | 546 (27.3%) | 541 (29.3%) | 374 (27.2%) | 1,461 (27.8%) | 711 (27.3%) | 278 (22.8%) | 785 (28.6%) | 365 (32.6%) |
| No | 1,454 (72.7%) | 1,305 (70.7%) | 1,003 (72.8%) | 3,762 (71.5%) | 1,871 (71.9%) | 939 (77.2%) | 1,955 (71.4%) | 756 (67.4%) |
| Don't know |  |  |  | 39 (0.7%) | 20 (0.8%) |  |  |  |
| **F13 Another chronic health condition (Q22)** | | | | | | | | |
| Yes | 912 (46.4%) | 827 (45.1%) | 645 (47.3%) | 2,384 (45.3%) | 1,199 (46.1%) | 447 (37.0%) | 1,245 (46.1%) | 638 (57.3%) |
| No | 1,054 (53.6%) | 1,006 (54.9%) | 720 (52.7%) | 2,780 (52.8%) | 1,363 (52.4%) | 760 (63.0%) | 1,457 (53.9%) | 475 (42.7%) |
| Don't know |  |  |  | 98 (1.9%) | 40 (1.5%) |  |  |  |

Table 90: Health related quality of life (EQ-5D-5L)

| **F2 Specific health conditions** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **F15 Mobility today (Q27)** | | | | | | | | |
| No problems in walking about | 840 (42.1%) | 794 (43.0%) | 562 (40.8%) | 2,196 (42.0%) | 1,042 (40.4%) | 711 (58.4%) | 1,154 (42.0%) | 277 (24.8%) |
| Slight problems | 474 (23.7%) | 443 (24.0%) | 359 (26.1%) | 1,276 (24.4%) | 641 (24.8%) | 302 (24.8%) | 687 (25.0%) | 256 (22.9%) |
| Moderate problems | 467 (23.4%) | 424 (22.9%) | 332 (24.1%) | 1,223 (23.4%) | 613 (23.8%) | 171 (14.1%) | 688 (25.1%) | 324 (29.0%) |
| Severe problems | 177 (8.9%) | 158 (8.5%) | 107 (7.8%) | 442 (8.5%) | 234 (9.1%) | 32 (2.6%) | 203 (7.4%) | 198 (17.7%) |
| Unable to walk about | 39 (2.0%) | 29 (1.6%) | 18 (1.3%) | 86 (1.6%) | 51 (2.0%) | 1 (0.1%) | 13 (0.5%) | 64 (5.7%) |
| **F16 Self-care today (Q27)** | | | | | | | | |
| No problems washing or dressing | 1,637 (81.4%) | 1,491 (80.6%) | 1,119 (80.9%) | 4,247 (81.0%) | 2,054 (79.2%) | 1,130 (92.6%) | 2,280 (82.8%) | 721 (64.2%) |
| Slight problems | 182 (9.1%) | 184 (10.0%) | 130 (9.4%) | 496 (9.5%) | 235 (9.1%) | 62 (5.1%) | 268 (9.7%) | 156 (13.9%) |
| Moderate problems | 138 (6.9%) | 119 (6.4%) | 99 (7.2%) | 356 (6.8%) | 205 (7.9%) | 27 (2.2%) | 175 (6.4%) | 145 (12.9%) |
| Severe problems | 28 (1.4%) | 36 (1.9%) | 20 (1.4%) | 84 (1.6%) | 58 (2.2%) |  | 28 (1.0%) | 53 (4.7%) |
| Unable to wash or dress | 25 (1.2%) | 19 (1.0%) | 15 (1.1%) | 59 (1.1%) | 42 (1.6%) | 1 (0.1%) | 4 (0.1%) | 48 (4.3%) |
| **F17 Usual activities today (Q27)** | | | | | | | | |
| No problems doing usual activities | 1,042 (52.2%) | 947 (51.2%) | 709 (51.4%) | 2,698 (51.6%) | 1,301 (50.3%) | 821 (67.4%) | 1,437 (52.2%) | 359 (32.3%) |
| Slight problems | 466 (23.4%) | 443 (23.9%) | 342 (24.8%) | 1,251 (23.9%) | 606 (23.4%) | 260 (21.3%) | 702 (25.5%) | 267 (24.0%) |
| Moderate problems | 341 (17.1%) | 334 (18.0%) | 235 (17.0%) | 910 (17.4%) | 475 (18.4%) | 112 (9.2%) | 479 (17.4%) | 290 (26.1%) |
| Severe problems | 80 (4.0%) | 71 (3.8%) | 51 (3.7%) | 202 (3.9%) | 107 (4.1%) | 16 (1.3%) | 78 (2.8%) | 103 (9.3%) |
| Unable to do usual activities | 66 (3.3%) | 56 (3.0%) | 42 (3.0%) | 164 (3.1%) | 96 (3.7%) | 10 (0.8%) | 55 (2.0%) | 93 (8.4%) |
| **F18 Pain or discomfort today (Q27)** | | | | | | | | |
| No pain or discomfort | 565 (28.3%) | 559 (30.1%) | 388 (28.1%) | 1,512 (28.9%) | 736 (28.5%) | 493 (40.5%) | 769 (28.0%) | 207 (18.5%) |
| Slight pain or discomfort | 686 (34.4%) | 607 (32.7%) | 488 (35.4%) | 1,781 (34.0%) | 863 (33.4%) | 454 (37.3%) | 979 (35.6%) | 294 (26.3%) |
| Moderate pain or discomfort | 565 (28.3%) | 537 (28.9%) | 405 (29.4%) | 1,507 (28.8%) | 768 (29.7%) | 234 (19.2%) | 818 (29.7%) | 423 (37.9%) |
| Severe pain or discomfort | 153 (7.7%) | 130 (7.0%) | 79 (5.7%) | 362 (6.9%) | 176 (6.8%) | 35 (2.9%) | 165 (6.0%) | 148 (13.2%) |
| Extreme pain or discomfort | 28 (1.4%) | 22 (1.2%) | 19 (1.4%) | 69 (1.3%) | 42 (1.6%) | 2 (0.2%) | 20 (0.7%) | 45 (4.0%) |
| **F19 Anxiety or depression today (Q27)** | | | | | | | | |
| Not anxious or depressed | 1,305 (65.3%) | 1,161 (62.8%) | 878 (63.7%) | 3,344 (64.0%) | 1,628 (63.0%) | 938 (77.0%) | 1,753 (63.9%) | 558 (49.8%) |
| Slightly anxious or depressed | 366 (18.3%) | 371 (20.1%) | 256 (18.6%) | 993 (19.0%) | 483 (18.7%) | 188 (15.4%) | 559 (20.4%) | 224 (20.0%) |
| Moderately anxious or depressed | 265 (13.3%) | 262 (14.2%) | 210 (15.2%) | 737 (14.1%) | 393 (15.2%) | 82 (6.7%) | 380 (13.9%) | 253 (22.6%) |
| Severely anxious or depressed | 43 (2.2%) | 36 (1.9%) | 25 (1.8%) | 104 (2.0%) | 51 (2.0%) | 3 (0.2%) | 40 (1.5%) | 57 (5.1%) |
| Extremely anxious or depressed | 18 (0.9%) | 19 (1.0%) | 10 (0.7%) | 47 (0.9%) | 30 (1.2%) | 7 (0.6%) | 10 (0.4%) | 29 (2.6%) |
| **F20 Total score (EQ-5D-5L)** | | | | | | | | |
| Mean (median) | 0.71 (0.74) | 0.71 (0.74) | 0.72 (0.74) | 0.71 (0.74) | 0.70 (0.74) | 0.81 (0.80) | 0.73 (0.75) | 0.57 (0.65) |
| Missing |  |  |  | 127 | 65 |  |  |  |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

## Patient-reported use of hospital services

Table 91: Hospital utilisation

| **I Hospital utilisation** | **Survey wave** | | | **Total** | | **Patient tier** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1** | **2** | **3** | **Total responses** | **Total individuals** | **1** | **2** | **3** |
| **I1 Patient attended an emergency department for their own medical care in last 12 months (Q23)** | | | | | | | | |
| Yes | 728 (36.1%) | 611 (32.9%) | 435 (31.5%) | 1,774 (33.7%) | 900 (34.6%) | 308 (25.2%) | 902 (32.7%) | 516 (45.6%) |
| No | 1,289 (63.9%) | 1,247 (67.1%) | 947 (68.5%) | 3,483 (66.2%) | 1,698 (65.3%) | 916 (74.8%) | 1,855 (67.3%) | 615 (54.4%) |
| **I2 Patient stayed one or more nights in hospital in last 12 months (Q24)** | | | | | | | | |
| Yes | 628 (31.2%) | 572 (30.8%) | 388 (28.1%) | 1,588 (30.2%) | 799 (30.7%) | 273 (22.3%) | 802 (29.1%) | 469 (41.6%) |
| No | 1,388 (68.8%) | 1,285 (69.2%) | 993 (71.9%) | 3,666 (69.7%) | 1,797 (69.1%) | 949 (77.7%) | 1,957 (70.9%) | 659 (58.4%) |

Source: Patient surveys Wave 1 Dec 2017–Mar 2019; Wave 2 Dec 2019–Mar 2020; Wave 3 Mar–Apr 2021.

# Appendix 8: Practice surveys detailed tables

## Practice characteristics

Table 92: Practice survey response rates by practice characteristic and evaluation round

| **Dimension** | **Strata** | **Participating practices** | | | | **Practice responses** | | | | **Response rate** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R2** | **R4** | **R5** | **R1** | **R2** | **R4** | **R5** | **R1** | **R2** | **R4** | **R5** |
| **Total** |  | **185** | **162** | **123** | **109** | **164** | **105** | **57** | **74** | **89%** | **65%** | **46%** | **68%** |
| Ownership | AMS | 25 | 22 | 17 | 16 | 21 | 10 | 6 | 4 | 84% | 45% | 35% | 25% |
| Corporate | 39 | 31 | 16 | 14 | 35 | 17 | 5 | 9 | 90% | 55% | 31% | 64% |
| Independent | 121 | 109 | 90 | 79 | 108 | 78 | 46 | 61 | 89% | 72% | 51% | 77% |
| Practice size (FTE GPs) | Large practice | 38 | 34 | 20 | 19 | 35 | 18 | 10 | 14 | 92% | 53% | 50% | 74% |
| Medium practice | 32 | 30 | 27 | 23 | 31 | 25 | 12 | 15 | 97% | 83% | 44% | 65% |
| Small practice | 94 | 77 | 62 | 56 | 78 | 47 | 30 | 37 | 83% | 61% | 48% | 66% |
| Sole practitioner | 21 | 21 | 14 | 11 | 20 | 15 | 5 | 8 | 95% | 71% | 36% | 73% |
| MMM category | MMM1 | 118 | 106 | 85 | 78 | 109 | 84 | 43 | 62 | 92% | 79% | 51% | 79% |
| MMM2 | 29 | 25 | 13 | 8 | 22 | 5 | 2 | 2 | 76% | 20% | 15% | 25% |
| MMM3 | 9 | 6 | 5 | 4 | 8 | 5 | 3 | 4 | 89% | 83% | 60% | 100% |
| MMM4\_5 | 11 | 7 | 6 | 6 | 10 | 5 | 3 | 4 | 91% | 71% | 50% | 67% |
| MMM6\_7 | 18 | 18 | 14 | 13 | 15 | 6 | 6 | 2 | 83% | 33% | 43% | 15% |
| SEIFA (IRDS) category | Deciles 1–3 most disadvantaged | 71 | 60 | 47 | 44 | 65 | 41 | 21 | 27 | 92% | 68% | 45% | 61% |
| Deciles 4–7 | 77 | 69 | 53 | 45 | 65 | 51 | 28 | 35 | 84% | 74% | 53% | 78% |
| Deciles 8–10 least disadvantaged | 37 | 33 | 23 | 20 | 34 | 13 | 8 | 12 | 92% | 39% | 35% | 60% |

| **Dimension** | **Strata** | **Participating practices** | | | | **Practice responses** | | | | **Response rate** | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R2** | **R4** | **R5** | **R1** | **R2** | **R4** | **R5** | **R1** | **R2** | **R4** | **R5** |
| PHN | PHN103 WentWest (Western Sydney) | 22 | 22 | 17 | 16 | 22 | 19 | 10 | 11 | 100% | 86% | 59% | 69% |
| PHN104 Nepean Blue Mountains | 13 | 11 | 10 | 9 | 11 | 9 | 6 | 6 | 85% | 82% | 60% | 67% |
| PHN108 Hunter New England and Central Coast | 16 | 10 | 5 | 3 | 12 | 5 | 1 | 2 | 75% | 50% | 20% | 67% |
| PHN203 South Eastern Melbourne | 24 | 19 | 16 | 12 | 24 | 20 | 9 | 9 | 100% | 105% | 56% | 75% |
| PHN301 Brisbane North | 17 | 16 | 14 | 14 | 16 | 9 | 3 | 13 | 94% | 56% | 21% | 93% |
| PHN401 Adelaide | 20 | 17 | 13 | 13 | 17 | 17 | 10 | 12 | 85% | 100% | 77% | 92% |
| PHN402 Country SA | 14 | 13 | 10 | 9 | 11 | 10 | 8 | 6 | 79% | 77% | 80% | 67% |
| PHN501 Perth North | 15 | 15 | 12 | 11 | 14 | 6 | 4 | 9 | 93% | 40% | 33% | 82% |
| PHN601 Tasmania | 17 | 12 | 7 | 6 | 12 | 4 | 0 | 4 | 71% | 33% | 0% | 67% |
| PHN701 Northern Territory | 27 | 27 | 19 | 16 | 25 | 6 | 6 | 2 | 93% | 22% | 32% | 12% |

Source: Practice surveys R1 Dec 2017–Jul 2018; R2 Nov 2018–Mar 2019; R4 Nov 2019–Mar 2020 and R5 Mar–May 2021.

## Practice staff levels

Table 93: Number of staff employed

| **Staff type** | **Practices reporting** | **Head Count (mean)** | **Full time equivalent (mean)** | **Vacancies (% of head count)** |
| --- | --- | --- | --- | --- |
| General practitioner | 73 | 8.1 | 5.7 | 7.8% |
| Other medical | 10 | 0.3 | 0.1 | 14.3% |
| Nurses | 71 | 4.1 | 2.6 | 5.0% |
| Allied health and other | 44 | 2.5 | 1.2 | 4.9% |
| Practice manager/receptionist/administrative/other | 73 | 6.5 | 4.3 | 2.8% |
| **Total** | **73** | **21.5** | **13.4** | **5.5%** |

Source: Practice survey R5 Mar–May 2021, question 27.

Table 94: Number of GPs in the practice, mean head count and FTE

| **Staff type** | **Practices reporting** | **Head count (mean)** | **Full time equivalent (mean)** |
| --- | --- | --- | --- |
| Owner/ partner | 55 | 1.7 | 1.5 |
| Salaried | 34 | 1.1 | 0.8 |
| Contract | 56 | 4.2 | 2.7 |
| Other | 6 | 0.4 | 0.2 |
| **Total** | **71** | **7.5** | **4.9** |

Source: Practice survey R5 Mar–May 2021, question 28.

Table 95: Number of GPs in the practice, mean head count per practice, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Owner/ Partner | 1.95 | 3.70 | 1.03 | 0.60 | 0.00 | 2.20 | 1.47 | 4.40 | 4.75 |
| Salaried | 1.16 | 1.30 | 1.08 | 0.20 | 2.33 | 1.18 | 0.82 | 3.00 | 3.00 |
| Contract | 3.47 | 5.15 | 2.58 | 5.80 | 1.33 | 3.36 | 3.55 | 1.40 | 5.00 |
| Other | 0.03 | 0.00 | 0.05 | 0.00 | 0.00 | 0.04 | 0.04 | 0.00 | 0.00 |

Source: Practice survey R5 Mar–May 2021, question 28.

Table 96: Additional staff employed due to HCH, by sampling strata

| **Practice subgroup** | **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **AMS** | **Corporate** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| **Did the practice employ additional staff as a result of implementing HCH** | | | | | | | | | | |
| Practices responding to R5:72 (No response:2) | Yes | 19 (26%) | 9 (33%) | 10 (22%) | 2 (50%) | 4 (50%) | 13 (22%) | 15 (25%) | 2 (33%) | 2 (33%) |
| No | 53 (74%) | 18 (67%) | 35 (78%) | 2 (50%) | 4 (50%) | 47 (78%) | 45 (75%) | 4 (67%) | 4 (67%) |
| chi-square |  | 0.577 (p=0.448) | | 4.133 (p=0.127) | | | 0.357 (p=0.836) | | |

Source: Practice survey R5 Mar–May 2021, question 29.

## Relationships with other local health services – baseline (round 1)

Table 97: GP/ local hospital arrangements, by sampling strata

| **Practice subgroup** | **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **AMS** | **Corporate** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| **Do GPs in the practice have formal arrangements for working with/in local hospitals** | | | | | | | | | | |
| Practices responding to R1 survey:119 (No response:1) | Yes | 21 (18%) | 13 (28%) | 8 (11%) | 3 (20%) | 4 (24%) | 14 (16%) | 9 (11%) | 8 (42%) | 4 (22%) |
| No | 98 (82%) | 34 (72%) | 64 (89%) | 12 (80%) | 13 (76%) | 73 (84%) | 73 (89%) | 11 (58%) | 14 (78%) |
| chi-square |  | 4.28 (p=0.039) | | 0.607 (p=0.738) | | | 10.591 (p=0.005) | | |
| Response to R1 survey, practices active 1 April 2021 & responding to R5:66 (No response:1) | Yes | 11 (17%) | 8 (31%) | 3 (8%) | 1 (50%) | 1 (14%) | 9 (16%) | 6 (11%) | 2 (33%) | 3 (60%) |
| No | 55 (83%) | 18 (69%) | 37 (92%) | 1 (50%) | 6 (86%) | 48 (84%) | 49 (89%) | 4 (67%) | 2 (40%) |
| chi-square |  | 4.582 (p=0.032) | | 1.66 (p=0.436) | | | 9.273 (p=0.01) | | |

*Source: Practice survey R1 Dec 2017–Jul 2018, question 12.*

## Access measures

Table 98: How long (in days) does the patient have to wait before seeing a GP, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| **In an emergency** | | | | | | | | | |
| Same day | 107 (89.2%) | 47 (97.9%) | 60 (83.3%) | 18 (100.0%) | 15 (100.0%) | 74 (85.1%) | 73 (88.0%) | 16 (84.2%) | 18 (100.0%) |
| Around 1 day | 13 (10.8%) | 1 (2.1%) | 12 (16.7%) |  |  | 13 (14.9%) | 10 (12.0%) | 3 (15.8%) |  |
| **Other appointment** | | | | | | | | | |
| Same day | 52 (43.3%) | 17 (35.4%) | 35 (48.6%) | 9 (50.0%) | 12 (80.0%) | 31 (35.6%) | 36 (43.4%) | 4 (21.1%) | 12 (66.7%) |
| Around 1 day | 51 (42.5%) | 26 (54.2%) | 25 (34.7%) | 9 (50.0%) | 2 (13.3%) | 40 (46.0%) | 35 (42.2%) | 11 (57.9%) | 5 (27.8%) |
| Around 2 days | 6 (5.0%) | 1 (2.1%) | 5 (6.9%) |  |  | 6 (6.9%) | 6 (7.2%) |  |  |
| Other | 11 (9.2%) | 4 (8.3%) | 7 (9.7%) |  | 1 (6.7%) | 10 (11.5%) | 6 (7.2%) | 4 (21.1%) | 1 (5.6%) |

Source: Practice survey R1 Dec 2017–Jul 2018, question 24.

Table 99: Arrangements for patient attending the practice to access after hours general practice services, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Doctor in practice | 22 (18.3%) | 10 (22.2%) | 12 (17.4%) | 4 (25.0%) | 4 (26.7%) | 14 (16.9%) | 12 (15.2%) | 5 (29.4%) | 5 (27.8%) |
| Nurse Triage + Doctor in practice | 4 (3.3%) |  | 4 (5.8%) |  | 4 (26.7%) |  |  |  | 4 (22.2%) |
| Doctor in Practice + After hours service/deputising service | 6 (5.0%) | 3 (6.7%) | 3 (4.3%) |  |  | 6 (7.2%) | 4 (5.1%) | 1 (5.9%) | 1 (5.6%) |
| After hours service/deputising service | 63 (52.5%) | 25 (55.6%) | 38 (55.1%) | 12 (75.0%) | 1 (6.7%) | 50 (60.2%) | 59 (74.7%) | 4 (23.5%) |  |
| Local ED/Hospital | 16 (13.3%) | 6 (13.3%) | 10 (14.5%) |  | 5 (33.3%) | 11 (13.3%) | 3 (3.8%) | 7 (41.2%) | 6 (33.3%) |
| Other | 3 (2.5%) | 1 (2.2%) | 2 (2.9%) |  | 1 (6.7%) | 2 (2.4%) | 1 (1.3%) |  | 2 (11.1%) |
| Don't know/ no response | 6 (5.0%) | 3 | 3 | 2 |  | 4 | 4 | 2 |  |

Source: Practice survey R1 Dec 2017–Jul 2018, question 23.

Table 100: Options available for patients to interact with practice or GP

| **Response** | **n (%)** |  | **Response** | **n (%)** |
| --- | --- | --- | --- | --- |
| Contact a doctor or nurse by telephone during the practice/ service's hours of operation? | 102 (85.0%) |  | Review letters from specialists/ hospital discharge summarised on a patient portal? | 11 (9.2%) |
| Request appointments online? | 85 (70.8%) |  | View test results on a patient portal? | 7 (5.8%) |
| Describe the problems they wish to discuss with the GP prior to the appointment? | 75 (62.5%) |  | Request refills for prescriptions online? | 6 (5.0%) |
| Send a medical question or concern via email or electronic message? | 48 (40.0%) |  | Don't know/ no response | 3 (2.5%) |
| Leave a voice message and get a return call from a doctor or nurse | 39 (32.5%) |  |  |  |

Source: Practice survey R1 Dec 2017–Jul 2018, question 25.

Table 101: At least one GP in the practice who makes home visits, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Yes | 105 (87.5%) | 45 (93.8%) | 60 (83.3%) | 16 (88.9%) | 12 (80.0%) | 77 (88.5%) | 74 (89.2%) | 17 (89.5%) | 14 (77.8%) |
| No | 15 (12.5%) | 3 (6.2%) | 12 (16.7%) | 2 (11.1%) | 3 (20.0%) | 10 (11.5%) | 9 (10.8%) | 2 (10.5%) | 4 (22.2%) |

Source: Practice survey R1 Dec 2017–Jul 2018, question 26.

Table 102: Access to health services within the local community, by sampling strata

| **Practice subgroup** | **Health service** | **Total** | | | **MMM 2, 3, 4+** | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Usually available** | **Sometimes available** | **Not usually available** | **Usually available** | **Sometimes available** | **Not usually available** |
| **Availability of selected health services within the local community:** | | | | | | | |
| Practices responding to R1 survey | Pharmacy | 111 (94%) | 7 (6%) |  | 30 (81%) | 7 (19%) |  |
| Physiotherapist | 100 (85%) | 15 (13%) | 3 (3%) | 24 (65%) | 11 (30%) | 2 (5%) |
| Dietitian | 94 (80%) | 19 (16%) | 5 (4%) | 21 (57%) | 14 (38%) | 2 (5%) |
| Psychologist | 96 (81%) | 14 (12%) | 8 (7%) | 23 (62%) | 8 (22%) | 6 (16%) |
| Social Worker | 64 (55%) | 33 (28%) | 19 (16%) | 17 (47%) | 12 (33%) | 7 (19%) |
| Dentist | 98 (83%) | 16 (14%) | 4 (3%) | 24 (65%) | 11 (30%) | 2 (5%) |
| Optometrist | 94 (80%) | 17 (14%) | 7 (6%) | 23 (62%) | 10 (27%) | 4 (11%) |
| Response to R1 survey, practices active 1 April 2021 & responding to R5 | Pharmacy | 64 (98%) | 1 (2%) |  | 10 (91%) | 1 (9%) |  |
| Physiotherapist | 58 (89%) | 5 (8%) | 2 (3%) | 9 (82%) | 1 (9%) | 1 (9%) |
| Dietitian | 56 (86%) | 6 (9%) | 3 (5%) | 8 (73%) | 3 (27%) |  |
| Psychologist | 57 (88%) | 5 (8%) | 3 (5%) | 8 (73%) | 2 (18%) | 1 (9%) |
| Social Worker | 37 (58%) | 15 (23%) | 12 (19%) | 7 (64%) | 3 (27%) | 1 (9%) |
| Dentist | 61 (94%) | 2 (3%) | 2 (3%) | 10 (91%) | 1 (9%) |  |
| Optometrist | 58 (89%) | 3 (5%) | 4 (6%) | 9 (82%) | 1 (9%) | 1 (9%) |

Source: Practice survey R1 Dec 2017–Jul 2018, question 13.

## Systems to support chronic disease management – baseline (round 1)

Table 103: Level of difficulty generating information from current systems

| **Practice subgroup** | **Description of system functionality** | **Easy** | **Somewhat difficult** | **Difficult** | **Not possible** |
| --- | --- | --- | --- | --- | --- |
| **Do GPs routinely receive and review data on:** | | | | | |
| Practices responding to R1 survey | Clinical summaries to give patients after each visit. | 104 (87%) | 14 (12%) | 1 (1%) | 1 (1%) |
| List of all laboratory results for an individual patient (including those ordered by other doctors). | 81 (68%) | 28 (23%) | 8 (7%) | 3 (2%) |
| List of all medications taken by an individual patient (including those that may have been prescribed by other doctors) | 87 (72%) | 24 (20%) | 8 (7%) | 1 (1%) |
| List of all patients taking a particular medication | 96 (81%) | 20 (17%) | 2 (2%) | 1 (1%) |
| List of patients by diagnosis or health problems (e.g. diabetes, cancer) | 109 (91%) | 11 (9%) |  |  |
| List of patients by laboratory result (e.g. HbA1c > 9.0) | 90 (75%) | 23 (19%) | 4 (3%) | 3 (2%) |
| List of patients who are due or overdue for tests or preventive care (e.g. flu vaccine) | 101 (84%) | 17 (14%) | 1 (1%) | 1 (1%) |
| Response to R1 survey, practices active 1 April 2021 & responding to R5 | Clinical summaries to give patients after each visit. | 55 (82%) | 11 (16%) | 1 (1%) |  |
| List of all laboratory results for an individual patient (including those ordered by other doctors). | 45 (67%) | 16 (24%) | 4 (6%) | 2 (3%) |
| List of all medications taken by an individual patient (including those that may have been prescribed by other doctors) | 49 (73%) | 13 (19%) | 4 (6%) | 1 (1%) |
| List of all patients taking a particular medication | 57 (85%) | 8 (12%) | 1 (1%) | 1 (1%) |
| List of patients by diagnosis or health problems (e.g. diabetes, cancer) | 64 (96%) | 3 (4%) |  |  |
| List of patients by laboratory result (e.g. HbA1c > 9.0) | 49 (73%) | 16 (24%) |  | 2 (3%) |
| List of patients who are due or overdue for tests or preventive care (e.g. flu vaccine) | 55 (82%) | 11 (16%) | 1 (1%) |  |

Source: Practice survey R1 Dec 2017–Jul 2018, questions 27 & 30.

Table 104: GPs routinely receive and review data on selected aspects of patient care

| **Practice subgroup** | **Type of clinical data** | **Yes** | **No** |
| --- | --- | --- | --- |
| **Do GPs routinely receive and review data on:** | | | |
| Practices responding to R1 survey | Clinical outcomes (e.g. percentage of patients with diabetes or asthma with good control) | 74 (62%) | 45 (38%) |
| Frequency of ordering diagnostic tests | 69 (57%) | 51 (42%) |
| Patients' hospital admissions or emergency department use | 92 (77%) | 28 (23%) |
| Prescribing practices | 82 (68%) | 38 (32%) |
| Surveys of patient satisfaction and experiences with care | 74 (62%) | 45 (38%) |
| Response to R1 survey, practices active 1 April 2021 & responding to R5 survey | Clinical outcomes (e.g. percentage of patients with diabetes or asthma with good control) | 39 (59%) | 27 (41%) |
| Frequency of ordering diagnostic tests | 34 (51%) | 33 (49%) |
| Patients' hospital admissions or emergency department use | 50 (75%) | 17 (25%) |
| Prescribing practices | 46 (69%) | 21 (31%) |
| Surveys of patient satisfaction and experiences with care | 40 (61%) | 26 (39%) |

Source: Practice survey R1 Dec 2017–Jul 2018, questions 28 & 31.

Table 105: Practice processes/systems

| **Practice subgroup** | **Process/system** | **Yes** | **No** |
| --- | --- | --- | --- |
| **Are the following processes/systems in place:** | | | |
| Practices responding to R1 survey | A checklist for preventive clinical practices (counselling, screening, immunisation) to carry out with patients, according to guidelines? | 104 (87%) | 16 (13%) |
| A reminder system to invite patients to recommend screening tests (e.g. Pap test, mammogram)? | 119 (99%) | 1 (1%) |
| A system to track laboratory tests ordered until results reach clinicians? | 88 (73%) | 32 (27%) |
| A tool to assist lifestyle counselling or to help modify behaviors (e.g. smoking cessation program, health education program)? | 86 (72%) | 33 (28%) |
| Response to R1 survey, practices active 1 April 2021 & responding to R5 survey | A checklist for preventive clinical practices (counselling, screening, immunisation) to carry out with patients, according to guidelines? | 58 (87%) | 9 (13%) |
| A reminder system to invite patients to recommend screening tests (e.g. Pap test, mammogram)? | 67 (100%) |  |
| A system to track laboratory tests ordered until results reach clinicians? | 50 (75%) | 17 (25%) |
| A tool to assist lifestyle counselling or to help modify behaviors (e.g. smoking cessation program, health education program)? | 49 (73%) | 18 (27%) |

Source: Practice survey R1 Dec 2017–Jul 2018, question 29 & 32.

## Other practice characteristics

Table 106: Practice Incentive Program (PIP) participation, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Diabetes Incentive | 114 (95.0%) | 44 (93.6%) | 70 (97.2%) | 17 (100.0%) | 15 (100.0%) | 82 (94.3%) | 77 (93.9%) | 19 (100.0%) | 18 (100.0%) |
| eHealth Incentive | 110 (91.7%) | 44 (93.6%) | 66 (91.7%) | 14 (82.4%) | 14 (93.3%) | 82 (94.3%) | 76 (92.7%) | 18 (94.7%) | 16 (88.9%) |
| Asthma incentive | 108 (90.0%) | 43 (91.5%) | 65 (90.3%) | 15 (88.2%) | 14 (93.3%) | 79 (90.8%) | 74 (90.2%) | 16 (84.2%) | 18 (100.0%) |
| Cervical Screening Incentive | 105 (87.5%) | 43 (91.5%) | 62 (86.1%) | 16 (94.1%) | 15 (100.0%) | 74 (85.1%) | 70 (85.4%) | 17 (89.5%) | 18 (100.0%) |
| Practice Incentive Program After Hours Initiative | 86 (71.7%) | 41 (87.2%) | 45 (62.5%) | 12 (70.6%) | 7 (46.7%) | 67 (77.0%) | 59 (72.0%) | 17 (89.5%) | 10 (55.6%) |
| Indigenous Health Incentive | 83 (69.2%) | 35 (74.5%) | 48 (66.7%) | 13 (76.5%) | 11 (73.3%) | 59 (67.8%) | 50 (61.0%) | 19 (100.0%) | 14 (77.8%) |
| Teaching Payment | 58 (48.3%) | 28 (59.6%) | 30 (41.7%) | 5 (29.4%) | 7 (46.7%) | 46 (52.9%) | 38 (46.3%) | 10 (52.6%) | 10 (55.6%) |
| Quality Prescribing Incentive (QPI) | 52 (43.3%) | 18 (38.3%) | 34 (47.2%) | 6 (35.3%) | 2 (13.3%) | 44 (50.6%) | 34 (41.5%) | 12 (63.2%) | 6 (33.3%) |
| General Practitioner Aged Care Access Incentive | 49 (40.8%) | 22 (46.8%) | 27 (37.5%) | 8 (47.1%) | 4 (26.7%) | 37 (42.5%) | 28 (34.1%) | 13 (68.4%) | 8 (44.4%) |
| Rural Loading Incentive | 23 (19.2%) | 7 (14.9%) | 16 (22.2%) | 1 (5.9%) | 8 (53.3%) | 14 (16.1%) | 2 (2.4%) | 9 (47.4%) | 12 (66.7%) |
| Procedural General Practitioner Payment | 16 (13.3%) | 8 (17.0%) | 8 (11.1%) | 3 (17.6%) | 3 (20.0%) | 10 (11.5%) | 5 (6.1%) | 6 (31.6%) | 5 (27.8%) |
| Don't know/ no response | 1 (0.8%) | 1 |  | 1 |  |  | 1 |  |  |

Source: Practice survey R1 Dec 2017–Jul 2018, question 16.

## Enrolment and risk stratification

Table 107: Practice focused on enrolling patients in HCH with specific chronic illnesses, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| **Yes: focused chronic illnesses** | **23 (25.0%)** | **12 (30.8%)** | **11 (21.2%)** | **1 (7.7%)** |  | **22 (31.0%)** | **19 (26.0%)** | **3 (37.5%)** | **1 (10.0%)** |
| Diabetes | 15 (16.3%) | 9 (23.1%) | 6 (11.5%) | 1 (7.7%) |  | 14 (19.7%) | 13 (17.8%) | 2 (25.0%) |  |
| COPD | 9 (9.8%) | 6 (15.4%) | 3 (5.8%) |  |  | 9 (12.7%) | 6 (8.2%) | 2 (25.0%) | 1 (10.0%) |
| CHD | 7 (7.6%) | 3 (7.7%) | 4 (7.7%) | 1 (7.7%) |  | 6 (8.5%) | 6 (8.2%) | 1 (12.5%) |  |
| Asthma | 3 (3.3%) | 3 (7.7%) |  |  |  | 3 (4.2%) | 3 (4.1%) |  |  |
| Arthritis | 2 (2.2%) | 2 (5.1%) |  | 1 (7.7%) |  | 1 (1.4%) | 2 (2.7%) |  |  |
| Hyperlipidaemia | 2 (2.2%) | 1 (2.6%) | 1 (1.9%) |  |  | 2 (2.8%) | 2 (2.7%) |  |  |
| Hypertension | 2 (2.2%) | 1 (2.6%) | 1 (1.9%) |  |  | 2 (2.8%) | 2 (2.7%) |  |  |
| CHF | 1 (1.1%) |  | 1 (1.9%) |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| Dementia | 1 (1.1%) |  | 1 (1.9%) |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| Lung cancer | 1 (1.1%) |  | 1 (1.9%) |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| Mental illness | 1 (1.1%) |  | 1 (1.9%) |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| Obesity | 1 (1.1%) | 1 (2.6%) |  |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| Stroke | 1 (1.1%) |  | 1 (1.9%) |  |  | 1 (1.4%) | 1 (1.4%) |  |  |
| **No** | **68 (73.9%)** | **27 (69.2%)** | **41 (78.8%)** | **12 (92.3%)** | **7 (100.0%)** | **49 (69.0%)** | **54 (74.0%)** | **5 (62.5%)** | **9 (90.0%)** |
| **Don't know/ no response** | **1 (1.1%)** |  | **1** |  | **1** |  |  |  | **1** |

Source: Practice survey R2 Nov 2018–Mar 2019, question 1.

Table 108: Ease of use of the risk stratification software/ patient enrolment

| **Response by practice status** | **The process was very smooth** | **We had some challenges, but we overcame them** | **We experienced ongoing difficulties** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| **Ease of use of the risk stratification software and associated processes** | | | | |
| Active | 17 (18.7%) | 61 (67.0%) | 13 (14.3%) | 1 |
| Withdrawn | 5 (38.5%) | 4 (30.8%) | 4 (30.8%) |  |
| **Rating of the administrative processes for enrolling patients in HCH** | | | | |
| Active | 21 (23.1%) | 57 (62.6%) | 13 (14.3%) | 1 |
| Withdrawn | 2 (16.7%) | 7 (58.3%) | 3 (25.0%) | 1 |

Source: Practice survey R2 Nov 2018–Mar 2019, questions 2 & 13.

Table 109: Did the practice use the GP override function, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| **Yes: reason for using this function** | **53 (57.6%)** | **24 (63.2%)** | **29 (58.0%)** | **10 (76.9%)** | **5 (71.4%)** | **38 (55.9%)** | **44 (62.9%)** | **3 (37.5%)** | **6 (60.0%)** |
| Missed by PRM | 15 (16.3%) | 9 (23.7%) | 6 (12.0%) | 6 (46.2%) | 2 (28.6%) | 7 (10.3%) | 12 (17.1%) |  | 3 (30.0%) |
| Psychosocial | 11 (12.0%) | 5 (13.2%) | 6 (12.0%) |  |  | 11 (16.2%) | 8 (11.4%) | 2 (25.0%) | 1 (10.0%) |
| Multiple diseases | 4 (4.3%) | 1 (2.6%) | 3 (6.0%) |  |  | 4 (5.9%) | 3 (4.3%) | 1 (12.5%) |  |
| Cancer | 3 (3.3%) | 1 (2.6%) | 2 (4.0%) |  |  | 3 (4.4%) | 2 (2.9%) | 1 (12.5%) |  |
| Carer stress/availability | 3 (3.3%) | 1 (2.6%) | 2 (4.0%) |  |  | 3 (4.4%) | 2 (2.9%) | 1 (12.5%) |  |
| Auto immune diseases | 2 (2.2%) | 1 (2.6%) | 1 (2.0%) |  |  | 2 (2.9%) | 1 (1.4%) |  | 1 (10.0%) |
| Disability | 2 (2.2%) |  | 2 (4.0%) |  |  | 2 (2.9%) | 2 (2.9%) |  |  |
| Financial | 2 (2.2%) |  | 2 (4.0%) |  |  | 2 (2.9%) | 1 (1.4%) | 1 (12.5%) |  |
| Osteoporosis | 2 (2.2%) | 2 (5.3%) |  | 1 (7.7%) |  | 1 (1.5%) | 1 (1.4%) | 1 (12.5%) |  |
| Other heart | 2 (2.2%) | 2 (5.3%) |  | 1 (7.7%) | 1 (14.3%) |  | 1 (1.4%) |  | 1 (10.0%) |
| Age | 1 (1.1%) | 1 (2.6%) |  | 1 (7.7%) |  |  | 1 (1.4%) |  |  |
| Acromegaly | 1 (1.1%) | 1 (2.6%) |  | 1 (7.7%) |  |  | 1 (1.4%) |  |  |
| Dementia | 1 (1.1%) | 1 (2.6%) |  | 1 (7.7%) |  |  | 1 (1.4%) |  |  |
| Haematological | 1 (1.1%) | 1 (2.6%) |  |  |  | 1 (1.5%) | 1 (1.4%) |  |  |
| Health literacy | 1 (1.1%) | 1 (2.6%) |  |  |  | 1 (1.5%) | 1 (1.4%) |  |  |
| Homelessness | 1 (1.1%) |  | 1 (2.0%) |  |  | 1 (1.5%) | 1 (1.4%) |  |  |
| MS | 1 (1.1%) | 1 (2.6%) |  |  |  | 1 (1.5%) | 1 (1.4%) |  |  |
| Obesity | 1 (1.1%) |  | 1 (2.0%) |  |  | 1 (1.5%) |  | 1 (12.5%) |  |
| Rheumatological | 1 (1.1%) | 1 (2.6%) |  |  |  | 1 (1.5%) | 1 (1.4%) |  |  |
| Sleep apnoea | 1 (1.1%) | 1 (2.6%) |  | 1 (7.7%) |  |  | 1 (1.4%) |  |  |
| **No** | **35 (38.0%)** | **14 (36.8%)** | **21 (42.0%)** | **3 (23.1%)** | **2 (28.6%)** | **30 (44.1%)** | **26 (37.1%)** | **5 (62.5%)** | **4 (40.0%)** |
| **Don't know/ no response** | **4 (4.3%)** | **1** | **3** |  | **1** | **3** | **3** |  | **1** |

Source: Practice survey R2 Nov 2018–Mar 2019, question 4.

Table 110: Usefulness of the HARP tool

| **Response** | **Very useful** | **Moderately useful** | **Limited usefulness** | **Not useful** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- |
| Usefulness of the HARP tool for assessing the care needs of patients | 13 (14.6%) | 36 (40.4%) | 30 (33.7%) | 10 (11.2%) | 3 |

Source: Practice survey R2, questions 8.

Table 111: Proportion of patients approached to enroll in HCH who actually enrolled (including responses from withdrawn practices)

| **Practice status** | **Practice estimate of proportion of patients who agreed to enrol** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **0%–20%** | **20%–40%** | **40%–60%** | **60%–80%** | **80%–100%** | **Don't know/ no response** |
| All practices responding to R2 survey | 19 (18.6%) | 8 (7.8%) | 12 (11.8%) | 19 (18.6%) | 44 (43.1%) | 3 |
| Practices responding to R2 survey and still active in April 2021 | 10 (17.2%) | 3 (5.2%) | 8 (13.8%) | 10 (17.2%) | 27 (46.6%) | 1 |

*Source:* Practice surveys R2 Nov 2018–Mar 2019, *question 11*.

## Shared care planning and use of My Health Record

Table 112: Did processes for shared care planning and review change from before HCH?, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Yes | 34 (37.0%) | 9 (23.1%) | 25 (49.0%) | 3 (23.1%) | 3 (50.0%) | 28 (39.4%) | 26 (35.6%) | 2 (25.0%) | 6 (66.7%) |
| No | 56 (60.9%) | 30 (76.9%) | 26 (51.0%) | 10 (76.9%) | 3 (50.0%) | 43 (60.6%) | 47 (64.4%) | 6 (75.0%) | 3 (33.3%) |
| Don't know/ no response | 2 (2.2%) |  | 2 |  | 2 |  |  |  | 2 |

Source: Practice survey R2 Nov 2018–Mar 2019, question 15.

Table 113: Main ways in which shared care planning and review processes changed following HCH implementation

| **Response** | **n (%)** |  | **Response** | **n (%)** |
| --- | --- | --- | --- | --- |
| Share care plans are more detailed | 8 (8.7%) |  | Patient reviews can be done by phone | 2 (2.2%) |
| Implemented electronic shared care / went online | 6 (6.5%) |  | More regular reviews | 1 (1.1%) |
| Shared care planning can be more easily forwarded to specialist and AH workers | 3 (3.3%) |  | Use of a patient centred measure to add more patient goals | 1 (1.1%) |
| Patient had more input | 2 (2.2%) |  |  |  |

Source: Practice survey R2 Nov 2018–Mar 2019, question 15.

Table 114: Main ways that the practice shares care plans with HCH patients and their carers or family (multiple may apply), by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| We give a printed version of the care plan to the patient and/or their carer/ family | 58 (63.0%) | 25 (64.1%) | 33 (67.3%) | 9 (69.2%) | 4 (66.7%) | 45 (65.2%) | 47 (66.2%) | 6 (75.0%) | 5 (55.6%) |
| We email an electronic version of the care plan to the patient and/or their carer/ family | 7 (7.6%) | 2 (5.1%) | 5 (10.2%) | 1 (7.7%) |  | 6 (8.7%) | 7 (9.9%) |  |  |
| We give the patient and/ or their carer/ family access to the care plan via a patient portal or through shared care planning software | 23 (25.0%) | 9 (23.1%) | 14 (28.6%) | 4 (30.8%) |  | 19 (27.5%) | 19 (26.8%) | 2 (25.0%) | 2 (22.2%) |
| We load the patient's care plan into their My Health Record | 23 (25.0%) | 9 (23.1%) | 14 (28.6%) | 3 (23.1%) | 3 (50.0%) | 17 (24.6%) | 18 (25.4%) | 3 (37.5%) | 2 (22.2%) |
| Other: Link it to the EHR/ allow patient to access | 4 (4.3%) | 1 (2.6%) | 3 (6.1%) |  |  | 4 (5.8%) | 4 (5.6%) |  |  |
| Other: Patient can have hard copy if they request it | 2 (2.2%) | 2 (5.1%) |  |  | 1 (16.7%) | 1 (1.4%) | 1 (1.4%) |  | 1 (11.1%) |
| Other: Verbally | 2 (2.2%) | 1 (2.6%) | 1 (2.0%) |  |  | 2 (2.9%) | 1 (1.4%) | 1 (12.5%) |  |
| Other | 7 (7.6%) | 5 (12.8%) | 2 (4.1%) | 2 (15.4%) |  | 5 (7.2%) | 6 (8.5%) |  | 1 (11.1%) |
| Don't know/ no response | 4 (4.3%) |  | 4 |  | 2 | 2 | 2 |  | 2 |

Source: Practice survey R2 Nov 2018–Mar 2019, question 16.

Table 115: Reflections on ways in which shared care planning has worked in practice

| **Sentiment** | **Response** | **Practices (n)** |
| --- | --- | --- |
| **Reflections on ways in which shared care planning has worked:** | | |
| Positive impact | Improved team care communication internal and external | 15 |
| Improved patient engagement | 5 |
| Improved patient access | 5 |
| Improved patient to practice communication | 3 |
| Enhanced chronic disease management | 3 |
| Neutral or negative impact | Not worked/ software issues | 11 |
| Complicated/ time consuming/ duplication of work | 11 |
| Need more effective ways to monitor patients | 11 |
| No change | 9 |
| Other health providers/allied health don't have access/ don't use | 8 |
| Don't use it | 6 |
| Most patients are not accessing their care plans | 4 |
| Issues with training/limited education | 2 |
| Too expensive | 1 |
| Patients over-reliant and overuse tools as form of communication | 1 |

Source: Practice survey R5 Mar–May 2021, question 2.

Table 116: Practice insights into how shared care planning could be improved

| **Type of suggestion** | **Suggestion** | **Practices (n)** |
| --- | --- | --- |
| **Suggestions for improving shared care planning:** | | |
| No change | No change required | 8 |
| Suggested changes | Better training/engagement of health care providers to increase access of shared care plans | 23 |
| Needs to integrate with practice software | 17 |
| Move to a single system | 10 |
| Enhance software by fixing issues around functionality | 9 |
| Better training/support for practice staff | 3 |
| Reliability | 1 |
| Additional patient education/make plans more patient-focussed | 1 |

Source: Practice survey R5 Mar–May 2021, question 3.

Table 117: Usefulness of My Health Record in sharing HCH patient information

| **Survey round/ Practice subgroup** | **Very useful** | **Moderately useful** | **Limited usefulness** | **Not useful** |
| --- | --- | --- | --- | --- |
| **Usefulness of My Health Record for sharing care plans with patients, carers or family** | | | | |
| R2 responses: All practices | 9 (15%) | 9 (15%) | 20 (33%) | 23 (38%) |
| R2 responses: Practices also responding to R5 | 5 (13%) | 4 (10%) | 18 (46%) | 12 (31%) |
| **Usefulness of My Health Record for sharing information about HCH patients with other service providers** | | | | |
| R5 responses | 20 (29%) | 18 (26%) | 26 (38%) | 5 (7%) |

Source: Practice R2 Nov 2018–Mar 2019, question 22; R5 Mar–May 2021, question 4.

Table 118: Usefulness of My Health Record in sharing information about HCH patients with other service providers, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Very useful | 20 (29.0%) | 6 (23.1%) | 14 (32.6%) | 3 (42.9%) | 2 (50.0%) | 15 (25.9%) | 17 (29.3%) | 1 (20.0%) | 2 (33.3%) |
| Moderately useful | 18 (26.1%) | 3 (11.5%) | 15 (34.9%) | 2 (28.6%) | 1 (25.0%) | 15 (25.9%) | 15 (25.9%) | 3 (60.0%) |  |
| Limited | 26 (37.7%) | 14 (53.8%) | 12 (27.9%) | 1 (14.3%) | 1 (25.0%) | 24 (41.4%) | 22 (37.9%) |  | 4 (66.7%) |
| Not useful | 5 (7.2%) | 3 (11.5%) | 2 (4.7%) | 1 (14.3%) |  | 4 (6.9%) | 4 (6.9%) | 1 (20.0%) |  |

Source: Practice survey R5 Mar–May 2021, question 4.

Table 119: Change in the level of use of My Health Record by GPs and other clinicians in the practice since the start of HCH, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Significant increase | 11 (16.2%) | 1 (4.3%) | 10 (22.2%) |  | 2 (50.0%) | 9 (15.8%) | 7 (12.3%) | 3 (60.0%) | 1 (16.7%) |
| Moderate increase | 25 (36.8%) | 7 (30.4%) | 18 (40.0%) | 3 (42.9%) | 1 (25.0%) | 21 (36.8%) | 20 (35.1%) | 1 (20.0%) | 4 (66.7%) |
| Much the same | 32 (47.1%) | 15 (65.2%) | 17 (37.8%) | 4 (57.1%) | 1 (25.0%) | 27 (47.4%) | 30 (52.6%) | 1 (20.0%) | 1 (16.7%) |
| Don't know/ no response | 6 | 6 |  | 2 |  | 4 | 5 | 1 |  |

Source: Practice survey R5 Mar–May 2021, question 5.

## Changes implemented within practice

Table 120: Initiatives that practices/ services have implemented as part of HCH

| **Initiatives practices implemented as part of HCH** | **Was this a feature of practice before HCH** | **Was a focus of change during HCH** | **Progress on implementation (% where this was a focus)** | | | **Impact of COVID-19 (% where this was a focus)** | | | **Extent the initiative helped during the COVID-19 pandemic (% where this was a focus)** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Completed** | **Plan to complete** | **Did not commence** | **Accelerated progress** | **No impact** | **Slowed progress** | **A lot** | **A little** | **Not at all** |
| A. Improving the completeness and quality of the data in the practice clinical management system | 61 (82%) | 42 (57%) | 25 (60%) | 17 (40%) |  | 12 (29%) | 9 (21%) | 21 (50%) | 8 (19%) | 27 (64%) | 7 (17%) |
| B. Regular meetings of HCH practice team (e.g. GPs, nurse, admin staff) to review HCH patients and their care needs | 33 (45%) | 45 (61%) | 25 (56%) | 19 (42%) | 1 (2%) | 10 (22%) | 3 (7%) | 32 (71%) | 13 (31%) | 20 (48%) | 9 (21%) |
| C. Reassigning components of care usually undertaken by a GP to a nurse (e.g. patients routinely see a nurse prior to seeing the GP when they attend the practice) | 53 (72%) | 38 (51%) | 30 (79%) | 8 (21%) |  | 9 (24%) | 7 (18%) | 22 (58%) | 14 (38%) | 19 (51%) | 4 (11%) |
| D. Reassigning components of care usually undertaken by a GP or nurse to a medical assistant (e.g. clinical measurements and assessments) | 23 (31%) | 21 (28%) | 12 (57%) | 2 (10%) | 7 (33%) | 3 (15%) | 8 (40%) | 9 (45%) | 5 (25%) | 8 (40%) | 7 (35%) |
| E. Introducing new roles within the practice (e.g. medical practice assistance, care coordinator, community care worker) | 17 (23%) | 24 (32%) | 13 (54%) | 2 (8%) | 9 (38%) | 6 (27%) | 7 (32%) | 9 (41%) | 4 (22%) | 10 (56%) | 4 (22%) |
| F. Improved systems for follow-up and re-call of HCH patients (e.g. for review or preventive services) | 53 (72%) | 47 (64%) | 34 (72%) | 12 (26%) | 1 (2%) | 8 (18%) | 15 (33%) | 22 (49%) | 16 (37%) | 19 (44%) | 8 (19%) |
| G. Proactive contact with patients to check how they are going (e.g. by telephone) | 40 (54%) | 45 (61%) | 35 (78%) | 10 (22%) |  | 18 (41%) | 11 (25%) | 15 (34%) | 22 (52%) | 15 (36%) | 5 (12%) |
| H. Dedicated clinics for HCH patients with specific chronic illnesses (e.g. diabetes, osteoarthritis) | 13 (18%) | 20 (27%) | 13 (65%) | 3 (15%) | 4 (20%) | 1 (5%) | 3 (16%) | 15 (79%) | 3 (18%) | 6 (35%) | 8 (47%) |
| I. Group consultations involving two or more patients | 7 (9%) | 15 (20%) | 3 (20%) | 2 (13%) | 10 (67%) | 1 (8%) | 2 (15%) | 10 (77%) | 3 (30%) | 2 (20%) | 5 (50%) |
| J. Joint consultations for a patient involving a GP, nurse and allied health (e.g. pharmacist) | 25 (34%) | 25 (34%) | 13 (52%) | 10 (40%) | 2 (8%) | 5 (22%) | 3 (13%) | 15 (65%) | 7 (33%) | 10 (48%) | 4 (19%) |
| K. HCH patients able to telephone the practice and talk to a nurse or GP about their health concerns | 50 (68%) | 53 (72%) | 49 (92%) | 4 (8%) |  | 32 (62%) | 14 (27%) | 6 (12%) | 30 (58%) | 15 (29%) | 7 (13%) |
| L. HCH patients able to communicate by email or secure messaging with the GP or nurse about their health concerns | 28 (38%) | 30 (41%) | 23 (77%) | 5 (17%) | 2 (7%) | 17 (59%) | 11 (38%) | 1 (3%) | 11 (38%) | 10 (34%) | 8 (28%) |
| M. Introducing a patient portal through which clinical information is shared with HCH patients | 9 (12%) | 22 (30%) | 10 (45%) | 9 (41%) | 3 (14%) | 3 (16%) | 11 (58%) | 5 (26%) | 2 (10%) | 8 (40%) | 10 (50%) |
| N. HCH patients able to refill scripts without a GP consultation | 44 (59%) | 47 (64%) | 42 (89%) | 4 (9%) | 1 (2%) | 28 (62%) | 12 (27%) | 5 (11%) | 25 (57%) | 10 (23%) | 9 (20%) |

Source: Practice survey R5 Mar–May 2021, question 9.

Table 121: Additional changes that have occurred in the last 12 months, in the practice’s processes for

managing patients' chronic illnesses

| **Response** | **Total** |
| --- | --- |
|
| Increased use of technology | 7 (19.4%) |
| Patient Outreach (Nurse) follow up with HCH patients | 6 (16.7%) |
| Introduced/ enhanced telehealth (including e-scripts) | 6 (16.7%) |
| Improved in practice collaboration | 6 (16.7%) |
| Increased scope of practice for non GP staff | 5 (13.9%) |
| Improved external collaboration | 4 (11.1%) |
| Increased service offering | 4 (11.1%) |
| Introduced/ enhanced recall system | 4 (11.1%) |
| Improved flexibility for staff: e.g. remote working | 4 (11.1%) |
| New staff/ increased hours | 3 (8.3%) |
| Installed/ changed/greater use of shared care platform | 3 (8.3%) |
| Improved practice culture and team | 3 (8.3%) |
| Increased non-GP staff involvement | 2 (5.6%) |
| Data cleansing/ improved use of practice data in patient care | 2 (5.6%) |
| Improved care plan processes | 2 (5.6%) |
| More patient engagement in care planning | 1 (2.8%) |
| Improved internal systems to support HCH | 1 (2.8%) |
| Don't know/ no response | 38 |

Source: Practice survey R5 Mar–May 2021, question 11.

Table 122: Changes the practice has made during the HCH trial that will be continued after the trial ends

| **Category** | **Changes** | **Practices (n)** |
| --- | --- | --- |
| **Changes made as a HCH that will be continued or discontinued when the trial ends:** | | |
| Continued | Internal collaborative/ team care approach | 6 |
| No appointment prescriptions | 6 |
| Quality Improvement including Data cleansing | 6 |
| Nurse led care | 5 |
| Team meetings/ huddles | 5 |
| Expanded scope of practice for staff | 5 |
| Care Plans and care plan review | 5 |
| External collaborative care approach | 3 |
| SMS and Email contact | 3 |
| Maintain HCH software incl. Shared Care | 3 |
| Training medical assistants | 2 |
| Telehealth | 19 |
| Dedicated Care coordination/ Chronic Disease staff | 14 |
| Recalls | 10 |
| Patient lifestyle groups / education | 1 |
| Increased recording of health data (Inc. Alcohol/tobacco use screening etc) | 1 |
| Discontinued | Discontinue use of Shared Care Platform | 4 |
| Reduce Nursing time | 4 |
| Discontinue no appointment prescriptions | 1 |

Source: Practice survey R5 Mar–May 2021, question 14.

## Impact of COVID-19

Table 123: Changes in the mode of contact with HCH patients since the start of the COVID-19 pandemic

| **Mode of contact** | **Practice subgroup** | **2020 compared with 2019** | | | |
| --- | --- | --- | --- | --- | --- |
| **Did more** | **Did less** | **No change** | **Mode not offered /used** |
| **Changes in the mode of contact with HCH patients during 2020 as a whole compared with 2019:** | | | | | |
| Face-to-face | All R5 practices | 2 (3%) | 59 (84%) | 9 (13%) |  |
| Practice enrolled <50 patients | 1 (3%) | 28 (78%) | 7 (19%) |  |
| Practice enrolled 50+ patients | 1 (3%) | 31 (91%) | 2 (6%) |  |
| Telephone | All R5 practices | 65 (92%) |  | 6 (8%) |  |
| Practice enrolled <50 patients | 32 (86%) |  | 5 (14%) |  |
| Practice enrolled 50+ patients | 33 (97%) |  | 1 (3%) |  |
| Video | All R5 practices | 20 (31%) |  | 7 (11%) | 37 (58%) |
| Practice enrolled <50 patients | 7 (21%) |  | 4 (12%) | 22 (67%) |
| Practice enrolled 50+ patients | 13 (42%) |  | 3 (10%) | 15 (48%) |
| Email | All R5 practices | 26 (39%) | 4 (6%) | 20 (30%) | 16 (24%) |
| Practice enrolled <50 patients | 14 (42%) |  | 13 (39%) | 6 (18%) |
| Practice enrolled 50+ patients | 12 (36%) | 4 (12%) | 7 (21%) | 10 (30%) |
| Shared care tool | All R5 practices | 1 (100%) |  |  |  |
| Practice enrolled 50+ patients | 1 (100%) |  |  |  |
| Text/SMS | All R5 practices | 1 (50%) |  | 1 (50%) |  |
| Practice enrolled <50 patients | 1 (100%) |  |  |  |
| Practice enrolled 50+ patients |  |  | 1 (100%) |  |
| Home visits | All R5 practices | 1 (100%) |  |  |  |
| Practice enrolled 50+ patients | 1 (100%) |  |  |  |
| Nurse consults | All R5 practices | 1 (100%) |  |  |  |
| Practice enrolled 50+ patients | 1 (100%) |  |  |  |

Source: Practice survey R5 Mar–May 2021, question 22.

Table 124: Factors that impacted implementation of HCH initiatives, including COVID

| **Category** | **Other factors** | **Practices (n)** |
| --- | --- | --- |
| COVID-19: General | Impacted group sessions/classes | 8 |
| Fewer face-to-face appointments/patients hesitant to come in | 5 |
| Impacted staffing/staffing changes | 4 |
| Stifled progress, COVID was priority | 18 |
| Fewer appointments allied health/specialists | 1 |
| Reduced nurse role | 1 |
| Negatively impacted patient management | 1 |
| COVID-19: Telehealth | telehealth and the rollout of other initiatives due to COVID negated some benefits of HCH | 5 |
| Difficult to contact patients or resistance to telehealth | 5 |
| Increased telehealth/introduced IT initiatives | 20 |
| HCH processes established prior to COVID made certain changes and less face-to-face engagement easier (i.e. patients used to telehealth/enhanced chronic disease management already in place) | 18 |
| Other factors | lack of qualified staff/limited staff availability | 2 |
| Introduced eScripts | 1 |
| Lack of prescriptive direction form DoH | 1 |

Source: Practice survey R5 Mar–May 2021, question 10.

Table 125: Impact of COVID-19 on regularity clinical or preventative measures/ screening were undertaken for HCH patients

| **Impact of COVID-19 on regularly of clinical or preventive measures/screening for HCH patients** | **Practices**  **n (%)** |
| --- | --- |
| COVID-19 had no effect: we continued our measurement/ screening with the same regularity as usual. | 22 (33%) |
| We reduced the regularity of these measures/ screening for a while, but we subsequently caught up and are now achieving our usual regularity. | 18 (27%) |
| We reduced the regularity of these measures/ screening for a while, and we are still catching up to achieve our usual regularity. | 27 (40%) |

Source: Practice survey R5 Mar–May 2021, question 23.

Table 126: Additional comments on the impact of COVID-19 on services delivered to HCH patients

| **Additional comments on the impact of COVID-19 on services delivered to HCH patients** | **Practices**  **n (%)** |
| --- | --- |
| Increased telehealth/introduced IT initiatives | 19 (40%) |
| limited/no change | 13 (28%) |
| Fewer face-to-face appointments/patients hesitant to come in | 10 (21%) |
| telehealth and the rollout of other initiatives (i.e. eScripts & eReferrals) due to COVID negated some benefits of HCH | 4 (9%) |
| Impacted staffing/staffing changes | 3 (6%) |
| Reduced preventative screening, procedures, clinical measures, etc. | 3 (6%) |
| HCH processes established prior to COVID made certain changes and less face-to-face engagement easier (i.e. patients used to telehealth/enhanced chronic disease management already in place) | 2 (4%) |
| Difficult to contact patients or resistance to telehealth | 2 (4%) |
| Impacted group sessions/classes | 1 (2%) |
| Stifled progress, COVID was priority | 1 (2%) |
| Fewer appointments allied health/specialists | 1 (2%) |
| Caused confusion amongst patients | 1 (2%) |

Source: Practice survey R5 Mar–May 2021, question 24.

## Patient engagement and activation

Table 127: Practice assessment of change engagement/ activation for HCH patients since start of HCH

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Significant improvement | 9 (12.9%) | 1 (4.0%) | 8 (17.8%) | 1 (14.3%) | 2 (50.0%) | 6 (10.2%) | 6 (10.2%) | 2 (33.3%) | 1 (20.0%) |
| Moderate improvement | 33 (47.1%) | 12 (48.0%) | 21 (46.7%) | 2 (28.6%) | 1 (25.0%) | 30 (50.8%) | 28 (47.5%) | 2 (33.3%) | 3 (60.0%) |
| Small improvement | 20 (28.6%) | 9 (36.0%) | 11 (24.4%) | 3 (42.9%) | 1 (25.0%) | 16 (27.1%) | 17 (28.8%) | 2 (33.3%) | 1 (20.0%) |
| No improvement/reduction | 8 (11.4%) | 3 (12.0%) | 5 (11.1%) | 1 (14.3%) |  | 7 (11.9%) | 8 (13.6%) |  |  |
| Don't know/ no response | 4 | 4 |  | 2 |  | 2 | 3 |  | 1 |

Source: Practice survey R5 Mar–May 2021, question 6.

Table 128: Factors contributing to or limiting improvements in patient engagement/ activation

| **Factors contributing to improvements** | | **Factors preventing/limiting improvements** | |
| --- | --- | --- | --- |
| **Description** | **Practices (n)** | **Description** | **Practices (n)** |
| Convenience (e.g. phone consults, not having to see GP for regular scripts) | 28 | Lack of resources locally to deliver HCH | 18 |
| More care from non GP staff | 23 | Patient attitude | 17 |
| Team Care | 18 | Covid | 17 |
| Continuity of care | 14 | Lack of HCH understanding by patients | 15 |
| Regular reminders | 11 | Lack of GP engagement | 10 |
| Improved Patient Health literacy | 11 | Staff turnover | 10 |
| Regular feedback/contact | 9 | Share care planning software limitations | 9 |
| Improved practice culture | 8 | Lack of engagement by Allied Health | 8 |
| Focus on patient's goals | 7 | Patient Value proposition | 5 |
| Improved service offering | 6 | Bundled Payments/ funding/ resourcing | 5 |
| Patient communication | 6 | Low Patient numbers | 5 |
| Access to their medical record | 3 | Lack of HCH understanding practice staff | 2 |
| Improved shared care plans | 1 | External service availability | 2 |
| Broadened programs and referrals | 1 | Language barriers | 2 |
|  |  | lack of Department of Health support | 2 |
|  |  | IT issues | 2 |
|  |  | Lack of staff (non GP) engagement | 2 |
|  |  | Lack of PHN support | 1 |

Source: Practice survey R5 Mar–May 2021, questions 7 & 8.

## Practice assessment of impact on outcomes

Table 129: Practice assessment of the overall impact of HCH on coordination of care, compared with usual care for similar patients

| **Outcome dimension /**  **Practice subgroup** | **Practice assessment of improvement compared with usual care** | | | | | **chi-square** |
| --- | --- | --- | --- | --- | --- | --- |
| **Significant** | **Moderate** | **Small** | **None** | **Worse** |
| **Impact on coordination of care** |  |  |  |  |  |  |
| All R5 practices | 16 (23%) | 21 (30%) | 21 (30%) | 12 (17%) | 1 (1%) | statistic=6.375 (p=0.095) |
| Practice enrolled <50 patients | 6 (17%) | 8 (22%) | 12 (33%) | 10 (28%) |  |
| Practice enrolled 50+ patients | 10 (29%) | 13 (37%) | 9 (26%) | 2 (6%) | 1 (3%) |
| **Impact on patient outcomes** |  |  |  |  |  |  |
| All R5 practices | 9 (14%) | 19 (30%) | 23 (37%) | 12 (19%) |  | statistic=4.081 (p=0.253) |
| Practice enrolled <50 patients | 3 (9%) | 9 (28%) | 11 (34%) | 9 (28%) |  |
| Practice enrolled 50+ patients | 6 (19%) | 10 (32%) | 12 (39%) | 3 (10%) |  |
| **Impact on quality of care** |  |  |  |  |  |  |
| All R5 practices | 15 (23%) | 17 (26%) | 18 (27%) | 16 (24%) |  | statistic=4.668 (p=0.198) |
| Practice enrolled <50 patients | 5 (15%) | 7 (21%) | 10 (30%) | 11 (33%) |  |
| Practice enrolled 50+ patients | 10 (30%) | 10 (30%) | 8 (24%) | 5 (15%) |  |
| **Staff experience & satisfaction** |  |  |  |  |  |  |
| All R5 practices | 9 (14%) | 18 (27%) | 19 (29%) | 18 (27%) | 2 (3%) | statistic=17.297 (p=0.001) |
| Practice enrolled <50 patients | 1 (3%) | 6 (18%) | 9 (27%) | 16 (48%) | 1 (3%) |
| Practice enrolled 50+ patients | 8 (24%) | 12 (36%) | 10 (30%) | 2 (6%) | 1 (3%) |

Source: Practice survey R5 Mar–May 2021, question 16.

## Economic issues

Table 130: Practice assessment of the impact of HCH on the financial viability of the practice

| **Response** | **All practices, R5** | **Practice enrolled 50+ patients** | **Practice enrolled <50 patients** |
| --- | --- | --- | --- |
| **Description of impact of HCH on the financial viability of the practice** | | | |
| Positive | 18 (28%) | 15 (44%) | 3 (10%) |
| Neutral or little to no financial advantage with HCH funding model | 14 (22%) | 5 (15%) | 9 (29%) |
| Negative | 13 (20%) | 5 (15%) | 8 (26%) |
| Viability dependent on patient tier | 7 (11%) | 5 (15%) | 2 (6%) |
| Viability concerns around staff time/work required to operate program | 7 (11%) | 3 (9%) | 4 (13%) |
| Small scale of HCH patients impacted viability or unable to sufficiently evaluate viability | 6 (9%) | 1 (3%) | 5 (16%) |

Source: Practice survey R5 Mar–May 2021, question 32.

Table 131: Changes in the approach practice undertook to co-payments for patients enrolled in the HCH trial, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| No payment/bulk billed | 21 (48.8%) | 8 (61.5%) | 13 (43.3%) | 2 (50.0%) | 1 (50.0%) | 18 (48.6%) | 15 (42.9%) | 3 (75.0%) | 3 (75.0%) |
| No change (bulk billed) | 10 (23.3%) | 1 (7.7%) | 9 (30.0%) | 1 (25.0%) | 1 (50.0%) | 8 (21.6%) | 8 (22.9%) | 1 (25.0%) | 1 (25.0%) |
| No change (no other details) | 4 (9.3%) | 3 (23.1%) | 1 (3.3%) | 1 (25.0%) |  | 3 (8.1%) | 4 (11.4%) |  |  |
| Annual payment | 2 (4.7%) |  | 2 (6.7%) |  |  | 2 (5.4%) | 2 (5.7%) |  |  |
| Per consult payment | 2 (4.7%) |  | 2 (6.7%) |  |  | 2 (5.4%) | 2 (5.7%) |  |  |
| No change (co-pay like other patients) | 2 (4.7%) |  | 2 (6.7%) |  |  | 2 (5.4%) | 2 (5.7%) |  |  |
| Co-payment not defined | 2 (4.7%) | 1 (7.7%) | 1 (3.3%) |  |  | 2 (5.4%) | 2 (5.7%) |  |  |
| No charge for other HCH Services | 1 (2.3%) |  | 1 (3.3%) |  |  | 1 (2.7%) | 1 (2.9%) |  |  |
| Co-pay for non HCH services | 1 (2.3%) |  | 1 (3.3%) |  |  | 1 (2.7%) |  | 1 (25.0%) |  |
| Did not attend fee | 1 (2.3%) |  | 1 (3.3%) |  |  | 1 (2.7%) | 1 (2.9%) |  |  |
| Don't know/ no response | 31 | 16 | 15 | 5 | 2 | 24 | 27 | 2 | 2 |

Source: Practice survey R5 Mar–May 2021, question 31.

## Wish to continue in HCH or a similar program

Table 132: Whether practice wishes to continue to participate in a program like HCH

| **Practice subgroup** | **Yes** | **Maybe** | **No** |
| --- | --- | --- | --- |
| **Does the practice wish to continue to participate in a program like HCH:** | | | |
| All R5 practices | 30 (42%) | 28 (39%) | 14 (19%) |
| Practice enrolled <50 patients | 9 (25%) | 16 (44%) | 11 (31%) |
| Practice enrolled 50+ patients | 21 (58%) | 12 (33%) | 3 (8%) |

Source: Practice survey R5 Mar–May 2021, question 33.

Table 133: Whether practice wishes to continue to participate in a program like HCH, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| Yes | 30 (41.7%) | 9 (33.3%) | 21 (46.7%) | 3 (37.5%) | 4 (100.0%) | 23 (38.3%) | 24 (40.0%) | 1 (16.7%) | 5 (83.3%) |
| Maybe | 28 (38.9%) | 13 (48.1%) | 15 (33.3%) | 4 (50.0%) |  | 24 (40.0%) | 25 (41.7%) | 3 (50.0%) |  |
| No | 14 (19.4%) | 5 (18.5%) | 9 (20.0%) | 1 (12.5%) |  | 13 (21.7%) | 11 (18.3%) | 2 (33.3%) | 1 (16.7%) |
| Don't know/ no response | 2 | 2 |  | 1 |  | 1 | 2 |  |  |

Source: Practice survey R5 Mar–May 2021, question 33.

Table 134: Final comments, feedback or observations about the HCH trial

| **Response** | **Practices n (%)** |
| --- | --- |
| Concerns around financial viability of the model/increase bundled payments | 11 (14%) |
| The program should have a broader rollout/continue | 8 (11%) |
| Created additional work and increased administrative burden for staff; reduce administrative burden | 6 (8%) |
| GP engagement/buy-in was challenging | 5 (7%) |
| Positive patient feedback/outcomes | 5 (7%) |
| Poor governance support and engagement across the health system | 5 (7%) |
| Provide more training/education on various aspects of the program and increase engagement | 5 (7%) |
| Positive practice experience with the trial and it should be continued | 5 (7%) |
| Difficulties registering/engaging patient cohort or demographic not appropriate for program | 4 (5%) |
| Difficulties engaging external health providers in shared care planning | 3 (4%) |
| Funding model has worked well | 2 (3%) |
| Need greater scale/higher volume of HCH patients | 2 (3%) |
| Program suffered from lack of patient awareness / Need more patient education | 2 (3%) |
| Program was successful | 2 (3%) |
| Survey was time consuming/confusing | 1 (1%) |
| Training was time consuming/costly as took away staff time | 1 (1%) |
| Enhanced chronic disease/ability to manage patients | 1 (1%) |
| Implementation of program processes helped transition workflows/implement new processes during the pandemic | 1 (1%) |
| Need software integration/fix issues with shared care planning tools | 1 (1%) |
| No changes in care delivery with implementation of program | 1 (1%) |
| Re-evaluate tiers | 1 (1%) |
| Register patients to a practice not a single GP | 1 (1%) |
| Appreciated flexibility in service delivery | 1 (1%) |
| Program required more clarity re acute v chronic billing | 1 (1%) |
| Trial needed greater scale, i.e. more GPs and more practices participating | 1 (1%) |

Source: Practice survey R5 Mar–May 2021, question 34.

# Appendix 9: HCH-A Practice self-assessment

Table 135: Number of participants in the HCH-A assessment

| **Response** | **Total staff  participating in HCH-A** | **Mean staff per practice  (practices responding)** |
| --- | --- | --- |
| GPs | 83 | 1.28 |
| Nurses | 78 | 1.20 |
| Practice managers | 51 | 0.78 |
| Aboriginal health practitioners | 2 | 0.03 |
| Allied health | 12 | 0.18 |
| Reception/admin | 52 | 0.80 |
| Other | 4 | 0.06 |
| Total | 282 | 4.34 |

*Source: Practice survey R5 Mar–May 2021, Part B, question 2.*

Table 136: Assistance from a PHN practice facilitator in reaching consensus

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM**  **2 & 3** | **MMM 4+** |
| No | 50 (77%) | 19 (76%) | 31 (78%) | 6 (86%) | 5 (100%) | 39 (74%) | 39 (75%) | 5 (83%) | 6 (86%) |
| Yes | 15 (23%) | 6 (24%) | 9 (22%) | 1 (14%) |  | 14 (26%) | 13 (25%) | 1 (17%) | 1 (14%) |

*Source: Practice survey R5 Mar–May 2021, Part B, question 3.*

Table 137: Change in HCH-A assessment from rounds 1 to 5

| **HCH-A dimension and item** | **Round** | **Practices** | **Min** | **25th percentile** | **Median** | **Mean** | **75th percentile** | **Max** | **Estimate of change in the mean (95% CI)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|
| **1 Engaged leadership** | | | | | | | | | |
| 01 Practice principals | 1B | 169 | 1 | 6 | 7.2 | 7.4 | 9.8 | 12 | 0.73 (0.08 to 1.43) |
| 5B | 65 | 1 | 6 | 8.3 | 8.2 | 10 | 12 |
| 02 Clinical leaders | 1B | 169 | 1 | 6 | 7.5 | 7.4 | 9 | 12 | 0.68 (0.09 to 1.32) |
| 5B | 65 | 1 | 7 | 8 | 8.1 | 10 | 12 |
| 03 The practice's recruitment and training processes | 1B | 169 | 1 | 5 | 7 | 6.9 | 8.7 | 12 | 1.02 (0.31 to 1.63) |
| 5B | 65 | 1 | 6 | 8 | 8 | 10 | 12 |
| 04 The responsibility for conducting quality improvement activities | 1B | 169 | 1 | 5 | 7 | 6.7 | 8.5 | 12 | 0.98 (0.34 to 1.69) |
| 5B | 65 | 1 | 6 | 8.3 | 7.8 | 10 | 12 |
| Average score | 1B | 169 | 1 | 5.8 | 7 | 7.1 | 8.7 | 11.5 | 0.85 (0.27 to 1.42) |
| 5B | 65 | 1 | 6.5 | 8.2 | 8 | 9.8 | 12 |
| **2 Patient enrolment** | | | | | | | | | |
| 05 Patients | 1B | 169 | 1 | 5.8 | 7.4 | 7.1 | 9 | 12 | 1.31 (0.69 to 1.88) |
| 5B | 65 | 1 | 8 | 9 | 8.5 | 10 | 12 |
| 06 Practice data | 1B | 169 | 1 | 6 | 7.9 | 7.5 | 9 | 12 | 1.01 (0.42 to 1.64) |
| 5B | 65 | 1 | 7.3 | 9 | 8.6 | 10 | 12 |
| 07 Patient records | 1B | 169 | 1 | 6 | 8 | 7.8 | 10 | 12 | 1.10 (0.45 to 1.68) |
| 5B | 65 | 1 | 8 | 9.2 | 8.9 | 10 | 12 |
| 08 Reports on care processes or outcomes of care | 1B | 169 | 1 | 5 | 6 | 6.5 | 8 | 12 | 1.13 (0.48 to 1.78) |
| 5B | 65 | 1 | 6 | 8 | 7.8 | 9.5 | 12 |
| Average score | 1B | 169 | 1 | 5.8 | 7.2 | 7.2 | 8.8 | 11.8 | 1.15 (0.63 to 1.75) |
| 5B | 65 | 1 | 7.8 | 8.5 | 8.5 | 9.9 | 12 |
| **3 Quality improvement strategy** | | | | | | | | | |
| 09 Quality improvement activities | 1B | 169 | 0 | 5 | 7 | 6.8 | 8.4 | 12 | 1.09 (0.38 to 1.74) |
| 5B | 65 | 1 | 6 | 8 | 7.9 | 10 | 12 |
| 10 Performance measures | 1B | 169 | 1 | 5 | 6 | 6.5 | 8 | 12 | 0.99 (0.39 to 1.62) |
| 5B | 65 | 1 | 6 | 7 | 7.5 | 9 | 12 |
| 11 Care team and patient involvement in QI activities | 1B | 169 | 1 | 4 | 6 | 5.9 | 8 | 11 | 1.24 (0.58 to 1.94) |
| 5B | 65 | 1 | 5 | 7 | 7.2 | 9 | 12 |
| 12 Clinical information systems that optimise use of information | 1B | 169 | 1 | 5 | 7 | 7 | 9 | 12 | 0.99 (0.33 to 1.58) |
| 5B | 65 | 2 | 7 | 8.5 | 8 | 10 | 12 |
| Average score | 1B | 169 | 1 | 5 | 6.4 | 6.6 | 8 | 11.2 | 1.07 (0.51 to 1.66) |
| 5B | 65 | 1.2 | 6.2 | 7.5 | 7.7 | 9.8 | 12 |
| **4 Continuous & team based healing relationships** | | | | | | | | | |
| 13 Patients are encouraged to see their nominated GP and care team | 1B | 169 | 1 | 7 | 9 | 8.3 | 10 | 12 | 0.99 (0.35 to 1.63) |
| 5B | 65 | 2 | 8.5 | 10 | 9.3 | 11 | 12 |
| 14 Non-GP care team members | 1B | 169 | 2 | 7 | 9 | 8.5 | 10 | 12 | 0.24 (-0.45 to 0.84) |
| 5B | 65 | 1 | 8 | 9 | 8.7 | 10 | 12 |
| 15 The practice | 1B | 169 | 1 | 6 | 7.8 | 7.4 | 9.8 | 12 | 0.49 (-0.26 to 1.24) |
| 5B | 65 | 1 | 6 | 9 | 8 | 10 | 12 |
| Average score | 1B | 169 | 3.3 | 6.7 | 8.3 | 8.1 | 9.3 | 12 | 0.57 (0.04 to 1.12) |
| 5B | 65 | 1.3 | 8 | 9 | 8.7 | 10.3 | 12 |
| **5 Organised, evidence-based care** | | | | | | | | | |
| 16 Comprehensive, guideline-based information on prevention or chronic illness treatment | 1B | 169 | 3 | 7 | 8 | 8.3 | 9.5 | 12 | 0.43 (-0.06 to 1.00) |
| 5B | 65 | 1 | 8 | 9 | 8.7 | 10 | 12 |
| 17 Visits | 1B | 169 | 2 | 7 | 8 | 8.2 | 9.5 | 12 | 0.76 (0.16 to 1.33) |
| 5B | 65 | 1 | 8 | 9 | 8.9 | 10 | 12 |
| 18 Care plans | 1B | 169 | 3.2 | 7 | 9 | 8.7 | 10 | 12 | 0.44 (-0.17 to 1.03) |
| 5B | 65 | 1 | 9 | 10 | 9.1 | 10.8 | 12 |
| 19 Coordinated care management services for high-risk patients | 1B | 169 | 1 | 6 | 8 | 7.8 | 10 | 12 | 0.37 (-0.39 to 1.07) |
| 5B | 65 | 1 | 6 | 9 | 8.1 | 10 | 12 |
| 20 Mental health, alcohol abuse and behaviour change outcomes such as improvement in depression | 1B | 169 | 1 | 6 | 7.4 | 7.3 | 9 | 12 | 0.69 (0.08 to 1.25) |
| 5B | 65 | 2 | 7.5 | 8.2 | 8 | 9 | 12 |
| Average score | 1B | 169 | 3.4 | 6.8 | 8.2 | 8.1 | 9.4 | 11.2 | 0.53 (0.03 to 1.09) |
| 5B | 65 | 1.4 | 7.8 | 9 | 8.6 | 9.8 | 12 |
| **6 Patient-centred interactions** | | | | | | | | | |
| 21 Assessing and respecting patient and family values and preferences | 1B | 169 | 3 | 7 | 8.7 | 8.4 | 10 | 12 | 0.95 (0.29 to 1.54) |
| 5B | 65 | 1 | 8.8 | 10 | 9.3 | 11 | 12 |
| 22 Involving patients in decision-making and care | 1B | 169 | 2 | 6.8 | 8 | 8 | 9.2 | 12 | 1.06 (0.43 to 1.70) |
| 5B | 65 | 1 | 8 | 9.5 | 9 | 10.7 | 12 |
| 23 Patient comprehension of verbal and written materials | 1B | 169 | 1 | 6 | 7 | 7.3 | 9 | 12 | 0.84 (0.20 to 1.51) |
| 5B | 65 | 1 | 6 | 8.8 | 8.1 | 10 | 12 |
| 24 Self-management support | 1B | 169 | 1.8 | 6 | 7 | 7.3 | 9 | 12 | 1.06 (0.45 to 1.68) |
| 5B | 65 | 1 | 7.9 | 9 | 8.3 | 10 | 12 |
| 25 The principles of patient-centred care | 1B | 169 | 1 | 5.6 | 7 | 7.1 | 9 | 12 | 1.31 (0.63 to 2.10) |
| 5B | 65 | 2 | 7.1 | 9 | 8.4 | 10 | 12 |
| 26 Measurement of patient-centred interactions | 1B | 169 | 1 | 3 | 5 | 5.5 | 7 | 12 | 1.12 (0.37 to 1.85) |
| 5B | 65 | 1 | 5 | 7 | 6.7 | 9 | 12 |
| Average score | 1B | 169 | 2.5 | 5.9 | 7.2 | 7.2 | 8.5 | 12 | 1.06 (0.52 to 1.64) |
| 5B | 65 | 1.2 | 7.5 | 8.7 | 8.3 | 9.5 | 12 |
| **7 Care coordination** | | | | | | | | | |
| 27 Medical and surgical specialty services | 1B | 169 | 1 | 5.5 | 7 | 7.2 | 9 | 12 | 0.76 (0.16 to 1.38) |
| 5B | 65 | 1 | 7 | 8 | 7.9 | 9 | 12 |
| 28 Mental health services | 1B | 169 | 1 | 5 | 7 | 6.9 | 8 | 12 | 0.47 (-0.21 to 1.19) |
| 5B | 65 | 1 | 6 | 7 | 7.4 | 9 | 12 |
| 29 Patients in need of specialty care, hospital care, or supportive community- based resources | 1B | 169 | 3 | 7 | 8 | 7.9 | 9 | 12 | 0.60 (0.06 to 1.19) |
| 5B | 65 | 1 | 7.6 | 9 | 8.5 | 10 | 12 |
| 30 Follow-up by the practice and care team with patients seen in the Emergency Department (ED) or hospital | 1B | 169 | 1 | 6 | 7 | 7 | 8 | 12 | 0.93 (0.31 to 1.53) |
| 5B | 65 | 2 | 6 | 8.1 | 7.9 | 10 | 12 |
| 31 Linking patients to supportive community- based resources | 1B | 169 | 1 | 6 | 7 | 7.1 | 9 | 12 | 0.88 (0.25 to 1.49) |
| 5B | 65 | 2 | 6 | 8 | 8 | 9 | 12 |
| 32 Test results and care plans | 1B | 169 | 4 | 7.7 | 9 | 8.7 | 10 | 12 | 0.75 (0.20 to 1.29) |
| 5B | 65 | 2 | 8.3 | 10 | 9.5 | 11 | 12 |
| Average score | 1B | 169 | 3.5 | 6.3 | 7.3 | 7.5 | 8.4 | 11.3 | 0.73 (0.18 to 1.25) |
| 5B | 65 | 1.5 | 7.2 | 8.3 | 8.2 | 9.7 | 12 |
| **8 Enhanced access** | | | | | | | | | |
| 33 Appointment systems | 1B | 169 | 1 | 8 | 9.1 | 9.1 | 11 | 12 | 0.50 (-0.10 to 1.12) |
| 5B | 65 | 1 | 8 | 10 | 9.6 | 12 | 12 |
| 34 Contacting the care team during regular business hours | 1B | 169 | 1 | 7 | 8 | 8.1 | 9 | 12 | 1.10 (0.50 to 1.69) |
| 5B | 65 | 2 | 8.5 | 9.5 | 9.2 | 11 | 12 |
| 35 After-hours access | 1B | 169 | 1 | 6 | 7 | 7.4 | 9 | 12 | 0.52 (-0.14 to 1.20) |
| 5B | 65 | 1 | 6.3 | 9 | 7.9 | 9.2 | 12 |
| 36 A patient's out-of-pocket expenses | 1B | 169 | 0 | 7 | 8 | 8 | 9 | 12 | 0.71 (0.05 to 1.40) |
| 5B | 65 | 1 | 7.5 | 9 | 8.7 | 10 | 12 |
| Average score | 1B | 169 | 2 | 7.2 | 8.2 | 8.1 | 9.2 | 11.2 | 0.71 (0.19 to 1.24) |
| 5B | 65 | 1.2 | 8 | 9.2 | 8.9 | 10 | 12 |

*Practice survey R1 Dec 2017–Jul 2018, Part B and R5* *Mar–May 2021, Part B.*

Table 138: Change in HCH-A assessment from round 1 to round 5

| **HCH-A dimension and item** | **Number of practices where score:** *1* | | | **Mean score** | | **Estimate of change in the mean (95% CI)** |
| --- | --- | --- | --- | --- | --- | --- |
| **Decreased** | **Did not change** | **Increased** | **R1** | **R5** |
| **1 Engaged leadership** | | | | | | |
| 01 Focus of practice principals | 19 (32%) | 10 (17%) | 31 (52%) | 7.58 | 8.14 | 0.56 (-0.22 to 1.34) |
| 02 Focus of clinical leaders | 22 (37%) | 9 (15%) | 29 (48%) | 7.68 | 8.1 | 0.42 (-0.29 to 1.13) |
| 03 The practice's recruitment and training processes | 17 (28%) | 8 (13%) | 35 (58%) | 7.34 | 7.94 | 0.59 (-0.18 to 1.37) |
| 04 Responsibility for quality improvement activities | 18 (30%) | 8 (13%) | 34 (57%) | 7.07 | 7.69 | 0.62 (-0.2 to 1.44) |
| Average score | 19 (32%) | 6 (10%) | 35 (58%) | 7.42 | 7.97 | 0.55 (-0.16 to 1.26) |
| **2 Patient enrolment** | | | | | | |
| 05 Patient linkage to nominated GP and care team | 15 (25%) | 14 (23%) | 31 (52%) | 7.76 | 8.57 | 0.81 (0.06 to 1.56) |
| 06 Practice data availability | 19 (32%) | 9 (15%) | 32 (53%) | 7.76 | 8.58 | 0.83 (0.09 to 1.57) |
| 07 Patient records availability for pre-visit planning & outreach | 16 (27%) | 10 (17%) | 34 (57%) | 8.17 | 8.79 | 0.62 (-0.1 to 1.35) |
| 08 Availability of reports on care processes & outcomes of care | 20 (33%) | 11 (18%) | 29 (48%) | 7.14 | 7.63 | 0.49 (-0.3 to 1.27) |
| Average score | 21 (35%) | 4 (7%) | 35 (58%) | 7.71 | 8.39 | 0.69 (0 to 1.37) |
| **3 Quality improvement strategy** | | | | | | |
| 09 Conduct of quality improvement activities | 21 (35%) | 7 (12%) | 32 (53%) | 7.1 | 7.88 | 0.78 (0.01 to 1.55) |
| 10 Availability of performance measures | 19 (32%) | 8 (13%) | 33 (55%) | 6.69 | 7.47 | 0.78 (0 to 1.56) |
| 11 Care team and patient involvement in QI activities | 16 (27%) | 10 (17%) | 34 (57%) | 6.1 | 7.2 | 1.09 (0.25 to 1.93) |
| 12 Clinical information systems that optimise use of information | 16 (27%) | 9 (15%) | 35 (58%) | 7.28 | 8.03 | 0.75 (-0.03 to 1.54) |
| Average score | 19 (32%) | 3 (5%) | 38 (63%) | 6.79 | 7.64 | 0.85 (0.11 to 1.59) |
| **4 Continuous & team based healing relationships** | | | | | | |
| 13 Patients are encouraged to see their nominated GP and care team | 23 (38%) | 8 (13%) | 29 (48%) | 8.94 | 9.32 | 0.38 (-0.39 to 1.16) |
| 14 Extent of role of non-GP care team members | 19 (32%) | 8 (13%) | 33 (55%) | 8.25 | 8.63 | 0.38 (-0.49 to 1.24) |
| 15 The practice approach to training needs of staff | 27 (45%) | 6 (10%) | 27 (45%) | 7.68 | 7.88 | 0.2 (-0.66 to 1.06) |
| Average score | 22 (37%) | 3 (5%) | 35 (58%) | 8.29 | 8.61 | 0.32 (-0.41 to 1.05) |
| **5 Organised, evidence-based care** | | | | | | |
| 16 Availability of comprehensive, guideline-based information on prevention & chronic illness treatment | 18 (30%) | 8 (13%) | 34 (57%) | 8.29 | 8.57 | 0.28 (-0.43 to 0.98) |
| 17 Focus during patient visits | 19 (32%) | 9 (15%) | 32 (53%) | 8.45 | 8.9 | 0.45 (-0.32 to 1.23) |
| 18 Development of care plans | 18 (30%) | 7 (12%) | 35 (58%) | 8.76 | 9.13 | 0.36 (-0.39 to 1.12) |
| 19 Availability of coordinated care management services for high-risk patients | 19 (32%) | 10 (17%) | 31 (52%) | 7.65 | 8.12 | 0.47 (-0.4 to 1.34) |
| 20 Measurement of mental health, alcohol abuse and behaviour change outcomes | 16 (27%) | 8 (13%) | 36 (60%) | 7.28 | 8.05 | 0.78 (0.06 to 1.49) |
| Average score | 21 (35%) | 3 (5%) | 36 (60%) | 8.09 | 8.55 | 0.47 (-0.21 to 1.15) |
| **6 Patient-centred interactions** | | | | | | |
| 21 Assessing and respecting patient and family values and preferences | 13 (22%) | 5 (8%) | 42 (70%) | 8.35 | 9.25 | 0.9 (0.09 to 1.72) |
| 22 Involving patients in decision-making and care | 13 (22%) | 4 (7%) | 43 (72%) | 8.1 | 8.91 | 0.81 (0 to 1.63) |
| 23 Assessment of patient comprehension of verbal & written materials | 17 (28%) | 7 (12%) | 36 (60%) | 7.32 | 8.03 | 0.71 (-0.11 to 1.53) |
| 24 Self-management support | 13 (22%) | 7 (12%) | 40 (67%) | 7.28 | 8.27 | 0.99 (0.27 to 1.72) |
| 25 Incorporation of the principles of patient-centred care | 16 (27%) | 5 (8%) | 39 (65%) | 7.24 | 8.32 | 1.08 (0.23 to 1.93) |
| 26 Measurement of patient-centred interactions | 20 (33%) | 8 (13%) | 32 (53%) | 5.72 | 6.7 | 0.98 (0.03 to 1.94) |
| Average score | 14 (23%) | 1 (2%) | 45 (75%) | 7.33 | 8.25 | 0.91 (0.19 to 1.64) |
| **7 Care coordination** | | | | | | |
| 27 Availability and coordination with medical & surgical specialty services | 21 (35%) | 7 (12%) | 32 (53%) | 7.5 | 7.93 | 0.43 (-0.34 to 1.19) |
| 28 Availability and coordination with mental health services | 21 (35%) | 9 (15%) | 30 (50%) | 7.11 | 7.47 | 0.36 (-0.44 to 1.16) |
| 29 Patients ability to obtain referrals to needed specialty or hospital care & community-based resources | 16 (27%) | 10 (17%) | 34 (57%) | 7.71 | 8.48 | 0.77 (-0.01 to 1.54) |
| 30 Follow-up by the practice and care team with patients seen in the Emergency Department (ED) or hospital | 18 (30%) | 7 (12%) | 35 (58%) | 7.2 | 8 | 0.8 (0.02 to 1.58) |
| 31 Practice approach to linking patients to supportive community-based resources | 13 (22%) | 11 (18%) | 36 (60%) | 6.89 | 7.95 | 1.07 (0.38 to 1.75) |
| 32 Communication of test results and care plans to patients | 17 (28%) | 12 (20%) | 31 (52%) | 9.02 | 9.36 | 0.33 (-0.39 to 1.05) |
| Average score | 18 (30%) | 1 (2%) | 41 (68%) | 7.57 | 8.2 | 0.62 (-0.03 to 1.28) |
| **8 Enhanced access** | | | | | | |
| 33 Flexibility in appointment systems | 18 (30%) | 14 (23%) | 28 (47%) | 9.54 | 9.65 | 0.11 (-0.66 to 0.87) |
| 34 Contacting the care team during regular business hours | 12 (20%) | 11 (18%) | 37 (62%) | 8.48 | 9.26 | 0.78 (0.08 to 1.48) |
| 35 After-hours access | 18 (30%) | 13 (22%) | 29 (48%) | 7.22 | 7.81 | 0.59 (-0.25 to 1.43) |
| 36 Approach to patient's out of pocket expenses | 22 (37%) | 8 (13%) | 30 (50%) | 8.16 | 8.66 | 0.5 (-0.3 to 1.3) |
| Average score | 16 (27%) | 4 (7%) | 40 (67%) | 8.35 | 8.85 | 0.49 (-0.15 to 1.14) |

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 18: Change in HCH-A assessment from round 1 to round 5, 1 Engaged leadership

Chart, diagram

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 19: Change in HCH-A assessment from round 1 to round 5, 2 Patient enrolment

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 20: Change in HCH-A assessment from round 1 to round 5, 3 Quality improvement strategy

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 21: Change in HCH-A assessment from round 1 to round 5, 4 Continuous & team-based healing relationships

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 22: Change in HCH-A assessment from round 1 to round 5, 5 Organised, evidence-based care

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 23: Change in HCH-A assessment from round 1 to round 5, 6 Patient-centred interactions

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 24: Change in HCH-A assessment from round 1 to round 5, 7 Care coordination

Chart, scatter chart

Description automatically generated

Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

Figure 25: Change in HCH-A assessment from round 1 to round 5, 8 Enhanced access

Chart, scatter chart

Description automatically generated*Notes: 1 Numbers are based on the 60 practices that completed the HCH-A tool in both R1 and R5.*

Source: Practice survey R1 Dec 2017–Jul 2018, Part B and R5 Mar–May 2021, Part B.

# Appendix 10: Practice staff surveys detailed tables

Table 139: Role of the respondent in the practice/service, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independent** | **MMM 1** | **MMM 2 & 3** | **MMM 4+** |
| **Number of practices** | 78 | 30 | 48 | 9 | 5 | 64 | 63 | 8 | 7 |
| **Number of staff responding** | 182 | 73 | 109 | 25 | 21 | 136 | 132 | 17 | 33 |
| **Staff role:** | | | | | | | | | |
| General practitioner, including GP registrar | 36 (20%) | 12 (16%) | 24 (22%) | 2 (8%) | 7 (33%) | 27 (20%) | 21 (16%) | 5 (29%) | 10 (30%) |
| Nurse including: practice nurse, nurse practitioner, other nursing roles | 45 (25%) | 21 (29%) | 24 (22%) | 7 (28%) | 2 (10%) | 36 (26%) | 34 (26%) | 4 (24%) | 7 (21%) |
| Practice manager/ Owner/ Executive role | 50 (27%) | 20 (27%) | 30 (28%) | 5 (20%) | 4 (19%) | 41 (30%) | 40 (30%) | 4 (24%) | 6 (18%) |
| Receptionist | 32 (18%) | 13 (18%) | 19 (17%) | 7 (28%) | 1 (5%) | 24 (18%) | 28 (21%) | 2 (12%) | 2 (6%) |
| Medical practice assistant | 5 (3%) | 1 (1%) | 4 (4%) |  |  | 5 (4%) | 3 (2%) | 1 (6%) | 1 (3%) |
| Other administration | 12 (7%) | 6 (8%) | 6 (6%) | 4 (16%) | 5 (24%) | 3 (2%) | 6 (5%) | 1 (6%) | 5 (15%) |
| Coordinator | 2 (1%) |  | 2 (2%) |  | 2 (10%) |  |  |  | 2 (6%) |

Source: Staff survey R5 Mar–May 2021, question 1.

Table 140: Employment arrangements

| **Response** | **Total** | **Employment arrangements** | | | |
| --- | --- | --- | --- | --- | --- |
| **Full-time (includes full-time partner)** | **Part-time (includes part-time partner)** | **Casual/ Locum/ Other** | **Don't know/ no response** |
| **Number of practices** |  | 50 | 39 | 14 | 1 |
| **Number of staff responding** | 182 | 84 | 74 | 23 | 1 |
| **Staff role:** | | | | | |
| General practitioner, including GP registrar | 36 | 21 | 13 | 2 |  |
| Nurse including: practice nurse, nurse practitioner, other nursing roles | 45 | 16 | 21 | 7 | 1 |
| Practice manager/ Owner/ Executive role | 50 | 29 | 18 | 3 |  |
| Receptionist | 32 | 6 | 17 | 9 |  |
| Medical practice assistant | 5 |  | 4 | 1 |  |
| Other administration | 12 | 10 | 1 | 1 |  |
| Coordinator | 2 | 2 |  |  |  |

Source: Staff survey R5 Mar–May 2021, question 3.

Table 141: Role of GPs, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM 2 & 3** | **MMM 4+** |
| **Number of GPs responding** | 36 | 12 | 24 | 2 | 7 | 27 | 21 | 5 | 10 |
| **GP role:** | | | | | | | | | |
| General medical practitioner, owner/partner | 19 (53%) | 6 (50%) | 13 (54%) | 1 (50%) | 1 (14%) | 17 (63%) | 11 (52%) | 5 (100%) | 3 (30%) |
| General medical practitioner, contract | 8 (22%) | 5 (42%) | 3 (12%) | 1 (50%) |  | 7 (26%) | 7 (33%) |  | 1 (10%) |
| General medical practitioner, salaried | 7 (19%) |  | 7 (29%) |  | 6 (86%) | 1 (4%) | 1 (5%) |  | 6 (60%) |
| General practice registrar/advanced trainee | 1 (3%) |  | 1 (4%) |  |  | 1 (4%) | 1 (5%) |  |  |
| General medical practitioner, other: associate | 1 (3%) | 1 (8%) |  |  |  | 1 (4%) | 1 (5%) |  |  |

Source: Staff survey R5 Mar–May 2021, question 2.

Table 142: Role of nurse/nurse assistants, by sampling strata

| **Response** | **Total** | **Size** | | **Type** | | | **Location** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Large/ medium** | **Small/sole** | **Corporate** | **AMS** | **Independ-ent** | **MMM 1** | **MMM 2 & 3** | **MMM 4+** |
| **Number of nurses responding** | 40 | 18 | 22 | 7 | 1 | 32 | 32 | 3 | 5 |
| **Nurse role:** | | | | | | | | | |
| Practice Nurse, Registered Nurse | 37 (95%) | 16 (89%) | 21 (100%) | 7 (100%) |  | 30 (94%) | 31 (97%) | 3 (100%) | 3 (75%) |
| Nurse Practitioner | 1 (3%) | 1 (6%) |  |  |  | 1 (3%) |  |  | 1 (25%) |
| Practice Nurse, Enrolled Nurse | 1 (3%) | 1 (6%) |  |  |  | 1 (3%) | 1 (3%) |  |  |
| Don't know/ no response | 1 |  | 1 |  | 1 |  |  |  | 1 |

Source: Staff survey R5 Mar–May 2021, question 2.1.

Table 143: Length of service at practice/service

|  | **0–3 months** | **4–12 months** | **1–2 years** | **3–5 years** | **6 years or more** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| How long have you worked at this practice/ service? | 1 (1%) | 15 (8%) | 23 (13%) | 50 (28%) | 90 (50%) | 3 |

Source: Staff survey R5 Mar–May 2021, question 4

Table 144: Involvement in developing general practice management plans for patients

| **question** | **Yes** | **No** | **Don't know/ no response** |
| --- | --- | --- | --- |
| Are you directly involved in developing general practice management plans for patients at this practice? | 38 (95%) | 2 (5%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 2.2.

Table 145: Care Coordinator or Case Manager role

| **question** | **Yes** | **No** | **Don't know/ no response** |
| --- | --- | --- | --- |
| Do you also play a role as a Care Coordinator or Case Manager for patients at this practice? | 20 (50%) | 20 (50%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 2.3.

Table 146: Primary care team roles and collaboration

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team...** | | | | | | |
| ... is made up of members with clearly defined roles, such as responsibility for patient self-management education, proactive follow up, and resource coordination | 151 (83%) | 21 (12%) | 4 (2%) | 6 (3%) |  | 0 |
| ... works with patients to help them understand their roles and responsibilities in care | 155 (86%) | 18 (10%) | 5 (3%) | 1 (1%) | 1 (1%) | 2 |
| ...is characterised by collaboration and trust. | 158 (87%) | 18 (10%) | 3 (2%) | 2 (1%) |  | 1 |

Source: Staff survey R5 Mar–May 2021, question 5.

Table 147: Primary care team roles and collaboration by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team...** | | | | | |
| ... is made up of members with clearly defined roles, such as responsibility for patient self-management education, proactive follow up, and resource coordination | 172 (95%) | 35 (97%) | 38 (84%) | 50 (100%) | 49 (96%) |
| ... is characterised by collaboration and trust | 176 (97%) | 36 (100%) | 42 (93%) | 50 (100%) | 48 (96%) |
| ... works with patients to help them understand their roles and responsibilities in care | 173 (96%) | 35 (97%) | 40 (91%) | 50 (100%) | 48 (96%) |

Source: Staff survey R5 Mar–May 2021, question 5.

Table 148: Primary care team roles and collaboration, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... is made up of members with clearly defined roles, such as responsibility for patient self-management education, proactive follow up, and resource coordination | 378 (89%) | 172 (95%) | 0.038 | 262 (91%) | 148 (94%) | 0.285 |
| ... is characterised by collaboration and trust | 389 (92%) | 176 (97%) | 0.020 | 266 (93%) | 153 (97%) | 0.034 |
| ... works with patients to help them understand their roles and responsibilities in care | 390 (92%) | 173 (95%) | 0.149 | 266 (93%) | 151 (96%) | 0.086 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 5.

Table 149: Primary care team and patient responsibility sharing

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| The primary care team and patients share responsibilities for managing patients' health... | 149 (83%) | 25 (14%) | 3 (2%) | 3 (2%) |  | 2 |

Source: Staff survey R5 Mar–May 2021, question 6.

Table 150: Primary care team and patient responsibility sharing by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| The primary care team and patients share responsibilities for managing patients' health... | 174 (97%) | 34 (94%) | 43 (96%) | 49 (98%) | 48 (98%) |

Source: Staff survey R5 Mar–May 2021, question 6.

Table 151: Primary care team and patient responsibility sharing, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| The primary care team and patients share responsibilities for managing patients' health... | 389 (92%) | 174 (96%) | 0.082 | 272 (95%) | 152 (97%) | 0.427 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 6.

Table 152: Practice management and ancillary systems

|  | **Very easy** | **Somewhat easy** | **Somewhat difficult** | **Very difficult** | **Not applicable** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **How easy/difficult is it for you to use the practice management system (clinical management system) or ancillary systems (care planning application/clinical data audit tool) to do the following for your patients?** | | | | | | |
| Review basic pathology results | 111 (61%) | 31 (17%) | 1 (1%) |  | 39 (21%) | 0 |
| Update medication list and drug allergies for patients | 86 (48%) | 30 (17%) | 3 (2%) |  | 62 (34%) | 1 |
| Review information from hospital discharge summaries | 78 (43%) | 48 (26%) | 12 (7%) | 1 (1%) | 43 (24%) | 0 |
| Review notes about patients | 120 (66%) | 23 (13%) | 3 (2%) |  | 36 (20%) | 0 |
| Order new patient pathology tests | 75 (42%) | 12 (7%) | 1 (1%) | 1 (1%) | 91 (51%) | 2 |
| Prescribe medications | 69 (39%) | 11 (6%) | 1 (1%) |  | 98 (55%) | 3 |
| Communicate electronically with other providers | 47 (26%) | 55 (31%) | 26 (15%) | 8 (4%) | 43 (24%) | 3 |
| Send or print after-visit summaries, instructions, educational information for patients | 70 (39%) | 58 (32%) | 14 (8%) | 1 (1%) | 38 (21%) | 1 |
| Send or receive messages from patients | 55 (31%) | 59 (33%) | 18 (10%) | 9 (5%) | 39 (22%) | 2 |
| Develop a care plan/shared care plan for patients | 57 (31%) | 46 (25%) | 17 (9%) | 1 (1%) | 61 (34%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 7.

Table 153: Practice management and ancillary systems, by staff type

|  | **Percentage responding Very easy or Somewhat easy** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **How easy/difficult is it for you to use the practice management system (clinical management system) or ancillary systems (care planning application/clinical data audit tool) to do the following for your patients?** | | | | | |
| Review basic pathology results | 142 (78%) | 36 (100%) | 43 (96%) | 40 (80%) | 23 (45%) |
| Update medication list and drug allergies for patients | 116 (64%) | 36 (100%) | 31 (69%) | 37 (74%) | 12 (24%) |
| Review information from hospital discharge summaries | 126 (69%) | 32 (89%) | 36 (80%) | 37 (74%) | 21 (41%) |
| Review notes about patients | 143 (79%) | 34 (94%) | 44 (98%) | 40 (80%) | 25 (49%) |
| Order new patient pathology tests | 87 (48%) | 36 (100%) | 16 (37%) | 24 (48%) | 11 (22%) |
| Prescribe medications | 80 (45%) | 36 (100%) | 11 (26%) | 24 (48%) | 9 (18%) |
| Communicate electronically with other providers | 102 (57%) | 24 (67%) | 27 (61%) | 34 (68%) | 17 (35%) |
| Send or print after-visit summaries, instructions, educational information for patients | 128 (71%) | 28 (78%) | 37 (84%) | 40 (80%) | 23 (45%) |
| Send or receive messages from patients | 114 (63%) | 21 (58%) | 27 (63%) | 37 (74%) | 29 (57%) |
| Develop a care plan/shared care plan for patients | 103 (57%) | 29 (81%) | 38 (84%) | 25 (50%) | 11 (22%) |

Source: Staff survey R5 Mar–May 2021, question 7.

Table 154: Practice management and ancillary systems, longitudinal analysis

| **Percentage responding Very easy or Somewhat easy** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| Review basic pathology results | 312 (73%) | 142 (78%) | 0.245 | 223 (78%) | 122 (78%) | 0.914 |
| Update medication list and drug allergies for patients | 234 (55%) | 116 (64%) | 0.070 | 160 (56%) | 97 (62%) | 0.228 |
| Review information from hospital discharge summaries | 271 (64%) | 126 (69%) | 0.207 | 186 (65%) | 110 (70%) | 0.253 |
| Review notes about patients | 328 (77%) | 143 (79%) | 0.673 | 228 (79%) | 120 (76%) | 0.574 |
| Order new patient pathology tests | 187 (44%) | 87 (48%) | 0.518 | 121 (42%) | 68 (43%) | 0.885 |
| Prescribe medications | 166 (39%) | 80 (44%) | 0.320 | 106 (37%) | 62 (39%) | 0.610 |
| Communicate electronically with other providers | 222 (52%) | 102 (56%) | 0.385 | 150 (52%) | 86 (55%) | 0.575 |
| Send or print after-visit summaries, instructions, educational information for patients | 288 (68%) | 128 (70%) | 0.490 | 197 (69%) | 109 (69%) | 0.817 |
| Send or receive messages from patients | 227 (53%) | 114 (63%) | 0.026 | 165 (57%) | 102 (65%) | 0.114 |
| Develop a care plan/shared care plan for patients | 218 (51%) | 103 (57%) | 0.227 | 153 (53%) | 86 (55%) | 0.769 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 7.

Table 155: Electronic data

|  | **Always** | **Usually** | **Sometimes** | **Rarely** | **Never** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team uses electronic data to...** | | | | | | |
| ... identify patients with complex health needs. | 81 (49%) | 61 (37%) | 23 (14%) | 1 (1%) | 1 (1%) | 15 |
| ... monitor and track patient health indicators and outcomes. | 76 (46%) | 66 (40%) | 22 (13%) | 2 (1%) | 1 (1%) | 15 |

Source: Staff survey R5 Mar–May 2021, question 8.

Table 156: Electronic data by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team uses electronic data to...** | | | | | |
| ... identify patients with complex health needs | 142 (85%) | 31 (86%) | 31 (69%) | 45 (90%) | 35 (97%) |
| ... monitor and track patient health indicators and outcomes | 142 (85%) | 31 (89%) | 30 (67%) | 43 (88%) | 38 (100%) |

Source: Staff survey R5 Mar–May 2021, question 8.

Table 157: Electronic data, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... identify patients with complex health needs | 304 (72%) | 142 (78%) | 0.075 | 210 (73%) | 118 (75%) | 0.581 |
| ... monitor and track patient health indicators and outcomes | 279 (66%) | 142 (78%) | 0.003 | 193 (67%) | 119 (76%) | 0.070 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 8.

Table 158: Electronic health record and other electronic systems

|  | **Always** | **Usually** | **Sometimes** | **Rarely** | **Never** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team uses an electronic health record system or other electronic systems to...** | | | | | | |
| ... support the documentation of patient needs. | 125 (73%) | 36 (21%) | 8 (5%) | 1 (1%) | 2 (1%) | 10 |
| ... develop care plans. | 127 (74%) | 35 (20%) | 6 (3%) | 1 (1%) | 3 (2%) | 10 |
| ... determine clinical outcomes. | 104 (64%) | 47 (29%) | 9 (6%) |  | 3 (2%) | 19 |

Source: Staff survey R5 Mar–May 2021, question 9.

Table 159: Electronic health record and other electronic systems, by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team uses an electronic health record system or other electronic systems to...** | | | | | |
| ... support the documentation of patient needs | 161 (94%) | 33 (92%) | 40 (91%) | 47 (96%) | 41 (95%) |
| ... develop care plans | 162 (94%) | 34 (94%) | 39 (87%) | 48 (98%) | 41 (98%) |
| ... determine clinical outcomes | 151 (93%) | 32 (91%) | 36 (86%) | 48 (98%) | 35 (95%) |

Source: Staff survey R5 Mar–May 2021, question 9.

Table 160: Electronic health record and other electronic systems, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... support the documentation of patient needs | 343 (81%) | 161 (88%) | 0.020 | 236 (82%) | 137 (87%) | 0.160 |
| ... develop care plans | 356 (84%) | 162 (89%) | 0.077 | 240 (84%) | 137 (87%) | 0.274 |
| ... determine clinical outcomes | 308 (72%) | 151 (83%) | 0.003 | 207 (72%) | 128 (82%) | 0.014 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 9.

Table 161: Patient care plans

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team...** | | | | | | |
| ... informs patients about any diagnosis in a way that they can understand. | 155 (92%) | 13 (8%) |  |  |  | 13 |
| ... helps patients understand all of the choices for their care. | 157 (92%) | 11 (6%) | 1 (1%) | 1 (1%) |  | 11 |
| ... considers and respects patients' values, beliefs and traditions when recommending treatments. | 163 (94%) | 9 (5%) |  | 1 (1%) |  | 9 |

Source: Staff survey R5 Mar–May 2021 question 10.

Table 162: Patient care plans by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team...** | | | | | |
| ... informs patients about any diagnosis in a way that they can understand | 168 (99%) | 36 (100%) | 44 (98%) | 47 (100%) | 41 (100%) |
| ... helps patients understand all of the choices for their care | 168 (98%) | 36 (100%) | 43 (96%) | 48 (100%) | 41 (98%) |
| ... considers and respects patients' values, beliefs and traditions when recommending treatments | 172 (99%) | 36 (100%) | 45 (100%) | 48 (100%) | 43 (98%) |

Source: Staff survey R5 Mar–May 2021, question 10.

Table 163: Patient care plans, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... informs patients about any diagnosis in a way that they can understand | 379 (89%) | 168 (92%) | 0.291 | 258 (90%) | 143 (91%) | 0.824 |
| ... helps patients understand all of the choices for their care | 380 (89%) | 168 (92%) | 0.302 | 259 (90%) | 144 (92%) | 0.684 |
| ... considers and respects patients' values, beliefs and traditions when recommending treatments | 386 (91%) | 172 (95%) | 0.136 | 258 (90%) | 148 (94%) | 0.109 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 10.

Table 164: Patient care plan input

|  | **Always** | **Usually** | **Sometimes** | **Rarely** | **Never** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team...** | | | | | | |
| ... asks for patients' input when making a plan for their care. | 115 (70%) | 45 (27%) | 1 (1%) | 2 (1%) | 1 (1%) | 18 |
| ... helps make care plans that patients can follow in their daily life. | 117 (70%) | 46 (28%) | 3 (2%) |  | 1 (1%) | 15 |
| ... develops care plans that incorporate recommendations from other health care providers that patients see. | 115 (69%) | 44 (26%) | 5 (3%) | 1 (1%) | 2 (1%) | 15 |

Source: Staff survey R5 Mar–May 2021, question 11.

Table 165: Patient care plan input, by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team...** | | | | | |
| ... asks for patients' input when making a plan for their care | 160 (98%) | 34 (97%) | 42 (95%) | 47 (100%) | 37 (97%) |
| ... helps make care plans that patients can follow in their daily life | 163 (98%) | 34 (97%) | 42 (95%) | 46 (100%) | 41 (98%) |
| ... develops care plans that incorporate recommendations from other health care providers that patients see | 159 (95%) | 34 (97%) | 38 (86%) | 46 (98%) | 41 (100%) |

Source: Staff survey R5 Mar–May 2021, question 11.

Table 166: Patient care plan input, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... asks for patients' input when making a plan for their care | 339 (80%) | 160 (88%) | 0.018 | 232 (81%) | 137 (87%) | 0.086 |
| ... helps make care plans that patients can follow in their daily life | 345 (81%) | 163 (90%) | 0.018 | 233 (81%) | 140 (89%) | 0.042 |
| ... develops care plans that incorporate recommendations from other health care providers that patients see | 340 (80%) | 159 (87%) | 0.039 | 230 (80%) | 135 (86%) | 0.160 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 11.

Table 167: Patient goals

|  | **Always** | **Usually** | **Sometimes** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| **Someone on the primary care team...** | | | | |
| ... helps patients set goals for managing their health. | 115 (66%) | 52 (30%) | 6 (3%) | 9 |
| ... checks to see if patients are reaching their goals. | 102 (61%) | 58 (35%) | 8 (5%) | 14 |

Source: Staff survey R5 Mar–May 2021, question 12.

Table 168: Patient goals by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **Someone on the primary care team...** | | | | | |
| ... helps patients set goals for managing their health | 167 (97%) | 35 (97%) | 42 (93%) | 47 (98%) | 43 (98%) |
| ... checks to see if patients are reaching their goals | 160 (95%) | 35 (97%) | 41 (93%) | 43 (93%) | 41 (98%) |

Source: Staff survey R5 Mar–May 2021, question 12.

Table 169: Patient goals, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... helps patients set goals for managing their health | 350 (82%) | 167 (92%) | 0.004 | 236 (82%) | 144 (92%) | 0.009 |
| ... checks to see if patients are reaching their goals | 311 (73%) | 160 (88%) | <0.001 | 212 (74%) | 137 (87%) | 0.001 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 12.

Table 170: Patient care plans

|  | **Always** | **Usually** | **Sometimes** | **Rarely** | **Never** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care team...** | | | | | | |
| ... gives patients a copy of their care plan. | 98 (56%) | 53 (30%) | 14 (8%) | 9 (5%) | 1 (1%) | 7 |
| ... follows through with the care plan. | 104 (61%) | 60 (35%) | 6 (4%) |  | 1 (1%) | 11 |
| ... uses patients' care plan to follow progress. | 102 (60%) | 56 (33%) | 9 (5%) | 3 (2%) | 1 (1%) | 11 |
| ... reviews and updates patients' care plan with them. | 115 (65%) | 50 (28%) | 8 (5%) | 2 (1%) | 1 (1%) | 6 |

Source: Staff survey R5 Mar–May 2021, question 13.

Table 171: Patient care plans by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care team...** | | | | | |
| ... gives patients a copy of their care plan | 151 (86%) | 30 (83%) | 36 (82%) | 44 (90%) | 41 (89%) |
| ... follows through with the care plan | 164 (96%) | 35 (97%) | 40 (93%) | 48 (100%) | 41 (93%) |
| ... uses patients' care plan to follow progress | 158 (92%) | 33 (92%) | 37 (86%) | 45 (96%) | 43 (96%) |
| ... reviews and updates patients' care plan with them | 165 (94%) | 30 (86%) | 40 (91%) | 49 (100%) | 46 (96%) |

Source: Staff survey R5 Mar–May 2021, question 13.

Table 172: Patient care plans, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... gives patients a copy of their care plan | 337 (79%) | 151 (83%) | 0.235 | 237 (83%) | 136 (87%) | 0.232 |
| ... follows through with the care plan | 338 (80%) | 164 (90%) | 0.001 | 237 (83%) | 142 (90%) | 0.026 |
| ... uses patients' care plan to follow progress | 313 (74%) | 158 (87%) | <0.001 | 217 (76%) | 137 (87%) | 0.003 |
| ... reviews and updates patients' care plan with them | 352 (83%) | 165 (91%) | 0.016 | 247 (86%) | 146 (93%) | 0.037 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 13.

Table 173: Behaviour change interventions and peer support

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **The primary care practice/service...** | | | | | | |
| ... has behaviour change interventions readily available for patients as part of routine care. | 93 (62%) | 45 (30%) | 9 (6%) | 3 (2%) | 1 (1%) | 31 |
| ... has peer support readily available for patients as part of routine care. | 74 (49%) | 47 (31%) | 19 (12%) | 5 (3%) | 7 (5%) | 30 |

Source: Staff survey R5 Mar–May 2021, question 14.

Table 174: Behaviour change interventions and peer support by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **The primary care practice/service...** | | | | | |
| ... has behaviour change interventions readily available for patients as part of routine care | 138 (91%) | 33 (92%) | 36 (86%) | 41 (98%) | 28 (90%) |
| ... has peer support readily available for patients as part of routine care | 121 (80%) | 23 (66%) | 33 (79%) | 38 (88%) | 27 (84%) |

Source: Staff survey R5 Mar–May 2021, question 14.

Table 175: Behaviour change interventions and peer support, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... has behaviour change interventions readily available for patients as part of routine care | 261 (61%) | 138 (76%) | <0.001 | 168 (59%) | 115 (73%) | 0.002 |
| ... has peer support readily available for patients as part of routine care | 244 (57%) | 121 (66%) | 0.040 | 157 (55%) | 102 (65%) | 0.041 |

Source: Staff survey R5 Mar–May 2021, question 14.

Table 176: Additional support services

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **Someone on the primary care team...** | | | | | | |
| ... asks patients about additional supportive services they may need including those that may be available in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services. | 135 (79%) | 31 (18%) | 3 (2%) | 1 (1%) |  | 12 |
| ... gives patients information about additional supportive services offered at the practice/ service or in the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services. | 131 (77%) | 35 (20%) | 4 (2%) | 1 (1%) |  | 11 |
| ... connects patients to needed services in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services. | 136 (79%) | 30 (17%) | 5 (3%) | 1 (1%) |  | 10 |

Source: Staff survey R5 Mar–May 2021, question 15.

Table 177: Additional support services by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **Someone on the primary care team...** | | | | | |
| ... asks patients about additional supportive services they may need including those that may be available in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 166 (98%) | 34 (94%) | 43 (96%) | 47 (100%) | 42 (100%) |
| ... gives patients information about additional supportive services offered at the practice/ service or in the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 166 (97%) | 33 (92%) | 42 (95%) | 47 (100%) | 44 (100%) |
| ... connects patients to needed services in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 166 (97%) | 33 (92%) | 42 (95%) | 46 (98%) | 45 (100%) |

Source: Staff survey R5 Mar–May 2021, question 15.

Table 178: Additional support services, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... asks patients about additional supportive services they may need including those that may be available in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 359 (84%) | 166 (91%) | 0.033 | 249 (87%) | 142 (90%) | 0.290 |
| ... gives patients information about additional supportive services offered at the practice/ service or in the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 366 (86%) | 166 (91%) | 0.087 | 250 (87%) | 143 (91%) | 0.212 |
| ... connects patients to needed services in the practice/service or the community, such as counselling programs, support groups, rehabilitation programs, home care, financial support, equipment and transportation services | 358 (84%) | 166 (91%) | 0.031 | 240 (84%) | 143 (91%) | 0.037 |

Source: Staff survey R5 Mar–May 2021, question 15.

Table 179: Specialist care

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **When a patient sees a specialist, the primary care team...** | | | | | | |
| ... is informed about the care patients received from the specialist. | 108 (62%) | 57 (33%) | 7 (4%) | 3 (2%) |  | 7 |
| ... receives information from the specialist about new prescriptions or if there was a change in medication. | 96 (57%) | 56 (33%) | 10 (6%) | 7 (4%) |  | 13 |
| ... receives information from the specialist about follow-up care. | 98 (57%) | 58 (34%) | 11 (6%) | 5 (3%) |  | 10 |

Source: Staff survey R5 Mar–May 2021, question 16.

Table 180: Specialist care by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **When a patient sees a specialist, the primary care team...** | | | | | |
| ... is informed about the care patients received from the specialist | 165 (94%) | 35 (97%) | 39 (89%) | 47 (96%) | 44 (96%) |
| ... receives information from the specialist about new prescriptions or if there was a change in medication | 152 (90%) | 33 (92%) | 37 (86%) | 42 (89%) | 40 (93%) |
| ... receives information from the specialist about follow-up care | 156 (91%) | 34 (94%) | 36 (84%) | 45 (94%) | 41 (91%) |

Source: Staff survey R5 Mar–May 2021, question 16.

Table 181: Specialist care, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... is informed about the care patients received from the specialist | 362 (85%) | 165 (91%) | 0.037 | 247 (86%) | 140 (89%) | 0.275 |
| ... receives information from the specialist about new prescriptions or if there was a change in medication | 346 (81%) | 152 (84%) | 0.376 | 240 (84%) | 130 (83%) | 0.935 |
| ... receives information from the specialist about follow-up care | 349 (82%) | 156 (86%) | 0.184 | 242 (84%) | 134 (85%) | 0.672 |

Source: Staff survey R5 Mar–May 2021, question 16.

Table 182: HCH patients referred to a community pharmacist as part of the HCH trial

| **question** | **All/majority of HCH patients (80–100%)** | **Most HCH patients (50–79%)** | **Some HCH patients (20–49%)** | **No/very few HCH patients (less than 20%)** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- |
| Approximately how many HCH patients that you are responsible for have you referred to a community pharmacist as part of the HCH trial (i.e. for a medication reconciliation and a medication management plan or other support)? | 6 (17%) | 4 (11%) | 14 (39%) | 12 (33%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 16A.

Table 183: Key reasons GPs have not referred more HCH patients to a community pharmacy

| **Response** | **n (%)** |
| --- | --- |
| Pharmacy intervention was not required | 5 (50%) |
| Lack of pharmacists available or not participating in HCH | 3 (30%) |
| Limited patient interest | 2 (20%) |
| Patients dispersed geographically | 1 (10%) |
| Small scale of HCH patients | 1 (10%) |
| Don't know/ no response | 2 |

Source: Staff survey R5 Mar–May 2021, question 16B.

Table 184: Proportion of HCH patients referred to a community pharmacist for whom the GP received a medication management plan from the community pharmacist

|  | **All/majority of HCH patients (80–100%)** | **Most HCH patients (50–79%)** | **Some HCH patients (20–49%)** | **No/very few HCH patients (less than 20%)** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- |
| For approximately what proportion of HCH patients that you referred to a community pharmacist have you received a medication management plan from the community pharmacist? | 9 (38%) | 3 (12%) | 6 (25%) | 6 (25%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 16C.

Table 185: Frequency of interaction with community pharmacist

|  | **5–6 times** | **3–4 times** | **1–2 times** | **Nil** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- |
| Thinking about the community pharmacist with whom you have most dealings, how often have you interacted over the last month? Interaction could be via telephone, video, email or face-to-face. | 5 (21%) | 8 (33%) | 5 (21%) | 6 (25%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 16D.

Table 186: Did community pharmacists outline supporting services that could be delivered to support achievement of patient medication management goals?

|  | **Yes** | **Maybe** | **No** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| In any of the interactions with this pharmacist throughout the trial period, did the pharmacist outline supporting services that he/she planned or could deliver to support the patient's achievement of their medication management goals? | 15 (83%) | 2 (11%) | 1 (6%) | 0 |

Source: Staff survey R5 Mar–May 2021, question 16E.

Table 187: Proportion of community pharmacists’ recommendations that GP acted on

| **Response** | **n (%)** |
| --- | --- |
| 0–20% | 6 (26%) |
| 21–40% | 2 (9%) |
| 41–60% | 6 (26%) |
| 61–80% | 5 (22%) |
| 81–100% | 4 (17%) |
| Don't know/ no response | 1 |

Source: Staff survey R5 Mar–May 2021, question 16F.

Table 188: Key reasons for GP not acting on the community pharmacists’ recommendations most of the time

| **Response** | **n (%)** |
| --- | --- |
| Did not agree with /or find pharmacist input valuable | 8 (62%) |
| Do not receive any communication from pharmacists | 2 (15%) |
| Service provided by GP | 1 (8%) |
| No HCH pharmacists locally | 1 (8%) |
| GP did not see the use | 1 (8%) |
| Don't know/ no response | 1 |

Source: Staff survey R5 Mar–May 2021, question 16G.

Table 189: GP’s perceptions of benefits of services provided by community pharmacists

| **Response** | **n (%)** |
| --- | --- |
| Patient education | 3 (21%) |
| Aid medication compliance | 2 (14%) |
| Reinforce GP decisions and/or provide medications suggestions and improvements | 2 (14%) |
| Help identify errors or interactions through checks and medication reconciliation | 2 (14%) |
| Promotes continuity and integration of care | 2 (14%) |
| Minimal to no benefits | 2 (14%) |
| Other | 1 (7%) |
| Don't know/ no response | 10 |

Source: Staff survey R5 Mar–May 2021, question 16H.

Table 190: Did communications between GP and community pharmacists in your local area improve?

| **question** | **Yes** | **No** | **Don't know/ no response** |
| --- | --- | --- | --- |
| Since the start of the community pharmacy component of the HCH trial, have communications between you and community pharmacists in your local area improved? | 8 (44%) | 10 (56%) | 6 |

Source: Staff survey R5 Mar–May 2021, question 16I.

Table 191: GP views on top three ways in which community pharmacists' expertise could be better used towards improving the care provided for HCH patients and other patients with chronic illnesses

| **Response** | **n (%)** |
| --- | --- |
| Provide more education and support | 13 (76%) |
| Offer additional services (i.e. delivery, e-scripts, home visits) | 7 (41%) |
| Better communication and feedback | 6 (35%) |
| More frequent medication reviews and patient follow up | 6 (35%) |
| More regular reporting and documentation | 6 (35%) |
| Additional involvement with general practice team based care arrangements (i.e. visits to practice) | 4 (24%) |
| Better use of and communication through shared care planning tools | 3 (18%) |
| Reminders | 1 (6%) |
| Don't know/ no response | 7 |

Source: Staff survey R5 Mar–May 2021, question 16J.

Table 192: Information received from the hospital after patient discharge

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **When patients are discharged from the hospital, the primary care team...** | | | | | | |
| ... is informed about the care patients received from the hospital. | 85 (49%) | 62 (36%) | 10 (6%) | 14 (8%) | 1 (1%) | 10 |
| ... receives information from the hospital about new prescriptions or if there was a change in medication. | 77 (46%) | 65 (39%) | 10 (6%) | 14 (8%) | 1 (1%) | 15 |
| ... receives information from the hospital about post-discharge follow-up care. | 73 (43%) | 67 (40%) | 8 (5%) | 19 (11%) | 1 (1%) | 14 |

Source: Staff survey R5 Mar–May 2021, question 17.

Table 193: Information received from the hospital after patient discharge by staff type

|  | **Percentage responding Agree or Somewhat agree** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| **When patients are discharged from the hospital, the primary care team...** | | | | | |
| ... is informed about the care patients received from the hospital | 147 (85%) | 28 (78%) | 32 (71%) | 46 (96%) | 41 (95%) |
| ... receives information from the hospital about new prescriptions or if there was a change in medication | 142 (85%) | 30 (83%) | 30 (68%) | 46 (96%) | 36 (92%) |
| ... receives information from the hospital about post-discharge follow-up care | 140 (83%) | 28 (78%) | 31 (69%) | 43 (93%) | 38 (93%) |

Source: Staff survey R5 Mar–May 2021, question 17.

Table 194: Information received from the hospital after patient discharge, longitudinal analysis

| **Percentage responding Agree or Somewhat agree** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| ... is informed about the care patients received from the hospital | 331 (78%) | 147 (81%) | 0.448 | 226 (79%) | 126 (80%) | 0.817 |
| ... receives information from the hospital about new prescriptions or if there was a change in medication | 318 (75%) | 142 (78%) | 0.432 | 214 (75%) | 121 (77%) | 0.617 |
| ... receives information from the hospital about post-discharge follow-up care | 313 (74%) | 140 (77%) | 0.442 | 212 (74%) | 119 (76%) | 0.761 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 17.

Table 195: When patients are discharged from the hospital results are incorporated into their primary care medical record

|  | **Always** | **Usually** | **Sometimes** | **Rarely** | **Never** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| When patients are discharged from the hospital and they have test results pending, the results are incorporated into their primary care medical record within two weeks: | 28 (18%) | 67 (42%) | 35 (22%) | 27 (17%) | 3 (2%) | 22 |

Source: Staff survey R5 Mar–May 2021, question 18.

Table 196: When patients are discharged from the hospital results are incorporated into their primary care medical record by staff type

|  | **Percentage responding Always or Usually** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| When patients are discharged from the hospital and they have test results pending, the results are incorporated into their primary care medical record within two weeks: | 95 (59%) | 14 (41%) | 20 (48%) | 32 (68%) | 29 (78%) |

Source: Staff survey R5 Mar–May 2021, question 18.

Table 197: When patients are discharged from the hospital results are incorporated into their primary care medical record, longitudinal analysis

| **Percentage responding Always or Usually** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| When patients are discharged from the hospital and they have test results pending, the results are incorporated into their primary care medical record within two weeks: | 194 (46%) | 95 (52%) | 0.113 | 120 (42%) | 80 (51%) | 0.076 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 18.

Table 198: Rating of coordination of care provided by the primary care practice/ service

|  | **Excellent** | **Very good** | **Good** | **Fair** | **Poor** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| In general, how would rate the coordination of care provided by your primary care practice/ service? | 44 (24%) |  | 42 (23%) | 9 (5%) |  | 1 |

Source: Staff survey R5 Mar–May 2021, question 19.

Table 199: Rating of coordination of care provided by the primary care practice/ service by staff type

|  | **Percentage responding Excellent or Very Good** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| In general, how would rate the coordination of care provided by your primary care practice/ service? | 130 (72%) | 29 (81%) | 27 (60%) | 34 (69%) | 40 (78%) |

Source: Staff survey R5 Mar–May 2021, question 19.

Table 200: Rating of coordination of care provided by the primary care practice/ service, longitudinal analysis

| **Percentage responding Excellent or Very Good** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| In general, how would rate the coordination of care provided by your primary care practice/ service? | 246 (58%) | 130 (71%) | 0.003 | 167 (58%) | 109 (69%) | 0.034 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 19.

Table 201: Staff assessment of whether coordination of care provided for patients improved since HCH started

|  | **Got better** | **Stayed the same** | **Got worse** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| Since the HCH program commenced, coordination of care provided for patients of your practice/service: | 98 (60%) | 64 (39%) | 1 (1%) | 19 |

Source: Staff survey R5 Mar–May 2021, question 20A.

Table 202: Top three changes that have occurred that improved the coordination of care provided for patients

| **Response** | **n (%)** |
| --- | --- |
| Improved flexibility for staff and patients (better access & remote working) | 47 (35%) |
| More patient engagement in care planning and otherwise | 34 (26%) |
| Improved external collaboration | 28 (21%) |
| Improved in practice collaboration | 24 (18%) |
| Patient Outreach (Nurse) follow up with HCH patients | 21 (16%) |
| Improved Care plan processes | 20 (15%) |
| Increased scope of practice for non GP staff / nurse led care | 18 (14%) |
| Increased non GP staff involvement | 14 (11%) |
| Introduced/ enhanced telehealth (including e scripts) | 14 (11%) |
| Improved practice culture and team | 13 (10%) |
| Increased service offering | 13 (10%) |
| Improved internal systems to support HCH | 12 (9%) |
| Introduced/ enhanced recall system | 12 (9%) |
| Installed/ changed/greater use of shared care platform | 11 (8%) |
| New staff/ increased hours | 9 (7%) |
| Data cleansing/ improved use of practice data in patient care | 8 (6%) |
| Continuity of care | 6 (5%) |
| No change | 5 (4%) |
| Increased use of technology | 3 (2%) |
| Improved patient outcomes | 2 (2%) |
| Don't know/ no response | 49 |

Source: Staff survey R5 Mar–May 2021, question 20B.

Table 203: Top three changes staff believe would further improve the coordination of care provided for patients

| **Response** | **n (%)** |
| --- | --- |
| More external provider support / communication /engagement | 47 (39%) |
| Improve IT infrastructure (includes supporting further interoperability) | 39 (32%) |
| Dedicated / increased staffing | 27 (22%) |
| More internal practice support / involvement / collaboration | 20 (16%) |
| More patient engagement / education / resources | 18 (15%) |
| Additional training and resources (for practice staff and/or other health providers) | 18 (15%) |
| Additional funding | 17 (14%) |
| More time to support HCH | 12 (10%) |
| Support continued use and/or expansion of telehealth | 11 (9%) |
| Specific involvement/ funding of allied health/ specialist care in HCH: Funding bulk billing etc | 10 (8%) |
| Extend program / expand enrolment | 9 (7%) |
| Better program monitoring and planning | 5 (4%) |
| Expanded practice offering | 5 (4%) |
| Lower administrative burden | 4 (3%) |
| Additional guidance and program structure | 4 (3%) |
| Enrolment to practice rather than GP | 3 (2%) |
| More opportunity for provider feedback | 2 (2%) |
| Don't know/ no response | 60 |

Source: Staff survey R5 Mar–May 2021, question 20C.

Table 204: Staff rating of the quality of care provided to patients

|  | **Excellent** | **Very good** | **Good** | **Fair** | **Poor** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| In general, how would rate the quality of care provided to patients by your primary care practice/ service? | 61 (34%) | 90 (50%) | 29 (16%) | 1 (1%) |  | 1 |

Source: Staff survey R5 Mar–May 2021, question 21.

Table 205: Staff rating of the quality of care provided to patients, by staff type

|  | **Percentage responding Excellent or Very Good** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| In general, how would rate the quality of care provided to patients by your primary care practice/ service? | 151 (83%) | 31 (86%) | 36 (82%) | 41 (82%) | 43 (84%) |

Source: Staff survey R5 Mar–May 2021, question 21.

Table 206: Staff rating of the quality of care provided to patients, longitudinal analysis

| **Percentage responding Excellent or Very Good** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| In general, how would rate the quality of care provided to patients by your primary care practice/ service? | 315 (74%) | 151 (83%) | 0.035 | 218 (76%) | 127 (81%) | 0.357 |

Source: Staff survey R5 Mar–May 2021, question 21.

Table 207: Top three changes that have occurred since the start of HCH that improved the quality of care provided to patients

| **Response** | **n (%)** |
| --- | --- |
| Improved access for patients | 40 (34%) |
| More patient engagement / improved patient relationship | 39 (33%) |
| Improved in practice collaboration | 24 (20%) |
| Improved Care plan processes | 24 (20%) |
| Patient recalls / Practice outreach | 20 (17%) |
| Introduced/ enhanced telehealth (including e scripts) | 17 (14%) |
| Improved external collaboration | 15 (13%) |
| Nurse led /nurse involved care | 12 (10%) |
| Data cleansing/ improved use of practice data in patient care | 10 (8%) |
| Continuity of care | 10 (8%) |
| Increased scope/ training to increase scope of non GP staff | 9 (8%) |
| Increased service offering | 8 (7%) |
| New staff or increased hours for HCH dedicated staff | 8 (7%) |
| Improved practice culture and team | 7 (6%) |
| Improved internal systems to support HCH | 6 (5%) |
| Improved patient outcomes | 6 (5%) |
| No change | 4 (3%) |
| Proactive care/ preventative health care | 4 (3%) |
| Increased non GP staff involvement | 3 (3%) |
| Increased use of technology | 3 (3%) |
| Installed/ changed/greater use of shared care platform | 3 (3%) |
| Increased options with flexible funding | 3 (3%) |
| PHN Support | 2 (2%) |
| Higher staff satisfaction | 1 (1%) |
| Improved Flexibility for staff (remote working) | 1 (1%) |
| Don't know/ no response | 63 |

Source: Staff survey R5 Mar–May 2021, question 22B.

Table 208: Top three changes staff believe would further improve the quality of care provided to patients

| **Response** | **n (%)** |
| --- | --- |
| Additional/ dedicated staff and or staff hours | 37 (37%) |
| More patient engagement / education / resources | 18 (18%) |
| Improve IT infrastructure (includes supporting further interoperability) | 18 (18%) |
| Specific involvement/ funding of allied health/ specialist care in HCH: Funding bulk billing etc | 16 (16%) |
| More external support / communication /engagement | 15 (15%) |
| Extend program / expand enrolment | 13 (13%) |
| Patient monitoring/ recalls / outreach | 13 (13%) |
| More internal practice support / involvement / collaboration | 12 (12%) |
| Additional training and resources (for practice staff and/or other health providers) | 10 (10%) |
| More funding/ improved targeting of funding | 10 (10%) |
| Lower administrative burden | 7 (7%) |
| Support continued use and/or expansion of telehealth | 7 (7%) |
| More GPs involved/ engaged | 5 (5%) |
| More time to support HCH | 4 (4%) |
| Physical HCH space within practice | 3 (3%) |
| No change | 2 (2%) |
| Nurse led /nurse involved care | 2 (2%) |
| Proactive care/ preventative health care | 2 (2%) |
| Data cleansing/ improved use of practice data in patient care | 2 (2%) |
| Don't know/ no response | 81 |

Source: Staff survey R5 Mar–May 2021, question 22C.

Table 209: Staff experience

|  | **Agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **Please indicate your level of agreement with the following statements about your job** | | | | | | |
| My work gives me a feeling of personal accomplishment | 82 (45%) | 90 (50%) | 7 (4%) | 2 (1%) |  | 1 |
| I have the tools and resources to do my job well. | 83 (46%) | 79 (44%) | 11 (6%) | 7 (4%) | 1 (1%) | 1 |
| My job makes good use of my skills and abilities. | 88 (49%) | 71 (39%) | 16 (9%) | 5 (3%) |  | 2 |
| I have clearly defined quality goals. | 85 (47%) | 76 (42%) | 14 (8%) | 4 (2%) | 1 (1%) | 2 |
| The practice/service leaders visibly demonstrate a commitment to quality. | 88 (49%) | 79 (44%) | 11 (6%) | 1 (1%) |  | 3 |
| The practice/service leaders keep employees informed about matters affecting us. | 81 (45%) | 80 (44%) | 13 (7%) | 3 (2%) | 3 (2%) | 2 |
| The practice/service leaders strongly support practice change efforts. | 80 (45%) | 80 (45%) | 15 (8%) | 2 (1%) | 2 (1%) | 3 |

Source: Staff survey R5 Mar–May 2021, question 23.

Table 210: Has your role in the practice/ service changed since the implementation of the HCH in your practice?

| **Response** | **n (%)** |
| --- | --- |
| I started work with the practice/ service after the HCH program commenced. | 35 (19%) |
| There have been no changes to my role since the HCH program commenced. | 63 (35%) |
| My role in the practice/ service has changed, but this has not been a result of the HCH program. | 34 (19%) |
| My role in the practice/ service has changed since the HCH program commenced, and this is a result of/ related to the HCH program. | 50 (27%) |

Source: Staff survey R5 Mar–May 2021, question 23A.

Table 211: Extent to which daily work relates to patients enrolled in HCH

| **question** | **All my daily work** | **Some of my daily work** | **None or very little** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| How much of your daily work relates to patients enrolled in the HCH program? | 3 (6%) | 43 (90%) | 2 (4%) | 2 |

Source: Staff survey R5 Mar–May 2021, question 23B.

Table 212: Change in staff members' role in the practice since start of HCH

| **question** | **Strongly agree** | **Somewhat agree** | **Neither agree nor disagree** | **Somewhat disagree** | **Strongly disagree** | **Don't know/ no response** |
| --- | --- | --- | --- | --- | --- | --- |
| **In what ways has your role in the practice/ service changed the implementation of the HCH in your practice?** | | | | | | |
| The depth of my job has increased (e.g. through extending my skills) | 19 (38%) | 19 (38%) | 9 (18%) | 1 (2%) | 2 (4%) | 0 |
| The breadth of my job has been expanded (e.g. wider range of tasks, and/or working with more organisations) | 19 (39%) | 21 (43%) | 5 (10%) | 2 (4%) | 2 (4%) | 1 |
| I now delegate more responsibility to others | 9 (19%) | 19 (40%) | 4 (8%) | 7 (15%) | 9 (19%) | 2 |
| I now have more responsibility delegated to me. | 22 (46%) | 13 (27%) | 7 (15%) | 4 (8%) | 2 (4%) | 2 |

Source: Staff survey R5 Mar–May 2021, question 23C.

Table 213: Change of aspects of job since start of HCH at the practice

| **question** | **Better than before** | **No change** | **Worse than before** | **Don't know/ no response** |
| --- | --- | --- | --- | --- |
| **In what ways has your role in the practice/ service changed the implementation of the HCH in your practice?** | | | | |
| Having clear planned goals and objectives for my job | 24 (48%) | 25 (50%) | 1 (2%) | 0 |
| Having an interesting job | 26 (54%) | 21 (44%) | 1 (2%) | 2 |
| Developing my role | 36 (75%) | 12 (25%) |  | 2 |
| I now have more responsibility delegated to me | 32 (67%) | 15 (31%) | 1 (2%) | 2 |

Source: Staff survey R5 Mar–May 2021, question 23E.

Table 214: Staff assessment of atmosphere within the practice

|  | **1. Calm** | **2.** | **3. Busy, but reasonable** | **4.** | **5. Hectic, chaotic** |
| --- | --- | --- | --- | --- | --- |
| Which number below best describes the atmosphere in your practice? | 9 (5%) | 7 (4%) | 95 (52%) | 54 (30%) | 17 (9%) |

Source: Staff survey R5 Mar–May 2021, question 24.

Table 215: Staff assessment of atmosphere within the practice, by staff type

|  | **Percentage responding Calm to Busy but reasonable** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| Which number below best describes the atmosphere in your practice? | 111 (61%) | 28 (78%) | 24 (53%) | 28 (56%) | 31 (61%) |

Source: Staff survey R5 Mar–May 2021, question 24.

Table 216: Staff assessment of atmosphere within the practice, longitudinal analysis

|  | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| Percentage responding Calm to Busy but reasonable | 281 (66%) | 111 (61%) | 0.162 | 190 (66%) | 94 (60%) | 0.202 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 24.

Table 217: Staff rating of their job satisfaction

|  | **Very satisfied** | **Satisfied** | **Neutral** | **Unsatisfied** | **Very unsatisfied** |
| --- | --- | --- | --- | --- | --- |
| In general, how do rate your satisfaction with your job? | 59 (32%) | 100 (55%) | 18 (10%) |  | 5 (3%) |

Source: Staff survey R5 Mar–May 2021, question 25.

Table 218: Staff rating of their job satisfaction, by staff type

|  | **Percentage responding Very satisfied or satisfied** | | | | |
| --- | --- | --- | --- | --- | --- |
| **Total** | **GP** | **Nurse** | **Manager** | **Other** |
| In general, how do rate your satisfaction with your job? | 159 (87%) | 32 (89%) | 38 (84%) | 46 (92%) | 43 (84%) |

Source: Staff survey R5 Mar–May 2021, question 25.

Table 219: Staff rating of their job satisfaction, longitudinal analysis

| **Percentage responding Very satisfied or satisfied** | **All responses** | | | **Responses by staff in practices responding to R1 & R5** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** | **R1** | **R5** | **Statistical significance of change from R1 to R5 (p-value)** |
| In general, how do rate your satisfaction with your job? | 364 (86%) | 159 (87%) | 0.603 | 247 (86%) | 137 (87%) | 0.771 |

Source: Staff survey R1 Dec 2017–Jul 2018 and R5 Mar–May 2021, question 25.

Table 220: Top changes staff believe would improve job satisfaction

| **Response** | **n (%)** |
| --- | --- |
| More hours/ additional staff: practice level | 40 (33%) |
| Improved internal communication / support / involvement / collaboration / culture | 39 (32%) |
| Training/ education / education support / career progression | 25 (21%) |
| Increased funding / MBS reimbursement | 18 (15%) |
| Increased wage: employee | 17 (14%) |
| Improved internal processes and systems | 17 (14%) |
| Quarantined hours for practice development tasks (admin QI) | 12 (10%) |
| Lower administrative burden | 10 (8%) |
| Improved Patient relationships / engagement / outcomes | 9 (7%) |
| improved external collaboration / access to AH or specialist care | 8 (7%) |
| Improved internal leadership | 7 (6%) |
| Improved work life balance | 7 (6%) |
| Improve/ embrace technology | 6 (5%) |
| Improved government communication /transparency | 6 (5%) |
| High job satisfaction currently | 5 (4%) |
| Employee / Professional recognition | 5 (4%) |
| Expand and or extend HCH | 5 (4%) |
| Increased role scope for Nurses/ Medical assistants | 4 (3%) |
| Reduced Staff turnover | 4 (3%) |
| Maintain / improve Telehealth | 3 (2%) |
| Improved information sharing – eMR | 3 (2%) |
| Improved physical space (larger space, renovated) | 2 (2%) |
| Don't know/ no response | 61 |

Source: Staff survey R5 Mar–May 2021, question 26.

Appendix 11: Sample practice benchmark report

Graphical user interface, text, application

Description automatically generated

Table

Description automatically generated

Graphical user interface, chart

Description automatically generated

Table

Description automatically generated with medium confidence

Table

Description automatically generated

Graphical user interface, application, table, Excel

Description automatically generated

Graphical user interface, application, table, Excel

Description automatically generated

A picture containing table

Description automatically generated

# References

Agency for Healthcare Research and Quality. (2015). *CAHPS® Clinician & Group Survey: Overview of the Questionnaires*. <https://www.ahrq.gov/cahps/surveys-guidance/cg/instructions/downloadsurvey3.0.html>

Agency for Healthcare Research and Quality. (2016). *Care Coordination Quality Measure for Primary Care (CCQM-PC)*. AHRQ. Retrieved 1 February 2017 from <https://www.ahrq.gov/professionals/prevention-chronic-care/improve/coordination/ccqmpc/index.html>

Australian Association of Practice Management. (2019). *AAPM Guidance for Health Care Homes*. Retrieved 5 September from <https://www.aapm.org.au/Knowledge-Hub/Healthcare-Homes>

Australian Bureau of Statistics. (2018a). 1270.0.55.005 - Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure, July 2016

Australian Bureau of Statistics. (2018b). *2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016*. Retrieved September from <https://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/6CD4E5CE952FEDBFCA257B3B001AC3E5?opendocument>

Australian Institute of Health and Welfare. (2013). *Expenditure on specialist attendances, 2012–13 [METeOR 547958]*. AIHW. <https://meteor.aihw.gov.au/content/index.phtml/itemId/547958>

Australian Institute of Health and Welfare. (2014). *Cardiovascular disease, diabetes and chronic kidney disease. Australian facts: Morbidity–Hospital care. Cardiovascular, diabetes and chronic kidney disease.*

Australian Institute of Health and Welfare. (2015). *Pharmaceutical Benefits Scheme (PBS) prescription-patient entitlement status (derived) [METeOR 604103]*. AIHW. <https://meteor.aihw.gov.au/content/index.phtml/itemId/604103>

Australian Institute of Health and Welfare. (2016). *General Practitioner attendance indicator [METeOR 603651]*. AIHW. <https://meteor.aihw.gov.au/content/index.phtml/itemId/603651>

Australian Institute of Health and Welfare. (2019a). *Medicare-subsidised GP, allied health and specialist health care across local areas, 2013–14 to 2017–18 Technical Note*. AIHW. <https://www.aihw.gov.au/getmedia/0185a2b5-5093-4194-85b3-e9776867f512/aihw-phe-254-tech-note.pdf.aspx>

Australian Institute of Health and Welfare. (2019b). *National Healthcare Agreement: PI 18–Selected potentially preventable hospitalisations, 2019 [METeOR 698954]*. AIHW. <https://meteor.aihw.gov.au/content/index.phtml/itemId/698954>

Devlin, N. J., & Krabbe, P. F. (2013). The development of new research methods for the valuation of EQ-5D-5L. *Eur J Health Econ, 14 Suppl 1*, S1-3.

Dillman, D. A., Smyth, J. D., & Christian, L. M. (2014). *Internet, Phone, Mail, and Mixed-Mode Surveys: The Tailored Design Method* (4th ed.). Wiley.

Gibbons, C. J., Small, N., Rick, J., Burt, J., Hann, M., & Bower, P. (2017). The Patient Assessment of Chronic Illness Care produces measurements along a single dimension: results from a Mokken analysis. *Health Qual Life Outcomes, 15*(1), 61.

Glasgow, R. E., Wagner, E. H., Schaefer, J., Mahoney, L. D., Reid, R. J., & Greene, S. M. (2005). Development and Validation of the Patient Assessment of Chronic Illness Care (PACIC) [Journal]. *Medical care, 43*, 436-444.

Goodall, I., Shephard, M., & Tate, J. (2010). *Position Statment. Recommended Changes in HbA1c Reporting Units for Australian Laboratories.* <https://www.aacb.asn.au/documents/item/1214>

Health Policy Analysis. (2019a). *Evaluation of the Health Care Homes program – Evaluation plan (Updated 2019)*.

Health Policy Analysis. (2019b). *Evaluation of the Health Care Homes program – Interim evaluation report 2019*. <https://www1.health.gov.au/internet/main/publishing.nsf/Content/Evaluation-of-the-Health-Care-Homes-Program>

Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res, 20*(10), 1727-1736.

Hibbard, J. H., Mahoney, E. R., Stockard, J., & Tusler, M. (2005). Development and testing of a short form of the patient activation measure. *Health Serv Res, 40*(6 Pt 1), 1918-1930.

Imbens, G. W., & Wooldridge, J. M. (2009). Recent Developments in the Econometrics of Program Evaluation. *Journal of Economic Literature, 47*(1), 5-86.

Independent Hospital Pricing Authority. (2019). *National Weighted Activity Unit (NWAU) calculators*. Retrieved June from <https://www.ihpa.gov.au/what-we-do/national-weighted-activity-unit-nwau-calculators>

Johns Hopkins ACG® System. (2021). *The Johns Hopkins ACG System*. Retrieved October from <https://www.hopkinsacg.org/resource-center/#documentation>

Nguyen, T.-L., Collins, G. S., Spence, J., Daurès, J.-P., Devereaux, P. J., Landais, P., & Le Manach, Y. (2017). Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. *BMC Med Res Methodol, 17*(1), 78.

NPS MedicineWise. (2021). *MedicineInsight Data Book version 4.0*. <https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-databook-4.0-December-2021.pdf>

Outcome Health. (2019). *POLAR GP*. Retrieved 5 July from <https://outcomehealth.org.au/polar.aspx>

Page, A. T., Falster, M. O., Litchfield, M., Pearson, S. A., & Etherton‐Beer, C. (2019). Polypharmacy among older Australians, 2006–2017: a population‐based study. *Med J Aust 211*(2), 71-75.

Pen CS. (2021). *Data mapping*. Retrieved 5 July from <https://help.pencs.com.au/display/ADM/Data+Mapping>

Pollack, C. E., Hussey, P. S., Rudin, R. S., Fox, D. S., Lai, J., & Schneider, E. C. (2016). Measuring Care Continuity: A Comparison of Claims-based Methods. *Medical Care, 54*(5), e30-e34.

Pratt, N. L., Kerr, M., Barratt, J. D., Kemp-Casey, A., Kalisch Ellett, L. M., Ramsay, E., & Roughead, E. E. (2018). The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. *BMJ Open, 8*(4), e021122.

Quan, H., Li, B., Couris, C. M., Fushimi, K., Graham, P., Hider, P., Januel, J. M., & Sundararajan, V. (2011). Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol, 173*(6), 676-682.

SAS Enterprise. (2021). *PSMATCH Procedure*. Retrieved October from <https://support.sas.com/rnd/app/stat/procedures/psmatch.html>

Schmittdiel, J., Mosen, D. M., Glasgow, R. E., Hibbard, J., Remmers, C., & Bellows, J. (2008). Patient Assessment of Chronic Illness Care (PACIC) and improved patient-centered outcomes for chronic conditions. *J Gen Intern Med, 23*, 77-80.

Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., & Ghali, W. A. (2004). New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol, 57*(12), 1288-1294.

Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A. (2020). Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. *BMC Medicine, 18*(1), 15.

1. Health Policy Analysis. (2019b). *Evaluation of the Health Care Homes program – Interim evaluation report 2019*. https://www1.health.gov.au/internet/main/publishing.nsf/Content/Evaluation-of-the-Health-Care-Homes-Program [↑](#footnote-ref-2)
2. Not all 20 practices participated in the three case study rounds. [↑](#footnote-ref-3)
3. Health Policy Analysis. (2019a). *Evaluation of the Health Care Homes program – Evaluation plan (Updated 2019)*. [↑](#footnote-ref-4)
4. Gibbons, C. J., Small, N., Rick, J., Burt, J., Hann, M., & Bower, P. (2017). The Patient Assessment of Chronic Illness Care produces measurements along a single dimension: results from a Mokken analysis. *Health Qual Life Outcomes, 15*(1), 61. [↑](#footnote-ref-5)
5. Hibbard, J. H., Mahoney, E. R., Stockard, J., & Tusler, M. (2005). Development and testing of a short form of the patient activation measure. *Health Serv Res, 40*(6 Pt 1), 1918-1930. [↑](#footnote-ref-6)
6. Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res, 20*(10), 1727-1736. [↑](#footnote-ref-7)
7. Agency for Healthcare Research and Quality. (2015). *CAHPS® Clinician & Group Survey: Overview of the Questionnaires*. https://www.ahrq.gov/cahps/surveys-guidance/cg/instructions/downloadsurvey3.0.html [↑](#footnote-ref-8)
8. Agency for Healthcare Research and Quality. (2016). *Care Coordination Quality Measure for Primary Care (CCQM-PC)*. AHRQ. Retrieved 1 February 2017 from https://www.ahrq.gov/professionals/prevention-chronic-care/improve/coordination/ccqmpc/index.html [↑](#footnote-ref-9)
9. Health Policy Analysis. (2019a). *Evaluation of the Health Care Homes program – Evaluation plan (Updated 2019)*. [↑](#footnote-ref-10)
10. MedicineInsight’s processes for collecting data from practices meets the definition of non-identifiable data in the NHMRC National Statement on Ethical Conduct in Human Research. Practices consent to use of non-identifiable data for research through a practice agreement. However, an important requirement for the evaluation was the capability to identify practices enrolled in the HCH program within the MedicineInsight extract. To enable this NPS MedicineWise sought and obtained explicit and informed consent from HCH enrolled practices so that consenting practices could be flagged and identified in the MedicineInsight data extract. [↑](#footnote-ref-11)
11. Pen CS. (2021). *Data mapping*. Retrieved 5 July from https://help.pencs.com.au/display/ADM/Data+Mapping [↑](#footnote-ref-12)
12. Outcome Health. (2019). *POLAR GP*. Retrieved 5 July from https://outcomehealth.org.au/polar.aspx [↑](#footnote-ref-13)
13. NPS MedicineWise. (2021). *MedicineInsight Data Book version 4.0*. https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-databook-4.0-December-2021.pdf, Pen CS. (2021). *Data mapping*. Retrieved 5 July from https://help.pencs.com.au/display/ADM/Data+Mapping. [↑](#footnote-ref-14)
14. NPS MedicineWise. (2021). *MedicineInsight Data Book version 4.0*. https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-databook-4.0-December-2021.pdf [↑](#footnote-ref-15)
15. Goodall, I., Shephard, M., & Tate, J. (2010). *Position Statment. Recommended Changes in HbA1c Reporting Units for Australian Laboratories.* https://www.aacb.asn.au/documents/item/1214 [↑](#footnote-ref-16)
16. NPS MedicineWise. (2021). *MedicineInsight Data Book version 4.0*. https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-databook-4.0-December-2021.pdf [↑](#footnote-ref-17)
17. Pen CS. (2021). *Data mapping*. Retrieved 5 July from https://help.pencs.com.au/display/ADM/Data+Mapping [↑](#footnote-ref-18)
18. NPS MedicineWise. (2021). *MedicineInsight Data Book version 4.0*. https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-databook-4.0-December-2021.pdf [↑](#footnote-ref-19)
19. Australian Association of Practice Management. (2019). *AAPM Guidance for Health Care Homes*. Retrieved 5 September from https://www.aapm.org.au/Knowledge-Hub/Healthcare-Homes [↑](#footnote-ref-20)
20. Ibid. [↑](#footnote-ref-21)
21. SAS Enterprise. (2021). *PSMATCH Procedure*. Retrieved October from https://support.sas.com/rnd/app/stat/procedures/psmatch.html [↑](#footnote-ref-22)
22. Nguyen, T.-L., Collins, G. S., Spence, J., Daurès, J.-P., Devereaux, P. J., Landais, P., & Le Manach, Y. (2017). Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. *BMC Med Res Methodol, 17*(1), 78. [↑](#footnote-ref-23)
23. Australian Bureau of Statistics. (2018a). 1270.0.55.005 - Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure, July 2016 [↑](#footnote-ref-24)
24. Australian Bureau of Statistics. (2018b). *2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016*. Retrieved September from https://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/6CD4E5CE952FEDBFCA257B3B001AC3E5?opendocument [↑](#footnote-ref-25)
25. Australian Bureau of Statistics. (2018a). 1270.0.55.005 - Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure, July 2016 [↑](#footnote-ref-26)
26. Australian Bureau of Statistics. (2018b). *2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016*. Retrieved September from https://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/6CD4E5CE952FEDBFCA257B3B001AC3E5?opendocument [↑](#footnote-ref-27)
27. Australian Institute of Health and Welfare. (2015). *Pharmaceutical Benefits Scheme (PBS) prescription-patient entitlement status (derived) [METeOR 604103]*. AIHW. https://meteor.aihw.gov.au/content/index.phtml/itemId/604103 [↑](#footnote-ref-28)
28. Johns Hopkins ACG® System. (2021). *The Johns Hopkins ACG System*. Retrieved October from https://www.hopkinsacg.org/resource-center/#documentation [↑](#footnote-ref-29)
29. Quan, H., Li, B., Couris, C. M., Fushimi, K., Graham, P., Hider, P., Januel, J. M., & Sundararajan, V. (2011). Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol, 173*(6), 676-682. [↑](#footnote-ref-30)
30. Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., & Ghali, W. A. (2004). New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol, 57*(12), 1288-1294. [↑](#footnote-ref-31)
31. Australian Institute of Health and Welfare. (2014). *Cardiovascular disease, diabetes and chronic kidney disease. Australian facts: Morbidity–Hospital care. Cardiovascular, diabetes and chronic kidney disease.* [↑](#footnote-ref-32)
32. Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A. (2020). Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. *BMC Medicine, 18*(1), 15. [↑](#footnote-ref-33)
33. Johns Hopkins ACG® System. (2021). *The Johns Hopkins ACG System*. Retrieved October from https://www.hopkinsacg.org/resource-center/#documentation [↑](#footnote-ref-34)
34. Pratt, N. L., Kerr, M., Barratt, J. D., Kemp-Casey, A., Kalisch Ellett, L. M., Ramsay, E., & Roughead, E. E. (2018). The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. *BMJ Open, 8*(4), e021122. [↑](#footnote-ref-35)
35. Page, A. T., Falster, M. O., Litchfield, M., Pearson, S. A., & Etherton‐Beer, C. (2019). Polypharmacy among older Australians, 2006–2017: a population‐based study. *Med J Aust 211*(2), 71-75.. [↑](#footnote-ref-36)
36. Australian Institute of Health and Welfare. (2016). *General Practitioner attendance indicator [METeOR 603651]*. AIHW. https://meteor.aihw.gov.au/content/index.phtml/itemId/603651 [↑](#footnote-ref-37)
37. Australian Institute of Health and Welfare. (2019a). *Medicare-subsidised GP, allied health and specialist health care across local areas, 2013–14 to 2017–18 Technical Note*. AIHW. https://www.aihw.gov.au/getmedia/0185a2b5-5093-4194-85b3-e9776867f512/aihw-phe-254-tech-note.pdf.aspx. [↑](#footnote-ref-38)
38. Australian Institute of Health and Welfare. (2013). *Expenditure on specialist attendances, 2012–13 [METeOR 547958]*. AIHW. https://meteor.aihw.gov.au/content/index.phtml/itemId/547958 [↑](#footnote-ref-39)
39. Australian Institute of Health and Welfare. (2019a). *Medicare-subsidised GP, allied health and specialist health care across local areas, 2013–14 to 2017–18 Technical Note*. AIHW. https://www.aihw.gov.au/getmedia/0185a2b5-5093-4194-85b3-e9776867f512/aihw-phe-254-tech-note.pdf.aspx [↑](#footnote-ref-40)
40. Ibid. [↑](#footnote-ref-41)
41. Ibid. [↑](#footnote-ref-42)
42. Pollack, C. E., Hussey, P. S., Rudin, R. S., Fox, D. S., Lai, J., & Schneider, E. C. (2016). Measuring Care Continuity: A Comparison of Claims-based Methods. *Medical Care, 54*(5), e30-e34. [↑](#footnote-ref-43)
43. Australian Institute of Health and Welfare. (2019b). *National Healthcare Agreement: PI 18–Selected potentially preventable hospitalisations, 2019 [METeOR 698954]*. AIHW. https://meteor.aihw.gov.au/content/index.phtml/itemId/698954 [↑](#footnote-ref-44)
44. Independent Hospital Pricing Authority. (2019). *National Weighted Activity Unit (NWAU) calculators*. Retrieved June from https://www.ihpa.gov.au/what-we-do/national-weighted-activity-unit-nwau-calculators [↑](#footnote-ref-45)
45. Health Policy Analysis. (2019a). *Evaluation of the Health Care Homes program – Evaluation plan (Updated 2019)*. . Note that this reference is to the version of the plan that was updated to accommodate the extension of the trial. The updated plan maintained the evaluation approach and measures published in the original plan but added data collection points due to the extension. [↑](#footnote-ref-46)
46. Dillman, D. A., Smyth, J. D., & Christian, L. M. (2014). *Internet, Phone, Mail, and Mixed-Mode Surveys: The Tailored Design Method* (4th ed.). Wiley. [↑](#footnote-ref-47)
47. Hibbard, J. H., Mahoney, E. R., Stockard, J., & Tusler, M. (2005). Development and testing of a short form of the patient activation measure. *Health Serv Res, 40*(6 Pt 1), 1918-1930. [↑](#footnote-ref-48)
48. Gibbons, C. J., Small, N., Rick, J., Burt, J., Hann, M., & Bower, P. (2017). The Patient Assessment of Chronic Illness Care produces measurements along a single dimension: results from a Mokken analysis. *Health Qual Life Outcomes, 15*(1), 61, Glasgow, R. E., Wagner, E. H., Schaefer, J., Mahoney, L. D., Reid, R. J., & Greene, S. M. (2005). Development and Validation of the Patient Assessment of Chronic Illness Care (PACIC) [Journal]. *Medical care, 43*, 436-444, Schmittdiel, J., Mosen, D. M., Glasgow, R. E., Hibbard, J., Remmers, C., & Bellows, J. (2008). Patient Assessment of Chronic Illness Care (PACIC) and improved patient-centered outcomes for chronic conditions. *J Gen Intern Med, 23*, 77-80. [↑](#footnote-ref-49)
49. Devlin, N. J., & Krabbe, P. F. (2013). The development of new research methods for the valuation of EQ-5D-5L. *Eur J Health Econ, 14 Suppl 1*, S1-3, Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res, 20*(10), 1727-1736. [↑](#footnote-ref-50)
50. Imbens, G. W., & Wooldridge, J. M. (2009). Recent Developments in the Econometrics of Program Evaluation. *Journal of Economic Literature, 47*(1), 5-86. [↑](#footnote-ref-51)